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 Education of health professionals about 
 adolescent  psychiatry 
 Leo  Sher and  Joav  Merrick 
 Psychiatric disorders in adolescents are an important social problem which is 
relevant to almost all health care professionals ( 1 – 3 ). According to the results of The 
National Comorbidity Survey – Adolescent Supplement (NCS-A), the lifetime preva-
lence of  anxiety, behavior,  mood, and substance use disorders among adolescents 
was 31.9%, 19.1%, 14.3%, and 11.4%, respectively ( 1 ). Approximately 40% of partici-
pants in this survey with one class of disorder also met criteria for another class of 
lifetime disorder. Comorbidity is increasingly recognized as a key feature of mental 
disorders among adolescents. Female adolescents are more likely than males to have 
 mood and anxiety disorders, but less likely to have behavioral and  substance use 
disorders ( 1 ,  3 ). 
 Regretfully, medical professionals are not sufficiently trained about adolescent 
psychiatric disorders. For example, primary care providers correctly identify less 
than a fourth of  youth with a depressive or anxiety disorder ( 3 ). Also, many clinici-
ans underestimate the importance of the problem of adolescent psychiatric illnesses 
and suicidal behavior ( 4 ). Lack of skilled medical providers impedes the delivery of 
needed services to adolescents with mental health issues. This coupled with a lag 
in the ability of primary health care services to incorporate psychiatric interven-
tions, and a failure of public health initiatives to pay attention to adolescent mental 
health problems has led to continuing gaps in care over decades despite the public 
pronouncements of needs. 
 Educating health care providers and trainees about the signs and symptoms of 
adolescent mental disorders and providing them with tools to recognize, evaluate, 
and manage these disorders are a very important task. The high prevalence, morbi-
dity, mortality, accessibility, and treatment responsiveness of many adolescent psych-
iatric issues make them a good and important target of care. 
 Adolescents of today are born into families and communities that differ in regard 
to ethnicity, culture, language, religion, environment and the opportunity to benefit 
from education and wealth. They are exposed to revolutionary new technology. Teen-
agers have exciting, rapidly changing lives of promise. Most adolescent patients, 
especially in today ’ s age of fragmented families and communities, value the chance 
to connect with an educated and responsible adult. Therefore, all medical providers 
may contribute a lot to the mental health care of adolescents. 
 One of the greatest documents in the history of the humankind, The Declaration 
of Independence of the United States of America pronounces that  “ We hold these 
truths to be self-evident, that all men are created equal, that they are endowed by 
their Creator with certain unalienable rights, that among these are life, liberty and the 
pursuit of happiness ” ( 5 ). We believe that adolescents all over the world have rights 
4   Education of health professionals about adolescent psychiatry 
that are inherent and inalienable, reflective of  adolescents being full members of the 
human society. The mental health of adolescents is essential for sustaining healthy 
and productive societies. 
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 Section I: Neurobiological aspects 

 1   Adolescents with psychiatric disorders: brain 
structural and functional changes 
 Jos é Javier  Miguel-Hidalgo 
 During  adolescence hormonal and neurodevelopmental changes geared to ensure 
reproduction and achieve independence are very likely mediated by growth of neural 
processes, remodeling of synaptic connections, increased myelination in cortical 
prefrontal areas, and maturation of connecting subcortical regions. These processes, 
greatly accelerated in adolescence, follow an asynchronous pattern in different brain 
areas.  Neuroimaging research using functional and structural magnetic resonance 
imaging has produced most of the insights regarding brain structural and functional 
 neuropathology in adolescent psychiatric disorders. In  schizophrenia, first episodes 
during adolescence are linked to greater-than-normal losses in gray matter density 
and white matter integrity, and show a divergence of maturational trajectories from 
normative neural  development, in a progression similar to that of adult-onset schizo-
phrenia.  Anxiety and  mood disorders in adolescence have been linked to abnormally 
increased activity in the amygdala and ventral prefrontal cortical areas, although 
some data suggest that neural abnormalities in the amygdala and anxiety maybe par-
ticularly more frequent in adolescents than in adults.  Alcohol misuse in adolescence 
results in reduced integrity in the white matter and reduced gray matter density that, 
given the high intensity of adolescent synaptic and myelin remodeling, may result 
in persistent and profound changes in circuits supporting memory, emotional and 
appetitive control. Interaction of persistent changes due to prenatal exposure with 
contemporaneous expression of genetic factors and disturbing environmental expo-
sure may be an important factor in the appearance of psychiatric disorders in adole-
scence. Further progress in understanding adolescent psychopathology will require 
 postmortem research of molecular and cellular determinants in the adolescent brain. 
 1.1  Introduction 
 Adolescence is a period in which the need for establishing new social and personal 
relationships, and reaching independence and reproductive success is supported by 
dramatic hormonal, neural and behavioral changes. Similar to other developmental 
dynamic processes, changes in brain circuits during adolescence are an integral part of 
genetically programmed developmental processes. At the same time, those processes 
allow ample room for plastic changes to  adapt to the social and natural environment. 
The ideal result of those processes is an emotionally balanced young adult. However, 
the unraveling of the developmental programs and the rapid neuroplastic changes 
during adolescence (when exposed to negative factors or influenced by inheritable 
or epigenetic deficits) are susceptible to the formation of faulty brain circuits that 
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manifest themselves as psychiatric or neurological disorders. In fact, first episodes for 
many of the main psychiatric disorders later diagnosed in adults occur during  adole-
scence or close to the end of adolescence or may depend of alterations primed in ado-
lescence. Determining which features of morphology and brain activity in  adolescents 
represent a pathological change when compared to adult brains requires, however, an 
understanding of characteristics of the normal, non-psychiatric adolescent brain as 
compared to the brain of maladapted psychiatrically adolescent individual. 
 While psychological and social aspects of psychiatric disorders have been exten-
sively researched since very early in adolescent  psychiatry studies, specific neuropa-
thological, neurological or physiological studies of brain areas involved in adolescent 
psychopathology is more recent. In the present review we present first a summary 
of cellular, neuroanatomical and  neuroimaging characteristics that differentiate 
the normal adolescent brain from the adults as well as those features that signal a 
transition towards the establishing of adult structure and connectivity. Then we will 
review studies that report the localization of structural and functional neuropatho-
logical changes to specific brain areas in  schizophrenia, anxiety,  depression and 
 substance abuse disorders in adolescents as revealed by neuroimaging techniques. 
This reporting will be followed by a consideration of the influence of relevant genetic 
variants on localized neural activity in the brain of adolescents with schizophrenia, 
 anxiety and  mood disorders. 
 During adolescence changing levels of cognitive abilities, impulse control, lan-
guage and motor coordination show great plasticity to allow for the transition to 
mature behavior and cognition. Insofar as the same systems that must display this 
plasticity are affected by disturbances during prenatal and postnatal life, adole-
scence could be particularly vulnerable to neuropathological alterations that result 
in psychopathology. So far, the majority of studies on structural or functional brain 
changes in adolescents with psychiatric disorders have been based on magnetic reso-
nance imaging ( MRI) ( 1 ,  2 ). Brain structural MRI is based on the differential behavior 
of protons of water molecules in gray and white matter when exposed to a variable 
magnetic field. The contrast between structures varying in the response to magnetic 
field alterations allows delineating local groupings of neurons and fibers and deter-
mining their size in absolute and relative terms. Computer software specially desi-
gned to assess morphometric parameters of MRI-discriminated brain components 
allows to measure cortical gray matter thickness, density of gray and white matter, 
volume of subcortical structures, cortical surface, size and shape of cortical gyri and 
sulci as well as brain growth. 
 Diffusion tensor imaging ( DTI) is an application of structural MRI to the measure-
ment of the diffusion of water molecules. Within a magnetic field these molecules tend 
to align into preferential directions according to their ability to diffuse across or along 
the arrangement of biological structures that surround them. If diffusion and align-
ment occur in many directions, a measurement of high fractional anisotropy is made. 
If, on the contrary, diffusion of water molecules is restricted to specific directions, 
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(for example in white matter along myelinated fiber bundles) then fractional 
anisotropy is reduced, which is interpreted as sign of greater integrity and maturity of 
the axons involved ( 3 ). Functional magnetic resonance imaging takes advantage of the 
differential magnetic properties of oxygenated versus deoxygenated hemoglobin in 
the brain blood circulation to determine blood oxygenation level-dependent contrast 
signal (BOLD signal) ( 4 ). Blood oxygenation changes caused by fluctuations in blood 
flow and oxygen extraction are considered to closely reflect neural activity, because 
there is a tight coupling between increases in local neuronal activity and required 
increases in blood flow to support augmented metabolic demand from neurons ( 5 ). 
All the structural and functional variables mentioned above experience significant 
changes in various brain regions during  adolescence, making  neuroimaging studies 
particularly appropriate to defining them. 
 Earlier studies that revealed developmental changes at the microscopic level in 
gray and white matter in the  adolescent brain were mainly based on histological exa-
mination of the  postmortem brain ( 6 – 8 ). However, most of what is known on brain 
 development at the cellular and molecular level in adolescents derives from studies 
in experimental animals, and there is no direct informationas yet on the cellular and 
molecular  neuropathology of the human adolescent brain in psychiatric disorders. 
Consequently, in this review we discuss knowledge on the neuropathological alte-
rations in adolescents with major psychiatric disorders mainly as they have been 
revealed in structural and functional  MRI studies, although evidence from other 
approaches is introduced when appropriate. The resolution of images in MRI-based 
neuroimaging research, although improving, is still insufficient for research at the 
cellular level. However, MRI neuroimaging studies present several distinct advanta-
ges: they do not involve the use of potentially deleterious ionizing radiation and thus 
can be used more than once in living subjects; unlike postmortem neuroanatomical 
studies, it is practical to include many subjects in a single study, thus increasing statis-
tical power; longitudinal studies are possible to determine developmental trajectories 
and effects of environmental changes ( 2 ). Thus, unless otherwise specified, research 
results discussed throughout this review will correspond to MRI-based studies. 
 1.2   Neuroanatomical and functional changes in the normal 
adolescent brain 
 In the early postnatal years the brain experiences an exponential increase in the 
numbers of synapses, dendritic and axonal branches and myelination that result in 
dramatic increases of brain size ( 9 ,  10 ). Later in childhood there is a stabilization of 
brain size and the number of synapses, although myelination continues to expand 
into several brain areas, and white matter connecting the  prefrontal cortex to other 
brain regions appears to increase. In fact, during adolescence the volume of frontal 
gray matter as visualized by structural MRI has been described to decrease while white 
10   1  Adolescents with psychiatric disorders: brain structural and functional changes
matter steadily increases ( 11 ). The process of synaptic change, however, retakes vigo-
rously at the beginning of  adolescence and for most of its duration, with initial overpro-
duction and later elimination of some synapses, resulting so-called synaptic pruning in 
the  prefrontal cortex and other cortical areas ( 7 ,  12 – 14 ). Myelination progresses further 
also in the prefrontal cortex ( 6 ), and in other regions highly relevant to  development of 
psychiatric disorders ( 15 ). Synaptic changes consist in a reduction of synaptic density 
that is likely reflected in a concomitant reduction in the volume of gray matter in the 
prefrontal cortex and the striatum, although volume reductions may not be entirely 
accounted for by synaptic changes ( 16 ), and in some structures such as the amygdala, 
the hippocampus and the posterior temporal cortex there is an increase of gray matter 
density during adolescence ( 1 ,  17 ,  18 ). The possibility that neuronal loss also contribu-
tes to gray matter size changes or synaptic pruning in specific cortical areas cannot be 
ruled out because Markham et al ( 19 ) have found decreases in neuronal numbers in 
the ventral prefrontal cortex of  adolescent rats. Despite the overall pattern of synaptic 
pruning, specific axonal pathways connecting the prefrontal cortex and the amygdala 
experience further grow and branching, and result in increased white matter volume 
during adolescence. As discussed by Sowell et al ( 1 ) some reductions of gray matter 
density, which are paralleled by increases in white matter volume, and the apparent 
thinning of the gray matter measured by MRI-based mapping methods, might result 
from changes in myelination at the border between gray and white matter and not just 
be a consequence of synaptic pruning. On the other hand, measurement of brain growth 
at the surface of the cerebral cortex reveals that, despite the reduction of gray matter 
density, there is growth at the cortical surface of specific brain regions between ado-
lescence and adulthood, particularly in the dorsal aspects of the frontal lobes and the 
left orbitofrontal cortex ( 1 ). In addition, the primary language cortex in the perisylvian 
region sets itself apart because thickness and density of the gray matter increase during 
adolescence and into early adulthood ( 11 ,  20 ,  21 ). Thus, there is a high degree of regi-
onal specificity and non-linear occurrence of structural and functional changes in the 
adolescent gray and white matter that attest to specific changes geared to adaptations 
for acquisition of relative independence and the ability to reproduce. Brain imaging 
techniques support that, in all, the various maturational processes taking place in the 
adolescent brain result in an increasing regulatory role by the prefrontal cortex ( 22 ). 
 A recent  DTI study in children, adolescents and adults, showed that measures of 
radial diffusivity (which diminishes as fiber bundles mature) decrease in particular 
but broadly distributed pathways connecting cortex and brain stem nuclei in adole-
scents, indicating an increase in the integrity of axon bundles and myelin maturation. 
However, other pathways supporting prefrontal-striatal and inter hemispheric con-
nections do not fully mature until adulthood ( 3 ). It is also important to note that new 
studies have found that an increase in white matter is largely dependent on hormonal 
changes and this hormonal influence very likely also affects the microstructure of 
fiber bundles in the gray matter ( 23 ). The dependence on hormonal changes and the 
difference in specific hormonal changes between males and females may underpin 
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distinct microstructural  development of white matter tracts in  adolescent in males 
and females and clearly deserves further studies. 
 1.3   Models of brain functional changes in adolescents with 
psychiatric disorders 
 Some behavioral features that in average appear to be concentrated in the adole-
scence years may be related to an adolescent pattern of brain activity that is not found 
during normal childhood or normal adulthood. Thus, absence of this pattern in ado-
lescent subjects might be a sign of psychopathology and be associated to maladaptive 
behaviors. On the other hand an exacerbation of, rather than a departure from, that 
pattern in comparison to normal adolescents might result in psychopathology as well. 
In other cases, structural and functional alterations in adolescents maybe similar to 
those observed in adults affected by the same disorders. This distinction between 
adolescent-specific and adult-like changes is important because therapeutic interven-
tions effective in adults maybe be amenable to the treatment of adolescents in some 
cases while, in others, interventions might be required to be also adolescent-specific. 
The distinction also applies to psychiatric or personality disorders that, being descri-
bed in adolescence and childhood, may be either associated with structural altera-
tions that are different in children and adolescents, or respond to the same type of 
cerebral alterations. For example, while a distinction is made between early-onset 
and adolescent-onset conduct disorder, regionally specific reductions of gray matter 
in the amygdala and insular cortex are common to both early- and adolescent-onset 
conduct disorder ( 24 ). 
 Neuroimaging studies show that the neural activity in various prefrontal regions 
of normal adolescents is increased or decreased during particular cognitive and emo-
tional tasks as compared to adults and that the relatively altered function is associa-
ted with emotional and cognitive responses reflecting more  impulsivity, and greater 
risk-taking by adolescents. Since these are normal features of  adolescence, there is 
a legitimate question of whether pathological behavior or emotions in adolescents 
correspond to just an exacerbation of normal adolescence function or if functional 
brain changes take onto a pattern that differs both from adults and from normal 
adolescents. A model has been put forward to explain emotional, cognitive and 
behavioral features of adolescence as they differ from adults in terms of brain 
functional changes ( 25 ). This model proposes the existence of three brain functional 
nodes representing different levels for the processing of stimuli, and the establish-
ment of motivations, decisions and plan making: the detection node (some occipital 
and temporal areas), the affective node (amygdala, hippocampus, ventral striatum 
and orbitofrontal cortex) and the cognitive-regulatory node (other prefrontal areas). 
Plasticity and rearrangements in the connectivity within and between these nodes 
would form the basis for the emotional and behavioral changes observed during 
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adolescence, and provide a substrate for alterations that can lead to the first time 
appearance of psychiatric disorders ( 25 – 27 ). 
 The above three-node model stresses the importance of connections between the 
nodes for the  development of social interactions during  adolescence. In fact, recent lon-
gitudinal studies on the responsiveness of relevant cerebral regions of  adolescents to 
facial affective displays have shown distinctive changes in BOLD fMRI signals in early 
adolescence as compared to late childhood ( 28 ). In adolescents, the activity in the ven-
tromedial  prefrontal cortex and the ventral striatum was significantly enhanced in res-
ponse to affective facial displays, while in the amygdala, although the displays caused 
an increase in BOLD signal, this was not increased as compared to late childhood ( 28 ). 
Most interestingly, a higher response in the ventral striatum has been related to higher 
positive affect and fewer depressive symptoms in adolescents ( 29 ,  30 ). Since the role of 
other prefrontal regions in emotional regulation appears not to be fully developed until 
late in adolescence or early adulthood, pathological alterations in the ventral striatum 
of ventromedial prefrontal cortex might have to be taken into account when establi-
shing the pathophysiology of affective disorders in adolescents to eventually ascertain 
the role, if any, of these alterations in adult psychopathology. Prenatal  alcohol exposure 
also results in specific effects on brain structure when examined in young adults ( 31 ). 
Although this study was not done strictly in adolescents one of the main conclusions is 
that overall and localized reductions in brain size and IQ scores associated to prenatal 
 alcohol exposure are not directly related to general physical development in the young 
adult but to head development and gestational factors ( 31 ), which could fully show 
their influence during adolescence and early adulthood. In adolescents, activity in 
brain areas involved in the development of cognition and language are also affected by 
the length of pregnancy (pre term versus full term birth), so that pre term birth is asso-
ciated with higher activity of the medial frontal gyrus when adolescents are confronted 
with syntactic difficulty in a task of sentence comprehension ( 32 ). The significance of 
these changes is, however, unclear, since formal test scores indicate no differences in 
scholar achievement between pre term and full term adolescents ( 32 ). 
 As explained by Sturman and Moghadam ( 25 ) another triadic node model of 
brain circuits that would underlie psychiatric alterations in adolescence puts the 
emphasis on the balance between affective processing and cognitive control, which 
might explain risk-taking behaviors in adolescence. The nodes in this model include 
the ventral striatum (reward approach), the amygdala (punishment avoidance) and 
the prefrontal cortex (modulation node). The balance between the reward approach 
and punishment avoidance would be controlled by the prefrontal cortex. Under-
development of the prefrontal cortex in adolescents as compared to adults would 
make it difficult to control a predominance of the reward-approach node in detri-
ment of the punishment-avoidance node and thus would generate heightened risk-
taking behavior. Recently, it has been observed that in the case of  substance abuse a 
significant link exist between lower than normal activity and reduced density of gray 
matter in the ventral striatum and higher risk taking in adolescents with potentially 
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problematic substance problems ( 33 ), further supporting the suggestion that an 
adequate level of activity in the ventral striatum during  adolescent is crucial for 
various aspects of emotional and behavioral control, particularly at a time when pre-
frontal circuits are still far from having achieved mature  development. Disruption of 
circuits served by the ventral striatum then could contribute to the appearance of 
psychiatric problems during  adolescence. 
 Despite the suspected implication of frontal brain plastic changes in the incre-
ase of risk taking behavior during adolescence there is recent evidence that type of 
behavior might be related to an accelerated maturation of particular circuits. Using 
 DTI, Berns et al ( 34 ) found that engagement in dangerous activities in adolescence 
was positively correlated with fractional anisotropy, and negatively correlated with 
transverse diffusivity in frontal white matter tracts, which was interpreted as incre-
ased myelination or increase in the density of fibers, both considered signs of matu-
ration. Thus, particular caution must be exercised in interpreting how behavioral, 
functional and structural maturation interact with behavior during adolescence to 
eventually achieve a pattern of adult-like behavior. Only the eventual maturation of 
the  prefrontal cortex would result in the fully developed, adult pattern of emotional 
control and behavior. In both models outlined above the role of a balanced influence 
of the brain nodes and the modulating role of the prefrontal cortex are paramount 
and offer opportunities to formulate hypotheses and test them experimentally. 
 1.4  Structural and functional changes in  schizophrenia 
 In adolescents and children diagnosed with schizophrenia, structural  MRI studies have 
shown a significantly lower volume of total cortical gray matter and superior frontal 
gyrus gray matter, suggesting that structural and functional pathology might precede 
the manifestation of schizophrenia in late childhood and adolescence ( 35 ). In addi-
tion, longitudinal studies in adolescents at very high risk for developing schizophrenia 
show that abnormal structural changes in gray and white matter during adolescence 
are critical for the transition to psychosis in adolescents. In subjects at very high risk 
for schizophrenia there is a marked reduction of the increase in white matter seen in 
control adolescent subjects, while the shrinkage in the gray matter of the left middle 
temporal gyrus is significantly greater than in controls or subjects with high risk who 
do not develop psychosis ( 36 ). Since maturity of white matter tracts is seen as a sign 
of increasing control by prefrontal cortical and association areas it is possible that a 
reduced maturation of the corresponding connecting pathways during adolescence 
is a critical anomaly leading to psychosis. Studies on the developmental progression 
during adolescence of gray and white matter abnormalities in adolescent-onset schi-
zophrenia, as compared to adult-onset schizophrenia, show a greater pathology in the 
adolescent-onset condition ( 37 ). In addition, as compared to gray and white matter 
development in non-psychiatric subjects, a longitudinal examination revealed that the 
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development of gray and white matter in  adolescent  schizophrenia is delayed from 
adolescent controls and progressively diverges from normal control subjects to follow 
a similar pattern to the abnormal progression of  neuropathology in adult-onset schi-
zophrenia ( 37 ). The progressive divergence from the normal developmental pattern in 
adolescent-onset schizophrenia would be in agreement with a study in which exami-
nation of gray and white matter structure in ultra high risk adolescent subjects (but not 
yet diseased) did not reveal significant differences from adolescents not at risk ( 38 ), 
suggesting that the appearance of psychotic symptoms is tightly linked to the  develop-
ment of detectable structural alterations and only upon manifestation of the disorder 
there is development of brain structural anomalies ( 36 ). 
 In addition to a role for detectable neuropathological alterations in cortical gray 
matter and the underlying white matter in adolescent schizophrenia, there is a model 
that stresses the role of pubertal and postpubertal changes in the HPA axis and hip-
pocampus as important contributors to the expression of vulnerability for psychosis 
in adolescents ( 39 – 41 ). According to this model, a developmental or genetically deter-
mined vulnerability to psychosis might find expression during  adolescence because 
there are dramatic hormonal and neural changes is the HPA-hippocampus link that, 
combined with heightened chance for stress responses, result in unraveling of the 
vulnerability. Stress responses result in the release of corticosteroids that, beside 
actions on various cell types across the body, exert an important modulatory role on 
mineralocorticoid and glucocorticoid receptors (MR and GR). These receptors are very 
abundant in the hippocampus and modulate responses of hippocampal cells. Sustai-
ned increases in corticosteroids, however, can be toxic to hippocampal neurons, and 
in fact in normal subjects or in subjects with pathologically high cortisol levels there 
is a significant inverse correlation between cortisol levels and hippocampal volume 
( 42 – 46 ). In first-episode, non-medicated subjects with schizophrenia there is eleva-
ted levels of basal cortisol ( 47 ) and there is also evidence for smaller hippocampal 
sizes than in non-psychiatric control subjects ( 48 ). One study specifically targeted 
changes in whole brain and hippocampal volumes, showing that whole brain volume 
was significantly smaller in subjects with schizophrenia, but that the difference in 
hippocampal volume was not statistically significant. However, both duration of 
illness and severity of psychopathology were negatively correlated with hippocam-
pal volume ( 49 ). More recent studies in adolescents with early onset schizophrenia 
further support marked structural deficits early in the disorder, showing a significant 
thinning of the gray matter bilaterally in both gyri and sulci of the superior frontal 
gyrus and in dorsal, ventral and medial locations within the  prefrontal cortex ( 50 ). 
These data together with the first-episode findings suggest that adolescence maybe 
a critical period when the fast progression and manifestation of schizophrenia result 
in immediate structural changes or these changes, upon appearing, immediately 
manifest as psychotic symptoms. More recently,  DTI, which examines the integrity 
of fiber bundles connecting brain areas, has further shown that there is a reduction 
in connectivity in children and adolescents with schizophrenia as reflected by a 
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decreased fractional anisotropy and increased average diffusivity ( 51 ). These results 
point to the possibility that a dysfunctional link between the HPA and hippocampus 
contributes to the first manifestations of  schizophrenia. 
 Higher stress sensitivity during  adolescence is proposed to be an important 
link between environmental influences and the manifestation of psychiatric disor-
ders, particularly psychosis ( 39 ). Prolonged exposure to stress would alter the HPA-
hippocampus reciprocal modulation to result in alterations increasing the risk for 
psychosis. While in normative adolescence there is the expectation of continued incre-
ase in hippocampal volume ( 52 ,  53 ), increased stress sensitivity may, in some predis-
posed individuals, result in reduced hippocampal volume as suggested by a smaller 
hippocampus in animals exposed to prolonged stress after the onset of puberty ( 54 ). 
 1.5   Neuroimaging in  adolescents with  anxiety disorders 
 While schizophrenia and  depression are described in childhood, most first episo-
des of these disorders occur mainly in late adolescence and early adulthood ( 39 ). 
Moreover, for schizophrenia diagnosed in early adulthood, progressive deterioration 
of function can be already detected early in adolescence ( 55 ). This temporal pattern 
does not necessarily apply to all psychiatric disorders. For instance, anxiety disorders 
are highly prevalent in childhood and adolescence ( 56 ). Although anxiety is frequent 
in the course of childhood, it seems to resolve by late adolescence in most cases, but 
if anxiety persists during adolescence there is an increased probability for anxiety 
taking a chronic course in the adult. Thus, chronicity in the adult may result from 
the inability to resolve during adolescence a disorder that is highly prevalent in ado-
lescence and childhood. The  development and refinement of attentional processes 
during adolescence has been proposed as a substrate for pathological enhancement 
of anxiety processes in adolescence and into adulthood ( 56 ). Since circuits and brain 
responses underlying attention have been relatively well identified and characterized, 
functional  MRI has been used to determine brain centers that may be altered during 
attentional tasks with emotional components. For instance, when subjects are pre-
sented with angry faces, fMRI studies are showing increased activity in the ventrola-
teral PFC of adolescents with generalized anxiety disorder (GAD) as compared to non-
anxious adolescents ( 57 ). Likewise, adolescents with GAD show greater activation of 
the amygdala to fearful faces than healthy controls, although greater response is only 
evident when the subjects are instructed to focus their attention on their own sub-
jective evaluation of fear, and not when viewing faces without specific instructions 
( 58 ), consistent with previous studies that found increased activation of the amyg-
dala in adolescents and children with anxiety and  depression ( 59 ). Other regions of 
the  prefrontal cortex such as the ventromedial orbitofrontal cortex have been found 
to display abnormally low activity in tests for fear sensitivity, which has lead to the 
proposal that a misbalance between limbic regions highly sensitive to the drastic 
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hormonal changes of  adolescence, and prefrontal regions responsible of cognitive 
control would greatly contribute to the  development of psychopathology during 
adolescence ( 60 ). This proposal also implies that, in the normally developing brain, 
hormonally driven high activation in reward and limbic systems must be progressi-
vely controlled by the more linearly developing cognitive influence of the  prefrontal 
cortex. Prolongation of the period between hormone-related limbic activation and 
progressive cognitive control would result in increased risk for manifestations of psy-
chopathology in  adolescents and young adults ( 60 ). 
 1.6   Neuropathology in adolescents with  depression 
 In adolescence,  major depressive disorder (MDD) and  bipolar disorder (BD) share an 
increased activation of the amygdala with  anxiety disorders ( 61 ). This greater amyg-
dalar activation appears to extend to healthy children and adolescents at high risk 
for depression (as compared to non-high-risk children) when presented with fearful 
faces ( 62 ). In addition, some studies describe a decrease in the volume of the amyg-
dala of adolescents with depression, although, intriguingly, the ratio of the amygdala 
volume to hippocampal volume is increased in adolescents with depression ( 63 ). The 
hippocampus itself has been the focus of  neuroimaging research. In one study resear-
chers found a decrease in hippocampal volume in adolescent depression, a finding 
similar to that in adult recurrent depression ( 64 ). However, another study with sub-
jects in early adolescence did not detect a significant difference between subjects with 
depression and healthy subjects ( 61 ), suggesting that progression of depression during 
adolescence might result in hippocampal volume reduction. Unlike studies in adults, 
fMRI studies in adolescents with bipolar depression did not find altered activation 
of prefrontal areas (although there was absence of the correlation of activation with 
age observed in controls), but noted an increase in activation of thalamic and striatal 
structures when adolescents were subjected to a cognitive color naming Stroop task 
(known to involve prefrontal circuits) ( 65 ). At a difference with decreased gray matter 
volume of the subgenual prefrontal of adults with MDD and BD, the same region in 
adolescents with BD is not changed as compared to healthy controls. Nonetheless, the 
volumes of gray and white matter of the prefrontal cortex of adolescents with MDD are 
significantly changed as compared to controls, with larger volume in the gray matter 
and smaller volume in the white matter ( 66 ). Application of  DTI to the adolescent 
brain has also shown that integrity of white matter fibers is affected, showing decre-
ased fractional anisotropy in fiber tracts that originate from the subgenual anterior 
cingulate cortex and involve frontolimbic connecting pathways ( 67 ). Since during 
normal adolescence there is a progressive increase in white matter volume and a 
reduction in the volume of gray matter, it seems that there is a defect in the maturation 
of brain pathways in adolescents with depression. Whether this defect is a cause for 
or an effect of depression remains to be fully elucidated. Functional consequences of 
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suspected altered connections in the  adolescent brain with  depression have been 
more recently examined in resting state fMRI. This approach has shown that connecti-
vity between several prefrontal cortical areas, superior temporal gyrus and the insular 
cortex is significantly reduced ( 68 ), while connectivity with between the amygdala of 
various prefrontal regions appears to be enhanced ( 69 ). 
 Postmortem neuropathological and molecular studies of the human brain in psy-
chiatric disorders during  adolescence are understandably scarce with the only excep-
tion of  suicide. Suicide is an important cause of death during teenage years ( 70 ) and in 
many cases is associated with psychiatric disorders. Studies on postmortem brain of 
 suicide adolescents have reported an increase in binding and mRNA for 5-HT2a sero-
tonin receptors, which, in the case of binding, is also observed in adult suicide ( 71 ).
Also in teenage suicide victims a postmortem study found that brain derived neuro-
trophic factor (BDNF) and its receptor, TrkB, were significantly reduced in the  prefron-
tal cortex and hippocampus ( 72 ). CREB (protein and mRNA) a transcription factor that 
participates in the transcription of BDNF mRNA was also lower in the prefrontal cortex 
of adolescent suicides as compared to controls subjects ( 73 ). Given the involvement of 
BDNF in synaptic plasticity and neurite growth, reduced BDNF in critical brain areas 
may result in reduced plasticity in the brain of suicide victims, which may contribute 
to psychopathology leading to suicide. Increased proinflammatory cytokine expres-
sion has been described in the postmortem brain of MDD and proposed to contribute 
to the pathophysiology of depression. Recent studies in brains from teenage suicides 
have found that there is an increase in the levels of TNF-alpha and IL-beta as compa-
red to controls ( 74 ), raising the possibility that neuroimmune alterations are also part 
of the pathological processes underlying depression in adolescents. 
 1.7   Neuropathology in the adolescent brain and substances 
of abuse 
 Due to their great medical and social importance the neuropathological effects of 
 alcohol intake during adolescence have received increasing attention. Binge and sus-
tained alcohol drinking have been shown to cause effects in adolescents that differ sig-
nificantly from the effects in adults, although the direction of many of those changes is 
similar ( 75 ). In adolescents, alcohol drinking results in a reduction of the volume of the 
hippocampus and prefrontal cortex and the reduction is positively correlated with the 
duration of alcohol abuse ( 76 – 78 ). Moreover, in binge-drinking adolescents not under 
medical treatment there is a significant and widespread decrease in the integrity of the 
white matter as studied by  DTI ( 79 ). These structural abnormalities in adolescents are 
very likely accompanied by physiological and molecular changes in brain regions and 
processes heavily involved in emotional and cognitive regulation of behaviors related 
to  substance abuse. For instance, alcohol abuse in human adolescents and in animal 
models causes larger memory impairments than in adults ( 80 – 83 ). Correspondingly, 
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some studies in rats show that binge-drinking causes larger neuronal damage in the 
frontal cortex of  adolescent than adult rats ( 84 ,  85 ), while other studies demonstrated 
greater inhibition of NMDA-based synaptic activity in the adolescent hippocampus and 
cingulate cortex, and a greater inhibition of long term potentiation (LTP) ( 86 ), which 
is considered a basic neurophysiologic mechanism involved in learning and memory. 
Some of the damage and long-term behavioral effects caused by  alcohol during  ado-
lescence would involve significant alterations in dopaminergic and glutamatergic 
pathways of frontocortical and striatal brain centers, which could be mediated by epi-
genetic changes in histone acetylation ( 87 ). Knowledge of these changes may open the 
door to designing treatments of alcohol-related disorders in adolescence based on the 
inhibition of histone deacetylases ( 88 ). 
 The involvement of addiction or exposure to cocaine in pathological brain 
changes during adolescence has been also studied with neuroimaging methods. For 
instance, prenatal exposure to cocaine has been found to result in changes of connec-
tivity as determined by DTI ( 89 ), which shows that at least 10 different landmarks in 
several fiber tracts of white matter are different between adolescents exposed to pre-
natal cocaine and non-exposed controls. It is important to determine these changes 
because adolescents prenatally exposed to cocaine show deficits in intelligence, exe-
cutive function and language skills which greatly depend on the systems affected by 
prenatal cocaine exposure ( 89 ). In turn, binge-like cocaine exposure during adole-
scence in experimental rats results in gene expression changes that involve chroma-
tin remodeling (indicating persistent changes) in the  prefrontal cortex in adulthood 
( 90 ). Thus, in adolescence there could be expression of pathological alterations as a 
consequence of prenatal exposure to cocaine or other brain altering agents while the 
brain is still susceptible to lasting changes due to adolescent drug abuse, raising the 
possibility of a compounded or synergistic damaging interaction between acute expo-
sure in adolescence and the consequences of past unwanted exposures. As in the case 
of adolescent exposure to alcohol, long-term consequences of cocaine abuse during 
adolescence may involve epigenetic changes as illustrated by reduced methylation of 
histone 3 in adolescent rats administered cocaine ( 90 ). 
 1.8  Gene variants and functional  neuroimaging 
 Recent studies have started to consider the contribution of relevant gene variants to 
the emergence or presence of  anxiety and  mood disorders in adolescents and their 
functional consequences in specific brain areas. Variants of the gene for the sero-
tonin transporter (5-HTT) have been shown to modulate the manifestation of sym-
ptoms of anxiety and  depression, with subjects (psychiatric and non-psychiatric) 
carrying the S and L(g) alleles more prone to anxiety and depression symptoms ( 91 ) and 
to higher activation of the amygdala measured by fMRI when looking to fearful faces 
in a fear-detecting mode than subjects with two L(a) alleles ( 92 ). In adolescents, 
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follow-up studies have further shown that in a fear monitoring situation fearful faces 
also cause higher amygdala activation in S and L(g) carriers but only when the pati-
ents are non-psychiatric ( 93 ). Surprisingly,  adolescent subjects with psychiatric dia-
gnosis had higher amygdala activation when they carried two L(a) alleles, an effect 
opposite to the one observed in adults. This peculiarity of allelic effects in adolescents 
may reflect a vulnerability of the asynchronous  development pattern of various corti-
cal and subcortical centers in adolescent subjects or a lack of experiences that even-
tually may result in greater effects of S/L(g) alleles ( 93 ) only in adults. 
 Allelic variants of brain-derived neurotrophic factor (BDNF), with probable 
effects on the activity of BDNF as a trophic factor, might be linked to  depression and 
 anxiety in adults ( 94 ,  95 ). To assess whether those gene variants also influenced psy-
chiatric diagnosis in adolescents, Lau et al ( 77 ) studied MRI-detected activity in brain 
regions that are activated when viewing faces with different emotional loads (fear, 
happiness, indifferent). It was found ( 96 ) that adolescents diagnosed with anxiety 
or depression had higher activation in amygdala and hippocampus in response to 
fearful faces than non-psychiatric controls, and that this activation was significantly 
higher in psychiatric adolescent subjects that carried the Met66 allele (as opposed 
to Val/Val homozygote carriers), suggesting that localized brain functional effects of 
genetically-based changes in the sequence and activity of BDNF are already detecta-
ble by fMRI in adolescence. 
 1.9  Conclusions 
 During  adolescence dramatic changes in behavior, bodily growth, and in cognitive 
and emotional control are concomitant with significant morphological and functio-
nal changes in brain areas implicated in the pathophysiology of psychiatric disorders. 
In some individuals, this maturational transition is associated with the first manifes-
tations of major psychiatric disorders during or shortly after the adolescent period. 
At different times during adolescence various processes of neural remodeling and 
growth take place at different locations within the frontal cortex and connecting sub-
cortical structures. Untimely exposure to challenging environmental events or drugs 
of abuse, in combination with the effects of expression of specific genetic variants 
may generate dysfunctional circuits, in which changes may have lasting consequen-
ces into adulthood psychopathology. So far the best evidence for the functional and 
neuroanatomical changes in the human adolescent brain that may underlie adole-
scent psychopathology has been obtained using different applications of structural 
and functional MRI. 
 Experiments in animals are providing and will continue to provide details about 
the basic cellular and molecular mechanisms responsible for the appearance of 
psychiatric disorders. However, application of knowledge obtained in animals to 
understanding actual biochemical changes and functional consequences in brain 
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circuits of human  adolescents will require a refinement of imaging, molecular and 
cellular biology tools. Although logistically challenging,  postmortem studies of the 
adolescent brain in psychiatric disorders would be key to identify specific molecular 
and cellular alterations in the neurobiology of psychiatric disorders in  adolescence. 
These postmortem studies should define neuronal and glial cell types implicated 
and the molecular pathways in specific brain gray and white matter regions in ado-
lescent pathology, so that the right experimental questions are put to test in animal 
models and the right conclusions are drawn about the neuropathological mecha-
nisms underlying  neuroimaging findings. 
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 2   Ecstasy and the serotonin syndrome 
 Yuriy  Dobry ,  Timothy  Rice and  Leo  Sher 
 There is presently scarce clinical and basic lab data concerning the risk of acute sero-
tonin toxicity from selective serotonin reuptake inhibitors ( SSRIs) and 3,4-methylene-
dioxymethamphetamine (MDMA, ecstasy) co-administration. The health care commu-
nity would strongly benefit from attending to the high risk of serotonin syndrome from 
this specific drug combination. Objective: To review the risk of serotonin syndrome in 
adolescents and young adults prescribed SSRIs who concurrently use ecstasy. Data 
Sources: An electronic search of the major behavioral science bibliographic databa-
ses (Pubmed, PsycINFO, Medline) was conducted to retrieve peer-reviewed articles 
detailing the clinical characteristics, biological mechanisms and social implications 
of SSRIs, MDMA, and their potential synergism in causing serotonin syndrome in the 
pediatric and young adult population. 
 Search terms included  “ serotonin syndrome, ”  “ ecstasy, ”  “ MDMA, ”  “ pediatric ” 
and  “ SSRI. ” Additional references were incorporated from the bibliographies of these 
retrieved articles. 
 Results: MDMA in combination with the widely-prescribed SSRI antidepres-
sant class can lead to rapid, synergistic rise of serotonin (5-HT) concentration in the 
central nervous system. This can result in acute medical emergency known as sero-
tonin syndrome. This chapter addresses this complication through an exploration of 
the theoretical mechanisms and clinical manifestations of this life-threatening phar-
macological interaction. Conclusion: Further research, as well as greater health care 
provider and regulatory body attention to this overlooked and increasingly relevant 
danger will prevent a growing threat to the public health, owing to the increasing 
incidences of recreational ecstasy use and SSRI pharmacotherapy among multiple 
psychiatric disorders in the  adolescent population. 
 2.1 Introduction 
 MDMA, or ecstasy, is an increasingly prevalent drug of abuse in the adolescent and 
young adult population ( 1 ). Most ecstasy-related deaths occur to teenagers and young 
adults in the in middle and upper middle class socioeconomic groups ( 2 ,  3 ). The 
problem appears to be global. More than 4% of the drug-related fatalities documen-
ted in the UK, for example, originated from MDMA ingestion ( 4 ), and ecstasy abuse 
resulted in 82 deaths in Australia from 2004 to 2009 ( 5 ). The 2003 National Survey 
on Drug Use and Health (NSDUH) reported over 2,000 young people who presented 
to the emergency departments across the country reporting MDMA as a major factor 
in their visit ( 6 ). Notably, the incidence of prescription drug use among these popu-
lations was unknown; it is likely that a greater incidence of fatality occurred among 
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individuals receiving medications for a psychiatric morbidity, such as the SSRI class, 
that potentiates the adverse effects of serotonin elevation. 
 SSRI therapy is both widespread and rising in  adolescents and young adults ( 7 – 10 ). 
In children,  depression disorder is seen in up to 6% and lifetime prevalence rate of 
depression in  adolescence ranging between 15% and 20%, with  SSRIs as the main 
pharmacological approach ( 8 ). Given the high comorbidity of psychiatric illness and 
illicit substance abuse disorders in children and adolescent ( 11 ), rising popularity of 
MDMA, and the rapid increase of SSRI use in patients with psychiatric illness, it is 
easy to foresee the dangerously high risk of developing acute serotonergic emergency 
in this specific population ( 12 – 14 ), especially considering the unique and vulnerable 
biology of the developing human central nervous system ( 15 – 18 ). 
 2.2 SSRI efficacy and toxicity in adolescents and young adults 
 Since the introduction of fluoxetine in 1988, the SSRI antidepressant class has become 
the most widely prescribed antidepressants in the USA across all demographic groups. 
In 2002, nearly half of all antidepressant prescriptions were SSRIs ( 19 ) and today with 
the help  “ direct to consumer advertising ” this number has enlarged to nearly 100% 
( 20 ). This pattern is mirrored in the care of child and adolescent  psychiatry patient 
population, with 11% of Americans age 12 and over tried on antidepressants at one 
time ( 21 ), and approximately 2% of children and adolescents in the United States 
treated with SSRIs ( 22 ). The rapid increase of SSRI use in children and adolescents 
has occurred in spite a scarcity of safety and efficacy data as well as a lack of clear gui-
delines for use in this population ( 23 ). For example, in a large survey of active general 
pediatricians and family physicians, 72% of physicians reported having prescribed an 
SSRI for a child or adolescent, despite reported insufficient training in treatment of 
childhood depression and related psychiatric disorders ( 24 ). 
 SSRI is the first class of antidepressants with rationally engineered mecha-
nisms, efficacy curves and toxicity profiles consistent with intrasynaptic serotonin 
elevation via a relatively specific inhibition of neuronal reuptake pump for sero-
tonin (5-hydroxytryptamine; 5-HT) ( 25 ,  26 ). It is theorized that SSRIs exert their 
effect on  mood and behavior through elevation of intrasynaptic serotonin level at 
the nearly 250,000 serotonergic synapses that make up the Raphe nucleus, and 
innervate  prefrontal cortex, hippocampus, and basal ganglia. The broad neuronal 
network of serotonergic neurons is hypothesized to account for the widespread 
clinical action of SSRIs including depression,  anxiety, and obsessive-compulsive 
disorder. Inhibition of presynaptic reuptake inhibitors as well as down regulation 
of 5-HT1 autoreceptors increase the serotonergic transmission and thereby affect 
clinical state ( 27 ,  28 ). Additionally, SSRIs are potent inhibitors of the CYP family of 
liver enzymes ( 29 ), creating a potential for a powerful interaction between SSRIs 
and any pro-serotonergic substance metabolized by the same system, including 
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other  SSRIs ( 30 ). Ecstasy is an example of such substance, and as Catterson et al 
( 31 ) clearly demonstrated, fluoxetine, citalopram and paroxetine have the poten-
tial to inhibit CYP2D6 and inhibit metabolism of MDMA. 
 The most common adverse effects of SSRI toxicity noted in children and  adole-
scents are headache, sedation, nervousness,  anxiety, agitation, and insomnia ( 29 ), 
consistent with excessive extracellular serotonin build up. Analyses from various 
health care centers reported that out of 26,733 cases of SSRI overdose, 14 – 16% showed 
some symptoms of serotonin syndrome ( 32 ). With concurrent administration of 
another pro-serotonergic agent, however, the risk of developing serotonin syndrome 
will undoubtedly increase ( 33 ). 
 2.3 MDMA use in adolescents treated with SSRIs 
 Synthesized in 1910 and patented in 1912, MDMA was initially used as an adjunct 
to psychotherapy in the 1950s, but rapidly gained popularity as a recreational 
 “ club ” drug by the 1980s ( 34 ,  35 ). MDMA is an amphetamine derivative that ope-
rates via two different molecular mechanisms to increase central nervous system 
serotonin concentration. At a typical dose of 1.7 mg/kg, for example, MDMA pro-
motes serotonin neuronal efflux by directly influencing the reuptake transporter 
and by altering the chemical gradient that moves serotonin away from the inter-
cellular space. The reuptake transporter that MDMA affects to increases serotonin 
level is the same transporter through which SSRIs exert their pharmacological 
effects ( 36 ). Similar to SSRIs, MDMA is metabolized by and can inhibit CYP2D6. 
MDMA also follows a non-linear pharmocokinetic metabolism, causing the poten-
tial for a disproportionately large rise of MDMA plasma level from a small increase 
of an oral dose ( 37 ). 
 MDMA administration can cause a number of different acute medical compli-
cations, for example, arrhythmias, hypertension, metabolic abnormalities, cere-
bral hemorrhages, convulsions, and coma ( 38 ). Many of these symptoms overlap 
with those of serotonin syndrome, suggesting that it may be an undercounted and 
under-appreciated manifestation of ecstasy toxicity ( 39 ). Many ecstasy-abusing 
nightclub patrons display mild signs of the serotonin syndrome ( 40 ), and a smaller 
number develop very severe form of serotonergic over activity with grave medical 
complications ( 41 ). 
 Beyond acute toxicity, ecstasy has been extensively shown to leave long lasting 
impairment in crucial higher brain functions, such as cognition and emotional regu-
lation, directly correlated to the degree of use ( 42 ). A retrospective study of 66 univer-
sity age subjects who have been using ecstasy on regular basis were found to manifest 
impairment with both immediate and delayed recall memory ( 43 ).  Impulsivity and 
fixed delusional thought content have also been demonstrated in subjects who have 
underwent repeated MDMA exposed subjects ( 44 ,  45 ). 
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 2.4 Serotonin syndrome 
 The signs and symptoms of serotonin syndrome were initially described soon after 
the introduction of monoamine oxidase inhibitors (MAOIs) and  tricyclic antide-
pressants (TCAs) for treatment of depressive disorders, but were noted as a signi-
ficant public health problem secondary to ergot use in Europe as early as the 11th 
century ( 46 ). The effects observed in animal models included enhanced motor acti-
vity and excessive excitability, as well as signs of autonomic instability, and finally 
seizures ( 47 ). 
 Multiple experiments demonstrated a direct correlation between elevation of 
brain serotonin and increased death rates, after inhibition of MAO-A and MAO-B 
enzymes together, rather than independently, suggesting a serotonin concentra-
tion dependent mechanism of toxicity ( 48 ). Given the observations that the con-
centration of synaptic 5-HT is the main determinant of the severity of serotonin 
syndrome and the risk of morbidity and mortality, it is essential to gain a better 
understanding of the capacity of SSRIs and MDMA combination to produce seroto-
nin syndrome as predicted by drug mechanisms, including difference in potency 
and pharmacokinetics. 
 Serotonin syndrome can occur by several mechanisms, but excess activation 
of postsynaptic serotonin receptors appears necessary to produce serotonin syn-
drome ( 32 ). The diagnosis is always made on clinical grounds alone, and there 
is a broad range in severity and spectrum of symptoms observed. The syndrome 
is neither rare nor idiosyncratic but is a continuum of signs and symptoms from 
mild to severe, with mild cases potentially missed or misdiagnosed. An important 
consideration of serotonin syndrome in the context of  “ club drug ” ecstasy use, 
especially in the high temperature, and with excess muscle activity, mild cases 
can quickly convert into serious medical serotonergic emergencies ( 40 ,  48 ,  49 ). 
An animal model study has shown a strong correlation between drugs ’ ability to 
raise serotonin levels, measured via microdialysis studies in rats, and the clinical 
degree of serotonin toxicity, further strengthening the concept of serotonin syn-
drome as a heterogeneous clinical entity determined by extracellular serotonin 
concentration ( 33 ). 
 Viewing serotonin syndrome on a spectrum of clinical severity suggests that 
many patients who are exposed to two or more synergistic serotonin elevating 
compounds such as  SSRIs and MDMA might experience some degree of serotonin 
syndrome, and will most likely be misdiagnosed to overall clinicians ’ lack of fami-
liarity with the milder clinical picture of the syndrome ( 50 ). Health care providers 
must inform their  adolescent patients when initiating them on SSRIs, warning 
that if combined with ecstasy, vigilance of even most mild symptoms should be 
exercised. 
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 2.5  Ecstasy in combination with SSRI increasing the risk 
of serotonin syndrome 
 In theory, any drug, or combination of drugs, which has the net effect of increasing 
serotonin neurotransmission can produce serotonin syndrome ( 51 ). The serotonin 
syndrome has been reported after co-administration of SSRI and lithium, trazodone, 
dextromethorphan, for example ( 52 – 54 ). Even an antimicrobial agent Linezolid ( 55 ) 
has been implicated in producing serotonin syndrome in combination with other 
pro serotenergic drugs, a warning outlined by the FDA in 2001 ( 56 ). Opioids such as 
meperidine, fentanyl, and pentazocine can also precipitate the symptoms of seroto-
nin excess in patients being treated with  SSRIs ( 57 – 59 ). 
 Despite a clear need, basic and clinical science has done little to investigate a 
physiological interaction between SSRIs and MDMA. This omission is concerning 
given the powerful potential of both drugs to tremendously raise synaptic cleft sero-
tonin. Microdyalisis and measured lab data has shown that SSRIs are capable of very 
rapid, and large increases of serotonin (5-HT) concentration in animal brains ( 60 – 62 ), 
and that MDMA administration releases serotonin at various brain sites at a rate pos-
sibly above that produced by the SSRIs ( 63 ,  64 ). 
 The combined pharmacokinetic drug-drug interaction additionally ensues when 
SSRIs that are also potent CYP450 2D6 inhibitors reduce MDMA metabolism ( 65 ,  66 ). 
MDMA can conversely exert metabolic effects upon SSRIs metabolism. Paroxetine 
and fluoxetine administration, for example, has been shown to increase MDMA 
levels as much as 30% ( 67 ). Furthermore, a significant proportion of the world popu-
lation may be more susceptible to serotonin syndrome when exposed to both MDMA 
and SSRIs. For example, 8% of the Caucasian population poorly metabolize CYP450 
2D6-dependent drugs such as paroxetine and fluoxetine ( 68 ,  69 ). MDMA can also 
cause hepatic necrosis with reductions in liver function and subsequent drastic 
decreases in SSRI and MDMA clearance, increasing further the chance of developing 
serotonin syndrome ( 70 ). Moreover, increased body heat from muscle use during 
prolonged dancing and cooling dysregulation brought about by dehydration can sig-
nificantly increase body temperature, and through amplified thermodynamic pro-
cesses cause excessive serotonin release rate ( 71 ,  72 ). 
 The cultural patterns of SSRI and MDMA use provide grounds for further concern. 
For example, preemptive use of SSRI either as a function of misguided belief in its 
neuroprotective effects against MDMA, is popular and a potentially dangerous 
practice ( 40 ,  73 – 75 ). Other populations may consume higher doses of MDMA to over-
come SSRI ’ s ability to attenuate some of the euphoric  – but not toxic  – effects of the 
drug ( 67 ). This dangerous effect is further magnified by the non-linear pharmokine-
tics of MDMA metabolism that produces disproportionally higher plasma and inter-
cellular concentrations of the drug with increased dosages ( 76 ). A survey of 216 young 
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adults from the Sydney, Australia who had used Ecstasy at least once in the previous 
6 months reported 19 cases of purposeful concomitant use of antidepressant medi-
cation with MDMA. A considerable number of these subjects took the SSRI either to 
enhance Ecstasy high or to prevent neurotoxic effects. This sample was analyzed for 
neuropsychiatric symptoms and a large proportion was shown to display symptoms 
consistent with serotonin syndrome of various severity ( 77 ). 
 Ecstasy users worldwide are frequently polydrug users, often combining 
MDMA with other serotonin releasing stimulants, increasing the risk of seroto-
nin syndrome  development even further ( 78 – 81 ). A neurotransmitter analysis in 
animal models, for example, demonstrated that MDMA and methamphetamine 
administration elevates 5HT level greater than with MDMA alone ( 82 ). Moreover, 
chemical analysis of Ecstasy pills often show myriad of psychoactive chemical 
additives. For example, a sample of Ecstasy sold on the black market today contain 
amphetamine derivatives such as MDA, an even more powerful serotonin relea-
ser than MDMA itself ( 83 ). This and other amphetamine molecules contained by 
the Ecstasy pills can release large quantities of serotonin and in combination with 
 SSRIs cause serotonin syndrome ( 84 ,  85 ). A number of clinical reports analyzing 
MDMA related fatalities showed that most of pills contained amphetamines in 
addition to or instead of MDMA, and one of the case reports describes death from 
combination of fluoxetine and MDMA ( 86 ). 
 2.6 Conclusions 
 The message to the regulatory bodies, physicians and patients should be clear: 
Ecstasy, in combination with the widely-prescribed SSRIs antidepressant class, 
can create dangerously high levels of brain and plasma serotonin (5-HT) leading 
to the acute and sometimes lethal medical emergency known as serotonin syn-
drome. Given significant amount of psychiatric comorbidity among individuals 
with  substance use disorders, it should not be overlooked that teenagers treated 
with SSRIs may suffer from MDMA abuse as well. The behavior of people who use 
Ecstasy often leads to concomitant SSRI use either to augment its affect or to neu-
roprotect against MDMA toxicity. It is a responsibility of all health care providers, 
but especially those managing the pediatric population, to communicate to their 
patients this overlooked and increasingly relevant health danger. Providers who opt 
to prescribe SSRIs should ask their patients about drug use and attempt to gain col-
lateral information (for example, from parents or friends) to make sure that they do 
not prescribe SSRIs for an Ecstasy user. Increased awareness and activism among 
the health care community may produce labeled warnings at the government level, 
a step which would likely protect this vulnerable patient population from the risk 
of serotonin syndrome. 
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 3   Testosterone levels and  suicidal behavior 
 Leo  Sher 
 Several lines of evidence suggest that there is an association between testosterone 
and suicidal behavior. A link between testosterone and the neurobiology of suicidal 
behavior may be related to: a) a direct effect of testosterone on  suicidality via certain 
brain mechanisms; and/or b) a testosterone influence on aggression and, conse-
quently, suicidality; and/or c) a testosterone effect on  mood and, consequently, sui-
cidality; and/or d) a testosterone effect on cognition and, consequently, suicidality. 
At least one study has demonstrated a relation between high levels of testosterone 
and  suicide in young people. A significant number of studies suggest that high tes-
tosterone levels are associated with aggression in  adolescents and adults. Multiple 
lines of evidence indicate that aggression is associated with suicidal behavior. The 
effect of high testosterone levels on suicidality in adolescents and young adults may 
be mediated by testosterone-related elevated aggression. It is also possible that in 
young people, high testosterone levels are directly linked to suicidality via certain 
brain mechanisms. In older men, decreased testosterone levels are associated with 
depressive symptoms and reduced cognitive function while higher blood levels of tes-
tosterone are associated with better  mood and cognitive functioning.  Depression and 
reduced cognition are associated with suicidal behavior and may mediate the effect 
of decreased testosterone levels on suicidality. Therefore, it is reasonable to propose 
that suicidal behavior in adolescents and young adults is associated with high testos-
terone levels while suicidality in older men is associated with decreased testosterone 
secretion. 
 3.1 Introduction 
 Testosterone, a hormone from the androgen group, was isolated, synthesized and 
described in the 1930s by European researchers ( 1 ). The first research papers on 
the protein nature and on the isolation of androgen receptors from androgen target 
tissues were published at the end of the 1960s by several groups of investigators. 
Confirmation for a specific androgen-binding protein isolated from prostate tissue 
cytosol, was published by the research groups of Ian Mainwaring from the ICRF in 
London, Shutsung Liao at the University of Chicago and  É tienne- É mile Baulieu at the 
INSERM Institute in Kremlin-Bic ê tre in Paris ( 2 – 4 ). 
 Testosterone is produced from cholesterol in the Leydig cells in the testis. Testo-
sterone synthesis in the fetal human testis begins during the sixth week of gestation. 
Leydig cell differentiation and the initial early testosterone production in the fetal 
testis are independent of luteinizing hormone (LH) ( 5 – 7 ). During testis  development 
production of testosterone occurs under the influence of LH which is produced by 
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the pituitary gland. Synthesis and release of LH is regulated by the hypothalamus 
through gonadotropin-releasing hormone (GnRH) and inhibited by testosterone via 
a negative feedback loop ( 8 ). Testosterone is metabolized in some tissues to a more 
active metabolite, 5 α -dihydrotestosterone. 
 Testosterone is present in the blood as free (unbound) testosterone, albumin 
bound and sex hormone-binding globulin (SHGB)-bound testosterone ( 5 – 8 ). Testoste-
rone is a C19 steroid with an unsaturated bond between C-4 and C-5, a ketone group in 
C-3 and a hydroxyl group in the b position at C-17. It is mostly produced in the testes of 
males and the ovaries of females, although small amounts of testosterone are produ-
ced by the adrenal glands. Testosterone is found in mammals and other vertebrates. 
Blood testosterone levels are much greater in males than in females: an adult male 
body produces approximately ten-times more testosterone than an adult female body. 
Females are more sensitive to testosterone than males. Testosterone regulates male 
sexual  development and affects muscle strength, levels of erythrocytes, bone density, 
sense of well-being and sexual and reproductive function in both males and females. 
 SHBG concentrations may be decreased or increased in many frequently  observed 
medical conditions. In clinical practice, changes in SBHG are critically important to 
consider in the diagnosis of male hypogonadism. Because plasma total testosterone 
concentrations are affected by alterations in SHBG levels, precise measurements 
of free or bioavailable testosterone are necessary to evaluate the sufficiency of 
Leydig cell function, to clarify whether a patient is hypogonadal, and to monitor the 
testosterone replacement treatment in patients with changes in circulating SHBG 
concentrations. 
 3.2 Testosterone and  suicide 
 Multiple studies suggest that testosterone plays a role in the regulation of  mood and 
behavior. The research studies of the relationship between testosterone and  suicidal 
behavior produced variable results ( 9 – 14 ). Some ( 10 – 13 ) but not all ( 14 ,  15 ) investi-
gations of the relationship between testosterone and  suicidality found associations 
between testosterone and suicidal behavior. 
 Tripodianakis et  al compared plasma testosterone concentrations in men after 
a suicide attempt with testosterone levels in healthy men of the same age ( 10 ). The 
authors found that the suicide attempters had lower testosterone levels compared 
with controls, and that the attempters who used violent methods had lower plasma 
testosterone concentrations compared with the non-violent attempters. Markianos 
et  al examined plasma testosterone levels in a group of male psychiatric patients 
who had attempted to commit suicide by jumping, in a group of male subjects who 
were hospitalized after unintentionally falling from a high height and in healthy con-
trols ( 11 ). Both accident and suicide attempt patients had lower testosterone levels 
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 compared with the control group, and there was a trend towards lower testosterone 
levels in  suicide attempters compared with the accident group. We have recently exa-
mined whether there is a relation between plasma testosterone levels and clinical 
parameters in bipolar suicide attempters and found that testosterone levels positively 
correlated with the number of manic episodes and the number of suicide attempts 
( 12 ). Some other observations have shown that testosterone/anabolic androgenic ste-
roids may play a role in the pathophysiology of  suicidality ( 13 ). 
 A recent study found no difference between male suicide attempters and male 
controls with regard to plasma testosterone levels ( 14 ). A study of associations 
between neuroactive steroids and suicidality in  military veterans with  posttraumatic 
stress disorder also found no association between serum testosterone levels and a 
history of a suicide attempt ( 15 ). 
 Disappointment over rejections at attempts for sexual interactions has been 
cited several decades ago as an important trigger for suicide ( 16 ). Impending divorce, 
marital difficulties, threat of losing a love partner and rejection by a loved one were 
also regarded as motives for suicide for many years ( 17 ). It has been observed that 
rejection of sexual intercourse was often associated with male suicides and suicidal 
ideation ( 18 ). A link between testosterone and the neurobiology of  suicidal behavior 
may be related to ( 9 ): 
(a)  A direct effect of testosterone on suicidality via certain brain mechanisms; 
and/or 
(b)  A testosterone effect on aggression and, consequently, suicidality; and/or 
(c)  A testosterone effect on  mood and, consequently, suicidality; and/or 
(d)  A testosterone effect on cognition and, consequently, suicidality. 
 3.2.1 Testosterone and suicidal behavior in  adolescents and young adults 
 Suicide and testosterone/anabolic androgenic steroids 
 At least one study has demonstrated a relation between high levels of testosterone and 
suicide in young people ( 19 ). Twenty-nine subjects (17 suicides, 12 sudden deaths) in 
the ages 23 – 45  years were included in the study. Analysis indicated no significant 
difference in ages between the two groups of subjects (suicide M  =  33.35 year, sudden 
death M  =  35.67 year). There was a significant difference in the mean testosterone 
level (p   <   0.007) between victims of suicide (M  =  376.41  ÷ 183.64 ng/ml) and victims of 
sudden death (M  =  241.83  ÷ 117.3 ng/ml). 
 Eight cases of suicide, in 21- to 33-year-old males, with a history of current or 
recent use of anabolic androgenic steroids (AAS) have been described in a case series 
report ( 20 ). Five suicides were committed during current use of AAS, and two fol-
lowing 2 and 6 months after AAS withdrawal. The authors suggested that long-term 
use of AAS may contribute to completed suicide in predisposed persons. 
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 A possible role of aggression 
 A significant number of studies suggest that high testosterone levels are associated 
with aggression ( 9 ). It has been shown that violent persons have higher plasma, saliva 
and CSF testosterone levels compared to non-violent controls ( 21 – 23 ). For example, in 
a study of impulsive offenders with alcoholism and antisocial personality disorder, 
higher CSF testosterone levels were observed compared to healthy controls ( 24 ). The 
authors proposed that high CSF testosterone levels may be associated with aggres-
siveness or interpersonal violence. In the same paper, the authors reviewed the sci-
entific literature on the link of testosterone to aggression in humans, and proposed 
that both a repetitive pattern of aggressive behavior starting early in life, and a repe-
titive pattern of aggressive behavior under the effect of  alcohol are associated with 
increased levels of testosterone. Researchers have observed that individuals receiving 
testosterone are more likely to have an aggressive reaction to perceived threats than 
subjects receiving placebo ( 25 – 27 ). 
 Fluctuations of testosterone concentration may be associated with aggression 
and  mood changes in  adolescents ( 28 – 30 ). Salivary testosterone concentrations were 
evaluated in 40 children, aged 7 – 14  years (37 boys and three girls), with a history 
of aggressive behaviors and an association between higher testosterone levels and 
aggressive behaviors was observed ( 29 ). In another study of adolescent males, higher 
testosterone levels were associated with provoked verbal and physical aggression, a 
finding suggesting that reactive impulsive aggression is correlated with higher tes-
tosterone levels ( 30 ). Fifty-eight healthy 15 – 17-year-old boys, public school students 
participated in this study. A high level of testosterone led to an amplified readiness 
to respond energetically and forcefully to provocations and threats. Testosterone also 
had an indirect and less strong effect on another aggression dimension: high plasma 
concentrations of testosterone made the boys less patient and more irritable, which 
in turn intensified their predisposition to engage in aggressive-destructive behavior. 
Therefore, aggression may mediate the effect of high testosterone levels on  suicidal 
behavior in adolescents and young adults. Not all studies have observed differences 
in testosterone levels between aggressive and non-aggressive boys ( 31 ). A study of 
4 – 10 year olds found no evidence of a relationship between testosterone levels and 
aggressive behaviors. This indicated that such a relationship may be non-existent in 
prepubertal children. 
 Animal models have contributed important data regarding the effects of ana-
bolic androgenic steroid (AAS) use on aggression ( 32 ,  33 ). For example, studies in 
rodents confirmed that exposure to the AASs testosterone and nandrolone increa-
ses aggression. A side effect of AAS use reported in humans is  “ roid rage, ” a state 
of unselective and unprovoked aggression. It has also been observed that pubertal 
rats receiving AASs respond appropriately to social cues and they are more aggres-
sive toward intact males than are castrates. Testosterone-treated male rats are most 
aggressive in their home cage. Probably, adolescent AAS exposure may increase 
aggressive behaviors. 
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 Some authors have postulated that there are substantial similarities between 
aggression against the self and aggression against others, based on the clinical and 
epidemiological observations that some  suicide attempters may share personality 
traits with violent criminals ( 34 ). We have also observed an association between 
aggression and  suicidal behavior in our studies ( 35 ,  36 ). For example, we have obser-
ved that a history of suicide attempt in  bipolar disorder is associated with lifetime 
aggressive traits ( 35 ). We have also shown that the higher prevalence of suicide 
attempters among depressed patients with a history of alcoholism compared to 
depressed patients without a history of alcoholism was related to higher aggression 
scores in the group with alcoholism ( 36 ). 
 In summary, high testosterone levels may be associated with suicidal behavior in 
 adolescents and young adults. This effect of testosterone on  suicidality in adolescents 
and young adults may be mediated by testosterone-related elevated aggression. It is 
also possible that in young people, high testosterone levels are directly linked to sui-
cidality via certain brain mechanisms. 
 3.2.2 Testosterone and suicidal behavior in older men 
 Testosterone deficiency or hypotestosteronemia is a commonly known hormonal 
change associated with male aging ( 37 – 39 ). The prevalence of testosterone deficiency 
may be as high as 30% in men aged 40 – 79 years ( 40 ,  41 ). In up to 12% of affected 
men, hypotestosteronemia can be associated with clinical symptoms ( 40 ,  41 ). Age-
related plasma testosterone decrease is a result of different biological alterations such 
as primary structural gonadal damage, age-related degenerative changes of the pitui-
tary gland, insufficiencies of the neurohypothalamic system, and primary peripheral 
metabolic abnormalities such as the age-associated increase in the concentration of 
serum SHBG, with a consequent decrease in free testosterone ( 39 ). In the aging man, 
there is about a 1 – 2% decrease of total testosterone levels per year with a more rapid 
drop in free testosterone levels because of a concomitant increase in SHBG with aging. 
Because of this gradual decrease in testosterone levels the androgen deficiency of the 
elderly man is defined as partial androgen deficiency of the aging male (PADAM) or 
late onset hypogonadism (LOH). 
 Symptoms of testosterone deficiency in men include sexual symptoms (such as 
reduced erectile function and diminished libido), decreased muscle and increased fat 
mass, and reduced bone density among others. It is unclear whether aging is to be 
considered as the only variable linked to age-related testosterone decrease. Various 
aspects such as genetic factors, chronic diseases, medications, obesity, and the life-
style may affect the testosterone metabolism ( 37 ,  42 – 44 ). 
 Decreased testosterone levels are associated with depressive symptoms, poor 
cognitive function and Alzheimer ’ s disease ( 9 ,  45 – 48 ). Increased incidence of hypo-
gonadism is observed in men with major  depression ( 9 ,  47 ). Depressed men frequently 
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have low plasma or serum testosterone ( 9 ,  48 ). Testosterone has mood-enhancing 
properties and antidepressant effects in men ( 9 ,  49 – 51 ). Testosterone replacement 
effectively improves  mood. Testosterone users sometimes develop manic or hypo-
manic symptoms during testosterone use and depressive symptoms during testoste-
rone withdrawal ( 52 – 55 ). In rodents, testosterone has antidepressant effects in aged 
male mice and protective effects against the  development of  depression-like beha-
viors in rats ( 56 ,  57 ). A recent study found a testosterone-dependent regulation of 
hippocampal ERK2 expression which suggests that ERK2 signaling within the dentate 
gyrus area of the hippocampus is a vital mediator of the antidepressant properties of 
testosterone ( 58 ). 
 Experimental studies suggest that testosterone has neuroprotective effects ( 59 ). 
However, intervention clinical research on elderly men showed that testosterone 
replacement had a beneficial influence on mood only if men had clearly subnormal 
testosterone levels ( 60 ). It is important note that sexual dysfunction can have a major 
effect on the quality of life and emotional well-being ( 61 ,  62 ). The results of placebo-
controlled randomized studies of the effects of testosterone on the quality of life and 
depressed mood have been inconsistent and often the quality of life as assessed by 
different questionnaires did not improve significantly ( 63 ). 
 Higher blood levels of testosterone are associated with better cognitive functio-
ning, especially in older men ( 45 ,  46 ). For example, greater serum levels of testos-
terone late in life predict a lower risk of future Alzheimer ’ s disease development in 
older men ( 45 ). Higher blood testosterone levels are associated with better visuospa-
tial abilities, semantic memory and episodic memory in men, with larger positive 
effect with increasing age ( 46 ). 
 Both depression and cognitive impairment are associated with  suicidal beha-
vior ( 64 – 67 ). At least 60% of individuals who commit  suicide suffer from depression. 
Hence, depression and cognitive impairment may mediate the effect of testosterone 
deficiency on  suicidality in older men. This suggests that the treatment of hypogo-
nadism in older men may improve mood and cognition, and consequently, reduce 
suicidal behavior. 
 3.3 Conclusions 
 In summary, it is reasonable to propose that suicidal behavior in young men is asso-
ciated with high testosterone levels while suicidality in older men is associated with 
decreased testosterone secretion. This indicates that the effects of testosterone on 
suicidality in men should be studied separately in young and old individuals. It is 
likely that plasma and salivary testosterone assays can help in identifying pediatric 
and adult patients that would respond best to certain treatments. Further studies of 
the role of testosterone in the pathophysiology of psychiatric disorders and suicidal 
behavior are merited. 
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 4   Buprenorphine in the treatment of  non-suicidal 
self-injury 
 Lisa J.  Norelli ,  Howard S.  Smith ,  Leo  Sher and 
 Tracey A.  Blackwood 
 A global public health problem, non-suicidal self-injury (NSSI) is highly prevalent in 
both males and females, and tends to first occur in  adolescence. NSSI is correlated 
with a history of  childhood trauma, and with a variety of developmental and psych-
iatric disorders. NSSI is associated with increased risk of morbidity and premature 
death from  suicide, accidents, and natural causes. Current treatment approaches are 
inadequate for a substantial number of people. Converging evidence for opioid system 
dysregulation in individuals with NSSI make this a promising area of investigation for 
more effective treatments. The pharmacological profile of buprenorphine, a potent 
 μ -opioid partial agonist and  κ -opioid antagonist, suggests that it may be beneficial. 
In this chapter we describe the successful treatment of severe NSSI with buprenor-
phine in six individuals, followed by discussion and further recommendations. 
 4.1  Introduction 
 Non-suicidal self-injury (NSSI) is an important public health problem with first onset 
commonly occurring during adolescence ( 1 ,  2 ). Individuals who engage in NSSI have 
double the expected all-cause mortality rate and are at increased risk of death from 
suicide, accidents, and natural causes compared to the general population ( 1 – 5 ). NSSI 
behaviors co-occur with a variety of psychiatric disorders, are associated with high 
health care utilization, and greater  functional impairment ( 6 – 10 ). Concerns regarding 
clinical representation and management of NSSI have prompted the proposed inclusion 
of NSSI Disorder into the Diagnostic and Statistical Manual of Mental Disorders ( 11 ). 
NSSI is generally defined as the intentional, direct destruction of body tissue without 
suicidal intent, and for purposes that are not socially sanctioned ( 12 ). Occurring 
equally often in men and women, the estimated prevalence is 4% in the general popu-
lation and 21% in clinical samples ( 9 ,  10 ,  13 ,  14 ). A recent literature review of NSSI 
among  adolescents indicates a lifetime prevalence range from 13 – 23% ( 1 ). About 70% 
of adolescents engaging in NSSI reported a lifetime history of suicide attempt and 
55% reported multiple attempts ( 15 ). 
 There is a clear medical need for new drugs that would expand the options for 
treating NSSI, especially for the substantial number of patients with NSSI who do 
not respond to existing treatments. Endogenous opioids have been implicated in the 
expression of NSSI in psychiatric and developmental disorders, including borderline 
personality disorder, major  depression, mental retardation, and autism ( 16 – 18 ). There 
are observations suggesting that opioid antagonists can be used for the treatment 
of NSSI in patients with borderline personality disorder, depression,  anxiety, 
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developmental, and other psychiatric disorders ( 19 – 23 ). Multiple reports demonstrate 
that naloxone or naltrexone is useful in diminishing NSSI ( 19 – 23 ). For example, in 
an open study, six of seven female patients with NSSI treated with naltrexone had 
complete remission of NSSI, and the seventh had significant reduction of NSSI ( 23 ). 
The use of opioid antagonists for the treatment of NSSI may lead to tapering or dis-
continuation of antipsychotics and  mood stabilizers that have significant metabolic 
and other side effects. 
 Examining the efficacy of buprenorphine for the treatment of NSSI is probably a 
promising avenue of research.  Buprenorphine is available and used safely for the treat-
ment of physical dependence to opioids ( 24 ) but has received virtually no attention for 
the use in psychiatric disorders in non-dependent populations. As a  μ -opioid recep-
tor partial agonist and  κ -opioid antagonist, buprenorphine has been studied exten-
sively in animal models of drug reward, physical dependence, and analgesia ( 25 – 27 ). 
The pharmacological profile of buprenorphine as a potent  μ -opioid partial agonist 
and  κ -opioid antagonist suggests that buprenorphine may produce beneficial effects 
on patients with NSSI. Taken together, the existing data suggest that there is a foun-
dation for considering the use of buprenorphine for new indications in psychiatric 
disorders including NSSI. In this paper, we report on six cases of successful treatment 
of NSSI with buprenorphine. 
 4.2  Clinical approach 
 This is a descriptive case series of six long-term psychiatric inpatients with severe, 
treatment refractory NSSI whose usual treatment was augmented with buprenor-
phine. The Institutional Review Boards of the Capital District Psychiatric Center 
and the New York State Office of Mental Health approved the case series protocol. 
The treating psychiatrist independently initiated treatment and adjusted the dose of 
buprenorphine according to response, and confirmed the participant ’ s capacity to 
consent to the case report. Data was collected from patient interview and a retros-
pective review of the medical record. Three outcomes were examined: all reported 
incidents (e.g., assault, self injury, falls, elopement, etc.), NSSI episodes, and seclu-
sion and restraint (S/R) episodes. For the purpose of statistical analysis, a comparison 
was made between the average monthly number of overall incidents, NSSI episodes, 
and S/R episodes without buprenorphine treatment, and the average number with 
buprenorphine treatment. A t-test comparison was used to determine the significance 
of the differences between these two data sets. t-Values were calculated for the overall 
combined data from all patients, and for each individual patient in the study. The 
t-value was calculated by dividing the overall increase or decrease from the base-
line over the standard deviation of post treatment data divided by the square root of 
the number of post treatment data points. 
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 4.3  Case descriptions 
 All six individuals are characterized by having long histories of severe repetitive NSSI 
behaviors refractory to more conventional approaches resulting in severe  functional 
impairment. Persistent NSSI has been a major barrier to attainment of satisfactory 
quality of life, wellness, school and occupational achievements, and has resulted in 
lengthy, numerous psychiatric hospitalizations since childhood. Invariably there has 
been a history of severe and recurrent interpersonal trauma and violence in child-
hood, including physical, sexual and emotional abuse and neglect. The complexity of 
their psychological and social issues and the inadequate integration of social medi-
cine approaches leads to them amassing multiple, disparate psychiatric diagnoses, 
and being exposed to numerous medications of limited benefit. Every participant 
has had suboptimal response to various combinations of medications (e.g., antipsy-
chotic medications including clozapine, antidepressants,  mood stabilizers including 
lithium, valproate, and carbamazepine, benzodiazepines, alpha-adrenergic and beta-
blockers, and the opiate antagonist naltrexone), and individual and group treatment 
(e.g., cognitive behavioral therapy, dialectic behavioral therapy, behavior contracts, 
social skills training, expressive therapy, wellness, recreation, and psychoeducation). 
Basic patient characteristics are summarized in  Table 4.1 . Buprenorphine treatment 
results for each patient and in aggregate regarding the three outcome measures are 
presented in  Table 4.2 . 
 Case 1 
 This 34-year-old single, unemployed woman has a history of childhood neglect, 
physical abuse, sexual abuse and chronic institutionalization. Serious disruptive 
and self-destructive behavior began at the age of 4, leading to her first psychiatric 
 Table 4.1:  Patient characteristics 
 Case  Age at 
trial 
(years) 








 Time period  % days 
inpatient 
 1  34  F  6  O, A, Ca, H  17  1992 – 2012  100 
 2  29  F  15  O, A, Ca, B  22  2008 – 2012  ** 
 3  29  F  12  O, A, Ca, Co, D  23  1985 – 2012  40 
 4  26  M  10  A, Ca  14  2003 – 2012  70 
 5  24  M  16  A  13  1994 – 2012  50 
 6  40  M  17  A, Ca, Co  4  1988 – 2012  62 
 O: opioid, A:  alcohol, Ca: cannabis, Co: cocaine, D: diphenhydramine, H: hallucinogen, 
B: benzodiazepine abuse or dependence. 
 * Information available from medical record lacked details from some earlier admissions. 
 ** Most recent hospital stay  =  429 days, details of other inpatient data unavailable. 
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hospitalization at age 6. Intermittent inpatient admissions throughout childhood 
were followed by the current continuous hospitalization that began in early  adole-
scence. Repetitive, impulsive NSSI and aggressive behavior towards others have been 
prominent features of her presentation throughout. Over the course of mental health 
treatment, she has received various diagnoses including: attachment disorder of 
childhood, oppositional defiant disorder, pervasive developmental disorder,  major 
depressive disorder without psychotic features, chronic  post traumatic stress disorder 
( PTSD), impulse control disorder, borderline personality disorder, personality disorder 
not otherwise specified with narcissistic and borderline traits, and  substance abuse 
( alcohol,  cannabis, opioids, and hallucinogens). She has claimed to have deliberately 
engaged in some NSSI for the purpose of being treated with opioid pain medications. 
NSSI includes foreign body ingestion, foreign body insertion into body orifices or 
under the skin, cutting, banging head or limbs, refusing urgent medical care, deli-
berate disruption of blood glucose control, reopening wounds, and provoking others 
to assault her. Her NSSI has led to serious harm and several life threatening injuries, 
including a nearly fatal intake of disinfectant solution, and esophageal perforation 
from foreign body ingestion. Medical history is significant for obesity (BMI  =  40), 
juvenile onset insulin dependent diabetes mellitus, and gastroesophogeal reflux 
disorder. There is an unconfirmed history of head injury at age of 11 due to exiting 
a moving vehicle. Laboratory screening and evaluation for chronic inflammation, 
heavy metal levels, vitamin B12, folate, endocrine disorders and chronic infectious 
diseases were negative. Computed tomography of the head at age 24 showed mild cor-
tical atrophy. Due to ongoing life disruptions, she never finished high school. Psycho-
logical testing scores are as follows: Weschler Intelligence Scale for Children, revised 
 Table 4.2:  Total number of reported incidents, NSSI episodes, and S/R episodes with and without 
buprenorphine treatment for individual cases and all cases combined 
 Case  Total incidents 
(average per 
month) 
 p-value  NSSI episodes 
(average per 
month) 




  − BUP  + BUP   − BUP  + BUP   − BUP  + BUP  
 1  6.80  3.11   <  0.01  3.13  1.44   <  0.01  17.00  4.11   <  0.01 
 2  2.67  1.69   <  0.05  1.33  0.77   <  0.05  2.33  0.92   <  0.05 
 3  1.78  0.29   <  0.01  1.67  0.00  *  0.67  0.00  * 
 4  2.33  1.45  ns  2.00  1.36  ns  2.77  0.64   <  0.01 
 5  8.00  3.00  **  4.00  2.00  **  4.00  0.00  ** 
 6  1.20  1.57  ns  0.80  0.86  ns  1.20  0.29   <  0.01 
 Combined  3.43  1.71   <  0.01  2.04  0.96   <  0.01  6.27  1.21   <  0.01 
 − BUP: without  buprenorphine treatment,  + BUP: with buprenorphine treatment. 
 NSSI:  non-suicidal self-injury, S/R: emergency seclusion or restraint, ns: non-signifi cant. 
 * unable to calculate p-value due to zero NSSI and S/R episodes during active treatment period. 
 ** unable to calculate p-value due to short duration of active treatment. 
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(WISC-R) full scale 95, verbal 95, performance 96 (age 11), full scale 71, verbal 79, 
performance 67 (age 13), and Weschler Adult Intelligence Scale, revised (WAIS-R) full 
scale 75, verbal 76, performance 77 (age 18). A neuropsychiatry consult was obtained 
when the patient was 28-year-old which concluded that there was no compelling evi-
dence a traumatic brain injury, and attributed the patient ’ s intellectual decline and 
mild cortical atrophy to a process of neurodevelopmental failure in the context of 
impaired attachment and chronic institutionalization. 
 A  buprenorphine trial was started with the aim to reduce  mood dysregulation, 
impulsive NSSI, aggression towards others, and S/R episodes. The patient received 
buprenorphine/naltrexone 2/0.5 mg sublingually for 2 days, then 1/0.25 mg sublingu-
ally for 15 days, reduced because of dizziness. After 17 days of treatment, the patient 
refused the medication despite rapid subjective and objective improvement in the 
target symptoms. She stopped treatment due to abandonment fears; staff complimen-
ted her on rapid and marked improvement and she believed she would lose their close 
attention and care. After 18 days without medication she admitted she felt better with 
the treatment and commenced a second trial of buprenorphine/naltrexone 1/0.25 mg 
daily for 30 days. Buprenorphine alone was continued thereafter with a dose range 
of 0.5 – 3 mg daily. Overall, 15 months of treatment without buprenorphine was com-
pared to nine months of buprenorphine treatment data. The patient had a significant 
reduction in total incidents, NSSI, and S/R episodes while taking buprenorphine. 
Subjectively the patient reported a marked improvement in her chronically dysphoric 
 mood and stated:  “ I ’ m less depressed. I still have impulsive thoughts but I don ’ t feel 
like I need to act on them, I can focus on other things I like to do. ” 
 Case 2 
 This 29-year-old single, unemployed woman has a history of childhood physical, 
sexual and emotional abuse beginning at age 6. She was repeatedly sexually and phy-
sically abused in subsequent  adolescent and adult relationships. She has had over 
20 psychiatric hospitalizations beginning in  adolescence for depressed mood, NSSI, 
and suicidal thoughts or attempts. NSSI includes cutting, high-risk sexual activity, 
and overdosing on medication. She reports that cutting and drug use have helped to 
relieve emotional distress. Over the course of psychiatric treatment, diagnoses have 
included: chronic  PTSD, depressive disorder not otherwise specified, nicotine depen-
dence, other  substance abuse (heroin,  cannabis, benzodiazepines, and  alcohol), 
and borderline personality disorder. She completed 1 year of college. Psychological 
testing with the WAIS-IV indicated a full scale IQ of 80. Medical history is significant 
for hypothyroidism, obesity (BMI  =  48), obstructive sleep apnea, gastroesophogeal 
reflux disease, irritable bowel syndrome, asthma, and chronic pain secondary to 
degenerative disc disease. 
 She was started on buprenorphine and titrated up to 2  mg twice daily. Three 
months of pre-treatment data was compared to 3 months of buprenorphine treat-
ment data. Buprenorphine treatment was associated with significant decreases in 
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total number of incidents, NSSI, and S/R episodes. Sustained improvement in NSSI 
and  mood facilitated discharge to a community residence and outpatient treat-
ment after 14 months of inpatient care. As an outpatient, she has continued to take 
 buprenorphine/naltrexone daily and has not used drugs or  alcohol. At the time of this 
writing, she has spent 3 months in the community, and has had no readmissions. She 
has reported mild mood fluctuations, occasional  “ voices ” telling her to harm herself 
that she can generally ignore, and has remained free of NSSI behaviors. The patient 
feels strongly that the buprenorphine/naltrexone has helped significantly with her 
mood and NSSI, and reports that prior to using the medication she was having urges 
to self-harm on a daily basis. 
 Case 3 
 This 29-year-old single, unemployed woman has a history of neglect, severe emotio-
nal, sexual, and physical abuse (including kidnapping, physical and sexual torture), 
during childhood. She has a history of over 15 instances of residential treatment and 
psychiatric hospitalizations beginning at age 12 for NSSI,  suicidal behavior,  depres-
sion, aggression towards others, and abuse of drugs including alcohol, opiates,  can-
nabis, and diphenhydramine. NSSI behaviors include cutting, biting, banging her 
head, dropping heavy objects on extremities, overuse of medications,  substance 
abuse, and starving herself. As an  adolescent she was diagnosed with anorexia and 
bulimia, conduct disorder, attention deficit hyperactivity disorder, and  PTSD. Additi-
onal diagnoses have included  major depressive disorder, dissociative disorder, schizo 
affective disorder, and borderline personality disorder. Developmental history is sig-
nificant for premature birth and developmental delays in speech and motor function-
ing. Medical history is significant for obesity (BMI  =  46), GERD, and asthma. She has 
bilateral 70% sensorineural hearing loss due to physical abuse in childhood. Psycho-
logical testing with the Wechsler Abbreviated Scale of Intelligence (WASI) showed a 
full-scale IQ score of 95. On the Repeatable Battery for the Assessment of Neuropsy-
chological Status (RBANS), a screening measure of cognitive ability, her performance 
across the different domains of functioning was within normal limits. 
 She was initially treated with buprenorphine 2 mg twice daily but complained of 
fatigue. The fatigue abated with a reduction to 2 mg daily that was maintained until 
discharge. Nine months of data without buprenorphine treatment were compared to 
7 months with treatment. While taking buprenorphine, there was a significant decre-
ase in total incidents. There were no episodes of NSSI or S/R while she received the 
medication. She was discharged from hospital after 4 months of sustained response. 
Despite the dramatic decrease in  impulsivity and NSSI observed and reported by the 
patient, her outpatient treatment provider had concerns about substance abuse and 
the lack of evidence in the literature and discontinued buprenorphine. Although 
details are limited, once buprenorphine was stopped the patient restarted engaging 
in NSSI and has had multiple psychiatric admissions. The potential rapid, marked, 
and sustained benefit observed in these highly symptomatic individuals should be 
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weighed against legitimate concerns regarding  substance abuse. Such risks could be 
mitigated with careful monitoring. 
 Case 4 
 This 26-year-old single, unemployed man with a history of psychiatric treatment 
since age 8 has had multiple inpatient admissions since age 10 for severe NSSI and 
aggressive behaviors. His NSSI consists of severe cutting, biting and head banging. 
During childhood he repeatedly witnessed physical violence between his parents 
and was sexually abused. The patient has had a variety of diagnoses including atten-
tion deficit hyperactivity disorder (ADHD), conduct disorder,  PTSD, schizo affective 
disorder, borderline personality disorder, and borderline intellectual functioning. 
Medical history is significant for asthma, non-insulin dependent diabetes mellitus, 
and obesity (BMI  =  41). He attended special education classes from 4th through 8th 
grade, then frequent hospitalizations and severe behavioral disturbances interrupted 
formal schooling. Intelligence is estimated to be in the low average range. Despite 
some decrease in  impulsivity with clozapine and antidepressant medications, the 
patient continued to have severe impulsive NSSI,  emotional dysregulation, and disso-
ciative symptoms. The impulsivity and NSSI did not respond to several long trials of 
naltrexone in doses up to 100 mg daily. 
 The patient received  buprenorphine up to a dose of 2 mg three times daily. Thirteen 
months of data without buprenorphine treatment was compared to eleven months 
with buprenorphine treatment. Treatment was associated with a non-significant 
decrease in total incidents, NSSI episodes, and a significant reduction in S/R episo-
des. The patient reports that the medication  “ helps my mood and I donʼt want to hurt 
myself as much when I take it. ” 
 Case 5 
 This is a 24-year-old single, unemployed man with a history of psychiatric treatment 
since age 15. Since  adolescence he has had over 20 hospitalizations for  depression, 
 suicide attempts, and difficulty regulating intense emotions and impulses. He has 
frequently engaged in NSSI, mainly severe cutting, in response to intense anger, agi-
tation, hopelessness, and interpersonal conflicts. He has denied a history of physical 
or sexual trauma, but reports being verbally bullied in school because of his appea-
rance. Psychiatric diagnoses have included ADHD, bulimia nervosa, depressive dis-
order not otherwise specified,  alcohol abuse,  cannabis abuse, nicotine dependence, 
and borderline personality disorder. Psychological testing with the WAIS-IV revealed 
a full scale IQ in the average range. Medical history is significant for hypothyroidism 
and vitamin D deficiency. 
 The patient took buprenorphine for 14 days and discontinued it due to nausea. 
Despite the short course of treatment there was a rapid reduction in impulses to self-
harm, and a decrease in incidents and restraint episodes that persisted for at least 
12  months after buprenorphine discontinuation. This allowed him to benefit more 
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fully from treatment, attain the skills and stability that facilitated discharge to the 
community. The patient stated:  “ When I took the medication the idea of cutting 
myself made me sick, I donʼt want to do it anymore. ” 
 Case 6 
 This 40-year-old single man has a history of psychiatric hospitalizations since late 
 adolescence and has been almost continuously hospitalized for over a decade for 
severe  depression,  emotional dysregulation, NSSI, and  suicide attempts. NSSI beha-
viors include cutting, piercing, burning, as well as engaging in drug use and high-risk 
sexual activity. There is a history of repetitive intrafamilial childhood sexual abuse. 
Developmental milestones were reported to be normal, however he attended special 
education classes starting in fifth grade. Psychological testing places his full scale 
IQ in the borderline intellectual range. Psychiatric diagnoses have included  major 
depressive disorder,  PTSD, paraphilia, polysubstance dependence ( alcohol,  cannabis, 
and cocaine), borderline personality disorder, and borderline intellectual functio-
ning. Medical history is significant for hyperlipidemia, vitamin D deficiency, obesity 
(BMI  =  30), and andontia. 
 He was treated with 2 – 4  mg of  buprenorphine daily. Data from ten months 
without treatment were compared to seven months during which the patient received 
buprenorphine. With treatment, the total number of incidents and NSSI slightly incre-
ased but the change was not significant. Episodes of S/R decreased significantly. The 
patient reports  “ I ’ m not sure if it helps or not, maybe sometimes. ” 
 4.4  Discussion 
 Buprenorphine is a partial  μ -opioid receptor agonist with high affinity but low intrin-
sic activity. In addition to its effects on the  μ receptor, buprenorphine also displays 
antagonistic activity at the  δ -and  κ - opioid receptors. In addition, buprenorphine also 
possesses affinity for the nociceptin/orphanin FQ (ORL1) receptor ( 28 ,  29 ). Due to its 
partial agonist properties with limited intrinsic efficacy, buprenorphine can behave 
as a pure  μ agonist, yet it can also antagonize the actions of morphine and other high-
efficacy  μ agonists ( 30 ,  31 ), i.e., it can have either  μ -agonistic or  μ -antagonistic effects, 
depending on the particular conditions under which it is evaluated. Buprenorphine 
exhibits antinociceptive effects when a low intensity stimulus (e.g., 50 ° C water) is 
used but not when a high intensity stimulus (e.g., 55 ° C water) is used in a tail with-
drawal test in rhesus monkeys ( 32 ). Buprenorphine can also attenuate the antinoci-
ceptive effects of higher efficacy agonists, e.g., alfentanil when it does not itself have 
antinocicpetion actions ( 32 ,  33 ). Buprenorphine displays an inverted U-shaped dose-
response function, e.g., in analgesia ( 34 ,  35 ). The actions of buprenorphine may vary 
significantly depending on the environment/circumstances/conditions surrounding 
its administration and the dose administered. 
 4.5  Conclusions   53
 Although  buprenorphine penetrates rapidly into the brain, it associates only 
slowly with the  μ receptor, and its dissociation rate is exceptionally long ( 36 ,  37 ). If a 
 μ -opioid receptor antagonist is injected once buprenorphine already has had time to 
associate with the receptor and produce its effects, these effects cannot or can only 
partially be antagonized by naloxone or naltrexone ( 34 ,  38 ). Buprenorphine has a 
remarkably long duration of action. Behavioral effects of single drug administration 
of buprenorphine have been found to persist even after several (up to 10) days in 
different procedures and paradigms in rats and monkeys ( 39 – 45 ). Dynorphin is asso-
ciated with  κ receptor activity and appears to be involved in chemical-induced and 
pressure-induced pain perception ( 46 ). Steiner and Gerfen ( 47 ) suggest that the spe-
cific function of dynorphin and enkephalin is to dampen excessive activation of pro-
jection neurons by dopamine and other neurotransmitters, and have proposed that 
dynorphin may be involved in the mechanisms of behavioral sensitization. The roles 
of beta-endorphin, met-enkephalin, and dynorphin may differ in NSSI because they 
play different roles in pain perception and behavior ( 16 ). If the  endogenous opioid 
system is central to repetitive NSSI, then treatment with a long-acting opioid antago-
nist could block the reward of enhanced endogenous opioids caused by such behavi-
ors and subsequently lead to their extinction ( 16 ). 
 Limitations should be noted: 
(a) this is not a controlled trial, there is no placebo group to compare and it is limited 
to a small sample of only six patients; 
(b) there are multiple confounding variables: 
1. a concomitant use of psychotropic medications; 
2. it is possible that patients treated with buprenorphine received more atten-
tion from the treatment team; and 
3. it is possible that there was a selection bias when these six patients were 
chosen for the buprenorphine trial. 
 4.5  Conclusions 
 Mounting evidence suggests that the endogenous system may be involved in NSSI. 
Thus, opioid receptor modulators may be able to contribute to beneficial alterations 
in NSSI. These six case reports demonstrate very impressive results of buprenorphine 
treatment for NSSI. This preliminary data reveals that buprenorphine may conceiva-
bly be an alternative therapeutic option to treat NSSI. Buprenorphine is abusable in 
part due to its opioid agonist effects, especially by individuals who are not physi-
cally addicted to opioids. This may lead to opposition towards the study and use of 
buprenorphine as a treatment for NSSI. However, buprenorphine is not likely a first-
line candidate for the treatment of NSSI, but rather reserved for circumstances of NSSI 
that are refractory to traditional therapy. The balance of evidence appears to be in 
favor of future studies of the role of buprenorphine in the management of NSSI. More 
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research including observational and pilot studies, and randomized controlled trials 
is needed to examine the usefulness of  buprenorphine in the treatment of NSSI and to 
develop effective treatment regimens. 
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 Section II:  Depression 

 5   Antidepressants for  major depressive disorder 
in children and  adolescents 
 Mar í a Dolores  Picouto and  Mar í a Dolores  Braquehais 
 Major depressive disorder (MDD) is a frequent condition among children and, espe-
cially, among adolescents, although its clinical presentation usually differs from that 
of adults. It is associated with other diagnoses and with an increased morbidity and 
mortality. However, MDD in this population remains under-recognized and under-
treated. Antidepressants (ATD) are chosen when psychoeducational, psychosocial 
and/or psychotherapeutic approaches have failed. They are generally used in severe 
cases, always in combination with psychological treatments. The objective of this 
work is to discuss the role of ATD for child and adolescent MDD. We focus on the 
recommendations of the most cited and updated clinical guidelines and discuss some 
controversial aspects with regard to efficacy and safety issues raised based on the 
information obtained from clinical trials. Finally, we offer some practical recommen-
dations for clinicians. All these findings also pose some doubt on the hypothesis of 
MDD as a homogeneous phenomenon during the human life cycle. 
 5.1  Introduction 
 Depressive disorders are frequent conditions among children and adolescents. In the 
US, the 12-month prevalence for depressive disorders is said to be 3.7%, 2.7% for  major 
depressive disorder (MDD), and 1.0% for dysthymia ( 1 ). Five to ten percent of child-
ren and adolescents suffer subsyndromal symptoms of  depression that, nonetheless, 
cause significant impairment ( 2 ). During childhood, prevalence is similar in men and 
females; however, after puberty it becomes twice as frequent in women compared to 
men. The risk of MDD begins to rise since early  adolescence. In community samples, 
the median age of onset of MDD is 13 years and the cumulative incidence by age 18 is 
18 – 20% ( 3 ,  4 ). 
 Child and adolescent depression is a serious disorder associated with a high-risk 
of  suicidality, recurrence, and chronicity ( 5 – 7 ). MDD is usually related to significant 
deleterious effects on the child ’ s normal  development, familial and/or academic 
functioning. Besides, it is frequently comorbid with other diagnostic conditions such 
as  substance use disorders, personality disorders and/or behavioral disorders ( 8 ), 
and it increases suicidal risk; in fact, as many as 50% of adolescents with suicidal 
behaviors meet diagnostic criteria for MDD ( 9 – 12 ). 
 From the phenomenological point of view, the clinical presentation of depres-
sion among adolescents, but especially among children, differs from that of adult 
patients. Therefore, although depression is not uncommon in both populations, it is 
not presented with the same signs and symptoms as during adulthood. The clinical 
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description of MDD in current diagnostic manuals should be modified when approa-
ching children and  adolescents; it is frequent to observe behavioral or physical mani-
festations instead of cognitive or emotional well defined complaints. Moreover, there 
are significant differences with regard to treatment responses in adolescents compa-
red to adults (psychotherapy proves to be more effective than ATD), and depression 
in these years is more associated with some specific, emotional stressful conditions 
compared to adults. These clinical aspects should be always taken into account and 
pose some doubt on the hypothesis of MDD as a homogeneous phenomenon during 
the life cycle. 
 In any case, effective treatment of  depression in this population may reduce its 
negative impact on psychosocial functioning and may lessen the risk of other adverse 
psychiatric sequelae. Unfortunately, only 25% of children and adolescents suffering 
MDD are estimated to be properly diagnosed and treated ( 13 ,  14 ). Preventive efforts 
should focus on early detection of first and recurrent episodes of depression as well 
as in identifying risk factors for MDD and/or its comorbid conditions. 
 The aim of this work is to discuss the role of antidepressants (ATD) when treating 
children and adolescents who suffer MDD. We focus on the recommendations of the 
most cited and updated clinical guidelines and address some critical aspects with 
regard to efficacy and security issues raised after the information obtained from clini-
cal trials. Finally, we offer some practical recommendations for clinicians. 
 5.2 Treating child and adolescent depression: an overview 
 Antidepressants are one out of a wide range of interventions in children and adole-
scent with MDD though they are not considered its first line treatment. All clinical 
guidelines recommend that first line interventions should include brief psychoedu-
cational treatment (education about depressive signs and symptoms, sleep hygiene, 
 anxiety management, and regular exercise) as well as psychosocial approaches 
(addressing recent family or peer group conflicts, problem solving strategies, and 
attention to parental psychopathology, particularly depression). Recent studies esti-
mate that these interventions can achieve a significant improvement in a substantial 
proportion of depressed patients, and not only in mild MDD but also in up to 20% of 
adolescents with severe MDD ( 15 ,  16 ). 
 When this basic routine care is not enough, or in children and adolescents with 
moderate to severe, chronic or recurrent depression, risk of  suicidality or signifi-
cant psychosocial impairment, patients should be referred to a specialist care clinic 
( 3 ,  17 ). In those cases, the next therapeutic option should be psychotherapy (brief 
family therapy, interpersonal therapy or cognitive behavioral therapy). In cases of 
severe MDD or when previous approaches have failed, antidepressants (ATD) should 
be considered, along with the combination/augmentation psychotherapy (especially 
cognitive behavioral therapy) the next therapeutic option. 
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 Antidepressant-only treatment is not recommended with the exception of extre-
mely severely depressed patients whose condition unable them to go into psychothe-
rapy ( 3 ). However, as soon as the adolescent is amenable to psychotherapy, combination 
therapy (i.e., ATD and psychotherapy) should be provided. Therefore, there is a 
limited role for ATD when treating children and  adolescent MDD. In cases where ATD 
are indicated, they should generally be combined with psychotherapy. 
 With regard to which ATD drugs should be used, only fluoxetine and escitalo-
pram have been approved by the US Food and Drug Administration (FDA) for acute 
and maintenance treatment of MDD in this population. These restrictions are due 
to the limited success of ATD versus placebo in most randomized controlled trials 
(RCT) conducted in the last decades, particularly in children below the age of 12 years 
( 18 – 20 ). However, response rates are usually high, ranging from 30% to 60% ( 21 – 23 ), 
and similar to those observed with ATD treatment for obsessive-compulsive disorder 
(OCD) or non-OCD  anxiety disorders ( 24 ). Nevertheless, the main difference is that 
the response to placebo is higher for  youths with MDD (50%) when compared with 
placebo response for those with OCD and non-OCD anxiety disorders (32% and 39%, 
respectively) ( 25 ). In a recently meta-analysis, Bridge et al ( 25 ) concluded that a higher 
rate of patients taking placebo who responded to treatment was associated to multi-
site trials, milder  depression at baseline and younger participants. This fact suggests 
that pharmacotherapy studies of pediatric depression that include only patients over 
12 years of age, with at least moderately-severe depression, may be more informative 
and efficient than most recent clinical trials. 
 5.3 Efficacy 
 Available studies assessing the efficacy of ATD in children and adolescents are scarce, 
compared to those in adult samples, and of variable quality. Some have design, metho-
dological and/or analytical problems that make cross-comparisons difficult (i.e., dif-
ferent psychometric evaluations, variability of outcomes, etc.). In fact, most primary 
outcomes usually refer to changes in clinical rather than in functional scales. In addi-
tion, secondary outcomes are generally subjective measurements (e.g., changes in the 
Clinical Global Impression Scale,  CGI). Some studies have failed to demonstrate signi-
ficant efficacy in primary outcomes but have suggested significant differences versus 
placebo in secondary outcomes ( 23 ). Moreover, significant changes in symptom scales 
do not always correlate with relevant clinical changes and studies are often too short 
to assess functional changes, long-term efficacy, and relapse rates ( 20 ). 
 Some well-designed placebo-controlled trials, like the Treatment for Adolescent 
Depression Study ( TADS) funded by the National Institute of Mental Health (NIMH), 
have tried to evaluate the short and longer-term effectiveness as well as the durability 
of  SSRIs. In particular, the TADS evaluated the efficacy of four treatments among ado-
lescents with MDD, at 12 and 36 weeks with a 5-year naturalistic follow-up: clinical 
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management with fluoxetine, cognitive-behavioral therapy ( CBT), combined fluoxe-
tine plus CBT, and clinical management with placebo ( 26 ). However, even in such a 
well-designed clinical trial, restrictive inclusion criteria make it difficult to generalize 
their results to  “ real-world ” populations. Patients seen in clinical practice are likely 
to be in worse conditions than those who meet RCT because severe symptoms, comor-
bidity, and/or acute  suicidality are often exclusion criteria for RCT ( 27 ). Therefore, it 
is unclear how the group of severely depressed patients (in fact, those who should 
receive ATD) will respond to them. 
 Meta-analyses deal with other difficulties and limitations. Outcome measures 
may not meet inclusion criteria and, therefore, keep excluded form the meta-analysis. 
Negative studies are also less likely to be published and hence are not available. 
 Despite all these methodological limitations, available data suggest that efficacy 
is not uniform among antidepressants. In any case, selective serotonin reuptake inhi-
bitors ( SSRIs), as a group, have proven to be the most effective agents in reducing 
depressive symptoms in children over 12 years. 
 In a meta-analysis conducted by Bridge et  al ( 24 ), that included 15 RCT asses-
sing effectiveness of SSRIs in child and  adolescent  depression, the estimated Number 
Needed to Treat to Benefit (NNTB) for the group was 10, meaning that for every ten 
 youths given an SSRIs instead of placebo for the treatment of depressive symptoms, 
one would experience improvement. 
 According to the 2009 Cochrane Systematic Review ( 27 ), there are marked diffe-
rences in efficacy among SSRIs. Clinical trials with fluoxetine have provided the most 
consistent evidences of effectiveness reducing depression symptoms in both children 
and adolescents ( 21 ,  28 ,  29 ). The Treatment for Adolescent Depression Study ( TADS) 
estimated that the NNTB with fluoxetine was 4 – 6 ( 30 ).  Fluoxetine is the only SSRIs 
that has proven efficacy in children younger than 12 years. It also has the best risk/
benefit ratio ( 18 ,  31 ,  32 ). These optimal results with fluoxetine may be due to the fact 
that some of these trials included a placebo washout and selected more persistently 
depressed patients resulting in a lower placebo response ( 21 ,  33 ). With regard to 
other SSRIs, paroxetine has not proven to be better than placebo and has a worse 
risk/benefit ratio compared to other ATD. There are no consistent data about the risk/
benefit ratio of escitalopram, citalopram, and sertraline ( 21 ,  33 ). 
 With regard to tricyclic ATD, in 2010 a Cochrane Review on the use of tricyclic 
drugs for depression in children and adolescents, that included 13 trials, did not find 
an overall improvement of tricyclic ATD versus placebo for children and adolescents 
( 34 ). However, it suggested some benefit of ATD versus placebo in reducing symptoms 
among adolescents. The effect was moderate and of questionable clinical importance. 
Besides, treatment with tricyclic antidepressant caused more vertigo, orthostatic 
hypotension, tremor, and dry mouth than did placebo. Its use is not supported by 
clinical guidelines due to the uncomfortable side-effects/benefit profile ( 17 ). 
 There has also been great debate over the efficacy of psychological versus phar-
macological approaches in adolescent MDD. The TADS assessed efficacy of fluoxetine, 
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 CBT, and the combination of both, compared to placebo. After 12 weeks of treatment, 
CBT alone was less effective than the combination of fluoxetine with CBT or fluoxetine 
alone, with response rates of 71% for combined fluoxetine plus CBT, 61% for fluoxetine 
alone, 43% for CBT alone and 34% for placebo ( 26 ). However, by week 36, the three 
active treatments converged (response rates: combined fluoxetine plus CBT 86%, fluo-
xetine 81%, CBT 81%) ( 35 ) suggesting that combined treatment with fluoxetine and CBT 
significantly accelerates response in  adolescent moderate MDD relative to CBT alone or 
fluoxetine alone. Consequently, clinical guidelines recommend combined treatment as 
the treatment of choice for moderate-severe  major depressive disorder in adolescents 
( 3 ,  17 ). However, evidence from other studies does not support this recommendation. The 
Adolescent Depression Antidepressants and Psychotherapy Trial ( ADAPT), a pragmatic 
randomized controlled superiority trial that compared the efficacy of a combination of 
fluoxetine and CBT together with clinical care versus fluoxetine and clinical care alone in 
adolescents with moderate to severe major  depression, found no evidence of an improved 
outcome by week 28 with the combination treatment ( 15 ). Melvin et al. ( 36 ) did not find 
the combination of CBT and sertraline to be superior to either treatment alone. Contrary 
to the  TADS, in this trial participants receiving CBT alone showed a better acute treatment 
response than those treated with sertraline alone (odds ratio  =  6.86; 95% CI, 1.12 – 41.82). 
 Published studies of sufficient design to produce meaningful results on managing 
resistant MDD in  adolescence are also very limited in number. Nonetheless, mention 
should be made to the Treatment of Resistant Depression in Adolescents ( TORDIA) 
randomized controlled trial. It evaluated the relative efficacy of four treatments stra-
tegies in adolescents who continued to have depression despite an adequate initial 
treatment with an SSRI and that had never received CBT. Treatment strategies were: 
1) switch to a second, different SSRI (paroxetine, fluoxetine or citalopram), 2) switch 
to a different SSRI plus CBT, 3) switch to venlafaxine, or 4) switch to venlafaxine plus 
CBT. The combination of CBT and a switch to another antidepressant showed a higher 
response rate than a medication switch alone (54.8%; 95% CI, 47% – 62% vs. 40.5%; 
95% CI 33% – 48%). Contrary to the authors ’ hypotheses, switching to venlafaxine 
was not superior to switching to another SSRI, but associated more adverse effects. 
Evidence from this trial supports the choice of another SSRI over venlafaxine as a 
second-line antidepressant in the treatment of MDD in adolescence ( 37 ). 
 5.4 Safety 
 Efficacy and safety issues with regard to ATD in children and adolescents have been 
under debate for the last three decades. Since the early 1990s, questions concerning 
a possible ATD induced suicidal ideation and behavior ( suicidality) in children and 
adolescents, based on uncontrolled clinical observations, were raised. These concerns 
reappeared in 2003 based on data from some RCT. The British Committee on Safety of 
Medicines (CSM) decided to undertake a comparison of published and unpublished data 
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on the risk and benefits of these drugs for the treatment of child and  adolescent MDD. 
The meta-analysis concluded that, although available published data at that point sug-
gested a positive risk-benefit profile for some  SSRIs, the risk could outweigh the benefits 
of these drugs (except for fluoxetine) when unpublished data were considered ( 32 ). That 
is the reason why, in June 2003, the British Medicines and Healthcare Products Regula-
tory Agency (MHRA) released a statement contraindicating the use of paroxetine and 
venlafaxine in this context. Soon, this contraindication was extended to the use of all 
SSRIs other than fluoxetine for patients younger than 18 years with depressive illness. 
 Simultaneously, the FDA commissioned its review of 24 randomized placebo-
controlled trials assessing use of ATDs in the treatment MDD,  anxiety disorders and 
of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents ( 38 ). It 
concluded that the use of antidepressant drugs in that population was associated with 
a modestly increased risk of  suicidality with an overall risk ratio for SSRIs in  depres-
sion trials of 1.66 (95% CI, 1.02 – 2.68). There were no completed suicides in any of these 
trials among the approximately 4,600 patients evaluated, but this sample was not large 
enough to detect such an effect. After that report, the FDA modified antidepressant 
drug labeling to include a boxed warning of this risk. However, the FDA did not con-
traindicate any of the antidepressant drugs for pediatric use. Instead, it encouraged 
prescribers to balance this risk with the clinical need and to closely monitor patients as 
a way of managing the risk of suicidality. An update was published in 2007, including 
data from 2 large clinical trials of pediatric MDD ( 22 ,  24 ,  26 ). It reported a 3% (95% 
CI, 2 – 4%) pooled absolute rate of suicidal ideation/ suicide attempt in antidepressant-
treated MDD participants and 2% (95% CI, 1 – 2%) in those receiving placebo. The 
pooled risk difference was 1% (95% CI,  − 0.1 – 2%) estimating that the Number Needed 
to Harm (NNT) was 112 ( 24 ). Therefore, they found evidence of an overall small but 
increased risk of treatment-emergent suicidal ideation/ suicide attempt. 
 Conclusions from these meta-analyses keep in line with a recent Cochrane review 
on this topic where, after analyzing data from 12 RCT, there was a reported evidence of 
an increase risk of suicidality for those prescribed SSRIs (R 2  = 1.80, 95% CI, 1.19 – 2.72) ( 27 ). 
 However, the  TADS study that included a systematic assessment of suicidality, 
found that suicidal ideation improved in the four treatment arms, with greatest impro-
vement in the combined treatment of fluoxetine and  CBT ( 31 ). However, at the 12-weeks 
assessment, patients with fluoxetine had more suicide-related events than those with 
placebo. Results of this large RCT support that suicidality in pediatric MDD, rather 
than increasing, would decrease with every treatment of MDD but to a lesser extend 
when treated with SSRIs only, compared to combined treatment of fluoxetine and CBT 
or CBT alone. It also suggests that CBT can offer some protection against suicidal risk. 
But other studies on the same topic such as  ADAPT do not confirm this findings ( 15 ). 
 There are other data that seem inconsistent with a role for ATD drugs in inducing 
suicidality in pediatric patients. Introduction of selective serotonin reuptake inhibi-
tors (SSRIs) may have played a crucial role in the reduction of  adolescent  suicide rates 
since the 1990s ( 39 ). In fact, between 2003 and 2005  youth  suicide rates increased 
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following the reduction of  SSRIs prescription after issuing of public health warnings 
about the possible association between antidepressant use and  suicide ideation ( 40 ). 
 In summary, there is enough evidence to support the need of monitoring  suicide 
risk in children and  adolescents in treatment with SSRIs. Some authors support the 
hypothesis of a causative link between ATD and  suicide risk in this population but, at 
the same time, others underline that, when the number of SSRI prescriptions decre-
ased after public health warnings, suicide rates in adolescents increased. Therefore, 
some confounding factors may intervene in the relation between  suicidal behavior 
and SSRIs that are not taken into account. 
 5.5 Clinical recommendations 
 In  Table 5.1 we summarize some clinical recommendations when treating children 
and  adolescents with antidepressants. 
 Table 5.1:  Clinical recommendations 
 Before 
prescription 
 –  Make sure the indication for ATD treatment is correct 
 –  Provide complete information to the patient and the family with regard to 
the objectives, side effects and expected benefits of the treatment 
 –  Evaluate and measure the clinical and functional status with validated 
scales such as the  CDRS-R (Children  Depression Rating Scale Revised), 
C-GAS (Children Global Assessment Scale) or the  GAF (Global Assessment of 
Functioning) 
 –  Note previous symptomatology such as suicidal ideation and/or  anxiety or 
depressive symptoms 
 –  Evaluate previous potential interactions between the ATD and other drugs 
 Choose the ATD  –  First line treatment:  Fluoxetine 
 –  Second line treatment: escitalopram, sertraline, or citalopram 
 –  Not recommended: paroxetine, venlafaxine, tricyclics, MAOIs, Hypericum 
 Dosage  –  Start with a lower dose (fluoxetine 5 – 10 mg per day, escitalopram 5 mg per 
day, citalopram 5 – 10 mg per day and/or sertraline 25 mg per day) 
 –  Start slow and go slow 
 –  In  adolescents the final dose may be similar to that of adults 
 Follow-up  –  Evaluate depressive symptoms every 4 weeks and wait untill 6 – 8 weeks to 
see if the ATD has been effective 
 –  Evaluate global functioning. If clinical improvement is not followed by better 
functioning, presence of comorbid conditions should be taken into account 
 –  Check the patient ’ s and family ’ s adherence to the treatment 
 –  Register any side effect and explore suicidal ideation (weekly during the first 
4 weeks of treatment) 
 Duration of 
treatment 
 –  Keep the effective dosage at least 6 – 12 months after remission 
 –  During this maintenance phase, follow-up visits should take place at least 
once every 1 – 3 months 
 Treatment 
withdrawal 
 –  Chose a low stressful period (e.g., vacation) 
 –  Go slow (descent in 6 – 12 weeks) 
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 5.6  Conclusions 
 Clinical recommendations about ATD use during childhood and  adolescence are 
limited due to the biases on the information about their efficacy and security obtained 
from RCT. Moreover, differences in the clinical presentation of MDD in these populati-
ons as well as in their treatment responses compared to adults challenge the hypothe-
sis of MDD as a homogeneous phenomenon during the human life span. 
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 6   Suicide prevention in depressed  adolescents 
 Timothy R.  Rice and  Leo  Sher 
 Adolescent  depression is a highly prevalent disorder with significant morbidity and 
 suicide mortality. It is simultaneously highly responsive to treatment. Adolescents 
wish to discuss depression with their providers. Providers routinely receive oppor-
tunities to do so. These characteristics of prevalence, morbidity, mortality, respon-
siveness, and accessibility make adolescent depression an excellent target of care. 
However, most health care trainees and professionals report low confidence in caring 
for adolescent depression. As a caregiver community we fare poorly in routine matters 
of assessment and management of adolescent depression. All health care professi-
ons are trained within a medical model. The conceptualization of adolescent depres-
sion and  suicidality within the medical model may increase provider confidence and 
performance. Epidemiology and neurobiology are presented with emphasis in this 
review. Legal concerns also affect health care professionals. Providers may deviate 
from evidence-based medicine owing to anxieties that the identification and treat-
ment of depression may induce suicide and consequent legal culpability. A review of 
the historical context and relevant outcome trials concerning the increased risk of sui-
cidality in depressed adolescents treated with selective-serotonin reuptake inhibitors 
( SSRIs) may increase provider comfort. Increased didactic and experiential training 
improve provider performance. Proven models are presented, and the testable hypo-
thesis is presented that education which incorporates the views of this article will 
produce the best care for depressed adolescents. 
 6.1  Introduction 
 Adolescent depression is relevant to a wide range health care trainees and providers. 
Depression affects about 1 in 6 American female adolescents and 1 in 12 males ( 1 ). 
At least a quarter of these adolescents will go on to have problems with their 
families and friends, half will drop out of school, and a third will end up invol-
ved with the police or court system ( 2 ). Over half of these adolescents will attempt 
suicide ( 3 ). 
 Providers have both the means and the opportunity to address this disorder. Ado-
lescent depression is highly responsive to treatment, and struggling adolescents want 
care. Help with handling stress and depression are two of the top three topics most 
frequently requested of their internists, pediatricians, and family practitioners ( 4 ). 
Unfortunately, clinicians are not sufficiently trained about adolescent depres-
sion and suicidality. Primary care providers correctly identify less than a fourth of 
 youth with a depressive or  anxiety disorder ( 5 ). Whereas 64% and 53% of primary 
care providers report routinely screening for adolescent depression and suicidal 
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thoughts, respectively, only 16% and 7% of their patients reported receiving these 
services at their last visit ( 6 ). The inability to detect depressed  adolescents hinders 
 suicide screening practices and prevention. If providers fail to identify at-risk 
depressed  youth, the sole opportunity for  suicide prevention may be missed. 
 Evidence suggests that trainees ( 7 ) and professionals ( 8 ) are interested in 
receiving additional training. In one study, over half (64%) of American pediatric 
residency directors report perceiving that their program’s training about  depres-
sion and suicide was inadequate ( 9 ). Individuals and institutions both appear 
open to targeted training. Self-perception as sufficiently trained translates into 
improved real-world practice ( 7 ). 
 All health care professions are trained within a medical model. Training may 
improve provider confidence by emphasizing the epidemiology and neurobiology to 
place the disorder within a familiar conceptual context. Patient suicide is a highly 
emotionally-charged fear of most providers. This fear is complicated by recent con-
cerns that effective depression treatment may induce  suicidality in adolescents. Legal 
factors compound the fear ( 10 ). Training should highlight the historical outcome trial 
data behind these concerns to advance rational processing and care. 
 We believe that the emphasis of the medical model is crucial to provider edu-
cation in the care for adolescent depression and suicide. Effective training methods 
have been empirically proven. We review the data to convey models by which these 
two concepts may be effectively taught. 
 6.2   Adolescence as a phase of human  development 
 The importance of care provision in adolescence begins with an understan-
ding of its biological context. Brain changes during adolescence are not just an 
extension of childhood development. Adolescence marks a new developmental 
phase ( 11 ). 
 Grossly anatomic, histologic, cellular, enzymatic, and neurochemical changes 
proceed in the brain. Non-linear and region-specific reductions in cortical volume 
occur ( 12 ). These are accompanied by increases in white matter density, increa-
ses in axonal diameter and myelination, and synaptic pruning ( 13 ). Developmen-
tal transformations in neuronal circuitry are associated with  prefrontal cortex 
under-recruitment in adolescents compared to adults ( 11 ). Amygdala activation 
in response to emotional cues is exaggerated as compared to both children and 
adults. A net effect of increased dopaminergic input to the prefrontal cortex (PFC) 
and a subsequent shift in the balance between subcortical and cortical dopa-
minergic drive dominance occurs ( 11 ). The increased capacity for understanding 
and responding to social, emotional, and interpersonal cues characteristic of 
adolescence results from these changes to biochemical foundation of adolescent 
experience. 
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 6.3   Depression in  adolescence 
 The importance of the problem 
 The high prevalence, morbidity, mortality, accessibility, and treatment respon-
siveness of  adolescent depression make it an ideal target of care. Treatment of 
depression additionally addresses comorbid psychiatric disorders. These include 
 substance use disorders, eating disorders, and delinquent behavior. These comor-
bidities are often poorly responsive to psychopharmacological treatment, and the 
treatment of comorbid depression is often the first-line treatment for these disorders. 
Depression serves as the gateway for addressing a wide range of psychiatric disorders 
in adolescence. 
 Depression is also highly comorbid with multiple problems prevalent in primary 
care that are typically characterized as non-psychiatric. These include problems such 
as obesity ( 14 ) and smoking ( 15 ). All providers are sensitively aware to the significant 
morbidity and mortality of these conditions, including diabetes and cancer. Effective 
treatment of adolescent depression is a crucial skill for all providers to improve multiple 
domains of adolescent health. 
 Epidemiology and prevalence 
 Depression surges in adolescence. The prevalence of depression is approximately 1% 
in children ( 16 ). This raises to a point prevalence of 5% and a lifetime prevalence as 
high as 25% by late adolescence ( 17 ). Concurrent with this surge is the  development 
of a gender gap. Depression afflicts female and male children equally. In contrast, 
a 2:1 female predominance develops during adolescence. This ratio persists through 
adulthood and is associated with pubertal status rather than chronologic age ( 18 ). 
 Psychiatric comorbidity is present in as much as two thirds  youth with depres-
sion ( 19 ,  20 ). Two or more disorders are comorbid in about one in eight. Frequent 
disorders are dysthymia and  anxiety disorders, disruptive disorders, and substance 
use disorders ( 19 ). Depression is additionally a risk factor for persisting conditions 
traditionally characterized as non-psychiatric, such as obesity ( 21 ). Comorbidity con-
versely influences depression: the greater the comorbidity, the greater the likelihood 
of parental conflict,  suicide attempts, and  functional impairment ( 22 ). 
 6.3.1  Neurobiology of adolescent depression 
 Biological context renders vulnerability to depression. Two key neuronal circuits are 
implicated in models of adolescent depression. Limbic system circuitry which con-
nects the ventral prefrontal cortex and the amygdala, hippocampus, and HPA axis is 
overactivated in depression ( 23 ). In contrast, reward system circuitry connecting the 
prefrontal cortex, striatum, and ventral tegmental dopamine neurons is underactive 
in depression ( 24 ,  25 ). 
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 Brain-Derived Neurotrophic Factor (BDNF), a growth factor which supports 
neuronal survival and synaptic plasticity, is implicated in the  development of such 
circuits ( 26 ) and thus in  adolescent  depression ( 27 ). It is also associated with  suici-
dal behavior ( 28 ). Adolescent-onset depression is associated with a specific geno-
type in this growth factor ( 29 ,  30 ). Sex hormones also influence neuronal circuit 
organization ( 31 ). The surge of female depression at puberty suggests that sex hor-
mones may contribute to organizational configurations associated with depression. 
Sex hormones may also exert direct effects upon circuit components; for example, 
estrogen promotes stress-induced  prefrontal cortex dysfunction ( 32 ). 
 The serotonergic system is the target of the first line treatment for both adolescent 
and adult depression. Dysfunction in this system has long been implicated in depres-
sion. Particular genetic variants within the system are associated with depression when 
exposed to stressors. With over 50 dedicated studies and several meta-analyses ( 33 ), 
the best researched genetic variant is the serotonin transporter allele (5-HTTLPR) ( 34 ). 
The strongest evidence for this association may exist in the adolescent population 
when gender and additional genetic variants are accounted for ( 35 ). 
 Models of adolescent depression extend beyond the brain. The hypothalamic-
pituitary-adrenal (HPA) axis shows dysfunction in adolescent depression ( 36 ). 
Chronically elevated corticosteroid concentrations impair serotonergic neurotransmis-
sion ( 37 ). Transversely, serotnonergic abnormalities impair HPA function: Newborns 
with 5-HTTLPR portray higher HPA activation in response to stress ( 38 ). In the future 
measures of the HPA axis functionality may serve as a biomarker for depression. 
 6.3.2  Treatment 
 Depression is a heterogenous disorder for which guidelines recommend a stratified 
treatment approach ( 39 ). Mild depression may be initially treated through education, 
support, and case management related to school and family stressors. More com-
plicated depression, or mild depression which does not resolve through the above 
interventions within 4 – 6 weeks, merit structured psychotherapy and/or medication 
management. 
 Multiple psychotherapy modalities have been applied to adolescent depres-
sion. No modality has ever been shown to be significantly more efficacious for the 
depressed adolescents as a whole. Though about 80% of published trials have tested 
Cognitive Behavioral Therapy ( CBT) and a sizeable evidence basis has accumulated 
supporting this modality ( 40 ), the process of choosing a psychotherapy should be 
tailored to the individual adolescent. For example, pronounced family conflict may 
indicate family-based therapy (FBT), or social isolation may indicate interpersonal 
therapy (IPT). A comprehensive review of psychotherapy for adolescent depression is 
beyond the scope of this paper, though particular therapies will be referenced where 
applicable. 
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 Medication management may be used alone or in combination with psychotherapy. 
To date, only fluoxetine (age 8 + ) and escitalopram (age 12 + ) are FDA-approved for the 
treatment of  adolescent  depression. The historical context, as has been reviewed else-
where ( 41 ,  42 ), merits summary. 
 Though fluoxetine was first commercially available in December of 1987, it was 
not until 1997 that the first positive randomized controlled trial in children and ado-
lescents with MDD was published ( 43 ). Practice parameters which recommended the 
Selective Serotonin Reuptake Inhibitors ( SSRIs) as initial therapy were published the 
following year ( 44 ), and within 4 years the use of antidepressants at the index visit 
of a new episode of depression in adolescents jumped from 5% to nearly 40% ( 45 ). 
The FDA approved fluoxetine for the treatment of childhood depression in 2003 fol-
lowing a second positive randomized trial ( 43 ). Escitalopram would follow in 2009 
( 46 ). 
 Two pivotal trials were published in the interim. These trials were the Treat-
ment for Adolescents with Depression Study ( TADS) ( 47 ) and the Treatment of 
SSRI-Resistant Depression in Adolescents ( TORDIA) ( 48 ). TADS found no signi-
ficant difference between response rates to  CBT, fluoxetine treatment, and com-
bined fluoxetine treatment with CBT in a group of depressed adolescents rando-
mized to these treatments after 24 weeks of treatment. Benefits were sustained at 
1-year follow-up ( 49 ). However, combination treatment showed the shortest time 
to response, was most cost-effective ( 50 ), and had significant impact upon  suici-
dality rates. TORDIA studied depressed adolescents who had failed a prior SSRI 
and were randomized to switch to either a second SSRI, a second SSRI with CBT, 
venlafaxine, or venlafaxine combined with CBT. TORDIA found higher response 
rates with combination therapy. This may reflect the greater prevalence of comor-
bid environmental and psychological conditions in this SSRI-resistant population 
as compared to that of the TADS. A greater incidence of adverse effects in venlafa-
xine treatment cemented combination therapy with an SSRI as the current optimal 
treatment strategy for depressed adolescents. 
 6.3.3  Suicidality in depressed adolescents 
 The importance of the problem 
 The preceding discussions of depression morbidity and treatment response have neg-
lected its association with suicidality. Suicidality is a broad term which encompasses 
suicidal ideation,  suicide attempts, and suicide. Suicidal ideation and attempts are 
both risk factors for  adolescent suicide ( 51 ). Suicide is the ultimate consequence of 
adolescent depression. Repercussions extend beyond the individual. Affected fami-
lies will experience defined responses including psychological shock, self-reproach, 
social stigmatization ( 52 ). Suicide additionally clusters, and the death of one adole-
scent can propagate without adequate postvention care ( 53 ). 
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 Epidemiology and prevalence 
 Suicide is the third leading cause of  adolescent death in the United States ( 54 ). Glo-
bally, it ranks second ( 55 ). For every American  adolescent suicide there are 100 to 200 
suicide attempts ( 56 ). About 1 in 15 American high school students reported having 
attempted suicide in 2009, and over twice that many (13.8%) reported having suicidal 
thoughts within the previous year ( 57 ). 
 The adolescent suicide rate slowly increased through most of the 20th 
century ( 58 ). In the US, a  youth rate of just under 10 per 100,000 in 1970 had 
increased to almost 15 per 100,000 by the mid 1990s. Subsequently, the suicide 
rate began to decline. In the US, the rate returned to just over 10 per 100,000 by 
the early 2000s ( 59 ); similar declines occurred in Australia ( 60 ), Canada ( 61 ), and 
select European countries ( 62 ). American data now show that this decline was 
temporary ( 63 ). 
 Age, sex, and country-specific variables effect suicide rates and methodology. 
Despite an increased frequency of suicide attempts among female adolescents, 
male suicide rates are generally two to six times higher than that of females ( 64 ). 
This difference is attributable to the greater average lethality of male  suicidal 
behavior. Males are more likely to use firearms than their female peers; in the US 
and in some European countries such as Switzerland where firearm ownership is 
high, suicide by firearm is significant (57% and 27% of suicides, respectively) ( 65 ). 
Hanging is another highly prevalent and lethal method which is less amenable 
to  means restriction prevention measures; new data show its incidence may be 
increasing ( 66 ). 
 Relation of adolescent  suicidality to  depression and comorbid conditions 
 Depression is the strongest risk factor for suicide among the adolescent psychiatric 
disorders. Depression raises the risk of a suicide attempt by a factor of 12 in boys and 
15 in girls ( 67 ). Over half of suicide victims are diagnosed with depression at the time 
of death ( 68 ). 
 Comorbid disorders, including  anxiety, substance use, and disruptive behavior 
disorders, all increase suicidality risk ( 22 ). The  alcohol use disorders, particularly in 
older male adolescents, impart significant risk of suicidality. Comorbidity between 
depression and alcohol abuse is as high as 73% in adolescent populations ( 69 ). 
Alcohol use predisposes to  impulsivity and aggression. Both these traits contribute 
to elevated suicide risk. 
 The comorbidity of Post-Traumatic Stress Disorder and  Major Depressive Dis-
order is also significant. Neurobiological evidence suggests that some or all indi-
viduals with this comorbidity have a separate psychobiological condition which is 
termed Post-Traumatic  Mood Disorder (PTMD) ( 70 ). Adolescents with PTMD have 
a higher risk of suicidality than expected with separate diagnoses of either PTMD 
or  PTSD ( 71 ). 
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 6.3.4   Relation of  adolescent  suicidality to medications (SSRIs) which are 
frequently used to treat  depression 
 Reports of increased suicidality in individuals treated with  SSRIs began shortly after 
fluoxetine ’ s commercial introduction in 1987 ( 72 ,  73 ). In adults, the first pooled data 
analysis of suicidality found a decreased risk of suicidality in adults treated with 
 SSRIs ( 74 ). A subsequent 2003 review found no statistically significant risk increase 
or decrease among treated adults ( 75 ). 
 The same year saw the first FDA approval of an SSRI for childhood depression. 
A series of reports in The Guardian, as well as two BBC television documentaries, prece-
ded a warning from the British Department of Health that a review of both unpublished 
and published proprietary data found an increased risk of suicidality in adolescents 
treated with paroxetine. The FDA convened a review of 24 controlled clinical trials of 
nine antidepressants which found a 4% risk of suicidality with SSRI compared to a 2% 
risk with placebo ( 76 ). The well-known  “ black box ” warning ensued in October of 2004. 
Its age range of concern was subsequently (May 2007) extended to young adults up to 
24 years of age. Increased media attention and governmental actions globally, inclu-
ding a similar precautionary notice from the Japanese Ministry of Health, followed ( 77 ). 
 Following the black box warning, prescription rates fell ( 78 ). A simultaneous 
increase in the national  suicide rate among adolescents was observed; concern for 
a causal relationship was expressed ( 63 ). A persisting decrease in the diagnosis of 
adolescent depression occurred ( 78 ,  79 ). The decrease in antidepressant prescriptions 
was not accompanied by an increase in non-pharmacologic treatments, such as psy-
chotherapy. Though causation is only implied, these findings suggest the black box 
warnings have had unintended consequences. Simultaneously, it may have prevented 
some suicides. Additional studies are needed. 
 What do we know today of the risk of suicidality in adolescents treated with SSRIs? 
First, as we have known since the original FDA review, there is no evidence supporting 
an increased suicide rate among adolescents treated with SSRIs. There is only an incre-
ase in the rate of suicidal ideation and behavior, such as suicide attempts. Epidemio-
logical data, though devoid of causal implications, may support treating depressed 
adolescents. Multiple studies have suggested that the late 20th century reversal of the 
gradually rising  adolescent suicide rate was attributable to the increase in use of SSRIs 
in depressed adolescents ( 80 ,  81 ). The return to a rising suicide rate following the FDA 
advisory and subsequent decrease in SSRI prescriptions has elicited great concern of 
causation and may support the targeted use of SSRIs in this population ( 63 ). 
 Additionally,  TADS found that  CBT erased the increased suicidality risk. Psychothe-
rapy may be key. However, this protective response was not replicated in  TORDIA. This 
differential finding may be related to population differences between the two studies. 
 Data will continue to accumulate. For example, a recent study which used 
 person-level data from four  youth trials failed to find any increased suicidality risk 
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( 82 ). Until then, a comfortable knowledge of the data will allow fact-based optimized 
care tailored the individual  adolescent. 
 Future neurobiological research and developments will improve individualized 
care. Pharmacogenetics, already an established field of study within adolescent  depres-
sion ( 83 ), will enable biologically-customized pharmacotherapy. Biomarkers will 
serve similarly. Biomarkers are objective measures associated with clinical disorders 
that ideally simultaneously serve as the target of reparative interventions ( 84 ). Endo-
phenotypes are heuristic intermediaries between upstream genotype products and 
clinical phenotypes which have already been developed in studies of depression ( 85 ) 
and  suicidality ( 86 ). These reliable, objective neurobiological methods will increasin-
gly gain clinical relevance. 
 6.4  Education of health care trainees and professionals 
 Recognition of depression in adolescents in psychiatric and primary care 
 Both primary care ( 87 ) and mental health ( 88 ) providers under-recognize adolescent 
depression. Primary care providers recognize depression or  anxiety in just under 
a third of diagnosable cases ( 5 ). Several factors may contribute to low recognition. 
Chiefly, adolescents often enact rather than verbalize the negative affect of depression. 
As only 56% of pediatricians report that they usually require about depression ( 89 ), 
the topic may indeed not be verbalized by either party. Somatic symptoms, functional 
impairment, behavioral problems, and sleep and appetite disturbances may replace 
direct verbalization of affect in the adolescent. The high prevalence of comorbidity in 
depression may distract from depression as a treatment-responsive disorder warran-
ting first line intervention. 
 It is our opinion that medical provider discomfort with depression in adolescents 
may predispose providers to focus preventative efforts elsewhere. Grounding ado-
lescent depression within a neurobiological medical model may increase provider 
comfort and subsequent recognition. 
 Recognition of suicidality in adolescents in psychiatric and primary care 
 Suicidal ideation is similarly withheld if not directly assessed ( 90 ). Direct questio-
ning revealed a suicidal ideation preceding two-week prevalence of 22% preceding 
two-week incidence among adolescents who presented to their primary care provider 
without any psychiatric complaints ( 91 ). 
 As in adults, there is no evidence of iatrogenic effects of  suicide screening in 
 adolescence ( 92 ). The straightest path to increased recognition of adolescent suici-
dality is simply to ask. Direct questioning, simple empathic support, and attentiven-
ess yield the greatest rates of emotional and behavioral disclosure from adolescents 
and their parents ( 93 ,  94 ). Reducing adolescent access to firearms and assessing for 
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past attempts or future plans of suffocation will appropriately target resources to 
 adolescents with the highest risk of  suicide completion. 
 Management of  depression and  suicidality in adolescents in psychiatric 
and primary care 
 Psychotherapy referral with or without medication management is a promising 
alternative. As aforementioned,  TADS found that the addition of  CBT to medication 
management erased the increased suicide risk. There is increasing evidence for psy-
chotherapy, in particular family-based interventions ( 95 ). For example, Attachment-
based family therapy (ABFT), was developed to reduce depression and suicidal 
ideation ( 96 ). It was recently shown in a randomized controlled trial to be more effica-
cious than community care in reducing depression and suicidality ( 97 ). 
 Fear of inducing or being powerless to prevent adolescent suicidality may pre-
dispose providers to under-recognize both suicidality and depression in adolescents. 
Evidence-based emphasis upon trial-outcome data will dispel myths, raise provider 
confidence, and contribute to greater recognition and treatment rates. 
 6.4.1   How to teach health care trainees and professionals to recognize 
and manage adolescent depression and suicidality in adolescents 
in psychiatric and primary care? 
 All providers should feel comfortable attending to suicidality in depressed adole-
scents. A sizeable (45%) proportion of non-specialist emergency room providers do 
not agree that screening is important; in fact, 70% support screening only when the 
chief complaint is psychiatric ( 98 ). We believe training must first address this preva-
lent provider belief and its underlying factors prior to instruction in more complex 
screening and management algorithms. 
 Over 40,000 individuals have participated in the twelve suicide workshops for 
mental health providers described in the literature ( 99 ). Many others have engaged 
in the greater number of trainings for non-specialist providers ( 100 ). These programs 
share common features. Didactics are often supplemented by the use of a standar-
dized patient. The use of these two strategies together are associated with greater 
training outcomes than the use of either alone ( 7 ). Video demonstration training 
increases provider confidence in discussing mental health concerns within pediatric 
populations. Web-based educational programs are also commonly employed. 
 Increased knowledge of the neurobiological context of  adolescence, the epi-
demiology and prevalence of adolescent depression and suicide, and treatment 
implications with a focus on the  SSRIs will increase provider comfort in addressing 
these important issues. Increased comfort and the perception of receiving adequate 
training will translate into improved screening and management practices ( 8 ). 
78   6  Suicide prevention in depressed adolescents
 References 
   1.  Merikangas KR, He J, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of 
mental disorders in US adolescents: Results from the National Comorbidity Survey Replication? 
Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010;49:980 – 9. 
   2.  Fleming JE, Boyle MH, Offod DR. The outcome of adolescent depression in the Ontario child health 
study follow-up. J Am Acad Child Adolesc Psychiatry 1993;32:28 – 33. 
   3.  Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, et  al. Depressed 
adolescents grown up. J Am Med Assoc 1999;281:1707 – 13. 
   4.  Joffe A, Radius S, Gall M. Health counseling for adolescents: What they want, what they get, and 
who gives it. Pediatrics 1998;82:481 – 5. 
   5.  Richardson LP, Russo JE, Lozano P, McCauley E, Katon W. Factors associated with detection and 
receipt of treatment for youth with depression and anxiety disorders. Acad Pediatr 2010;10:
36 – 40. 
   6.  Klein J, Allan M, Elster A, Stevens D, Cox C, Hedberg VA, et al. Improving adolescent preventive 
care in community centers. Pediatrics 2001;107:318 – 27. 
    7.  Fallucco E, Hanson M, Glowinski A. Teaching pediatric residents to assess adolescent suicide risk 
with a standardized patient module. Pediatrics 2010;125:953 – 9. 
  8.  Frankenfield D, Keyl P, Gielen A, Wissow L, Werthamer L, Baker S. Adolescent patients: healthy or 
hurting? Missed opportunities to screen for suicide risk in the primary care setting. Arch Pediatr
Adolesc Med 2000;154:162 – 8. 
    9.  Sudak D, Roy A, Sudak H, Lipschitz A, Maltsberger J, Hendin H. Deficiencies in suicide training in 
primary care specialties: A survey of training directors. Acad Psychiatry 2007;22:21 – 8. 
 10.  Simon RI, Shuman DW. Therapeutic risk management of clinical-legal dilemmas: Should it be a 
core competency? J Am Acad Psychiatr Law 2009;37:155 – 61. 
 11.  Weir JM, Zakama A, Rao U. Developmental risk I: Depression and the developing brain. Child 
Adoles Psychiatric Clin North Am 2012;21:237 – 59. 
 12.  Durston S, HulshoffPol HE, Casey BJ, Giedd JN, Buitelaar JK, van Engeland H. Anatomical MRI 
of the developing human brain: What have we learned? J Am Acad Child Adolesc Psychiatry 
2001;40:1012 – 20. 
 13.  Giorgio A, Watkins KE, Chadwick M, James S, Winmill L, Douaud G, et al. Longitudinal changes in 
grey and white matter during adolescence. Neuro Image 2010;49:94 – 103. 
 14.  McClure HH, Eddy JM, Kjellstrand JM, Snodgrass JJ, Martinez CR Jr. Child and adolescent affective 
and behavioral distress and elevated adult body mass index. Child Psychiatry Hum Dev 2012 Mar 
27. [Online ahead of print] 
 15.  Mendel JR, Berg CJ, Windle RC, Windle M. Predicting young adulthood smoking among adolescent 
smokers and nonsmokers. Am J Health Behav 2012;36:542 – 54. 
 16.  Kessler RC, Avenevoli S, RiesMerikangas K. Mood disorders in children and adolescents: an 
epidemiologic perspective. Biol Psychiatry 2001;49:1002 – 14. 
 17.  Essau CA, Chang WC. Epidemiology, comorbidity, and course of adolescent depression. In: 
Treatments for Adolescent Depression: Theory and Practice. Oxford: Oxford University Press, 
2009. 
 18.  Joinson C, Heron J, Araya R, Paus T, Croudace T, Rubin C, et  al. Association between pubertal 
development and depressive symptoms in girls from a UK cohort. Psychol Med 2012 Apr 12. 
[Online ahead of print] 
 19.  Angold A, Costello EJ. Depressive comorbidity in children and adolescents: empirical, theoretical, 
and methodological issues. Am J Psychiatry 1993;150:1779 – 91. 
 20.  Costello EJ, Foley DL, Angold A. 10-year research update review: the epidemiology of child and 
adolescent psychiatric disorders: II. Developmental epidemiology. J Am Acad Child Adolesc 
Psychiatry 2006;45:8 – 25. 
 References   79
 21.  Pine DS, Goldstein RB, Wolk S, Weissman MM. The association between childhood depression 
and adulthood body mass index. Pediatrics 2001;107:1049 – 56. 
 22.  Lewinsohn PM, Rohde P, Seeley JR. Adolescent psychopathology: III. The clinical consequences of 
comorbidity. J Am Acad Child Adolesc Psychiatry 1995;34:510 – 9. 
 23.  Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, et al. Brain metabolic 
changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatr Res 
1999;91:127 – 39. 
 24.  Forbes EE, Hariri AR, Martin SL, Silk JS, Moyles DL, Fisher PM, et al. Altered striatal activation 
predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatry 
2009;166:64 – 73. 
 25.  Forbes EE, May JC, Siegle GJ, Ladouceur CD, Ryan ND, Carter CS, et al. Reward-related decision-
making in pediatric major depressive disorder: an fMRI study. J Child Psychol Psychiatry 
2006;47:1031 – 40. 
 26.  Cohen-Cory S, Kidane AH, Shirkey NJ, Marshak S. Brain-derived neurotrophic factor and the 
development of structural neuronal connectivity. Dev Neurobiol 2010;70:271 – 88. 
 27.  Castren E, Rantamki T. The role of BDNF and its receptors in depression and antidepressant drug 
action: Reactivation of developmental plasticity. Dev Neurobiol 2010;70:289 – 97. 
 28.  Sher L. Brain-derived neurotrophic factor and suicidal behavior in adolescents. World J Pediatr 
2011;7:197 – 8. 
 29.  Hilt LM, Sander LC, Nolen-Hoeksema S, Simen AA. The BDNF Val66Met polymorphism predicts 
rumination and depression differently in young adolescent girls and their mothers. Neurosci Lett 
2007;429:12 – 6. 
 30.  Chen J, Li X, McGue M. Interacting effect of BDNF Val66Met polymorphism and stressful life events 
on adolescent depression. 2012 Aug 29. [Online ahead of print] 
 31.  Vigil P, Orellana RF, Cortes ME, Molina CT, Switzer BE, Klaus H. Endocrine modulation of the 
adolescent brain: A review. J Pediatr Adolesc Gynecol 2011;24:330 – 7. 
 32.  Shansky RM, Glavis-Bloom C, Lerman D, McRae P, Benson C, Miller K, et al. Estrogen mediates sex 
differences in stress-induced prefrontal cortex dysfunction. Mol Psychiatry 2004;9:531 – 8. 
 33.  Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), 
stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen 
Psychiatry 2011;68:444 – 54. 
 34.  Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on 
depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386 – 9. 
 35.  Priess-Groben HA, Hyde JS. 5-HTTLPR X stress in adolescent depression: Moderation by MAOA 
and gender. J Abnorm Child Psychol 2012 Jul 27. [Online ahead of print] 
 36.  Lopez-Duran NL, Kovacs M, George CJ. Hypothalamic-pituitary-adrenal axis dysregulation in depressed 
children and adolescents: a meta-analysis. Psychoneuroendocrinology 2009;34:1272 – 83. 
 37.  Leonard BE. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur 
Psychiatry 2005;20:S302 – 6. 
 38.  Mueller A, Brocke B, Fries E, Lesch KP, Kirschbaum C. The role of the serotonin transporter 
polymorphism for the endocrine stress response in newborns. Psychoneuroendocrinology 
2010;35:289 – 96. 
 39.  Birmaher B, Brent D, Bernet W, Bukstein O, Walkter H, Benson S, et al. Practice parameter for 
the assessment and treatment of children and adolescents with depressive disorders. J Am Acad 
Child Adoles Psychiatry 2007;46:1503 – 26. 
 40.  Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and 
adolescents: a meta-analysis. Psychol Bull 2006;132:132 – 49. 
 41.  Kratochvil CJ, Vitiello B, Walkup J, Emslie G, Waslick BD, Weller EB, et  al. Selective serotonin 
reuptake inhibitors in pediatric depression: Is the balance between benefits and risks favorable? 
J Child Adol Psychol 2006;16:11 – 24. 
80   6  Suicide prevention in depressed adolescents
 42.  Yu Z, Kratochvil CJ, Weller RA, Mooreville M, Weller EB. From TADS and SOFTADS to TORDIA and 
beyond: Whatʼs new in the treatment of adolescent depression. Curr Psychiatry Rep 2010;12:88 – 95. 
 43.  Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute 
treatment of depression in children and adolescents: A placebo-controlled, randomized clinical 
trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205 – 15. 
 44.  Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment 
and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc 
Psychiatry 1998;37:1234 – 8. 
 45.  Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide 
attempt by adolescents with major depressive disorder: A propensity-adjusted retrospective 
cohort study. CNS Drugs 2004;18:1119 – 32. 
 46.  Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent 
depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 
2009;48:721 – 9. 
 47.  March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et  al. Treatment for Adolescents With 
Depression (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination 
for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) 
randomized controlled trial. J Am Med Assoc 2004;292:807 – 20. 
 48.  Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to another SSRI or 
to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant 
depression: the TORDIA randomized controlled trial. J Am Med Assoc 2008;299:901 – 13. 
 49.  The Treatment for Adolescents With Depression (TADS) Team. The Treatment for Adolescents 
With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 
2009;166:1141 – 9. 
 50.  Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, et al. Relative cost-effectiveness 
of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am 
Acad Child Adolesc Psychiatry 2009;48:711 – 20. 
 51.  Reinherz H, Tanner J, Berger S, Beardslee W, Fitzmaurice G. Adolescent suicidal ideation as 
predictive of psychopathology, suicidal behavior, and compromised functioning at age 30. Am J 
Psychiatry 2006;163:1226 – 32. 
 52.  Lindqvist P, Johansson L, Karlsson U. In the aftermath of teenage suicide: A qualitative study of 
the psychosocial consequences for the surviving family members. BMC Psychiatry 2008;8:26. 
 53.  Cox GR, Robinson J, Williamson M, Lockley A, Cheung YTD, Pirkis J. Suicide clusters in young 
people: Evidence for the effectiveness of postvention strategies. Crisis 2012;33:208 – 14. 
 54.  Centers for Disease Control and Prevention. WISQARS leading causes of death reports, 
1999 – 2009. Atlanta, GA: CDC, 2012. 
 55.  Patton GC, Coffey C, Sawyer SM, Viner RM, Haller DM, Bose K, et al. Global patterns of mortality in 
young people: a systematic analysis of population health data. Lancet 2009;374:881 – 92. 
 56.  Macintosh J. USA suicide: 2007 official data: Report for the American Association of Suicidology. 
2007. Available online at  http://www.suicidology.org/c/document_library/get_file?folderId=
228&name=DLFE-494.pdf . Accessed April 25th, 2012. 
 57.  Centers for Disease Control and Prevention. Youth Risk Behavior Surveillance  – United States, 
2009. MMWR 2010;59(SS-5):1 – 142. 
 58.  Hawton K, Saunders KEA, O ’ Connor RC. Self-harm and suicide in adolescents. Lancet 
2012;379:2373 – 82. 
 59.  McKeown RE, Cuffe SP, Schulz RM. US suicide rates by age group, 1970 – 2002: An examination of 
recent trends. Am J Public Health 2006;96:1744 – 51. 
 60.  Morrell S, Page AN, Taylor RJ. The decline in Australian young male suicide. Soc Sci Med 
2007;64:747 – 54. 
 61.  Kutcher SP, Szumilas M. Youth suicide prevention. Can Med Assoc J 2008;178:282 – 285. 
 References   81
 62.  Varnik A, Kolves K, Allik J, Arensman E, Aromaa E, van Audenhove C, et al. Gender issues in suicide 
rates, trends and methods among youths aged 15 – 24 in 15 European countries. J Affect Disord 
2009;113:216 – 26. 
 63.  Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the 
effects of regulators ’ suicidality warnings on SSRI prescriptions and suicide in children and 
adolescents. Am J Psychiatry 2007;164:1356 – 63. 
 64.  Wasserman D, Cheng Q, Jiang GX. Global suicide rates among young people aged 15 – 19. World 
Psychiatry 2005;4:114 – 20. 
 65.  Hepp U, Stulz N, Unger-Koppel J. Methods of suicide used by children and adolescents. Eur Child 
Adolesc Psychiatry 2012;21:67 – 73. 
 66.  Skinner R, McFaull S. Suicide among children and adolescents in Canada: trends and sex 
differences, 1980 – 2008. Can Med Assoc J 2012;184:1029 – 34. 
 67.  Andrews JA, Lewinsohn PM. Suicidal attempts among older adolescents: prevalence and 
co-occurrence with psychiatric disorders. J Am Acad Child Adolesc Psychiatry 1992;31:655 – 62. 
 68.  Hawton K, van Heeringen K. Suicide. Lancet 2009;373:1372 – 81. 
 69.  Ganz D, Sher L. Suicidal behavior in adolescents with comorbid depression and alcohol abuse. 
Minerva Pediatr 2009;61:333 – 47. 
 70.  Sher L. The concept of post-traumatic mood disorder. Med hypotheses 2005;65:205 – 10. 
 71.  Sher L. The concept of post-traumatic mood disorder and its implications for adolescent suicidal 
behavior. Minerva Pediatr 2008;60:1393 – 9. 
 72.  Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine 
treatment. Am J Psychiatry 1990;147:207 – 10. 
 73.  King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, et  al. Emergence of 
self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad 
Child Adolesc Psychiatry 1991;30:179 – 86. 
 74.  Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, et  al. 
Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. Br Med J 
1991;303:685 – 92. 
 75.  Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, 
and placebo: Analysis of FDA reports. Am J Psychiatry 2003;160:790 – 2. 
 76.  Hammad TA. Results of the Analysis of Suicidality in Pediatric Trials of Newer Antidepressants. 
Psychopharmacology Drugs Advisory Committee and the Pediatric Advisory Committee, 
September 13 – 14, 2004. Online document at:  www.fda.gov/ohrms/dockets/ac/04/briefing/ 
2004 – 4065b1 – 10-TAB08-Hammads-review.pdf . 
 77.  Barry CL, Busch SH. News media coverage of FDA warnings on pediatric antidepressant use and 
suicidality. Pediatrics 2010;125:88 – 95. 
 78.  Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. 
Arch Gen Psychiatry 2009;66:633 – 9. 
 79.  Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric 
depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007;164:884 – 91. 
 80.  Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication 
treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60:978 – 82. 
 81.  Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription 
rates and rate of early adolescent suicide. Am J Psychiatry 2006;163:1898 – 904. 
 82.  Gibbons RD, Kwan H, Brown H, Davis JM, Mann JJ. Benefits from antidepressants: Synthesis 
of 6-Week patient-level outcomes from double-blind placebo-controlled randomized trials of 
fluoxetine and venlafaxine. Arch Gen Psych 2012 Mar 5. [Online ahead of print] 
 83.  Blazquez A, Mas S, Plana MT, Lafuente A, Lazaro L. Fluoxetine pharmacogenetics in child and 
adult populations. Eur Child Adolesc Psychiatry 2012 Jul 12. [Online ahead of print] 
82   6  Suicide prevention in depressed adolescents
  84.  Macaluso M, Preskorn SH. How biomarkers will change psychiatry: from clinical trials to 
practice. Part I: introduction. J Psychiatr Pract 2012;18:118 – 21. 
  85.  Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, 
and pathophysiology. Neuropsychopharmacology 2011;36:2375 – 94. 
  86.  Mann JJ. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 
2009;65:556 – 63. 
  87.  Wren FJ, Scholle SH, Heo J, Comer DM. Pediatric mood and anxiety syndromes in primary care: 
Who gets identified? Int J Psychiatry Med 2003;33:1 – 16. 
  88.  Basco MR, Bostic JQ, Davies D, Rush AJ, Witte B, Hendrickse W, et  al. Methods to improve 
diagnostic accuracy in a community mental health setting. Am J Psychiatry 2000;157:1599 – 605. 
  89.  Stein RE, Horwitz SM, Storfer-Isser A, Heneghan A, Olson L, Hoagwood KE. Do pediatricians 
think they are responsible for identification and management of child mental health problems? 
Results of the AAP periodic survey. Ambul Pediatr 2008;8:11 – 7. 
  90.  Isometsa E, Heikkinen M, Marttunen M, Henriksson M, Aro H, Lonngvist J. The last appointment 
before suicide: Is suicide intent communicated? Am J Psychiatry 1995;152:919 – 22. 
   91.  Mckelvey R, Pfaff J, Acres J. The relationship between chief complaints, psychological distress, 
and suicidal ideation in 15 – 24-year-old patients presenting to general practitioners. Med J Aust 
2001;175:550 – 2. 
   92.  Gould M, Marrocco F, Kleinman M, Thomas JG, Mostkoff K, Cote J, et al. Evaluating iatrogenic risk of 
youth suicide screening programs: a randomized controlled trial. J Am Med Assoc 2005;239:1635. 
   93.  Cox A, Holbrok D, Rutter M. Psychiatric interviewing techniques, VI: experimental study: eliciting 
feelings. Br J Psychiatry 1981;139:144 – 52. 
   94.  Wissow L, Modena M, Roter D. Pediatrician interview style and mother ’ s disclosure of 
psychosocial issues. Pediatrics 1994;93:289. 
   95.  Tompson MC, Boger KD, Asarnow JR. Enhancing the developmental appropriateness of treatment 
for depression in youth: Integrating the family in treatment. Child Adolesc Psychiatric Clin North 
Am 2012;21:345 – 84. 
   96.  Diamond GS, Reis BF, Diamond GM, Siqueland L, Issacs L. Attachment-based family therapy for 
depressed adolescents: a treatment development study. J Am Acad Child Adolesc Psychiatry 
2002;41:1190 – 6. 
   97.  Diamond GS, Wintersteen MB, Brown GK, Diamond GM, Gallop R, Shelef K, et al. Attachment-
based family therapy for adolescents with suicidal ideation: A randomized controlled trial. J Am 
Acad Child Adolesc Psychiatry 2010;49:122 – 31. 
   98.  Habis A, Tall L, Smith J, Guenther E. Pediatric emergency medicine physicians ’ current practices 
and beliefs regarding mental health screening. Pediatr Emer Care 2007;23:387 – 93. 
   99.  Pisani A, Cross W, Gould M. The assessment and management of suicide risk: state of workshop 
education. Suicide Life Threat Behav 2011;41:255 – 76. 
 100.  Rice TR, Sher L. Educating non-mental health care providers about suicide assessment in adole-
scents. Neuropsychiatry 2012;2:267 – 70. 
 Section III: Violence and abuse 

 7   Child sexual abuse and  suicide in  adolescents 
and adults 
 Betsy S.  O ’ Brien and  Leo  Sher 
 Child Sexual Abuse (CSA) is widespread and is associated with various psychopa-
thology, including Axis I and II disorders, maladaptive and impulsive behaviors, 
and  suicidal behavior in  adolescence and adults. The pathophysiology of this asso-
ciation is not well understood. However, it is clear that suicidal behavior in indivi-
duals with a history of CSA is a significant social and medical problem warranting 
further investigation. Methods: An electronic search of the major behavioral science 
databases (limited to the most recent studies in the last 20 years) was conducted to 
retrieve studies detailing the social, epidemiological, and clinical characteristics of 
child sexual trauma and their relation to suicidal behavior in adolescents and adults. 
Results: Studies indicate that child sexual abuse is related to an increase in Axis I 
and II diagnoses including  depression,  PTSD, conduct disorders, eating disorders, 
 alcohol and drug abuse, panic disorders, and borderline personality disorder. CSA is 
also related to an increase in  impulsivity and risky behaviors. CSA has been linked to 
an increase in  suicidality as well. CSA makes both direct and indirect contributions 
to suicidal behavior. It is a complex process involving multiple variables that include 
psychopathology, maladaptive personality features, as well as the direct contribution 
of CSA itself. Psychopathologies such as  mood and personality disorders and impulsi-
vity may modulate the relationship between CSA and suicidal behavior. Some preven-
tive measures for decreasing the prevalence of child sexual abuse and suicidality may 
include education as well as increasing access to mental health services. 
 7.1  Introduction 
 Due to the differences between the assessment tools used to conceptualize Child 
Sexual Abuse, there is a lot of variability in what is included in the definition of CSA 
( 1 ,  2 ). Some sources, for example, include rape or attempted rape in their definition 
of CSA, whereas other sources also include contact abuse (fondling) and non-contact 
abusive experiences, such as genital exposure. The age criterion also varies between 
different sources, with some investigators claiming that 16 should be the cut off age, 
while others propose to increase this arbitrary set limit to 18 years ( 1 ,  2 ). 
 The data on the prevalence of CSA also contains tremendous variability, partly 
due to the differences in the definitions of CSA, underestimation due to the retrospec-
tive nature of recall studies and variance in sampling methods and data collection ( 1 ). 
Vogeltanz et al ( 1 ,  3 ) used the Wyatt Criteria, which defines CSA as an intrafamilial 
sexual activity before the age of 18 years that was unwanted, or that involved a family 
member 5 or more years older than the respondent; and any extrafamilial sexual 
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activity that occurred before age of 18 and that was unwanted or that occurred before 
age of 13 years and involved another person 5 or more years older than the respon-
dent ( 1 ,  3 ). Vogeltanz and colleagues ( 1 ,  4 ) estimated CSA prevalence in women to be 
21 – 32% using the most inclusive definition of child sexual abuse, and 15 – 26% using 
a less inclusive criterion ( 1 ). Emphasizing the variability that exists in the estimated 
prevalence of CSA, Laaksonen and colleagues reported a CSA prevalence of 1.8 – 7.5% 
versus 15 – 26% reported by Vogeltanz and colleagues ( 1 ,  4 ). Laakson and colleagues 
estimated prevalence comes from a sample of 13,000 responders to the  Childhood 
trauma Questionnaire ( 4 ), the disparity in estimated prevalence of CSA between 
Vogeltanz and colleagues and Laaksonen and colleagues may reflect a difference in 
their definition of CSA or some variance in sampling methods and data collection. 
The disparity may also reflect a true decline in CSA prevalence in the 10 years between 
the two publications as Laaksonen and colleagues suggested in their paper ( 1 ,  4 ). 
 Although there seems to be some variability in the definition of child sexual 
abuse and its prevalence, numerous studies have consistently demonstrated that 
child sexual abuse is widespread and is associated with a spectrum of psychiatric 
conditions and maladaptive behaviors including higher risk of intimate partner vio-
lence, more permissive and less effective parenting behaviors, Axis I diagnoses such 
 depression,  PTSD,  bipolar disorder, Axis II diagnoses such as borderline personality 
disorder, as well as risky sexual and suicidal behaviors ( 5 – 10 ). 
 7.1.1  Literature search 
 An electronic search of the major behavioral science databases (PUBMED, PSYCINFO, 
MEDLINE) was conducted to retrieve studies between the years of 1990 – 2012 detailing 
the social, epidemiological, and clinical characteristics of psychological trauma in 
female  adolescents and their relationships to behavior. Search terms included  “ child 
abuse, ”  “ childhood trauma, ”  “ sexual abuse, ”  “ suicidal behavior, ”  “ suicidal idea-
tion, ” and  “ suicide attempt. ” Additional references were incorporated from the bib-
liographies of the retrieved articles. 
 7.2   Child sexual abuse and psychopathology associated with 
suicidal behavior 
 Sexual abuse and trauma in childhood and adolescents is associated with a higher 
lifetime prevalence of psychopathology, both Axis I and II disorders, as well as patho-
logic behaviors ( 5 – 9 ). Axis I disorders associated with CSA include PTSD, depression, 
conduct disorder, panic disorders,  alcohol and drug abuse, and eating disorders ( 11 , 
 12 ). Associated Axis II disorders include Borderline Personality Disorder, Paranoid, 
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and Antisocial Personality Disorder ( 13 ,  14 ). Even when the factor of a formal Axis I or 
II diagnosis is controlled for, sexual abuse and trauma in childhood and  adolescents 
is associated with higher rates of  psychiatric symptoms including depressed  mood, 
impairing experience of loneliness, feelings of being overweight and poor body image 
and increased risk of conduct behavior including shoplifting, theft, and vandalism 
( 15 ). 
 Additionally, CSA can modify the onset and trajectory of psychopathology. 
Numerous investigators have shown that CSA is associated with an earlier onset of 
psychiatric disorders and symptoms and may worsen the severity of Axis I and II dis-
orders. Zanarini and colleagues found that severe CSA worsens the severity of BPD in 
the core sectors of the disorder including affect, cognition,  impulsivity, and disturbed 
interpersonal relationships ( 16 ). Other studies have also found correlation between 
CSA and borderline personality symptomatology ( 17 ). CSA has been correlated with 
an increase utilization of psychotropic medications ( 15 ,  17 ,  18 ). CSA has also been 
 correlated with increased utilization of health care including increased telephone 
contacts to health care facilities, physician visits, ongoing and acute prescriptions, 
and specialist referral ( 17 ). 
 7.3  Child sexual abuse and impulsivity 
 Child sexual abuse has also been linked with  development of impulsivity and impul-
sive behaviors ( 14 ,  19 – 21 ). Braquehais et al ( 14 ) defined impulsivity as a spectrum of 
behaviors that is characterized by an immediate, unplanned response to internal 
and external stimuli and can include high risk sexual behavior and violence ( 14 ). 
Examples of high risk sexual behavior include engaging in unprotected sex, having 
more than one partner, sex with a stranger, engaging in anal intercourse, and having 
an STD ( 9 ,  15 ). CSA is also associated with an increase in violence. Female adole-
scents who suffered from CSA report higher violence perpetuation ( 9 ). Furthermore, 
child sexual abuse sets a tone for continuation of violence in intimate partner rela-
tionships. Studies have shown that females who suffer from CSA are more likely to 
become the victims of intimate partner violence as adults and more likely to perpe-
tuate violence ( 9 ,  22 ). 
 7.4  Sexual abuse and  suicide 
 Perhaps the most devastating outcome of the association between sexual abuse and 
trauma is the increased risk of  suicidal behavior. Although the most important risk 
factor for completed suicide continues to be prior suicide attempt ( 21 ,  23 ), much of the 
literature identifies CSA as another major risk factor for suicidal behavior in adults 
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and young adults ( 10 ,  11 ,  18 ,  21 ,  24 – 26 ). Molnar and colleagues used multivariate 
discrete time event survival analysis to generate models to calculate the attributable 
risk of child sexual abuse to  suicidal behavior ( 7 ). They found that by controlling for 
the effects of other adversities towards the respondant such as verbal and physical 
abuse, verbal and physical abuse of parents towards each other, substance problems 
in mother and father, and attempts or completed suicides by either parent, the risk 
of suicidal behaviors that could be prevented by removing the factor of CSA, speci-
fically in women, was 11 – 14.5% ( 7 ). Although this study looked at suicidal behavior 
in a population of 15 – 54 who had experienced CSA, the study found that the highest 
probability of first  suicide attempts in the females in this population was during  ado-
lescence between ages 14 – 19  years ( 15 ). In another study, Ystgaard and colleagues 
have looked at a population of  adolescents in a psychiatric hospital who had made 
a suicide attempt ( 24 ). They found that the prevalence of repeated sexual abuse 
amongst this population of patients who have made a suicide attempt was higher 
than the reported sexual abuse in the general population ( 24 ). 
 The nature and pattern of the suicidal behavior have also been shown to be 
related to history of prior child sexual abuse. Studies have found that people who 
suffered from child sexual abuse have increased prevalence and severity of repea-
ted suicide attempts ( 11 ,  13 ,  16 ). Not only does sexual abuse increase the prevalence 
of suicidal behavior, but it also increases the prevalence of  non-suicidal self-injury 
(NSSI), a risk factor for suicidal behavior, such as cutting, burning, biting, hitting, 
ingesting non-food, skin picking, and placing objects under skin ( 25 ,  27 ). 
 Child sexual abuse further increases suicidal risk in patients who have Axis I and 
II disorders or high  impulsivity that independently raises the risk for suicidal beha-
vior. For example, Fergusson and colleagues in looking for factors that distinguish 
those patients who have  depression and develop suicidal behavior from those that 
don ’ t, found that in addition to being a risk factor for depression, CSA appeared to 
make patients with depression more vulnerable to suicidal thoughts ( 28 ). Carballo 
and colleagues found that in patients with another Axis I disorder,  Bipolar Disorder, 
a personal history of childhood abuse including sexual abuse and a family history of 
suicidal behavior increased prevalence of suicidal behavior ( 29 ). Similarly, in pati-
ents with  PTSD, child sexual abuse appears to be responsible, at least partially, for 
the relationship between its symptoms and suicidal behavior ( 30 ). Studies have also 
shown child sexual abuse has also been associated with increased suicidal behavior 
in patients with pathologic impulsivity ( 14 ). 
 7.5  CSA and adolescent  suicidality 
 Adolescent suicidality is a significant medical and social problem that warrants 
special investigation. Sources report that 9.7% of adolescents have attempted to 
take their own lives at some point and 29.9% have experienced suicidal ideation 
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( 31 ). CSA is linked to  suicidal behavior in young adults and  adolescents specifi-
cally as well as adults. Evans and colleagues investigated risk factors for  suicidality 
in adolescents and identified multiple sources and using multivariant analyses 
demonstrated a correlation between child sexual abuse and suicidal phenomena 
in adolescents ( 31 ). Evans et al also demonstrated a correlation between suicidal 
behavior and other Axis I and II pathology in adolescents including  depression, 
eating disorders and body image in female adolescents, recreational drugs and 
drinking, and antisocial behaviors ( 32 ). Evans et al concluded that the association 
between CSA and suicidal ideation and behavior in adolescents appears to be a 
direct association, although certainly other factors such as self-esteem and Axis I 
and II pathologies may mediate this relationship ( 32 ). Bruffaerts et al also found a 
correlation between sexual abuse and onset and persistence of suicidal behavior in 
adolescents even when adjusting for the mental health of the adolescent ( 33 ). Fur-
thermore, Bruffaerts et al suggest that the correlation between child sexual abuse 
and suicidal behavior is most pronounced during adolescents especially in regard 
to actual  suicide attempts whereas the correlation between suicide attempts and 
CSA becomes less strong in adulthood ( 33 ). 
 7.6  Discussion 
 The relationship between suicidal behavior and sexual abuse is clearly multifactorial. 
While there is a clearly established relationship between sexual abuse and suicidal 
behavior in both adolescents and adults, the pathophysiology of this relationship 
warrants further exploration. 
 Psychopathology as a mediator between CSA and suicidal behavior 
 Psychopathology may mediate the relationship between CSA and suicidal behavior. 
Patients who suffer from Axis I pathology including  PTSD, Depression, and  Bipolar 
Disorder as well as Axis II pathology including Antisocial, Borderline, and Paranoid 
Personality Disorders have an increased risk of suicidal behavior ( 14 ,  34 – 37 ). CSA 
also increases the risk for the  development of Axis I and II pathologies including 
PTSD, Depression, Eating Disorders, Substance Disorders, and Borderline Persona-
lity Disorder in both adolescents and adults ( 7 ,  12 ,  13 ,  36 ). Patients with these disor-
ders and a history of CSA are more likely to engage in suicidal behavior ( 29 ,  30 ,  35 , 
 37 ), thereby CSA may be a risk factor for the development of psychopathology and 
it is the presence of psychopathology that may mediate the link between CSA and 
suicidal behavior. 
 Impulsivity as a mediator between CSA and suicidal behavior 
 Child sexual abuse is associated with the development of pathologic impulsi-
vity and with psychiatric disorders including antisocial personality disorder and 
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substance dependence that are associated with  impulsivity ( 14 ,  19 ). Pathologic impul-
sivity is also associated with an increased risk of  suicidal behavior ( 14 ,  19 ). Patho-
logic impulsivity can include behaviors associated with violence, eating disorders, 
 substance abuse disorders, gambling, and risky sexual behavior ( 19 ). As suggested 
by other sources ( 14 ), child sexual abuse may increase impulsive behavior and the 
presence of impulsivity may mediate the relationship between CSA and sexual abuse. 
 CSA as an independent risk factor for suicidal behavior 
 Child sexual abuse may also be an independent variable that directly increases the 
risk of suicidal behavior. Molnar and colleagues found that even when controlling 
for other adversities, patients who suffered from child sexual abuse were more likely 
to go on to develop suicidal behavior in  adolescence and adulthood ( 10 ). Even when 
controlling for Axis I and II pathology, studies have shown at least some increased 
risk of suicidal behavior in adult and young adult patients who have suffered from 
CSA ( 26 ,  36 ). 
 Overall, CSA makes both direct and indirect contributions to suicidal behavior. 
It is a complex process involving multiple variables that include psychopathology, 
maladaptive personality features, as well as the direct contribution of CSA itself. 
 CSA and prevention of suicidal behavior 
 Improving education of the general population, medical community, mental health 
providers, and gatekeepers may help to mobilize earlier interventions that address 
these risk factors may improve outcome as measured by decreased child sexual abuse 
and suicidal behavior ( 38 ). 
 Increase access to care including emergency, medical, and mental health servi-
ces may improve outcome. It is important to increase and improve emergency room 
care of sexual assault needs including availability of toxicology, pregnancy tests, 
and training of health care workers to perform HEADSS (home, education, activi-
ties, drug use and abuse, sexuality, and  suicidality and  depression) assessment in 
every case suspected to have involved child sexual trauma and abuse ( 39 ). Impro-
ving access to mental health resources for patients with psychopathology and child 
sexual abuse including access to multimodal therapy such as dynamic psychothe-
rapy,  CBT, DBT for suicidal behavior, and psychopharmacologic treatment may 
improve outcome ( 38 ,  40 ). 
 Studies have suggested a role for the education of gatekeepers ( 38 ). These studies 
have proposed a more formal role for gatekeepers who may formally mediate access 
to care ( 38 ). 
 In summary, a link exists between child sexual abuse and adverse outcomes inclu-
ding  development of psychopathology, impulsivity, and suicidal behavior. However, 
the pathophysiology of this relationship is complex and determining measures to 
prevent CSA and suicidal behavior warrants a multifactorial approach. 
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 8   Improving future physiciansʼ responses 
to  adolescent maltreatment 
 Michele  Knox ,  Heather  Pelletier and  Victor  Vieth 
 The purpose of this chapter was to examine the effects of training first year medical 
students using a Child Advocacy Studies Training (CAST) elective course. The 9 month 
course was taught by a multi-disciplinary group of professionals and addressed pre-
vention, identification, reporting and responding to all forms of child and adolescent 
maltreatment. It was hypothesized that, relative to students in a comparison group, 
students who completed the elective would report being significantly more prepared 
to identify signs of maltreatment, to report a case of suspected maltreatment, and 
to recommend or secure needed services for a maltreated child or adolescent, more 
likely to report suspected maltreatment, even if they did not know for sure it happened, 
and demonstrate improved knowledge in the areas of maltreatment identification 
and reporting. Results supported all five of the study ’ s hypotheses and indicate that 
the CAST program may be an effective method of better preparing future physicians 
to address child and adolescent maltreatment. 
 8.1  Introduction 
 Every year, thousands of children and adolescents suffer from the impact of child 
abuse and neglect in US. Approximately 2,000 children and  youths die each year as 
a result of abuse or neglect ( 1 ). There are 9.2 victims per 1,000 children in US ( 2 ). 
Although very young children are the most vulnerable to maltreatment, in a recent 
survey, 23.5% of maltreatment victims were aged 12 – 17 years ( 2 ). Maltreatment during 
 adolescence has been shown to increase the risk of arrest, delinquency, violence, 
drug use, internalizing problems, and externalizing problems ( 3 – 6 ). 
 Among the many types of professionals involved in efforts to prevent and reduce 
maltreatment are physicians who, because of characteristics of their professional 
roles and involvement in patient care, have opportunities to address maltreatment on 
many levels. For example, all physicians in US are required by law to report suspected 
abuse. Identification of some forms of maltreatment involves medical examinations 
by physicians. Physicians have important roles involving educating parents about 
issues such as parenting, child  development, and safety that are highly relevant to 
the prevention of abuse and neglect. Furthermore, physicians are at times are called 
on by courts as expert witnesses. Physicians are also involved in the development and 
revisions of medical definitions of child and adolescent abuse that are used by courts 
and policy-makers. 
 Specialists such as family physicians and pediatricians also have the advantage 
of a high degree of patient access compared to other professionals. That is, although 
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many other health professionals are exposed at some point in their career to cases 
involving abuse and violence, they treat only a small percentage of children and  ado-
lescents seeking specialized care. In contrast, most children and  youths have contact 
with a pediatrician or family practitioner; most children in US see such physicians for 
well-child visits and following illness or injury. Thus, pediatricians and family prac-
titioners are in important positions involving contact with otherwise hard to reach 
families who may be at risk for child abuse. Furthermore, pediatricians and family 
practitioners are in key positions for the provision of preventive care. They are often 
sought by parents and caregivers for advice on parenting and methods to prevent and 
handle behavior problems. All of these factors, in tandem with physician ’ s ultimate 
goal of maintaining the safety and welfare of their patients, make physicians impor-
tant figures in the fight against maltreatment. 
 There are indications, however, that some physicians are experiencing obstacles 
to successfully meeting their responsiblities regarding to child and adolescent protec-
tion. For example, the vast majority of children and adolescents suspected of being 
abused are not reported into the system ( 7 ,  8 ). Research indicates that over half of 
mental health and health care providers do not report all cases of suspected abuse 
( 7 ,  8 ) and that impediments to reporting among physicians are associated with lower 
than optimal rates of reporting ( 9 – 11 ). For example, in a study with 327 primary care 
clinicians examining mandated reporting of suspected physical abuse (i.e., physici-
ans, nurse practitioners and physician assistants), only 24% of the children conside-
red possibly abused by caregivers were reported by the clinicians. Even more alar-
ming, only 73% of the children and adolescents considered to be likely or very likely 
abused were reported by the clinicians ( 10 ). This explanation has been supported by 
other research indicating that physicians sometimes do not feel prepared to intervene 
effectively when faced with cases of child and adolescent maltreatment ( 8 ,  9 ,  11 ). 
 Research suggests that limited or poor quality training in maltreatment is a 
major barrier. Physicians and other health care providers often report having recei-
ved very little training, if any, on child abuse prevention ( 9 ,  12 ) child and adole-
scent advocacy, identification of maltreatment and reporting procedures ( 8 ). In one 
study, the following areas of knowledge pertaining to reporting maltreatment were 
listed by medical professionals as areas of educational need: knowledge about the 
actual reporting process, their role in the reporting process, and reporting laws ( 11 ). 
Such findings suggest that future physicians may benefit from education regarding 
not only the identification of child maltreatment, but also on the reporting process 
and the providers ’ role in that process. In fact, many medical professionals have 
expressed a desire for more education in the area of child maltreatment, suggesting 
that it would increase adherence rates to mandated reporting ( 13 ). Further, child 
protection has explicitly been identified as an area of neglected training in pediatric 
residency ( 14 ). 
 Experts and professional organizations involved in medical school educa-
tion have suggested standards for training in child maltreatment. According to 
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Reece and Jenny ( 12 ),  “ Training for the detection and treatment of medical pro-
blems relies on a shared foundation of biomedical knowledge. Similarly, the 
knowledge of various etiologic theories of child maltreatment is essential for the 
health care provider to evaluate cases of suspected abuse and neglect. Now here 
in medical practice is knowledge about the social constructs of a medical condi-
tion more necessary than in the evaluation of a child and family for the possibility 
of child maltreatment. ” In the medical school accreditation standards, the Liaison 
Committee on  Medical Education states,  “ The curriculum of a medical education 
program must prepare medical students for their role in addressing the medical 
consequences of common societal problems (e.g., provide instruction in the dia-
gnosis, prevention, appropriate reporting, and treatment of violence and abuse) ” 
( 15 ). Further, the Council on Medical Student Education in Pediatrics (COMSEP), 
which functions under the auspices of the Association of Medical School Pediat-
ric Department Chairs and works to define and promote exemplary teaching practi-
ces in medical student education ( 16 ), suggests the following competencies for 
medical students in the area of child abuse: list characteristics of the history and 
physical examination that should trigger concern for possible physical, sexual, and 
psychological abuse and neglect such as inconsistency in the history, unexplai-
ned delays in seeking care, injuries with specific patterns or distributions on the 
body, or injuries incompatible with the child ’ s  development; describe the medical-
legal importance of a full, detailed, carefully documented history and physical exa-
mination in the evaluation of child abuse; discuss the concurrence of domestic vio-
lence and child abuse and describe markers that suggest the occurrence of family 
violence; describe the unique communication skills required to work with families 
around issues of maltreatment; summarize the responsibilities of the  “ mandatory 
reporter ” to identify and report suspected child abuse; know to whom such a report 
should be made ( 17 ). 
 Although these standards provide important guidance on what medical education 
in maltreatment should address, such training remains scarce and inconsistent. For 
example several studies have documented very limited training on child and  adolescent 
abuse prevention and advocacy for emerging medical professionals ( 8 – 11 ,  13 ,  18 , 19). 
When it does exist, it is often a single offering, separated from the medical curricu-
lum, rather than a coordinated, multifaceted, multi-disciplinary approach ( 20 ). 
 To date, there is not an evidence-based approach to medical training in child 
and adolescent protection. Although standards exist for medical student training in 
maltreatment and protection, there is not clear consensus on how to incorporate 
these objectives into a medical school curriculum, and existing approaches have not 
been rigorously evaluated ( 21 ,  22 ). Thus, although some researchers and educators 
have attempted to develop proposed model curricula, the efficacy of such curricula 
has not been well-tested. 
 Research suggests that targeted training at the graduate level may be effective ( 23 ). 
Participants in one study involving students and professionals in mental health, for 
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example, demonstrated improved knowledge of State and Federal laws, improved 
identification of child and  adolescent maltreatment, and improved knowledge of 
requisite skills involved in reporting suspected maltreatment. In a recent study of a 
medical student course, medical students ’ self-reported preparedness to identify and 
report maltreatment, as well as their likelihood of reporting, improved significantly 
from just prior to just following the training ( 24 ). Although promising, that study 
suffered from limitations including a very small sample and lack of control group. 
One additional study examined whether or not training first and second year medical 
residents in child and adolescent maltreatment issues is effective; this study found 
a medium effect size for training medical residents in the area of maltreatment ( 25 ). 
Although this study found training medical residents to be efficacious, training efforts 
can begin much earlier in medical school, thus reaching future physicians who even-
tually practice in a variety of fields. 
 Because too little or poor quality training in maltreatment may strictly impair 
the ability of physicians to meet their responsibilities in the area of child and ado-
lescent protection, it is imperative that evidence-based training be established. The 
Child Advocacy Studies Training (CAST) program is based on the notion that the 
large majority of college-educated students eventually will become involved in pro-
fessions that involve child advocacy ( 26 ). The purpose of CAST is to educate future 
professionals to more effectively prevent, identify, and respond to maltreatment. 
Through CAST, students in medicine, law, criminal justice, public health, early 
childhood, computer science, sociology, women ’ s studies, psychology, education, 
social work, nursing, and other fields are trained in evidence-supported methods 
of preventing, identifying, and responding to child/adolescent abuse and neglect. 
Students also are taught how to implement and improve maltreatment prevention 
and child/adolescent protection systems of care the communities they join after 
graduation. The CAST program places emphasis on teaching and consultation by 
a wide variety of professionals in the field (e.g., psychologists, physicians, law 
enforcement, CPS workers, etc.) to keep the curriculum both current and reality-
based. The program utilizes and promotes multi-disciplinary approaches to the 
problem of child and adolescent maltreatment. 
 Although the CAST program has been implemented nationally at several univer-
sities at the undergraduate and graduate levels, the program has not yet been imple-
mented broadly in medical school settings. However, as reviewed above, physicians 
can be highly effective educators and leaders in such efforts ( 12 ,  14 ,  27 ), and use of 
the CAST program for improving the training of future physicians in maltreatment 
prevention, intervention and advocacy holds significant promise. 
 The purpose of the current study was to examine the effects of training medical 
students using a CAST elective course. It was expected that medical students ’ 
self-reported preparedness to address maltreatment and likelihood of reporting 
suspected maltreatment would increase significantly following CAST training, rela-
tive to a comparison group. In addition, it was anticipated that students ’ knowledge 
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in the areas of maltreatment identification and reporting would improve relative to 
comparisons. Specifically, it was hypothesized that: 
1.  Relative to students in the comparison group, students who complete the 
CAST elective will report being significantly more prepared to identify signs of 
maltreatment; 
2.  Relative to students in the comparison group, students who complete the CAST 
elective will report being significantly more prepared to report a case of suspected 
maltreatment; 
3.  Relative to students in the comparison group, students who complete the CAST 
elective will report being significantly more likely to report suspected maltreat-
ment, even if they did not know for sure it happened; 
4.  Relative to students in the comparison group, students who complete the CAST 
elective will report being significantly more prepared to recommend or secure 
needed services for a maltreated child or  adolescent; and 
5.  Relative to students in the comparison group, students who complete the CAST 
elective will demonstrate improved knowledge in the areas of maltreatment iden-
tification and reporting. 
 8.2  Our project 
 Eighty-nine of a total class of 177 first year medical students at a large Mid-western 
college of medicine stated their intentions to participate and were enrolled in the 
study. Of these, forty chose to enroll in the elective course, and all of these students 
completed both pre- and post-test measures. This group ( “ CAST elective group ” ) 
included nine males and 31 females. Of these, 30 students identified as  “ Caucasian or 
White, ” seven as  “ Asian ” and three as  “ Other. ” Thirty-two students in the CAST elec-
tive group reported having received 0 – 1 hour of training in the area of maltreatment 
prior to study participation. Six in the CAST elective group reported having received 
2 – 4 hours. Two students in the CAST elective group reported 8 + hours of prior trai-
ning in the area of maltreatment. 
 The comparison group consisted of 49 students who did not sign up for the elec-
tive but agreed to participate in the study. This group consisted of 31 males and 18 
females. Fourteen students in the comparison group failed to complete the post-test 
measure for unknown reasons. Thirty-three students in the comparison group iden-
tified as  “ Caucasian or White, ” three as  “ Black/African American, ” nine as  “ Asian, ” 
one as  “ Hispanic/Latino ” and three as  “ Other. ” Thirty-five students in the comparison 
group reported having received a total of 0 – 1 hour of training in the area of maltreat-
ment prior to study participation. Twelve students in the comparison group reported 
having received 2 – 4 hours. One student in the comparison group reported 5 – 7 hours 
of training prior to participation. One student in the comparison group reported 8 + 
hours of prior training in the area of maltreatment. 
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 A total of 75 students fully completed the study. The mean age for the entire 
sample was 22.82 years (SD  =  1.74). Participants ranged in age from 19 to 29 years old. 
Of the study completers, 52 students identified as  “ Caucasian or White, ” 2 as  “ Black/
African American, ” 14 as  “ Asian, ” one as  “ Hispanic/Latino ” and 6 as  “ Other. ” 
 8.2.1  Measures 
 Demographic information on all participants was collected before all other questions 
on the pre-test measure were asked. Participants reported their age, gender, ethnicity, 
and total number of hours of prior training in maltreatment. At both pre- and post-
test, medical students ’ perceived preparedness to identify and report maltreatment 
were both assessed using a 5-point Likert scale ranging from  “ Very Unprepared ” to 
 “ Very Prepared, ” with a neutral mid-point. Additionally, participants were asked how 
prepared they feel to recommend or secure needed services for a victim of maltreat-
ment using a 5-point Likert scale ranging from  “ Very Unprepared ” to  “ Very Prepared. ” 
Participants also were asked to determine how likely they would be to report suspec-
ted maltreatment even though they did not know for sure that it was occurring using 
a 5-point Likert scale ranging from  “ Very Unlikely ” to  “ Very Likely, ” with a neutral 
mid-point. 
 Students ’ actual ability to identify and report maltreatment was measured at 
both pre- and post-test using analog vignettes. Vignettes were written to depict 
situations likely to occur in medical practice settings. Although the larger study 
included vignettes depicting maltreatment in a variety of different developmental 
stages, to be consistent with the focus of this issue, only those pertaining to  adole-
scence (four) were included in this analysis. To most effectively evaluate true mastery 
of the concepts taught, the vignettes illustrated challenging or difficult aspects of 
 adolescent maltreatment cases (e.g., threatened harm without evidence of actual 
prior abuse; individuals with physical and/or developmental disabilities who are 
older than 18 years of age; see Appendices A – D). Some vignettes were developed 
to evaluate participants ’ ability to identify levels of suspicion and possible harm 
that may require reporting in cases that lack objective, definitive data indicating 
maltreatment. This dilemma parallels reality in that physicians often do not report 
suspected or questionable maltreatment because they believe they do not have 
enough information to be sure ( 10 ). The vignettes used were written according to the 
state laws on reporting abuse and neglect for the state in which the medical school 
was located. The vignettes used in this study were independently validated by a 
Board Certified Child and Adolescent Psychiatrist, a Licensed Clinical Psychologist, 
a Licensed Professional Clinical Counselor-Supervisor and an Attorney specializing 
in child and adolescent advocacy. There was 100% agreement in correct respon-
ses, across all raters, for all vignettes reported in this study. In accordance with 
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the expert responses,  “ Yes ” responses were considered correct for each of the eight 
vignette questions. Total scores were obtained by adding together the total number 
of correct responses on the scale. 
 8.2.2  Procedures 
 All first-year medical students at the medical school were contacted by email and 
invited to participate in a credit/no-credit elective course. Students were told that 
they would learn about child and  adolescent advocacy, maltreatment and its conse-
quences, and professional responses to maltreatment. The elective was one of 17 pre-
clinical elective courses offered to the students. The elective courses are optional for 
medical students, and offered to provide more in-depth training in areas of interest 
than is typically covered in the main curriculum. All preclinical electives are graded 
on a Credit/No Credit basis. Full participation in preclinical electives results in the 
receipt of  “ credit ” for the elective on the student ’ s transcript. Failure to meet parti-
cipation requirements for an elective in which a student has enrolled results in the 
receipt of  “ no credit ” recorded on the transcript. 
 Students enrolled in the elective course were asked to participate in a study exa-
mining the effectiveness and utility of the course material. They were informed that 
participation in the study would require their time and effort to complete a battery of 
self-report questions and questions about short vignettes prior to completion of the 
elective course and again after completing the course. 
 Students in the CAST elective group received an orientation at the beginning 
of the elective and attended didactic presentations to learn and discuss a variety of 
topics concerning maltreatment and advocacy. Students also met with faculty for 
informal, small group mentoring sessions. The students ’ involvement included a total 
of 20 hours of didactics and case discussion, approximately 2–4 hours of time with 
patients on the inpatient unit, independent study and preparation of papers/presen-
tations as follows: 
1.  Two-hour meeting every other month, during which faculty and related pro-
fessionals presented relevant topics, presented videos and documentaries, 
and facilitated discussion. Topics included: definition of child and adolescent 
maltreatment, prevalence, risk and protective factors, role of professionals 
in addressing maltreatment, reporting suspected maltreatment, physical and 
mental health indicators of maltreatment, medical perspectives on maltreat-
ment, cycles of family violence, promoting social change, corporal punishment 
and physical abuse, physician anticipatory guidance for prevention of maltreat-
ment, child and adolescent sexual abuse prevention, advocacy for maltrea-
ted children and adolescents, characteristics of sexual offenders and sexual 
offenses, domestic violence and health care, screening for maltreatment 
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and domestic violence, and resources for families affected by maltreatment. 
Professionals leading these lectures and discussions were from the following 
professions:  psychiatry, psychology, pediatrics, social work, and advocacy/law 
2.  1–2 hours in smaller group (15 – 20 students per smaller group) case discussion 
with faculty in child and  adolescent psychiatry, pediatrics and related professio-
nals on alternating months 
3.  Observation of one patient on the child and adolescent psychiatric inpatient unit 
with focus on the impact of adverse events on children and  youths. Students 
interacted with their assigned patients using games and casual discussion only 
(not clinical interviews, etc.). They read the patients ’ charts and discussed the 
cases with inpatient staff members. Students were required to initiate discussion 
about the cases at the smaller-group discussion meetings. There were no time 
requirements for students ’ case discussions. Cases were discussed for approxi-
mately 5 – 30 minutes, depending on the number and type of questions raised by 
the other students and the case 
4.  Each student studied one de-identified case involving suspected maltreatment. 
These were outpatient cases that had been evaluated and treated at the child and 
adolescent psychiatric mental health facility at the medical college hospital. Stu-
dents were required to develop and submit a (3 page) paper or 20 minute presen-
tation about the case. Thirty-six students wrote a paper, and four students made 
presentations about their assigned cases 
 A comparison group of first-year medical students was included in the study 
design in order to thoroughly examine the efficacy of the elective course compared 
to the usual medical curriculum. Students in the comparison group were recrui-
ted via the clubs and groups in the medical school and were asked participate in 
a study examining the effectiveness and utility of course material on maltreat-
ment. Comparison group participants were also informed that study participation 
would require their time and effort in completing a battery of self-report questi-
ons and questions about short vignettes during the fall semester of the 2011 – 2012 
academic year and again at the end of spring semester of the 2011 – 2012 academic 
year. Participants in the comparison group completed the same battery of self-
report questions and vignettes as the elective group at the same data collection 
time points. 
 The Institutional Review Board designated the study  “ exempt ” and did not require 
written consent for participation. Students were told verbally that their answers are 
anonymous, they should not write any personally identifying information on the 
questionnaires, and that they had the right to refuse to take part or withdraw at any 
time without consequences. The pre- and post-test questionnaires were administe-
red by study personnel (not faculty or other educators) in the classroom immediately 
prior and immediately following students ’ completion of the elective. 
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 8.2.3  What we found 
 Chi square and t-tests analyses were used to compare the CAST elective and com-
parison groups on the following demographic variables: sex, age, ethnicity, and 
number of hours of prior training in maltreatment. The groups differed only on the 
sex  variable chi squared (χ2) (1, N  =  75)  =  14.79, p   <  0.0001, indicating that there 
were more males in the comparison group. In addition, to determine if there were 
any identifiable  patterns of attrition, the 14 students who dropped out of the study 
were compared to the rest of the sample on the same demographic variables. These 
groups did not differ on sex, age, ethnicity or number of hours of prior training in 
maltreatment. Due to the imbalanced proportion of males to females between groups, 
all subsequent analyses conducted controlled for sex. 
 Repeated measure ANOVAs (with the variable  “ sex ” as a covariate) were con-
ducted to compare the responses of students in the elective and comparison groups 
over time. There was a statistically significant time by group interaction for perceived 
preparedness to identify signs of maltreatment, F(1,72)  =  29.87, p   <  0.0001, η 2   =  0.29. 
This effect favored the CAST elective group, suggesting this group ’ s scores on this 
item increased significantly more than did the comparison group ’ s scores from pre-
test to post-test. There was also a significant time by group interaction favoring the 
CAST elective group for students ’ perceived preparedness to report a case of sus-
pected maltreatment, F(1,72)  =  47.62, p   <  0.0001, η 2    =  0.40. There was a statistically 
significant time by group interaction favoring the CAST elective group for perceived 
likelihood of reporting maltreatment if they suspected, but did not know for sure, 
that maltreatment occurred, F(1,72)  =  17.10, p   <  0.0001, η 2    =  0.20. Lastly, there was a 
significant time by group effect on students ’ perceived preparedness to recommend 
and/or secure services for a maltreated child, F(1,72)  =  27.91, p   <  0.0001, η 2   =  0.28. 
 Table 8.1 depicts percentages of the CAST elective and comparison groups with 
correct responses to each of the eight vignette questions. To examine changes in student 
knowledge about maltreatment, CAST elective and comparison group vignette total 
scores were compared across time using repeated measures ANOVA (with the variable 
 “ sex ” as a covariate). There was a statistically significant time by group interaction on 
vignette total scores favoring the CAST elective group, F(1,72)  =  4.77, p  =  0.032, η 2   =  0.06. 
 8.3  Conclusions 
 The purpose of the current study was to examine the effects of training medical 
students using a CAST elective course. It was expected that medical students ’ self-
reported preparedness to address maltreatment and likelihood of reporting suspected 
maltreatment would increase significantly following CAST training, relative to a com-
parison group. In addition, it was anticipated that students ’ knowledge in the areas 
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of maltreatment identification and reporting would improve relative to comparisons. 
Results supported all five of the study ’ s hypotheses. Results indicate that students in 
the CAST elective reported higher degrees of preparedness to report and likelihood of 
reporting suspected maltreatment. Results also suggest that students in the elective 
group did, in fact, demonstrate improved knowledge in identification and reporting 
of  adolescent maltreatment compared to students in the comparison group who did 
not receive training in the areas of advocacy and maltreatment. Students in the elec-
tive group not only did better at identifying the maltreatment depicted in the vignet-
tes, but they also demonstrated improved ability to determine which cases should be 
reported. Thus, these results indicate that both perceptions and actual knowledge 
were improved for students who completed the CAST elective. The fact that elective 
students ’ knowledge and preparedness improved relative to a comparison group indi-
cated that the students ’ scores on the measures did not increase due to some factor 
(e.g., other medical didactics, life experience) other than the CAST training. Results 
suggest that general training in child and adolescent maltreatment and advocacy in 
the first year of medical school has the potential to improve future physicians ’ know-
ledge and likelihood of effectively identifying and reporting suspected maltreatment. 
 Although as expected, the percentage of correct responses to vignette questions 
did increase for the elective group, relative to comparisons, it is important to note 
there was not 100% correct responding in the elective group. This finding suggests 
 Table 8.1:  Percent correct on vignette questions at pre and post by group 
(N  =  75, CAST elective: n  =  40, comparison: n  =  35) 
 Vignette  Elective group (%)  Comparison group (%) 
 Pre-test vignette #1: Abuse  52.2  38.8 
 Post-test vignette #1: Abuse  87.5  40.0 
 Pre-test vignette #1: Report  40.0  30.6 
 Post-test vignette #1: Report  77.5  34.3 
 Pre-test vignette #2: Abuse  97.5  98.0 
 Post-test vignette #2: Abuse  100.0  97.1 
 Pre-test vignette #2: Report  90.0  91.8 
 Post-test vignette #2: Report  100.0  91.4 
 Pre-test vignette #3: Abuse  90.0  87.8 
 Post-test vignette #3: Abuse  97.5  88.6 
 Pre-test vignette #3: Report  77.5  71.4 
 Post-test vignette #3: Report  92.5  68.6 
 Pre-test vignette #4: Abuse  77.5  89.8 
 Post-test vignette #4: Abuse  95.0  91.4 
 Pre-test vignette #4: Report  85.0  87.8 
 Post-test vignette #4: Report  92.5  91.4 
 CAST: child advocacy studies training. 
 Abuse:  “ Is this child being maltreated?  ” , Report:  “ Would you report this case to Children ’ s 
Services? ” , All responses were  “ yes ” or  “ no. ” 
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that there is room for improvement in teaching the identification and reporting of 
 adolescent maltreatment. For example, the first vignette depicted an 18-year-old 
with severe mental retardation who often stays home alone for long periods of time. 
The majority of the total sample responded incorrectly to questions about this vig-
nette at pre-test. Although most elective students ’ scores improved following the elec-
tive, twelve percent still got this answer wrong at post-test. This may suggest a need 
for more thorough training or case examples about reporting maltreatment of indi-
viduals with disabilities, indicators of neglect, and/or age limits stipulated in state 
reporting laws. 
 Furthermore, it is important to note that reporting rates should have been con-
sistent with rates of identifying maltreatment. That is, if a case was endorsed as an 
example of suspected maltreatment, it should also have been endorsed as worthy of 
reporting, and therefore rates of identifying and reporting should have been identical. 
However, there was not 1:1 correspondence in that some cases judged to be maltreat-
ment were not judged to be reportable. This pattern of findings suggests a need to 
improve teaching about mandatory reporting of all cases of suspected abuse. 
 Results of the current study should be considered in light of certain limitations. 
Although the use of a comparison group was a strength of the study, there was 
not random selection from the medical student population nor was there random 
assignment to groups. Random assignment would have improved the likelihood 
of true group equivalency and improved the generalizability of the findings. The 
groups in the present study were not equivalent with respect to participant sex, with 
the comparison group having a higher proportion of males. Because males have 
been shown in some studies to be less likely to report maltreatment ( 11 ), this may 
have affected the findings. Further, the lack of random selection increases the like-
lihood that the students who chose to take the CAST course are not representative of 
medical students in general. Lastly, there was disproportionate drop-out in that all 
of the non-completers were from the comparison group. If possible, to prevent these 
issues, future studies should make use of random selection and random assignment 
to groups. 
 The fact that the sample was restricted to only one school limits the implications 
that can be made from the study. Future studies should replicate these findings at 
multiple sites in a variety of geographical regions, from schools with diverse student 
populations. Subsequent studies on the CAST program also should evaluate whether 
the effects last beyond medical training, and improve physician practice in maltreat-
ment and advocacy. 
 If replicated, these results would suggest that the CAST program may be an effec-
tive method of better preparing future physicians to address child and adolescent 
maltreatment. Broad dissemination of the program in medical schools across US 
could, in turn, have a significant positive impact on reducing child and adolescent 
maltreatment on a national level. This would represent a major advance in protecting 
children and adolescents and reducing human suffering. 
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 8.4  Appendices 
 8.4.1  Appendix A 
 An 18-year-old female with developmental disabilities (severe mental retardation) 
attends her annual physical exam. During the appointment, the girl ’ s mother talks 
about how stressed she has been as she struggles to work three jobs in order to make 
ends meet while trying to tend to the constant special needs of her teenager. She also 
mentions that finding someone to stay with the girl while she goes to work has been 
problematic. Mother mentions that the girl often stays home alone while she is at work. 
1.  Is this child being maltreated? (Please circle one.) Yes No 
2.  Would you report this case to Children ’ s Services?  Yes No
(Please circle one.)  
 8.4.2  Appendix B 
 A 15-year-old girl comes in for a physical to get medical clearance to play soccer 
for her high school. During the visit, the teenager asks the physician for advice 
about a situation that happened at her friend ’ s house the last two weekends. She 
explains that her friend ’ s stepfather has been watching pornography and does not 
allow the girls to leave the room. The teenager says that she feels uncomfortable 
because her friend ’ s stepfather touches his private parts while watching the por-
nography. 
1.  Is this child being maltreated? (Please circle one.) Yes No 
2.  Would you report this case to Children ’ s Services?  Yes No
(Please circle one.)  
 8.4.3  Appendix C 
 A 20-year-old male with transverse myelitis is seen for a regular check-up. The young 
man relies on a wheelchair for mobility and has to depend on his father ’ s girlfriend 
when he wishes to leave the home. His father reports that his son recently admitted to 
showing his penis to his father ’ s girlfriend on several occasions. Per father ’ s report, 
the young man told his father he did not want to show his penis, but he only does it 
because father ’ s girlfriend refuses to take him to the store if he does not follow her 
sexual requests. 
1.  Is this child being maltreated? (Please circle one.) Yes No 
2.  Would you report this case to Children ’ s Services?  Yes No
(Please circle one.)  
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 8.4.4  Appendix D 
 The mother of a 12-year-old girl and 10-year-old boy reports that her ex-husband has 
been threatening to lock her children in the dark basement for the weekend with no 
food if they continue to refuse to eat dinner while at his house every other weekend. 
While mother is explaining her concerns, the girl interjects and says,  “ He really will 
do it, too  – he did it to Kris before! ” Mother reports that Kris is her children ’ s half 
sibling. 
1.  Is this child being maltreated? (Please circle one.) Yes No 
2.  Would you report this case to Children ’ s Services?  Yes No
(Please circle one.)  
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 9   Bullying, psychiatric pathology and  suicidal 
behavior 
 Yuriy  Dobry ,  Mar í a Dolores  Braquehais and  Leo  Sher 
 Bullying is a highly prevalent behavior which carries a significant social, medical and 
financial cost for its victims and perpetrators, with powerful and long lasting psycho-
logical and social impact. Bullying has been defined as a specific form of intentio-
nal, repeated aggression, that involves a disparity of power between the victim(s) and 
perpetrators(s). The aggression can take physical, verbal, or gestural forms. The beha-
vior of bullying crosses sociodemographic categories of age, gender, ethnicity, level of 
academic achievement and professional environment. It has been abundantly observed 
by teachers and parents in elementary schools, but has also shown its negative presence 
in corporate boardrooms. The direst outcome of bullying, for both victims and perpetra-
tors, is an increased risk of psychiatric disorders including  depression, post-traumatic 
stress disorder,  anxiety disorders,  substance abuse, and suicidal behavior. Cruelty (and 
bullying, as one of its manifestations) break the basis of morality. Mental health pro-
fessionals usually treat the victims of those actions unfortunately long after they have 
been exposed to the harm. The evidence does not support the idea that the majority of 
cruel actions are intrinsically  “ pathological, ” in the sense of being motivated by  “ mental 
disorders. ” Therefore, only moral rules and legal actions  – but not psychiatric or psycho-
logical interventions  – may dissuade humans from this form of cruelty. 
 9.1  Introduction 
 The behavior of bullying carries a direct, significant social, medical and financial 
cost for its victims and perpetrators. Bullying can also cause an indirect harm to our 
social progress, a cost that is much harder to measure. Data demonstrates that bully-
ing is a highly prevalent behavior, with powerful and long lasting psychological and 
social impact on its victims and perpetrators ( 1 ). Interestingly, the behavior of bul-
lying crosses sociodemographic categories of age, gender, ethnicity, level of acade-
mic achievement and professional environment. It has been abundantly observed by 
teachers and parents in elementary schools, but has also shown its negative presence 
in corporate boardrooms ( 2 – 4 ). 
 Any involvement in bullying can impair the quality of life in victims, as well 
as for perpetrators of this reprehensible behavior. For example, Connoly and colle-
agues ( 5 ) have demonstrated that children who bully are at higher risk of developing 
severe relationship problems as adults. The trauma of bullying has been shown to 
be associated with severe and chronic psychiatric pathology, including  mood and 
anxiety disorders,  PTSD,  alcohol and drug abuse as well as personality disorders ( 6 ). 
The most alarming sequela of bullying, however, is its significant association with 
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 suicidal behavior ( 7 ). Thus, given the high social, personal and medical cost of bul-
lying, these social behavioral phenomena should be conceptualized as a source of 
severe trauma that can lead to psychiatric conditions. Thus, it should be approached 
from a multidisciplinary perspective involving teachers, parents, and mental health 
professionals ( 7 ). 
 9.2  Definition 
 There is a lack of consensus on exactly what comprises  “ bullying, ” and academic 
arguments continue reshaping the surface if its definition. A general framework of 
bullying, however, has been established and accepted by the community of resear-
chers involved in this subject matter. Olweus ( 8 ) defined bullying as a specific form 
of intentional, repeated aggression, that involves a disparity of power between the 
victim(s) and perpetrators(s). The aggression can take physical, verbal, or gestural 
forms. It can also be enacted through intentional exclusion of a person from a group, 
without apparent provocation on the part of the person being excluded. What sets 
bullying apart from other forms of abuse or violence is the social context in which it 
occurs and the imbalanced power relationship of the parties involved ( 8 ). 
 9.3  Demographics of bullying behavior 
 Wang and colleagues ( 9 ) have recently shown that, among US  adolescents, the preva-
lence of having bullied others or having been bullied at school for at least once in the 
last 2 months were 20.8% physically, 53.6% verbally, 51.4% socially, and 13.6% elec-
tronically. Males were more involved in physical and verbal bullying, whereas girls 
were more involved in relational bullying. Boys were more likely to be cyber bullies, 
whereas girls were more likely to be cyber bullying victims. Compared with 6th 
graders, 9th and 10th graders were less involved in bullying for physical (as bullies, 
victims, or bully-victims), verbal (as victims or bully-victims), relational (as victims or 
bully-victims), and cyber (bullies) form. 
 African-American adolescents were involved in more physical, verbal, or cyber 
bullying, but were found less likely to be victims of bullying. Higher parental support 
was associated with less involvement across all forms of bullying, and having more 
friends was associated with more bullying and less victimization for physical, verbal, 
and relational forms. However, this did not have a protective effect for cyber bullying. 
Lemstra et al ( 10 ) investigated bullying in 4,197  youth subjects in which 23% repor-
ted being physically bullied at least once or twice in the previous four weeks. They 
demonstrated that being male, attending a school in a low-income neighborhood, 
perception of having unhappy home life, arguments with parents and the desire to 
leave home have been found to be factors that may leave youth vulnerable to bullying. 
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 It is also important to recognize that bullying occurs outside of middle and high 
school settings. Murhtar and colleagues ( 2 ) found that almost 70% of medical stu-
dents had experienced some form of bullying in the past 6 months. Balducci et al ( 3 ) 
demonstrated that bullying is a prevalent behavior in the workplace, and a study of 
the Norwegian workforce by Nielsen and colleagues ( 4 ) demonstrated that, even in 
egalitarian Norway, almost 5% of people see themselves as victims of bullying, with 
nearly 7% reporting that they are exposed to a high degree of bullying behaviors and 
1% reporting that they are exposed to severe bullying. 
 9.4  Bullying and  suicidal behavior 
 As previously mentioned, the direst outcome of bullying, for both victims and per-
petrators, is an increased risk of suicidal ideation, suicidal attempts and completed 
 suicide. A study that involved 838 9th – 12th graders attending public high school 
demonstrated that subjects involved in bullying as a perpetrator, victim, or victim-
perpetrator were more likely than controls to report having seriously considered or 
attempted suicide within the past year ( 11 ). Fisher and colleagues ( 12 ) demonstrated in 
twin studies that exposure to frequent bullying predicted higher rates of self-injurious 
behavior, even after controlling for pre-morbid emotional or behavioral problems and 
environmental risk factors. A study by Winsper et al ( 13 ) showed that pre-adolescence 
subjects involved in bullying, especially in the role of being both a bully and a victim, 
were at increased risk for suicidal ideation, suicidal attempts and self-injurious beha-
vior. Brunstein and colleagues ( 14 ), however, suggested that bullying behavior in the 
absence of  depression or  suicidality is not an independent risk factor, but rather amp-
lifies inherent risk of suicidal behavior associated with depression. 
 9.5  Bullying and psychiatric pathology 
 Regardless of whether bullying increases the risk of suicidal behavior independently 
of psychiatric pathology, it is important to understand that bullying is, in fact, associ-
ated with a number of psychiatric conditions, all with inherent risk for suicidal beha-
vior. Kumpulainen et al ( 6 ) have shown that young subjects involved in bullying are 
more likely to struggle with disorders such as attention-deficit hyperactivity disorder, 
depression,  anxiety, and personality disorders. 
 9.6  Bullying and depression 
 Multiple studies have demonstrated a clear correlation between involvement in bully-
ing and a higher risk of developing a depressive disorder. Lemstra and colleagues ( 15 ) 
110   9  Bullying, psychiatric pathology and suicidal behavior
showed that children who were physically bullied multiple times per week were 80% 
more likely to develop symptoms of  depression in comparison to controls who never 
experienced bullying. A retrospective study by Lund et al ( 15 ) claimed that adult men 
with a self-reported history of being bullied at school were significantly more likely to 
be diagnosed with a depressive disorder later in life. A prospective study that looked 
at 2,348 young boys ( 16 ) demonstrated that subjects who were both perpetrators and 
victims of bullying were at higher risk for developing depression and  suicidal beha-
vior later in life. 
 9.7  Bullying and  PTSD 
 Bullying, although not considered to be a form of acute trauma, has been shown to be 
associated with symptoms of Post-Traumatic Stress Disorder (PTSD). Positive corre-
lation between symptoms of PTSD and exposure to bullying were also demonstrated 
among subjects who experienced bullying at work ( 17 ). Another study that attempted 
to assess prevalence and intensity of PTSD symptomatology among victims of bully-
ing at work demonstrated that more than 70% of bully victims developed symptoms 
of PTSD and displayed a moderate or severe impairment in social functioning ( 18 ). 
 9.8  Bullying and  anxiety disorders 
 People involved in bullying also appear to be at a higher risk of anxiety disorders 
other than PTSD. One study demonstrated that social phobia, obsessive compulsive 
disorder and panic disorder were all positively associated with severe teasing and bul-
lying experiences ( 19 ). Kumpulainen et al ( 20 ) showed that, among children victims 
of bullying, anxiety symptoms were as frequent as 8.7%, significantly higher than 
controls. Another study demonstrated that being a bully, victim of bullying, or having 
a role of being both a bully and victim in preadolescence (aged 10 – 12 years) ( 21 ) sig-
nificantly predicted  development of anxiety symptoms in  adolescence (aged 10 – 17 
years) ( 22 ). Data also supports a strong, positive correlation between involvement in 
bullying and development in anxiety symptoms in younger children, those in grades 
5 through 8, and students aged 12 – 17 years ( 23 ). 
 9.9  Bullying and substance and  alcohol abuse and dependence 
 Finally, research has consistently demonstrated that subjects involved in bullying are 
more likely to use alcohol and illicit psychoactive substances. In one large sample, 
it was shown that substance use and bullying behaviors co-occurred among 5.4% of 
 adolescents in the US ( 24 ). A nationally representative survey of 6th – 10th graders in 
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the US found that  alcohol use was associated with increased odds of bullying ( 25 ). 
A study of  adolescents ages 12 – 17 years who were admitted to inpatient  psychiatry 
units showed that the use of any substance (e.g.  tobacco, alcohol and drugs) was 
generally more common among bullies ( 26 ). Finally, a large study based on school 
children demonstrated that students who were engaged in bullying were more likely 
to be smokers and to have had a history of alcohol use ( 27 ). 
 9.10  Philosophical considerations 
 “ Bullying ” is a term that describes the nature of some  “ cruel ” action (taking place 
primarily, but not exclusively, in the school environment), as the term  “ child sexual 
abuse ” perpetrated by relatives is the new, scientific word currently used when refer-
ring to  “ incest ” . Cruelty, though not always violent, is always aggressive. Moreover, it 
is a phenomenon linked to human nature. It happens when one inflicts pain on the 
other with apparent provocation (as opposed to  “ revenge ” or even  “ justice ” ). Most 
importantly, cruelty happens in asymmetric relationships: a  “ master ” (who possess 
and exerts the power) uses physical and/or verbal violence against a  “ slave ” (the 
victim) who is always in a weaker position and has no or insubstantial defense ( 28 ). 
Sometimes the  “ master ” is not represented by a single individual but by a group, and 
the nature of this relationship is not stable and may change in the future. Victims may 
be cruel to other victims, or they may engage in cruel behavior to a former master if a 
former master  “ falls ” in the social order. 
 In any case, the gratuitous nature of cruel actions and their independence from 
sexual gratification make them different from  “ sadomasochism. ” It also differs from 
revenge as it has not been motivated by any previous harm. From an evolutionary per-
spective, we could add that it has no relationship with self-defense and/or with the 
 “ struggle for life. ” The German philosopher Schopenhauer (1788 – 1860) said that 
the unbearable suffering of living leads to those expressions of violence, following 
the fantasy of being able to  “ master ” that life anguish through the exercise of power 
against another human being ( 29 ). 
 From the philosophical point of view, we can either follow the Hobbesian view, 
according to which cruelty is an innate characteristic of all human beings ( “ homo 
homini lupus ” ) ( 30 ), or we can share Rousseau ’ s thesis (mankind is a good and innocent 
specie that has been spoiled by society) ( 31 ). Some philosophers underline the role of the 
individual, others, the role of the nature of the relation (i.e., the  “ systemic ” approach). 
 Nevertheless, cruelty (and bullying, as one of its manifestations) break the basis 
of morality. We, as mental health professionals, usually treat the victims of those 
actions unfortunately long after they have been exposed to the harm. Perpetrators of 
bullying generally (but not always) must bear with the sanctions society has develo-
ped to control violence, and they are often reluctant to participate in psychological 
interventions. In any case, the evidence does not support the idea that the majority 
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of cruel actions are intrinsically  “ pathological, ” in the sense of being motivated by 
 “ mental disorders, ” but a human phenomenon related to the nature of our condi-
tion. Therefore, only moral rules (expressed, for instance, in educational models) and 
legal dispositions  – but not psychiatric or psychological interventions  – may dissu-
ade humans from this form of cruelty. 
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 10   Dating violence and  suicidal behavior 
in  adolescents 
 Kristin  Holmes and  Leo  Sher 
 The aim of this chapter is to assess the possible consequences of adolescent physical, 
emotional and sexual dating violence through a review of the literature on the topic. 
An electronic search of major biomedical bibliographic databases (Pubmed, ISI, Psyc
INFO) was used to retrieve articles providing information on the prevalence rates, 
risk factors, associated consequences and possible preventive measures for adole-
scent dating violence across different populations. Currently, there have been few 
longitudinal studies conducted to identify potential risk factors for entering a violent 
dating relationship in adolescents. Risky behaviors such as earlier sexual intercourse 
may predispose someone for victimization. Dating violence itself is also a predictor of 
future dating violence. Adolescent dating violence was associated with an increase 
in other violence-related behaviors, substance use,  depression, poorer educational 
outcomes, post-traumatic stress, unhealthy weight control, and risky sexual behavior. 
The association between adolescent dating violence and an increase in suicidal beha-
vior is a major public health concern. Future research should focus on longitudinal 
studies so that a causal relationship between dating violence and  suicidality may be 
better understood. 
 10.1  Introduction 
 Approximately 9% of adolescents are victims of dating violence ( 1 ). As this review of 
the current literature reveals, dating violence has numerous physical and psycholo-
gical implications, the most serious of which is suicidality. The prevalence of dating 
violence in adolescent relationships and its consequences (including suicidality) is 
discussed and purported risk factors for its occurrence are reviewed. Additionally, 
limitations of the current research are examined and directions for future research 
and prevention are proposed. 
 According to the Center for Disease Control and Prevention (CDC), adolescent 
partner violence can be characterized along four dimensions: emotional, physical, 
sexual, and stalking ( 1 ). Each categorization consists of a number of violent behaviors, 
which range in severity. Emotional dating violence includes verbal abuse, and jealous 
or controlling behaviors such as preventing the partner from talking to members of 
the opposite sex, checking text messages or emails, or not allowing the partner to 
keep in touch with members of his or her friends and family. Physical dating violence 
consists of everything from pushing or restraining to hitting, punching, choking, or 
the use of a weapon against one ’ s partner. Sexual dating violence includes uncomfor-
table remarks as well as any unwanted sexual experiences. Stalking includes threats 
or patterns of harassment that are used to instill fear in the victim ( 1 ). 
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 10.1.1  Literature search 
 An electronic search of the major biomedical bibliographic databases (Pubmed, ISI, 
PsycINFO) was conducted to retrieve articles published between the years 2000 and 
 2012 describing the social, epidemiological and clinical characteristics of dating 
violence and its relationship to  suicidal behavior in  adolescents. Key words for the 
search included  “ adolescent, ”  “ teen, ”  “ dating violence, ”  “ victimization, ”  “ abuse, ” 
 “ suicide, ” and  “ suicidal behavior. ” 
 10.2  Findings 
 Upon analysis of the prevalence of dating violence in adolescents, it becomes appa-
rent that this is a widespread problem among  youth. Across both genders, approxi-
mately 9 – 17% of adolescents report physical dating violence ( 2 ,  3 ). The variation in 
prevalence rates may be attributable to differences in sample populations. Among 
New York City youth, 10.6% of females and 9.5% of males reported physical dating 
violence ( 4 ). Similar results were found in a nationally representative sample of boys 
with 9.13% reporting physical dating violence ( 5 ). 
 A study focusing on Black and Hispanic youth found that approximately 10% of 
youths reported dating violence victimization in the past year ( 6 ). In a survey study of 
Latino youths aged 11 – 13 residing in suburban Washington DC, prevalence of dating 
violence was 14.4% for girls and 12.9% for boys (13.5% across the sample) ( 7 ). Preva-
lence of dating violence among adolescent boys was highest for those who classified 
themselves as black or ethnically  “ other ” ( 5 ). These slightly higher rates of dating vio-
lence among minorities may be due to socio-economic status or cultural differences. 
 In a study of New York City youth, 9.6% of females and 5.4% of males reported a 
lifetime history of sexual assault ( 4 ). 13.2% of adolescents in a large survey of students 
in grades 7 – 12 reported unwanted sexual experiences perpetrated by a peer ( 2 ). A study 
focusing on Black and Hispanic youth found that approximately one in 10 youths 
reported dating violence victimization in the past year and 1 in 10 girls reported a 
history of sexual assault in her lifetime ( 6 ). Analysis of the 1997 and 1999 Massachu-
setts Youth Risk Behavior Surveys revealed that about one in five female adolescents 
had been a victim of physical and/or sexual dating violence (20.2% in 1997 and 18.0% 
in 1999) ( 8 ). Another large survey-based study found that 24.6% of youths in grades 
7 – 12 reported at least one of these forms of victimization ( 2 ). 
 Although both boys and girls experience dating violence victimization, in a study 
of 190 high school students, girls reported higher levels of severity and frequency of 
dating violence ( 9 ). In concurrence, another study found that males are more apt to 
engage in severe forms of physical aggression (4.6% vs. 2.0%) that result in serious 
medical consequences for the victim ( 10 ). Females, however, reported a significantly 
higher percentage of verbal aggression than males ( 10 ). 
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 10.2.1  Risk factors 
 To date, most research on  adolescent dating violence has been cross-sectional in 
nature. Thus, while many risk factors for engaging in adolescent dating violence have 
been proposed (i.e., exposure to domestic violence in the family of origin, low socio-
economic status, etc.), they have yet to be validated scientifically. Similarly, a causal 
relationship between mental health symptoms such as  depression,  anxiety, or  suici-
dality and dating violence cannot be established. There have been a few longitudinal 
studies, however, that provide some insight into precursors for and consequences of 
adolescent dating violence. 
 One such study proposed several potential risk factors for dating violence ( 11 ). 
This study followed girls dating in grade 9 in an attempt to predict profiles of dating 
relationships in grade 11 based on the girls ’ relationships with families and peers. 
They found that an adolescent girl ’ s involvement in a mutually violent dating rela-
tionship in grade 11 could be facilitated by several risk factors (i.e., delinquency, 
parental rejection, and sexual harassment perpetration) evident during grade 9. 
Moreover, girls in grade 11 who reported being solely victims in violent dating rela-
tionships had higher rates of sexual intercourse in grade 9 ( 11 ). This implies that 
early relationships may predispose a girl to future victimization during later  ado-
lescence. Sexual relationships at this young of an age may directly place girls at 
more risk for later physical violence. Or, perhaps these girls have some personality 
characteristics that lead them to relationships with a certain aggressive type of male 
or to engage in riskier behaviors that consequently make them more vulnerable to 
victimization. 
 Dating violence in itself is a risk factor for further dating violence. One study found 
that 8% of boys and 15% of girls were persistently aggressive with the same partner 
over a period of 3 months. In a year-long longitudinal study of dating aggression in 
Canadian high-school students, 13% of participants reported recurrent dating aggres-
sion across two different relationships ( 12 ). Of the remaining participants, 55% repor-
ted no dating aggression at either point and 32% reported dating aggression in one of 
their relationships during this time period. This study was unique as it was the first 
to study recurrent aggression across multiple dating relationships. Different patterns 
of aggression emerged from these groups. For those who reported dating violence in 
only one relationship, frequency of dating aggression was low (most reporting that 
the acts occurred  “ rarely ” ) and the severity was reported as being minor (pushing, 
grabbing, or shoving). For those who reported aggression in two relationships, the 
frequency of aggression was higher at the second data collection point. Also, most 
adolescents reported that aggression occurred in both directions, with each partner 
acting as a victim and a perpetrator ( 12 ). Another study also found that victimiza-
tion in a dating relationship predicted perpetration ( 13 ). Therefore, being a victim of 
dating violence not only puts an adolescent at risk for further victimization, but also 
becomes a risk factor for perpetration. 
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 These findings suggest that patterns emerge in early relationships that make 
an  adolescent vulnerable to victimization and/or perpetration of physical dating 
violence. If these risk factors are identified early on, later dating violence could be 
prevented. Perpetration of physical violence can be predicted by previous victimi-
zation and engagement in psychological aggression (i.e., verbal aggression, jealous 
behavior, and controlling behavior) ( 14 ). Due to this  “ circle-of-violence ” in which 
the victim evolves into the perpetrator, it is especially important to intervene at early 
stages and break this cycle before violent patterns are materialized. 
 10.2.2  Psychiatric and social consequences of dating violence 
 Cross-sectional studies found that dating violence was associated with an increase 
in other  risk behaviors and mental health consequences such as violence-related 
behaviors, substance use,  depression and suicidal ideation ( 3 ). Dating violence was 
also associated with poorer educational outcomes ( 2 ), post-traumatic stress ( 9 ), and 
unhealthy weight control including diet pill use, laxative use and vomiting ( 8 ). In 
a nationally representative sample, risky sexual behavior was also associated with 
physical dating violence ( 5 ,  8 ). More specifically, those boys who reported two or more 
sexual partners in the past 3 months, compared with those who reported none, were 
over three times more likely to report violence ( 5 ). 
 Two different US surveys of risk behavior in youths found an association between 
drinking  alcohol, smoking cigarettes and using cocaine with dating violence ( 5 ,  8 ). In 
a study of Latino early adolescents, girls who binge drank were 27 times more likely to 
report dating violence ( 7 ). The association between current alcohol consumption and 
dating violence was also seen among male high-school students in central Thailand 
further proving that this finding extends to many different cultures ( 15 ). 
 10.2.3  Dating violence and  suicidality 
 Suicidality is a serious consequence of adolescent dating violence. The  adolescent 
 suicide attempt rate is high, with a 2005 New York City survey finding that 11.7% of 
female and 7.2% of male adolescents have made one or more suicide attempts ( 4 ). 
Dating violence victimization may be a significant risk factor for adolescent suici-
dality as they were found to be associated in several studies ( 6 ,  16 ). In one study of 
adolescent abortion patients, dating violence was related to severity of suicidal thin-
king; and, as the severity of the adolescent females ’ general problems with aggressive 
behavior rose, the magnitude of the relationship between dating violence and seve-
rity of suicidal thinking increased ( 17 ). This suggests that there may be personality 
traits or psychiatric illnesses that mediate the relationship between dating violence 
and suicidality. In another study, female Asian-American and Pacific Islander  youth 
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were significantly more likely to consider  suicide and to have made a suicide attempt 
than males ( 18 ). Therefore, dating violence victimization may be a greater hazard 
for female  adolescents than male. Even though dating violence can increase the fre-
quency and severity of suicidal thoughts and increase the risk of making an attempt, 
research on this topic is sparse. Additional research with a broader sample would 
be beneficial to the  development of prevention initiatives for both adolescent dating 
violence and  suicidality. 
 10.3  Discussion 
 There are many theoretical mechanisms which may account for an increase in sui-
cidality resulting from dating violence. While dating violence can directly increase 
the risk for suicidality in the victim, it more often leads to other health consequen-
ces, which in turn bolster suicidal ideation and behavior. These consequences act as 
mediators, as they facilitate the risk for suicidality, due indirectly to engagement in 
dating violence. 
 One such mediator could be the multitude of negative mental health consequen-
ces that were discussed earlier such as  depression,  anxiety, post-traumatic stress, 
substance use, or disordered eating patterns. These mental health outcomes in turn 
increase the risk for suicidal thoughts or behaviors in the victim. Another possible 
mediator, which requires further study, is the medical consequences associated with 
dating violence. Some medical consequences of dating violence such as bruises, 
broken bones, and cuts have been discussed. As these adolescents grow older, the 
medical consequences may become even more severe leading to injuries requiring 
major medical stabilization or a lifetime of disability such as traumatic brain injuries 
(TBIs). It is very likely that these medical consequences can lead to an increase in 
 suicidal behavior. For example, multiple lines of evidence suggest that TBIs are asso-
ciated with suicide attempts and suicides ( 19 ,  20 ). 
 There may also be more complicated mechanisms facilitating suicidality in this 
population. Psychiatric illnesses such as depression or substance use may predispose 
an adolescent to violent dating relationships. Therefore, the adolescent is more likely 
to have an increase in suicidality after involvement in dating violence because of the 
pre-existing mental health issue. Suicidal behavior may have a possible genetic com-
ponent that may be mediated by familial transmission of impulsive aggression ( 21 ). 
 Finding a method to reduce suicidality in adolescents is of extreme importance. 
Dating violence is one reason an adolescent may suffer from suicidal thoughts and 
have made one or more suicide attempts. Identifying at-risk  youth should be the first 
step towards prevention of both dating violence and suicidality. Early detection of 
risk factors for suicidal behavior may help identify families that are at risk ( 21 ). This 
is important because the family unit is an integral part of the adolescents ’ develop-
ment and family connectedness is inversely related to dating violence ( 3 ). If an at-risk 
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family is identified early-on, perhaps the family can receive the resources they need 
to promote family connectedness and prevent negative developmental outcomes such 
as  depression,  substance abuse, dating violence and  suicidality. 
 Educating those families and  youth that are at risk about dating violence should 
be the next step after identification towards prevention. Media may be a beneficial 
means to educating  adolescents because teens tend to be influenced by what they see 
in the media and pop-culture. Informative and positive media campaigns may reduce 
the negative effects of other forms of mass media that may instigate teen dating vio-
lence or other risky behaviors ( 22 ). Youth are also influenced by the environment in 
which they live. Therefore, attempts at educating youth should extend past the use of 
media to include the family, schools and community programs. A multi-dimensional 
approach between pediatricians, families, schools, and communities would be the 
most effective strategy towards prevention of  suicide attempts in adolescents ( 6 ). This 
multi-dimensional approach should include as stated, education, but also include 
attempts to get youth involved in positive programs that will make them feel connec-
ted to the community, enhance their sense of self and reduce involvement in risky 
behaviors and past-times. Sports and art, music, or drama programs are examples 
of some positive activities that families, schools, and communities can offer youth to 
prevent negative behaviors that may lead to dating violence and suicidality. 
 Future research on this very important topic should focus on longitudinal studies 
so that a causal relationship between dating violence and suicidality might be better 
understood. Mediating factors (i.e., medical problems,  depression, and substance 
use) should also be examined due to their role in adolescent suicidality and violence. 
Identifying all risk factors for dating violence and suicidality is essential for imple-
menting effective intervention strategies. 
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 Section IV: Post-traumatic stress disorder 

 11   Post-traumatic stress disorder, medical illness 
and  suicidal behavior 
 Yuriy  Dobry and  Leo  Sher 
 Post-traumatic stress disorder ( PTSD) is concerning because of not only the severity 
and chronicity of its symptoms  – including distressing nightmares, flashbacks,  anxiety 
attacks, and maladaptive patterns of avoidant and nearly paranoid behavior  – but also 
the wide spectrum of clinical and social impairments it is tightly associated with. The 
most striking example of clinical morbidity associated with PTSD is the well-known 
increase in the risk of suicidal behavior. Given that PTSD and medical illnesses increase 
the likelihood of  suicide separately and independently, it is reasonable to suggest that 
the risk of suicidal behavior differs between patients suffering from PTSD comorbid with 
medical illnesses and patients having either condition alone. The available data point 
toward a novel clinical notion  – an altered risk of suicidal behavior in patients suffe-
ring from comorbid PTSD and medical illnesses. This area of overlap between medicine 
and  psychiatry is still in its infancy, with many unanswered questions about the rate, 
patterns, and psychobiological mechanisms of suicidal behavior in this patient popula-
tion. The positive association between PTSD, medical illness and suicidal behavior that 
appears to exist in adult population, most likely affects the pediatric population as well. 
Closer investigation into the significance of the association between chronic medical 
illnesses, PTSD and  suicidality in children,  adolescents, and adults is necessary. 
 11.1  Introduction 
 Post-traumatic stress disorder (PTSD) is a set of pathological, emotional, and beha-
vioral responses to severe trauma, which are often associated with a sense of help-
lessness and loss of control ( 1 ,  2 ). This disorder can be triggered by a wide range of 
traumatic events  – war related violence, school bullying, or even parental neglect ( 1 ). 
Consequently, it is widely prevalent. Upto 6% of men and 14% of women in the US are 
expected to be diagnosed with PTSD in their lifetimes ( 1 ). Additionally, the return of 
massive numbers of traumatized combat  veterans from wars in Iraq and Afghanistan 
is anticipated to bring with it a tidal wave of patients with new onset PTSD. 
 Unfortunately, PTSD is a relatively novel diagnosis, known only superficially to 
the general public, and is often underdiagnosed by the clinicians in every field of 
medicine, including mental health ( 3 ,  4 ). Nevertheless, the illness has progressively 
been recognized for its role as one of the most prevalent and debilitating psychiatric 
conditions. Such recognition is necessary for clinical, academic, and social resources 
to be allocated to the understanding, treatment, and prevention of PTSD, which is 
considered one of the most individually debilitating and socially costly psychiatric 
conditions for reasons explained below. 
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 11.2   PTSD and  suicidality 
 PTSD is concerning because of not only the severity and chronicity of its symptoms  – 
including distressing nightmares, flashbacks,  anxiety attacks, and maladaptive 
patterns of avoidant and nearly paranoid behavior  – but also the wide spectrum of 
clinical and social impairments it is tightly associated with ( 5 ,  6 ). The most striking 
example of clinical morbidity associated with PTSD is the well-known increase in 
the risk of  suicidal behavior ( 7 ,  8 ). Of all individual anxiety disorders, only PTSD is 
strongly and independently associated with suicidal ideation and  suicide attempts, 
as revealed by Sareen et al ( 9 ) using a large, civilian sample from the US. Moreover, 
PTSD is strongly correlated with suicidal behavior, as shown in the 50-article meta-
analysis by Krysinska et al ( 10 ) .
 11.3  PTSD, medical illness and suicidality 
 The relationship between PTSD and suicidal behavior appears to be more complex 
than a simple, direct correlation. A growing amount of data indicate PTSD not only 
carries a strong, independent risk for suicidality but also is frequently comorbid with 
a number of medical conditions ( 11 ,  12 ). For example, respiratory, cardiovascular, 
neurological, and rheumatologic disorders, each of which constitutes an indepen-
dent risk factor for suicidal behavior (as evidenced by data from hospitalized patients 
with medical illnesses, who demonstrated greater than eight times the rate of suicide 
of the standardized general population ( 13 ). 
 Given that PTSD and medical illnesses increase the likelihood of suicide separa-
tely and independently, it is reasonable to suggest that the risk of suicidal behavior 
differs between patients suffering from PTSD comorbid with medical illnesses and 
patients having either condition alone. The first line of evidence that supports this 
idea is a study by Freeman et al ( 14 ) who used a general health survey to examine pati-
ents with PTSD in terms of self-reported assessments of physical functioning. Interes-
tingly, they found that  military  veterans with PTSD and a history of suicide attempts 
scored lower in such categories as vitality, bodily pain, and general health perception 
than matched controls without histories of suicidal behavior. These results suggested 
that poorer general health status and lower perception of physical health are associa-
ted with a higher risk of suicidal behavior in patients with diagnoses of PTSD. Additi-
onally, the demonstration that negative self-perceptions of health might be positively 
correlated to a risk of suicidality in this patient population hints at a potential psycho-
logical mechanism of these findings. 
 Further evidence on the relationship between PTSD and suicidal behavior is provi-
ded by Brenner et al ( 15 ) who studied patients with comorbid PTSD and traumatic brain 
injury (TBI). They statistically demonstrated that the risk of suicidal behavior is signifi-
cantly higher in patients with comorbid PTSD and TBI than in patients diagnosed with 
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TBI only. Even more evidence is provided by Barnes et al ( 16 ) who found that mild TBI 
increases the severity of  PTSD symptoms in patients suffering from the co-occurrence 
of these disorders, possibly increasing the risk of  suicidal behavior in this population 
indirectly. These findings further suggest an interplay between TBI and PTSD that might 
alter the risk of  suicide. Providing additional evidence that the interaction between 
symptoms of medical conditions and those of PTSD can potentially augment the risk of 
suicide, another study demonstrated that cancer patients with acute stress disorder (a 
syndrome similar to PTSD) had an increased risk for suicidal ideation compared with 
cancer patients without ASD ( 17 ). 
 11.4   How PTSD and medical illness interact to influence 
suicidal behavior? 
 From an examination of the above findings, two relationships emerge: medical dis-
orders are more common among PTSD sufferers than in the general population, and 
this co-occurrence appears to pose a unique risk for suicidal behavior when compa-
red with the independent risks inherent to both PTSD and medical conditions. To the 
best of our knowledge, however, the psychobiological mechanisms governing these 
comorbidities and the altered suicide rates associated there with have not been ade-
quately investigated. We propose several possible ways in which PTSD and medical 
illness might interact to influence suicidal behavior, regardless of the cause-and-
effect relationships between the two diagnoses (whether PTSD precedes a medical 
illness, or results from it). First, PTSD from some, initial traumatic event may become 
exacerbated by a new onset of PTSD symptoms caused by a medical illness, and this 
interaction could modulate the risk of suicide. Second possibility is that the sym-
ptoms of  anxiety or  mood disorders, which are associated with numerous medical 
diseases, might augment the risk of suicidal behavior in patients suffering from PTSD. 
Finally, neurological, endocrine, and immune abnormalities known to be associated 
with various medical disorders might influence PTSD symptomology (and conse-
quently, the risk of  suicidality). For example, the hypothalamic-pituitary-adrenal axis 
and several immunomodulators have been shown to play critical roles in chronic, 
severe diseases such as cancer and diabetes, as well as in PTSD ( 18 ,  19 ). 
 The available data point toward a novel clinical notion  – an altered risk of sui-
cidal behavior in patients suffering from comorbid PTSD and medical illnesses. This 
area of overlap between medicine and  psychiatry is still in its infancy, with many 
unanswered questions about the rate, patterns, and psychobiological mechanisms 
of suicidal behavior in this patient population. For instance, does the risk of suicide 
increase, decrease, or remain unchanged after the addition of a particular medical 
comorbidity in PTSD patients, and is the change additive or synergistic? How do the 
risks of suicidal ideation, suicide attempts, and completed suicide differ between a 
person in whom medical illness caused PTSD and a person who experienced PTSD 
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before a medical illness? Finally, can biological markers in this patient population 
provide some clues regarding the mechanism of altered  suicide risk, and can these 
markers serve as targets for therapeutic agents? Regardless of the underlying mecha-
nism of the risk of  suicidality in patients with comorbid  PTSD and medical illnesses, 
future studies need to address the above questions with the goal of devising better 
approaches to screening and treatment, given the medical, social, and economic 
implications of suicide. 
 11.5  Implications for children and  adolescents 
 The positive association between PTSD, medical illness and  suicidal behavior that 
appears to exist in adult population, most likely affects the pediatric population 
as well. Thus, it is an extraordinarily alarming but very poorly understood overlap 
between the fields of pediatric medicine and  psychiatry that deserves serious aca-
demic attention. The following studies underscore the link between PTSD, medical 
conditions and suicide in children and adolescents. Stuber and colleagues ( 20 ) 
demonstrate in their paper that PTSD is tightly associated with pediatric medical 
illness, and is often a psychiatric product of a physical disease. Seedat et  al ( 21 ) 
investigated medical comorbidities in female children and  adolescents with PTSD 
in a cross-sectional, epidemiologic case-control analysis and showed that PTSD is 
associated with adverse health outcomes affecting almost every organ system, both 
in children and adults. At the same time, Vajda and colleagues ( 22 ) showed through 
a retrospective medical record review that adolescent patients with chronic medical 
conditions and illness are more likely to have a history of repeat suicide attempts. 
Finally,  Lipschitz and colleagues ( 23 ) described clinical correlates of PTSD in over 
70 adolescent (aged 11.1 – 18.3 years) who were assessed using a structured diag-
nostic interview. Male and female adolescent subjects diagnosed with PTSD were 
significantly more likely to have attempted suicide and report greater depressive and 
dissociative symptoms. Closer investigation into the significance of the association 
between chronic medical illnesses, PTSD and suicidality in children and adolescents 
is necessary. We recommend a broad based, multidisciplinary approach to the aca-
demic and clinical aspects of this relationship. 
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 12   Prevention of  suicidal behavior in  adolescents 
with post-traumatic stress disorder 
 Eugene  Ruby and  Leo  Sher 
 Post-traumatic stress disorder ( PTSD) is significantly associated with an increased 
risk for suicidal behavior among adolescents.  Suicide is one of the top three causes 
of  adolescent deaths worldwide. Despite the strong relationship between PTSD and 
 suicidal behavior, precise causal pathways linking PTSD to suicide in adolescents 
remains unclear. A slew of mediating factors and variables commonly present 
 themselves with both suicide and PTSD, including comorbid psychiatric disorders, 
exposure to different forms of trauma and stressful life events, core  neurobiological 
changes, and mental, emotional, and physiological states like hyperarousal, 
 impulsivity, and aggression. Because  youth is such a critical stage of  development, 
it is very important that at-risk adolescents are identified and referred for treatment. 
With many  treatment challenges in these populations, effective implementation and 
use of prevention methods are of increasing importance. The most proven prevention 
methods include  physician education,  means restriction, and  gatekeeper training. 
Other strategies that have received empirical support are public education campaigns 
and implementing guidelines for the media, including those for television, print 
media, and the Internet. 
 12.1  Introduction 
 A 2010 report, using the National Comorbidity Survey-Adolescent Supplement, found 
the lifetime prevalence of post-traumatic stress disorder (PTSD) in 10,123 adolescents 
aged 13 – 18 years to be 5% (and 7% for those aged 17 – 18 years) ( 1 ). A 1999 literature 
review found this number ranged from 3.5 – 8.1% for adolescents, compared with 
adult populations which exhibited figures as low as 0.8 – 1.2% ( 2 ). Adolescents are at a 
 particularly high risk for experiencing traumatic events ( 3 ) and developing PTSD as a 
result of these experiences ( 4 ). This is especially worrisome because youth is a critical 
stage of development, and having PTSD can hinder maturation and identity  formation 
and lead to life-long deficits with necessary mental and emotional skills ( 2 ). 
 Post-traumatic stress disorder is significantly associated with an increased risk 
for suicidal behavior ( 5 ,  6 ), though this association has been much less researched 
than the relationship between suicidal behavior and other disorders known to be risk 
factors, like major  depression and substance-use disorders ( 7 ). One study found that 
among 3,021 adolescents and young adults, aged 14 – 24 years, who made past suicide 
attempts, PTSD corresponded with a higher risk for suicide attempts than any other 
psychiatric illness ( 8 ). 
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 According to the World Health Organization (WHO) ( 9 ),  suicide is one of the top 3 
causes of death among those aged 10 – 24 years. About 4 million  adolescents attempt 
suicide every year and more than 100,000 of attempters successfully take their own 
life, resulting in one  youth suicide every 5 minutes around the world ( 10 ). Annually, 
suicides are responsible for 1.6% of all deaths in the US, but 15.6% of deaths among 
those aged 15 – 24 years ( 11 ). Judging by the fact that suicide is  extremely  difficult to 
predict in the clinical setting ( 12 ), focusing a great deal of effort on  preventing  sui-
cidal behavior outside of the clinical setting is of the utmost  importance (e.g., limi-
ting access to lethal means or implementing guidelines for the media to follow when 
reporting about suicides). The purpose of this review is to discuss and critically 
analyze prevention methods for suicidal behavior in  adolescents with  PTSD. 
 12.2  PTSD and suicidal behavior in adolescents 
 More than 90% of youth suicide victims have at least one diagnosable psychiatric 
disorder at the time of death ( 13 ). Seventy-five percent of those with PTSD have other 
mental health problems ( 14 ). Comorbidity of PTSD with other psychiatric conditions 
(like  mood disorders, substance-use disorders, and psychosis) is associated with an 
increased suicide risk and higher rates of suicidal behavior ( 7 ).  Depression is the 
most prevalent disorder among youths who have taken their own lives ( 13 ,  15 ). Taken 
together, this might lead one to consider a few of the (many) possibilities of causal 
interaction between PTSD and suicidal behavior; certain PTSD symptoms cause 
depression, which in turn leads to suicidal behavior or even that specific  attributes 
or symptoms common to all or some of the disorders mentioned above (such as sleep 
disturbances) independently predict suicidal behavior ( 7 ). However, with so many 
variables and risk factors to take into account, the causal chain of events linking PTSD 
and suicidal behavior remains unclear. As a number of studies have pointed out, 
while almost all suicide victims have at least one psychiatric disorder, most  patients 
who have only one or more psychiatric disorders (without any other risk factors) do 
not actually commit suicide ( 16 ). Thus, in mapping out possible avenues of causality 
between PTSD and suicide, all other risk factors for suicide that might play a role 
must be taken into account. 
 There is some evidence that PTSD can be an independent risk factor for suicidal 
behavior ( 17 ,  18 ). For example, a cohort study of 1,698 young adults who grew up in 
Baltimore revealed a significantly increased risk of suicide attempts for those who had 
PTSD compared to those without the disorder and those who experienced a traumatic 
event without developing the illness; and this increased risk remained unchanged 
even after adjusting for some other notable risk factors, like depression and sex ( 17 ). 
Research conducted by Mazza on 106 adolescents in grades 9 – 12 revealed that PTSD 
symptomology was significantly related to a heightened risk of suicidal ideation 
after adjusting for depression and gender ( 18 ). Unfortunately, these studies failed to 
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control for a sufficient amount of associated risk factors, like childhood sexual abuse, 
in order to rule out the effects of confounding variables that were not statistically 
 analyzed in these studies. 
 It is also possible that trauma and stressful experiences can lead to  suicidality 
without a mediating  PTSD diagnosis. Traumatic and stressful events, such as expo-
sure to terrorism and physical and sexual abuse have all been found to be risk factors 
for PTSD,  suicide, or other suicidal behaviors ( 19 – 21 ). However, the cohort study that 
was already described ( 17 ) found that only PTSD, and not traumatic experiences, 
independently predicted suicide attempts. Also of important note in this study was 
the finding that PTSD caused by trauma that involves assaultive violence was signi-
ficantly associated with suicide attempts, whereas PTSD caused by trauma that did 
not involve assaultive violence was not significantly related to suicide attempts. This 
finding may suggest a differential association between  suicidal behavior and the type 
of trauma experienced. 
 One way of assessing the association between suicide and PTSD is to focus on 
some of the specific symptoms of PTSD that might be risk factors for suicide. One study 
found that increased levels of hostility,  depression, and arousal were related to higher 
suicide risk ( 22 ). Hostility and increased arousal fall within the hyperarousal cluster 
of PTSD symptoms. However, levels of avoidance (avoidance cluster) were negatively 
correlated with suicide risk, leading the authors to hypothesize that  avoidance may 
serve to lessen the chances of suicide. In a longitudinal study,  Sourander and col-
leagues looked at a group of 580 adolescents and found that those who exhibited 
aggressive behaviors (which fall into the hyperarousal cluster) at age 8 were signi-
ficantly more likely to show suicidal behaviors (specifically, suicide attempts and 
suicidal thinking) 8 years later, at age 16 years ( 23 ).  Impulsivity (associated with the 
hyperarousal cluster) has also been documented to have strong ties to both PTSD and 
suicidal behavior. For example, Kotler and colleagues found a positive association 
between impulsivity and risk of suicide in patients with PTSD, as compared with 
matched controls, who showed no association between these two factors ( 24 ). Given 
the fact that the majority of suicidal crises are short-lived, unplanned, and associa-
ted with ambivalent feelings of whether to live or to die ( 25 ), impulsivity seems to be 
an especially strong link between PTSD and suicide. The re-experiencing symptom 
cluster of PTSD has also been positively associated with PTSD and suicide ( 26 ). With 
regards to the efficacy of different coping strategies, Amir et al documented that in 
PTSD patients, psychological coping mechanisms like minimization, mapping, and 
replacement were associated with lower risk of suicide, and that suppression was 
associated with an increased risk of suicide ( 27 ). 
 Other risk factors for suicide include gender, a family history of suicide, and past 
suicide attempts. Men successfully complete suicide more often and tend to use highly 
lethal means, as compared with females who attempt more suicides using low-lethality 
procedures ( 20 ). A family history of suicide and previous suicide attempts are two of the 
most significant risk factors for suicide ( 28 ). A family history of suicide may increase the 
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chance of developing  PTSD ( 29 ) and previous  suicide attempts are potentially trauma-
tizing experiences in and of themselves. Having a family history of suicide or having a 
history of suicide attempts can also potentially lead to contagion-like effects. 
 Contagion, a phenomenon by which interpersonal contact with suicidal indivi-
duals results in the spread of suicidal behaviors (with suicide methods often being 
mimicked or imitated), sometimes throughout entire communities, is more common 
among youth than among those in other age groups ( 13 ,  29 ). A special type of conta-
gion called the  Werther effect refers to copycat suicides spurred on by media coverage 
of people taking their own lives. Media induced contagion effects will be discussed in 
detail later on. 
 In terms of neurobiological underpinnings, serotonergic abnormalities are a 
common finding in post-mortem analyses of the brains of suicide victims ( 16 ,  30 ). 
Compared with those who die of causes other than suicide, suicide victims are gene-
rally found to have lower levels of pre-synaptic serotonin transporter sites in various 
brain regions, including the hypothalamus, the brainstem, the  prefrontal cortex, and 
especially in the ventral medial region of the prefrontal cortex ( 31 ,  32 ). Suicide victims 
also tend to have higher levels of 5-HT1A post-synaptic receptors, with this also being 
most evident in the ventral medial prefrontal cortex ( 31 ). The ventral medial pre-
frontal cortex is associated with executive functioning, so impairment of this brain 
region may result in deficits in the ability to inhibit distressing, aggressive, or suicidal 
emotions, and thus lead to more  impulsivity ( 16 ,  30 ). As mentioned, impulsivity and 
aggression are strongly linked to both PTSD and  suicidal behavior. Reduced levels of 
the principal metabolite of serotonin, 5-HIAA, in the cerebrospinal fluid have been 
consistently observed in both those who have committed suicide and those who have 
attempted suicide ( 16 ,  30 ,  33 ). Amongst suicide attempters, 5-HIAA has been reported 
to be negatively correlated with the lethality of the suicide attempt ( 30 ). Decreased 
serotonergic activity has also been observed in victims of childhood abuse ( 16 ) and 
other traumatic experiences, as well as in patients with PTSD. One recent study ( 34 ) 
found that patients with PTSD had significantly reduced levels of serotonin 1B recep-
tors as compared to those without PTSD. Furthermore, those who were exposed to 
traumatic experiences without developing PTSD also had lower levels of serotonin 1B 
receptors (though levels were not as those with full blown PTSD). Perhaps the most 
important evidence for serotonergic abnormalities in PTSD patients is the relative 
effectiveness of selective serotonin reuptake inhibitors ( SSRIs) in the treatment of this 
disorder ( 35 ). In terms of the prefrontal cortex, imaging studies have revealed lower 
levels of activation in the medial prefrontal region when patients with PTSD are pre-
sented with various stress-inducing stimuli ( 36 ,  37 ). These deficits may lead to some 
of the symptoms and behaviors associated with PTSD, like aggression, impulsivity, 
depression, heightened startle response, and suicidal behavior. Also, when taken 
alone, these symptoms and behaviors are indirect evidence of serotonergic impair-
ments, as well as prefrontal cortex deficits ( 35 ). 
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 Trauma,  PTSD, and  suicide have all been associated with dysregulation of the 
hypothalamic-pituitary-adrenal (HPA) axis ( 16 ,  29 ). As suggested by animal models 
using maternal deprivation procedures, hyperactivity of the HPA axis (including 
physiological alterations like elevated glucocorticoid levels and increased sensitivity 
to stress) appears to be linked to traumatic experiences ( 38 ,  39 ). Surprisingly, PTSD 
is frequently associated with an increased inhibition of the HPA stress response and 
average or reduced levels of cortisol ( 40 ). However, as Yehuda explains, it is not 
necessarily the case that individuals with PTSD display lowered HPA and stress and 
stress responsiveness ( 40 ), as indicated by reports that increased cortisol and HPA 
responses are exhibited by individuals with PTSD who are exposed to reminders of 
traumatic events (in comparison with controls) ( 41 ,  42 ). Some of these contrasting 
findings might be explained by individual differences in genetic predisposition, the 
type of trauma experienced, or the age at which trauma is experienced. A much more 
consistent finding in the literature is a reduced hippocampal volume, which is consi-
dered a core feature of PTSD ( 29 ). Because memory, learning, and fear conditioning 
are highly dependent on the hippocampus, damage to this brain area may play a role 
in PTSD by causing traumatized individuals to over-generalize fear responses asso-
ciated with their traumatic experiences to novel environments or people and exhibit 
hypervigilance and stressful reactions in even the safest of situations ( 29 ). Overacti-
vity of the amygdala, as shown in patients with PTSD who are presented with stress-
inducing stimuli ( 43 ,  44 ), may also help to explain such fear and stress responses. 
Taken together, these deficits can cause symptoms related to both PTSD and suicide, 
such as helplessness, aggression, negative expectations, low self-esteem, and self-
destructiveness ( 16 ,  29 ). The HPA axis also has connections with the sympathetic 
nervous system via the hypothalamus, where fear signals are passed along. Overac-
tivity of the sympathetic nervous system, as evidenced by heightened norepineph-
rine responsiveness to perceived threat, and elevated heart rate and blood pressure, 
is also associated with the hyperactivity of the stress response ( 35 ). Furthermore, 
abnormalities in neurotransmitter systems associated with controlling and media-
ting the stress response such as the neuropeptide Y, endogenous opioid, gamma-
aminobutyric acid (GABA), and glutamate systems have also been linked to PTSD 
and the dysregulated stress reaction associated with sensitization ( 29 ). 
 Finally, it may be the case that  PTSD,  suicide, and other associated conditions 
all share a similar genetic, epigenetic, and/or neurobiological predisposition ( 16 ,  29 ). 
For example, genetic and neurobiological differences associated with sex may play 
a role in predisposing someone to PTSD and  suicidal behavior. As previously menti-
oned, women commit suicide less often than men do. Women have been reported to 
exhibit higher levels of 5-HIAA in the cerebrospinal fluid as compared to men ( 45 ). 
Thus, sex may represent a predisposition towards higher rates of both suicide and 
PTSD in men because these disorders are associated with hypoactvity of serotonergic 
functioning. What seems most likely is that these disorders are caused by a mixture of 
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both a shared underlying predisposition and deficits acquired after the  development 
of PTSD (or other common comorbid conditions). 
 12.3  Prevention 
 There has been a good deal of research conducted on  suicide prevention for the general 
population and also some dealing with suicide prevention in  adolescent populations. 
However, there have been no empirical investigations of prevention methods tailored 
to suicidal  adolescents with PTSD. 
 There are two general options when it comes to suicide prevention: decreasing 
risk factors for suicide or case finding, which refers to looking for and identifying at 
risk persons for referral and treatment ( 5 ). A literature review by Mann et al found that 
the three most effective prevention techniques have proven to be  means restriction, 
education of primary care physicians, and  gatekeeper training ( 46 ). 
 12.3.1  Means restriction 
 Means restriction refers to any measures taken to decrease access to or availability 
of suicide means ( 24 ). Suicide attempters tend to use specific, favored methods, and 
when they are unable to attain the means for these favored methods, they are less 
likely to make a suicide attempt ( 47 ). 
 The main justification for implementing means restriction measures is that the 
majority of suicidal crises and feelings of wanting to kill oneself are brief and tran-
sient, unplanned or impulsive, and often accompanied by mixed feelings of whether 
to live or to die ( 24 ). Thus, with more lethal means unavailable or inaccessible during 
this short window of opportunity, the suicidal person will either not go through with 
the attempt or use less lethal means ( 24 ). Given the evidence that  impulsivity may 
serve as a strong link between PTSD and suicide, means restriction seems as if it 
might be just as effective if a suicidal crisis is spurred on by PTSD-related impulsivity 
or other PTSD symptoms associated with suicide. 
 According to the Centers for Disease Control and Prevention (CDC), the top three 
methods used by young people in suicides are firearms (45%), suffocation (40%), 
and poisoning (8%) ( 48 ). One study found that across US,  suicide rates are higher 
for people living in locations where there are more guns in homes and that this 
 association is most prominent for adolescents aged 5 – 19 years ( 49 ). In support of 
 means restriction, studies consistently show that passing firearm control laws lead to 
reductions in suicide rates ( 50 ,  51 ). For example, the passing of gun control legislation 
in 1976 in the District of Columbia led to a 23% reduction in firearm-related suicides 
( 50 ). Similarly, gun control laws in South Australia led to significant decreases in sui-
cides using firearms, in comparison with other Australian states without similar gun 
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laws in place (where there was an increase suicide rates) ( 51 ). For suicidal  adolescents 
with PTSD, one potentially beneficial future avenue for research might be to focus on 
figuring out if  PTSD caused by certain types of trauma leads to using specific suicide 
means or methods more often than others. For example, it seems reasonable to think 
that those who experience gun-related trauma might be less likely to choose firearms 
as their means because they will probably seek to avoid any reminder of the trauma 
at the risk of triggering re-experiencing symptoms. The finding that avoidance beha-
viors are negatively correlated with suicide risk ( 22 ), might provide some support for 
this hypothesis. 
 12.3.2   Physician education and training 
 One of the most promising prevention methods of suicide in  adolescents is to 
educate and train primary care physicians to better screen, identify, and treat pati-
ents with  psychiatric disorders, as well as to refer such patients to mental health 
care  professionals ( 46 ). However, an excessive amount of physicians fail to identify 
and effectively give much needed support or treatment to patients with suicidal inc-
linations and associated psychiatric disorders, like  depression ( 15 ). This failure to 
recognize depression and other risk factors related to suicide may be a major reason 
why most suicide victims go untreated before taking their own lives ( 46 ). Physician 
education may be of particular importance in children and  youth because it is often 
the case that physicians are a youth ’ s only source of mental health care service ( 52 ). 
The prevention of suicide in the primary care setting can potentially be an extremely 
effective method because about 75% of all victims have contact with a physician 
within a year of suicide and almost half of all victims have contact with a physician 
within a month of taking their own lives ( 53 ). In one study based in Australia, primary 
care physicians took part in a training workshop that was intended to help them to 
better identify and effectively respond to young people at risk for suicide. Despite 
the fact that the workshop only lasted for one day, identification of suicidal patients 
increased by 130% ( 54 ). Other studies also show that this prevention method leads to 
reductions in  suicide rates and increases in rates of identifying those at an elevated 
risk for suicide ( 55 ,  56 ). 
 Physicians should screen all adolescents to assess coping skills and any 
thoughts or behaviors, past and present, which are associated with suicidal behavi-
ors ( 57 ). With regards to helping suicidal  adolescents with  PTSD, physicians should 
also be adept in screening for, identifying, and triaging adolescents with PTSD (and 
other disorders related to increased risk of suicide). The Society for General Internal 
Medicine enlisted the help of the American Association of Medicine and  Psychia-
try, the American Psychiatric Association, The American College of Physicians, and 
the American Academy of Physician in order to provide physicians with literature 
and guidelines to effectively diagnose and treat psychiatric disorders commonly 
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 observed in primary care ( 58 ). Furthermore, physicians might also want to assess 
which type of trauma led to PTSD for different individuals so as to understand avo-
idance patterns and to get a grasp on which suicide methods might be most favora-
ble for each individual. Taking screening and assessment results into account, the 
clinician can also serve to form a support system for the  youth patients by opening 
lines of communication with parents and other adults and potential gatekeepers 
in the local community, including teachers, activity partners, etc. ( 59 ). In general, 
by forming respectful, encouraging, and most importantly, understanding relation-
ships with  adolescent patients, primary care physicians can open a much needed 
line of support for adolescents in times of crisis or distress ( 59 ), which would be 
especially useful for those suicidal youth with comorbid or particularly distressing 
disorders, like PTSD and  depression. 
 Screening instruments, which may focus on risk factors for suicide or suicide 
alone ( 46 ), are valuable tools that physicians should utilize. These instruments reli-
ably lead to accurate recognition of and significantly higher detection rates of at-risk 
youth populations ( 60 ,  61 ). 
 12.3.3  Mental health care 
 Of all of the many varieties of therapies that are typically utilized in an attempt to treat 
suicidal people, dialectical behavioral therapy is the only one that has continuously 
proven to be effective in lessening  suicidal behavior in the adult population ( 20 ). 
Unfortunately, none of the research found on this topic has focused any attention 
specifically on suicidal behavior in  adolescents with PTSD. With specific regards to 
coping strategies, clinicians should teach and encourage PTSD patients to use coping 
strategies associated with lower risk of suicide in PTSD patients, like replacement, 
mapping, and minimization, and to avoid those associated with higher risk of suicide 
in PTSD patients, like suppression ( 25 ). According to Sher and Ganz, a combination 
of pharmacotherapy and psychotherapy is likely to be the best treatment option for 
mental health professionals to give to adolescents with PTSD ( 29 ). 
 12.3.4   Gatekeeper training 
 Gatekeeper training refers to educating and training adult community members who 
communicate and interact with adolescent populations on a day-to-day basis to reco-
gnize youth at risk for  suicide, assess their level of risk, and refer them to mental 
health professionals for treatment when necessary ( 46 ). Examples of potential gate-
keepers are teachers, guidance counselors, coaches, prison and  military officials, 
clergy and other religious professionals, police, first responders, nurses, primary 
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care physicians, and social workers ( 46 ,  62 ). Unfortunately, many potential gatekee-
pers lack either knowledge of the risk factors for youth suicide or do not possess the 
appropriate attitudes or intervention skills to effectively take action when needed. 
For example, a nationwide survey of US high school teachers showed that fewer than 
10% of all teachers felt that they could identify at-risk students, and even amongst 
counselors who possessed knowledge of the risk factors; two thirds did not think that 
they could recognize students at risk for suicide ( 63 ). It becomes even more important 
to contrive gatekeeper strategies when one takes into account a finding by Wyman 
and colleagues: of a mixed sample of 2,059 8th and 10th grade students surveyed with 
regards to help-seeking attitudes, those who mentioned a past suicide attempt were 
much less likely than those without a past suicide attempt to seek help or believe that 
any school personnel could help them ( 64 ). 
 The cumulative literature on this topic has not yet proven  gatekeeper training 
to have an independent or significant effect on diminishing  suicidal behavior ( 62 ). 
However, there have been some reports that point towards positive effects of these 
training programs. 
 A study based in Quebec ( 65 ) gave gatekeeper training to 43 adult  “ helpers ” who 
worked with  youth populations. Within 6 months of the training date, over 60% of the 
helpers made an intervention with a suicidal youth, and the adults given the training 
attained increased intervention skills and knowledge of suicidal behavior as compa-
red with 28 helpers in a control group who didn ’ t receive the training. 
 12.3.5  Public education programs 
 Public education programs attempt to provide suicide awareness information and 
inform the public about risk factors and identification strategies, as well as to help 
cultivate appropriate attitudes towards suicide and suicidal behavior. These programs 
are often targeted at  adolescent populations ( 13 ) and especially in the school setting 
( 28 ). In one study, a school-based education campaign was utilized. Adolescents par-
ticipated in meetings that focused on opening them up to inner conflicts and nega-
tive life experiences associated with suicidal behavior, as well as promoting positive 
coping mechanisms to help them to deal with distressing feelings and emotions. 
Results showed that because of the intervention, students were able to cope more 
effectively with stress and negative feelings like hopelessness ( 66 ).  Hopelessness 
is a symptom associated with both  PTSD and  suicidal behavior in  adolescents. 
However, there is not enough empirical evidence investigating the efficacy of this 
method of  suicide prevention to make any definite conclusions or recommendations 
( 28 ,  46 ). Such  preventative interventions can also aim to target more specific at-risk 
 populations like suicidal  adolescents with PTSD by including information about 
identifying  individuals in this population, risk factors, and treatment options. 
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 12.3.6  Media guidelines 
 As evidenced in the literature, the media (print, television, internet) can help to 
facilitate reductions of  youth  suicide by providing supportive advice and educating 
the public or can have potentially disastrous outcomes, invoking mass contagion 
effects as a result of irresponsible coverage of suicides (e.g., romanticizing or glamo-
rizing suicide, or dramatizing more lethal suicide methods) ( 24 ,  46 ,  67 – 69 ). Impro-
per coverage can even lead to the teaching of new or alternative suicide methods 
( 24 ), as well as draw attention to suicide hot spots ( 70 ). In this context, the effects of 
contagion can be far more calamitous than contagion via person-person contact in 
community and local settings (as already discussed) ( 67 ). Furthermore, there is good 
evidence that youth populations are at the greatest risk to media-related contagion 
effects ( 68 ,  71 ): Phillips and Carstensen ( 68 ) reported that TV news and feature stories 
about suicide caused significant increases in teenage suicide over the week following 
these broadcasts (almost a 7% increase) compared with adult suicides that increased 
by less than half of a percent. In addition, broader coverage of these stories by more 
news stations led to higher numbers of  teen suicide. It should be noted that because 
this study took place in the US, the generalizability of these results to other countries 
(where the impact of TV news might be different) is unknown. 
 Media contagion (also commonly referred to as the  “ Werther effect ” ) can in large 
part be explained by social learning theory ( 67 ). In the case of the Werther effect, 
greater public attention can serve as a reward to the observer and can present as 
longer duration of coverage, greater amounts of coverage ( 67 ), and greater promi-
nence of coverage, including front page placement or covering celebrity suicides 
( 72 ). Furthermore, observers are more likely to model behavior off of others that they 
share similar characteristics with (like age or gender) and maintain more attention 
on viewing stories that involve such people ( 73 ,  74 ). For example, for upto 70 days 
after the showing of a weekly serial that depicted the railway suicide of a 19-year-old 
male student, the number of railway suicides was highest amongst the population of 
15 – 19-year-old males (with rates increasing by upto 175%), as compared to all other 
age/gender populations ( 74 ). 
 There are also a few studies looking into the potential relationship between PTSD 
and media effects. Researchers dealing with 69 youths in the sixth grade who lived near 
Oklahoma City when the 1995 bombing took place, but were not directly exposed to the 
event, found that indirectly witnessing the event via media sources was significantly 
associated with acquiring  PTSD symptoms ( 75 ). Another study based in Ontario study-
ing 143 undergraduate students (aged 17 – 37 years), looked at the PTSD symptomology 
related to media exposure to the 9/11 terrorist attacks. Media exposure was significantly 
associated with two of the three PTSD symptom clusters, including hyperarousal and 
re-experiencing symptoms, but was not associated with the avoidance cluster ( 76 ). 
Taken in light of results already mentioned, that PTSD symptoms like hyperarousal 
 12.3  Prevention   141
and re-experiencing symptoms in  youth lead to an increased risk of  suicide, it can be 
inferred that media coverage of certain events can serve to heighten these risk factors 
even more and create an even shorter bridge between PTSD and suicide. 
 As already briefly mentioned if conducted in a responsible manner, media reports 
on suicide can have potentially beneficial effects (the Papageno effect). The main pre-
vention method for suicidal contagion and other adverse effects of the media is provi-
ding reporting guidelines for media organizations to follow ( 46 ,  77 ). Such guidelines 
may include avoidance of sensationalizing or dramatizing suicides, encouraging sui-
cidal people to seek treatment and care, and educating them about the risk factors 
and effective coping mechanisms, educating those involved in the production and 
reporting about contagion, avoidance of elaborating on specifics of suicide methods 
or hot-spots, and limiting the coverage and prominence of suicide cases and avoiding 
front page placement ( 67 ). These guidelines listed are some that help to form a set of 
national guidelines developed by the American Foundation for  Suicide Prevention 
( 78 ). The Centers for Disease Control and Prevention has also released similar guideli-
nes for media reporting ( 79 ). Although no research has focused on the efficacy of these 
specific guidelines ( 46 ,  67 ), there has been some work done on others. For example, 
in Vienna, Austria suicide rates, and in particular, rates of subway suicides, increased 
dramatically after the subway system was put into place in 1978. Elmar and Sonneck 
documented an 80% decrease in subway suicides after guidelines were developed by 
the Austrian Association for Suicide Prevention and spread via a media campaign in 
1987 ( 80 ). In another study, after Swiss newspapers and magazines implemented a set 
of guidelines, researchers found that in comparison to before the guidelines, articles 
received less prominent placement, were not as lengthy, less sensational, and inclu-
ded less pictures ( 81 ). Taking into account the studies on media coverage of PTSD, 
similar guidelines can be put into place with minor additions to account for the risk 
factors and symptoms associated with suicidal  adolescents with PTSD. 
 There have been relatively few research efforts that have looked to see if the 
Internet might have a relationship with  suicidality ( 82 ). However, the internet is of 
particular concern in light of the facts that social networking sites can be utilized to 
spread information in just minutes ( 24 ), there are suicide chat rooms and websites 
containing instructions for different suicide methods ( 46 ), and almost all young 
Americans and adolescents have Internet access to one degree or another (with 93% 
of all 12 – 17 year olds and 89% of 18 – 24 year olds being online in 2009) ( 83 ). 
 The most used social media site, Facebook, reached 500 million registered users 
in 2010 ( 84 ) and in 2009, in general, social networking sites were used on a regular 
basis by 73% of teens, including 55% of 12 – 13 year olds and 82% of 14 – 17 year olds ( 85 ). 
There is evidence that Facebook and other social media sites may actually serve to 
increase social support and boost mental well-being ( 86 ) and even stop or decrease 
suicidal ideation in young people and adolescents ( 82 ). One especially worrisome 
online venue is websites devoted to promoting  suicide by detailing information on 
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suicide means and methods, of which there were found to be more than 100,000 in 
1999 ( 87 ). These websites suggest suicide as a solution to life ’ s issues and contain 
detailed descriptions of methods yielding the maximum effect, as well as suicide 
notes and pictures of people who committed suicide. They exert group pressure to 
fulfill suicide plans, glorifying those who have committed suicide. Other potential 
avenues for obtaining information about suicide include forums and self-help pages, 
in which other users can leave comments or feedback. In 2010, Ries ( 88 ) documented 
a case in which a 24-year-old male posted a comment on a forum about the intention 
to kill himself. While some showed support and sympathy, others egged him on. The 
young man went on to kill himself. In terms of Internet-related  PTSD effects, one study 
found that amongst elementary school children who indirectly witnessed or heard 
about the 9/11 terrorist attacks via different media outlets, children who saw or heard 
about it on the Internet reported more PTSD symptoms than those who witnessed the 
event by way of television or print media ( 89 ). 
 A recent cohort study ( 82 ) conducted with 719 14 – 24 year olds found that 59% of 
participants saw or learned about suicide stories on the Internet. Mental health infor-
mation was also attained from the participants. Although hopelessness and knowing 
someone who attempted or committed suicide at baseline were both highly related to 
learning about suicides from social networking sites, social media was not related to 
increases in suicidal ideation in these groups, suggesting that these sites may actually 
serve to be effective mediums for social support and preventing  suicidal behavior. The 
same beneficial effects were not observed with online forums, which were related to 
increases in suicidal ideation, providing evidence that forums may serve to encou-
rage or facilitate suicidal behavior. The same goes for blogging, which was related 
to hopelessness. These results may indicate that  youths with PTSD or other mental 
health problems associated with suicide may be best off visiting social media sites as 
opposed to forums or blogs. 
 Like with other types of media prevention, the Internet can also be a medium used 
to adequately educate  adolescents about suicide, its causes, risk factors, and treat-
ment options. In order to combat the deleterious effects of suicide-promotion sites 
and other harmful venues, suicide-prevention websites can be utilized to support and 
guide suicidal youth to teach effective coping strategies and proper treatment options 
( 82 ). Furthermore, mental health providers and gatekeepers like primary care phy-
sicians and teachers can help educate youth of the dangers and benefits of Internet 
use. Also, as already discussed, Facebook and other social media sites may actually 
help to prevent  suicide by allowing support and guidance from friends and other 
people in one ’ s social network ( 13 ,  86 ). Finally, media guidelines for reporting suicide 
on the Internet have been put together, but thus far no research investigations have 
studied the effects of such guidelines ( 46 ,  78 ,  90 ). All of the fore mentioned preven-
tion options could be  utilized for suicidal  adolescents with  PTSD and/or other psych-
iatric conditions. 
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 12.3.7  Multi-dimensional prevention methods 
 Given the demonstrated efficacy of most of the prevention methods discussed thus far, 
it seems reasonable to hypothesize that a more versatile, multi-dimensional  suicide 
prevention method, combining all or some of these methods, might prove to have the 
best results of all. In a study based in Nuremberg, Germany ( 91 ) both primary care phy-
sicians and community gatekeepers (clergy, help-lines, mental health care workers, 
policemen, prison officers) were given suicide prevention training. Furthermore, media 
organizations (TV, radio, and newspaper) were given guidelines to follow concer-
ning reporting of suicides in order to prevent copycat suicides and contagion-related 
effects. There was also a public education campaign launched which organized lectu-
res for the general public and enlisted the help of public officials and various media 
outlets (including a cinema trailer and an internet website) to help educate community 
members and health care workers about depression (which of course, is one of the 
main risk factors for suicide) and to encourage people with depression or depressive 
symptoms to seek help. Results showed that over a 2-year period, there was a 24% 
reduction in suicidal acts (which included completed suicides and suicide attempts), 
and that this reduction was significant compared with the control region (Wuerzburg, 
Germany) that did not receive the prevention programs. In Wuerzburg, suicidal acts 
increased by over 7% over the 2-year span. More research needs to be conducted on 
such multi-dimensional approaches in order to come to any concrete conclusions 
about the efficacy of this method compared with the other methods discussed. 
 References 
 1.  Merikangas KR, He J-P, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence 
of mental disorders in US adolescents: results from the National Comorbidity Study-Adolescent 
Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010;49(10):980 – 9. 
  2.  Deykin EY. Posttraumatic stress disorder in children and adolescence: a review. Medscape 
Psychiatry and Mental Health eJournal 1999;4(4). URL:  http://www.westga.edu/~vickir/Healthcare/
HC07%20PTSDPrimer/Link%207%20--%20PTSD%20in%20Children%20&%20Adolescents.pdf. 
Accessed 01 October, 2012. 
  3.  Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P. Trauma and posttraumatic 
stress disorder in the community: the 1996 Detroit Area Survey of trauma. Arch Gen Psychiatry 
1998;55(7):626 – 32. 
  4.  Costello EJ, Erkanli A, Fairbank JA, Angold A. The prevalence of potentially traumatic events in 
childhood and adolescence. J Trauma Stress 2002;15(2):99 – 112. 
  5.  Sareen J, Houlahan T, Cox BJ, Asmundson GJG. Anxiety disorders associated with suicidal ideation 
and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis 2005;193:450 – 4. 
  6.  Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson C. Posttraumatic stress disorder in the 
National Comorbidity Survey. Arch Gen Psychiatry 1995;52:1048 – 60. 
  7.  Panagioti M, Gooding P, Tarrier M. Post-traumatic stress disorder and suicidal behavior: a 
narrative review. Clin Psychol Rev 2009;(6):471 – 82. 
144   12  Prevention of suicidal behavior in adolescents with post-traumatic stress disorder
  8.  Wunderlich U, Bronisch T, Wittchen HU. Comorbidity patterns in adolescents and young adults 
with suicide attempts. Eur Arch Psychiatry Clin Neurosci 1998;248(2):87 – 95. 
   9.  World Health Organization. Suicide prevention (SUPRE), 2012. URL:  http://www.who.int/mental_
health/prevention/suicide/suicideprevent/en/. Accessed 01 October, 2012. 
 10.  World Health Organization. The second decade: improving adolescent health and development, 
1998. URL:  http://www.who.int/mip2001/files/2281/2ndDecadefulldocument.PDF. Accessed 01 
October, 2012. 
 11.  American Association of Suicidology. USA suicide: Official financial data, 2010. URL:  http://www.
suicidology.org/c/document_library/get_file?folderId=248&name=DLFE-618.pdf. Accessed 01 
October, 2012 
 12.  Sher L. Preventing suicide. Q J Med 2004;97:677 – 80. 
 13.  Gould MS, Greenberg T, Velting DM. Youth suicide risk and preventive interventions: a review of 
the past 10 years. J Am Acad Child Adolesc Psychiatry 2003;42(4):386 – 405. 
 14.  Kataoka S, Langley AK, Wong M, Baweja S, Stein B. Responding to students with PTSD in schools. 
Child Adolesc Psychiatr Clin N Am 2012;21(1):119 – 33. 
 15.  Lake CR. How academic psychiatry can better prepare students for their future patients. Part I: 
the failure to recognize depression and risk for suicide in primary care; problem identification, 
responsibility, and solutions. Behav Med 2008;34(3):95 – 100. 
 16.  Mann JJ. Neurobiology of suicidal behavior. Nat Rev Neurosci 2003;4:819 – 28. 
 17.  Wilcox H, Storr CL, Breslau N. Posttraumatic stress disorder and suicide attempts in a community 
sample of urban American young adults. Arch Gen Psychiatry 2009;66(3):305 – 11. 
 18.  Mazza JJ. The relationship between posttraumatic stress symptomatology and suicidal behavior 
in school-based adolescents. Suicide Life Threat Behav 2000;30(2):91 – 103. 
 19.  Johnson JG, Cohen P, Gould MS, Kasen S, Brown J, Brook JS. Childhood adversities, interpersonal 
difficulties, and risk for suicide attempts during late adolescence and early adulthood. Arch Gen 
Psychiatry 2002;59(8):741 – 9. 
 20.  Mazza, JJ. Youth suicidal behavior: a crisis in need of attention. Adolesc Ment Health 2006:156 – 77. 
 21.  Chemtob CM, Horenczyk RP, Madan A, Ptiman SR, Wang Y, Doppelt O, et al. Israeli adolescents with 
ongoing exposure to terrorism: suicidal ideation, posttraumatic stress disorder, and functional 
impairment. J Trauma Stress 2011;24(6):756 – 9. 
 22.  Ben-Ya ’ acov Y, Amir M. Posttraumatic symptoms and suicide risk. Pers Individ Diff 2004;36:
1257 – 64. 
 23.  Sourander A, Helstela L, Haavisto A, Bergroth L. Suicidal thoughts and attempts among 
adolescents: a longitudinal 8-year follow-up study. J Affect Disord 2001;63(1 – 3):59 – 66. 
 24.  Kotler M, Iancu I, Efroni R, Amir M. Anger, impulsivity, social support, and suicide risk in patients 
with posttraumatic stress disorder. J Nerv Ment Dis 2001;189(3):162 – 7. 
 25.  Yip PFS, Caine E, Yousuf S, Chang S-S, Wu KC-C, Chen Y-Y. Means restriction for suicide prevention. 
Lancet 2012;379:2393 – 9. 
 26.  Bell JB, Nye EC. Specific symptoms predict suicidal ideation in Vietnam combat veterans with 
chronic post-traumatic stress disorder. Mil Med 2007;172(11):1144 – 7. 
 27.  Amir M, Kaplan Z, Efroni R, Kotler M. Suicide risk and coping styles in posttraumatic stress 
disorder patients. Psychother Psychosom 1999;68(2):76 – 81. 
 28.  Kuthcer SP, Szumilas M. Youth suicide prevention. Can Med Assoc J 2008;178(3):282 – 5. 
 29.  Ganz D, Sher L. Terror and suicidal behavior in adolescents with posttraumatic stress disorder. 
Minerva Pediatr 2010;62(4):363 – 70. 
 30.  Mann JJ, Oquendo M, Underwood MD, Arango V. The neurobiology of suicide risk: a review for the 
clinician. J Clin Psychiatry 1999;60(2):7 – 11. 
 31.  Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre and postsynaptic 
serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 
1995;688(1 – 2):121 – 33. 
 References   145
 32.  Mann JJ, Henteleff RA, Lagattuta TF, Perper JA, Li S, Arango V. Lower 3H-paroxetine binding in 
cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites. J Neural 
Transm 1996;103(11):1337 – 50. 
 33.  Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide. 
A review of post-mortem studies. Br J Psychiatry Suppl 1989;(8):7 – 14. 
 34.  Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot D, Gueorguieva R, et  al. The effect of 
early trauma exposure on serotonin type 1B Receptor expression revealed by reduced selective 
radioligand binding. Arch Gen Psychiatry 2011;68(9):892 – 900. 
 35.  Heim C, Nemeroff CB. Neurobiology of posttraumatic stress disorder. CNS Spectr 2009;14(Suppl 1):
13 – 24. 
 36.  Shin LM, Orr SP, Carson MA, Rauch SL, Macklin ML, Lasko NB, et  al. Regional cerebral blood 
flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female 
Vietnam veterans with PTSD. Arch Gen Psychiatry 2004;61(2):168 – 76. 
 37.  Shin LM, Wright CI, Cannistraro PA, Wedig MM, McMullin K, Martis B, et al. A functional magnetic 
resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented 
fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry 2005;62(3):273 – 81. 
 38.  Plotsky PM and Meaney MJ. Early, postnatal experience alters hypothalamic corticotropin-
releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult 
rats. Brain Res Mol Brain Res 1993;18(3):195 – 200. 
 39.  Rentesi G, Antoniou K, Marseios M, Fotopoulos A, Alboycharali J, Konstandi M. Long-term 
consequences of early maternal deprivation in serotonergic activity and HPA function in adult rat. 
Neurosci Lett 2010;480(1):7 – 11. 
 40.  Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann N Y Acad Sci 
2009;1179:56 – 9. 
 41.  Elzinga BM, Schmahl CG, Vermetten E, van Dyck R, Bremmer JD. Higher cortisol levels following 
exposure to traumatic reminders in abuse-related PTSD. Neuropsychopharmacology 2003;
28(9):1656 – 65. 
 42.  Liberzon I, Abelson JL, Flagel SB, Raz J, Young EA. Neuroendocrine and psychophysiologic 
responses in PTSD: a symptom provocation study. Neuropsychopharmacology 1999;21(1):40 – 50. 
 43.  Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR, et al. A symptom provocation 
study of posttraumatic stress disorder using positron emission tomography and script-driven 
imagery. Arch Gen Psychiatry 1996;53(5):380 – 7. 
 44.  Liberzon I, Taylor SF, Amdur R, Jung TD, Chamberlain KR, Minoshima S, et al. Brain activation in 
PTSD in response to trauma-related stimuli. Biol Psychiatry 1999;45(7):817 – 26. 
 45.  McBride PA, Tierney H, DeMeo M, Chen JS, Mann JJ. Effects of age and gender on CNS serotonergic 
responsivity in normal adults. Biol Psychiatry 1990;27(10):1143 – 55. 
 46.  Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, et al. Suicide prevention strategies: a 
systematic review. J Am Med Assoc 2005;294(16):2064 – 74. 
 47.  Griffith EH. Suicide: closing the exits. J Am Med Assoc 1990;263(22):3091 – 2. 
 48.  Centers for Disease Control and Prevention. Suicide prevention. URL:  http://www.cdc.gov/
violenceprevention/pub/youth_suicide.html. Accessed 01 October, 2012. 
 49.  Miller M, Lippmann SJ, Azrael D, Hemenway D. Household firearm ownership and rates of suicide 
across the 50 United States. J Trauma 2007;62(4):1029 – 35. 
 50.  Loftin C, McDowall D, Wiersema, B, Cottey TJ. Effects of restrictive licensing of handguns on 
homicide and suicide in the District of Columbia. N Engl J Med 1991;325:1615 – 20. 
 51.  Snowdon J, Harris L. Firearms suicides in Australia. Med J Aust 1992;156(2):79 – 83. 
 52.  Horwitz SM, Kelleher K, Boyce T, Jensen P, Murphy M, Perrin E, et al. Barriers to health care research 
for children and youth with psychosocial problems. J Am Med Assoc 2002;288(12):1508 – 12. 
 53.  Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before 
suicide: a review of the evidence. Am J Psychiatry 2002;159(6):909 – 16. 
146   12  Prevention of suicidal behavior in adolescents with post-traumatic stress disorder
 54.  Pfaff JJ, Acres JG, McKelvey RS. Training general practitioners to recognise and respond to psychological 
distress and suicidal ideation in young people. Med J Aust 2001;174(5):222 – 6. 
 55.  Rutz W, von Knorring L, W å linder J. Long-term effects of an educational program for general practitioners 
given by the Swedish Committee for the Prevention and Treatment of Depression. Acta Psychiatry 
Scand 1992;85(1):83 – 8. 
 56.  Hannaford PC, Thomson C, Simpson M. Evaluation of an educational programme to improve the 
recognition of psychological illness by general practitioners. Br J Gen Pract 1996;46(407):333 – 7. 
 57.  Duke NN, Boroswki I. Suicidal events in adolescents: how clear are the warning signs? Ped Health 
2009;3(6):551 – 63. 
 58.  Cole SA, Sullivan M, Kathol R, Warshaw C. A model curriculum for mental disorders and behavioral 
problems in primary care. Gen Hosp Psychiatry 1995;17(1):13 – 8. 
 59.  Taliaferro L, Oberstar J, Borowsky IW. Prevention of youth suicide: the role of the primary care 
physician. J Clinical Outcomes Manag 2012;19(6):270 – 85. 
 60.  Shaffer D, Scott M, Wilcox H, Maslow C, Hicks R, Lucas CP, et al. The Columbia Suicide Screen: 
validity and reliability of a screen for youth suicide and depression. J Am Acad Child Adolesc 
Psychiatry 2004;43(1):71 – 9. 
 61.  Joiner TE Jr, Pfaff JJ, Acres JG. A brief screening tool for suicidal symptoms in adolescents and 
young adults in general health settings: reliability and validity data from the Australian National 
General Practice Youth Suicide Prevention Project. Behav Res Ther 2002;40(4):471 – 81. 
 62.  Isaac M, Elias B, Katz LY, Belik S, Deane FP. Gatekeeper training as a preventative intervention for 
suicide: a systematic review. Can J Psychiatry 2009;54(4):260 – 8. 
 63.  King KA, Price JH, Telijohann SK, Wah J. High school teachers ’ perceived efficacy in identifying 
students at risk for suicide. J Sch Health 1999;69(5):202 – 7. 
 64.  Wyman PA, Brown CH, Inman J, Cross W, Schmeelk-Cone K, Guo J, et al. Randomized trial of a 
gatekeeper program for suicide prevention: 1-year impact on secondary school staff. J Consult 
Clin Psychol 2008;76(1):104 – 15. 
 65.  Chagnon F, Houle J, Marcoux I, Renaud J. Control-group study of an intervention training program 
for youth suicide prevention. Suicide Life Threat Behav 2007;37(2):135 – 44. 
 66.  Orbach I, Bar-Joseph H. The impact of a suicide prevention program for adolescents on suicidal 
tendencies, hopelessness, ego identity, and coping. Suicide Life Threat Behav 1993;23(2):120 – 9. 
 67.  Gould MS. Suicide and the media. Ann NY Acad Sci 2001;932:200 – 21. 
 68.  Phillips DP, Carstensen LL. Clustering of teenage suicides after television news stories about 
suicide. N Engl J Med 1986;315(11):685 – 9. 
 69.  Sisask M, Varnik A. Media roles in suicide prevention: a systematic review. Int J Environ Res Public 
Health 2012;9(1):123 – 38. 
 70.  Pirkis J, Blood RW. Suicide and the media. Part I: reportage in nonfictional media. Crisis 
2001;22(4):146 – 54. 
 71.  Gould MS, Jamieson P, Romer D. Media contagion and suicide among the young. Am Behav Sci 
2003;46(9):1269 – 84. 
 72.  Stack S. Media impacts on suicide: a quantitative review of 293 findings. Soc Sci Q 2000;81(4):957 – 71. 
 73.  Stack S. Social correlates of suicide by age: Media impacts. In: Linaars AA, ed. Life Span 
Perspectives of Suicide: Time-lines in the Suicide Process. New York: Plenum, 1991:187 – 213. 
 74.  Schmidtke A, Hafner H. The werther effect after television films: new evidence for an old 
hypothesis. Psychol Med 2009;18(3):665 – 76. 
 75.  Pfefferbaum B, Seale TW, McDonald NB, Brandt EN Jr, Rainwater SM, Maynard BT, et al. Posttraumatic 
stress two years after the Oklahoma City bombing in youths geographically distant from the explosion. 
Psychiatry 2000;63(4):358 – 70. 
 76.  Collimore KC, McCabe RE, Carleton RN, Asmundson GJ. Media exposure and dimensions of 
anxiety sensitivity: differential associations with PTSD symptom clusters. J Anxiety Disord 
2008;22(6):1021 – 8. 
 References   147
 77.  Ramadas S, Kuttichira P. The development of guidelines and its impact on the media reporting of 
suicide. Indian J Psychiatry 2011;53(3):224 – 8. 
 78.  The American Federation for Suicide Prevention. Recommendations for reporting on suicide. 
URL:  http://www.afsp.org/files/Misc_/recommendations.pdf. Accessed 01 October, 2012. 
 79.  O ’ Carroll PW, Potter LB. Suicide contagion and the reporting of suicide: recommendations from a 
national workshop. MMWR Recomm Rep 1994;43(RR-6):9 – 17. 
 80.  Etzersdorfer E, Sonneck G. Preventing suicide by influencing mass-media reporting. The Viennese 
experience 1980 – 1996. Arch Suicide Res 1998;4:64 – 78. 
 81.  Michel K, Frey C, Wyss K, Valach L. An exercise in improving suicide reporting in print media. 
Crisis 2000;21(2):71 – 9. 
 82.  Dunlop SM, More E, Romer D. Where do youth learn about suicides on the Internet, and what 
influence does this have to suicidal ideation? J Child Psychol Psychiatry 2011;52(10):1073 – 80. 
 83.  Jones S, Fox S. Generations online in 2009. URL:  http://www.pewinternet.org/~/media//Files/
Reports/2009/PIP_Generations_2009.pdf. Accessed 01 October, 2012. 
 84.  Zuckerberg M. 500 million stories, 2010. URL:  http://blog.facebook.com/blog.php?post=
409753352130. Accessed 01 October, 2012. 
 85.  Lenhart A, Purcell K, Smith A, Zickuhr K. Social media and mobile Internet use among teens and 
young adults. 2010. URL:  http://web.pewinternet.org/~/media/Files/Reports/2010/PIP_Social_
Media_and_Young_Adults_Report_Final_with_toplines.pdf. Accessed 01 October, 2012. 
 86.  Ellison NB, Steinfeld C, Lampe C. The benefits of Facebook  “ friends: ” Social capital and college 
students ’ use of online social network sites. J Comput Mediat Commun 2007;12(4):1143 – 68. 
 87.  Dobson R. Internet sites may encourage suicide. Br Med J 1999;319(7206):337. 
 88.  Ries B. Anatomy of an Internet suicide, 2010. URL:  http://www.thedailybeast.com/articles/2010/
08/31/reddit-suicide-how-the-internet-can-help-and-hurt.html. Accessed 01 October, 2012. 
 89.  Saylor CF, Cowart BL, Lipovsky JA, Jackson C, Finch Jr AJ. Media exposure to September 11: elementary 
school students ’ experiences and posttraumatic symptoms. Am Behav Sci 2003;46(12):1622 – 42. 
 90.  Ganz D, Braquehais MD, Sher L. Secondary prevention of suicide. PLoS Med 2010;7(6):e1000271. 
 91.  Hegerl U, Althaus D, Schmidtke A, Niklewski G. The alliance against depression: 2-year evaluation 




 Section V:  Substance abuse 

 13   Attention-deficit hyperactivity disorder 
and dual disorders: educational needs 
for an underdiagnosed condition 
 Jos é  Mart í nez-Raga ,  Nestor  Szerman ,  Karl  Knecht 
and  Raquel  de Alvaro Lopéz 
 A wide range of comorbid psychiatric disorders overlap with attention-deficit 
 hyperactivity disorder (ADHD) across the life span. There is a robust and complex 
intersection between ADHD and  substance use disorders (SUD). In the present report 
it is aimed to review the neurobiological and other vulnerability factors explaining 
the comorbidity of ADHD and an addictive disorder, as well as the key aspects of 
the assessment and diagnosis of dually diagnosed ADHD patients. A comprehensive 
and systematic search of relevant databases (PubMed, Embase, and PsychINFO) was 
conducted to identify studies published in peer-reviewed journals until July 31, 2012, 
exploring the association of ADHD and SUD with postgraduate training and residency 
education. Across the life span, ADHD is associated with significant impairment and 
comorbidity. Data from epidemiological and clinical studies show a very solid link 
between ADHD and SUD. It is therefore very important to carefully and systematically 
assess for any substance use in patients with a suspected ADHD coming to initial 
assessment, and vice versa. Whilst there are various valid and reliable rating and 
screening scales, for both SUD and ADHD in adult patients with dual pathology, diag-
nosis cannot solely rely on any of the instruments available. The most important and 
effective tool in the assessment of dually diagnosed patients with ADHD and a SUD 
is a full and comprehensive clinical and psychosocial assessment. It is essential to 
actively incorporate training opportunities on the assessment,  diagnosis and manage-
ment of adult ADHD and dually diagnosed ADHD patients during  postgraduate edu-
cation residency or specialist training. 
 13.1  Introduction 
 Training in the management of addictions remains very limited in medical training 
as well as in postgraduate specialist education, including psychiatric residency pro-
grams compared to other major psychiatric disorders ( 1 ,  2 ). However, comorbidity 
of addictive disorders with other psychiatric disorders is extremely common ( 3 – 6 ). 
It is rather unusual to encounter an individual presenting to treatment solely with an 
addiction problem. Optimal treatment of dually diagnosed patients requires aware-
ness and adequate assessment of concurrent symptoms, syndromes and disorders, 
and vice versa. 
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 Attention-deficit/hyperactivity disorder (ADHD) is a complex and multifactorial 
neurodevelopmental disorder characterized by age inappropriate levels of inatten-
tion, hyperactivity, and/or  impulsivity ( 7 ,  8 ). Once considered solely as a childhood 
disorder, the persistence of ADHD from childhood throughout  adolescence into 
adulthood is now fully acknowledged ( 9 ). Indeed, both ADHD as defined in the Diag-
nostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision) (DSM-
IV-TR) ( 7 ) and hyperkinetic disorder, as defined in the International Classification 
of Diseases, 10th revision (ICD-10) ( 10 ) are recognized to persist beyond childhood 
into adulthood, and several national and cross-national guidelines now recommend 
that ADHD should be recognized and appropriately treated throughout the life span 
( 11 – 13 ). Nonetheless, many clinicians are still unaware that this disorder frequently 
persists into adulthood ( 14 ). A wide range of comorbid psychiatric disorders overlap 
with ADHD across the life span. Comorbid conduct disorders, oppositional defiant 
disorder, learning impairments,  anxiety disorders and  mood disorders are amongst 
the most common psychiatric disorders in children with ADHD ( 8 ,  15 ,  16 ). Similarly, 
 depression,  bipolar disorder, anxiety disorders,  substance use disorders (SUD), per-
sonality disorders, or eating disorders are very frequent among adults with ADHD 
( 4 ,  15 ,  17 – 22 ). There is a robust and complex intersection between ADHD and SUD, 
with important substantial societal burden and implications in daily clinical practice 
and research ( 17 ,  21 ,  23 – 27 ). 
 Clinicians not trained to adequately assess, identify and diagnose the disor-
der often overlook a highly prevalent psychiatric condition and ascribe symptoms 
to other disorders or personality types, therefore resulting in low recognition and 
underdiagnosis of ADHD, with or without a comorbid SUD, in many world regions 
( 12 ,  28 ). The general psychiatrist and other specialists involved in the management 
of patients with ADHD and comorbid SUD will require a better understanding of the 
factors underlying comorbid ADHD and SUD, to gain effective knowledge, skills and 
attitudes for raising awareness and for a assessment and an accurate diagnosis of 
individuals with this dual disorder. In the present report it is aimed to review the 
neurobiological and other vulnerability factors explaining the comorbidity of ADHD 
and an addictive disorder, particularly in adults and older  adolescents, as well as the 
crutial aspects of the assessment and diagnosis of dually diagnosed ADHD patients, 
aspects, all of them, that are key in raising awareness and improving recognition of 
this complex comorbidity. 
 13.1.1  Literature search 
 A comprehensive and systematic search of relevant databases (PubMed, Embase, 
and PsychINFO) was conducted to identify for studies published in English in peer-
reviewed journals until July 31, 2012, using the following MESH terms and key-
words:  “ ADHD, ”  “ substance use disorder, ”  “ residency education ” and  “ postgraduate 
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 training. ” In addition, reference lists were scrutinized to identify and retrieve further 
relevant reports and studies from additional sources and scientific databases. The lite-
rature search included clinical studies/reports as well as retrospective or prospective 
 population-based studies with children,  adolescents or adults as participants. There 
were no restrictions on the identification or inclusion of studies in terms of date of 
publication, publication status, type of publication and design type. However, abs-
tracts of presentations to specialist meetings and conferences were not included. Titles 
and abstracts were screened for inclusion/exclusion, and appropriateness, and full 
text versions were retrieved. 
 A total of 130 records were identified through database searches (92 from Embase, 
27 from PubMed and 11 from PsychInfo). Fifteen duplicate reports were excluded 
from the list. Of the remaining 115 documents, 66 further reports were excluded after 
careful evaluation of the titles and abstracts for considering them not eligible for the 
purpose of the present review. Therefore, a total of 49 documents identified through 
database searches were included in the report. 
 13.2  Epidemiology 
 ADHD is the most frequent childhood psychiatric disorder. The estimated prevalence 
of ADHD in age-school children is 3 – 7%, as reported in DSM-IV-TR ( 7 ). Similar estima-
tes were reported in a systematic review and meta regression analysis that reported 
a worldwide-pooled prevalence of ADHD for children and  adolescence of 5.29% ( 29 ). 
Contrary to the lay belief that ADHD is a disorder exclusively of western societies, 
the differences in prevalence rates reported in different studies may be related to 
methodological aspects rather than to real geographical variations, which supports 
the notion that ADHD is a global disorder, independent of culture or geographical 
location ( 29 ). However, like other psychiatric disorders, cultural and social atti-
tudes may influence how ADHD, particularly in adult individuals, is understood and 
addressed, and may play a significant role in the diagnosis and varying  acceptance 
of the  condition ( 28 ). 
 As revealed in longitudinal controlled studies, a significant proportion of child-
ren and adolescents diagnosed with ADHD experience persistent symptoms and func-
tional impairments into early adulthood, so that up to 35% of children continue to 
meet full DSM-IV criteria, while up to 78% show persistent symptoms or impairment 
( 17 ,  30 – 34 ). Symptom persistence has been associated to childhood ADHD symptom 
profile. Highest persistence is associated with the combined subtype, symptom seve-
rity, comorbid  major depressive disorder, elevated comorbidity (three or more child-
adolescent disorders in addition to ADHD), paternal (but not maternal) anxiety-mood 
disorder, and parental antisocial personality disorder ( 30 ,  31 ,  33 ,  34 ). 
 In adult samples, the prevalence of ADHD in general population is approximately 
3 – 5% ( 4 ,  35 ). In a systematic review with meta-analysis and meta-regression of the 
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epidemiological data on adult ADHD, the pooled prevalence of ADHD in adulthood 
was 2.5% [range, 1 – 7.3%], although the authors of this report concluded that due to 
the problems of validity with DSM – IV diagnostic criteria for this disorder prevalence 
rates may be reduced by underestimation of the prevalence of adult ADHD ( 36 ). In 
any case, the estimated prevalence of ADHD is higher than other more researched 
psychiatric disorders like  schizophrenia or  bipolar disorder. These rates are even 
higher in clinical samples with patients with a primary SUD ( 23 ,  24 ,  26 ,  27 ,  37 ), or 
other psychiatric disorders ( 18 ,  22 ,  38 ,  39 ), as well as in studies conducted with prison 
inmates ( 40 – 42 ). 
 13.3  Clinical characteristics of ADHD 
 13.3.1  The road to DSM-IV-TR 
 Although the initial example of a disorder that appears to be similar to ADHD was 
given by Sir Alexander Crichton in 1798 ( 43 ) and the first accepted clinical descrip-
tions of what currently is recognized as ADHD dates to 1902 when Sir George Frederic 
Still published in the Lancet his Goulstonian Lectures, a series of three lectures to the 
Royal College of Physicians of London ( 44 ), ADHD was not incorporated to DSM until 
1968 with DSM-II, where it was named  “ hyperkinetic reaction of childhood ” ( 45 ) and 
has undergone revision with each new edition of the DSM ( 46 ). 
 In DSM-III the disorder was renamed  “ attention-deficit disorder with hyperacti-
vity, ” although it distinguished a second subtype,  “ attention-deficit disorder without 
hyperactivity ” for describing individuals fulfilling criteria for inattention and  impul-
sivity but not hyperactivity ( 47 ). In contrast, with DSM-III-R the dimensions of inat-
tention, impulsivity, and hyperactivity were merged into one, so that to qualify for a 
diagnosis  “ attention-deficit hyperactivity disorder ” there had to be evidence of eight 
of 14 symptoms ( 48 ). However, DSM-III-R also included a diagnosis of  “ undifferenti-
ated attention deficit disorder. ” Finally, in DSM-IV the term used to coin these disor-
ders was  “ attention-deficit/hyperactivity disorder ” (ADHD), and the list of symptoms 
was expanded and divided into domains of inattention and hyperactivity/impulsivity 
( 46 ). 
 In DSM-IV-TR ( 7 ) the defining feature of ADHD is a persistent pattern of inatten-
tion and/or hyperactivity-impulsivity that is more frequently displayed and is more 
severe than what is typically observed in individuals at comparable level of  develop-
ment. In addition, as a disorder of childhood onset, symptoms must have been present 
before 7 years of age. Another requisite for the diagnosis is that some impairment from 
the symptoms must be present in at least two settings, consequently there must be 
clear evidence of interference with developmentally appropriate social, academic or 
occupational functioning. Finally, to make a diagnosis ADHD, symptoms cannot be 
better accounted for by another mental disorder or occur exclusively during the course 
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of a pervasive developmental disorder, schizophrenia, or other psychotic disorders. 
However, neither DSM-IV and ICD-10 criteria take account of age-dependent changes 
in terms of the number and severity of symptoms, or changes in the way that the 
symptoms of ADHD might present in adults, which probably is another reason for 
underdiagnosis and treatment of ADHD in adults ( 12 ). 
 DSM-IV ( 49 ) and subsequently in DSM-IV-TR ( 7 ) defines three subtypes, as follows: 
 –  ADHD predominantly inattentive type. Individuals affected meet six (or more) 
diagnostic criteria of inattention (but less than six symptoms of hyperactivity-
 impulsivity) that have persisted for at least 6 months. 
 –  ADHD predominantly hyperactive-impulsive type. Individuals characteristically 
show six (or more) symptoms of hyperactivity-impulsivity (but less than six of 
inattention) that persisted for at least 6 months. 
 –  ADHD combined type. This subtype should be used when six (or more) symptoms 
of inattention and six (or more) symptoms of hyperactivity-impulsivity have per-
sisted for at least 6 months. 
 In addition, DSM-IV-TR ( 7 ) includes two further subtypes, ADHD in partial remission, 
for patients who met criteria as a child but no longer meet full criteria as  adolescents 
of adults, although continue to display some impairing symptoms, and ADHD not 
otherwise specified, for patients who do not meet full criteria for the disorder and it is 
unclear whether criteria for the disorder have previously been met. 
 The combined presentation is the most common of all three ADHD subtypes, both 
in childhood and  adolescence, as well as in adulthood, followed by the predomi-
nantly inattentive type and lastly the predominantly hyperactive-impulsive subtype 
( 7 ,  49 ,  50 ). 
 13.3.2  New DSM, more changes. What is new in DSM-5? 
 The upcoming DSM-5 will incorporate some important modifications in the symptom 
descriptions and diagnosis of ADHD, in an attempt to solve the problems with the lack 
of adequate validation of DSM-IV diagnostic criteria in adults, which do not reflect 
appropriately clinical presentations across the life span and may lead to underdia-
gnosis in adult populations ( 46 ,  51 ). One of the essential features of ADHD that has 
undergone revision is the age-of-onset criterion, so that the onset of impairing sym-
ptoms has been moved from age 7 to 12  years ( 52 ). Interestingly, a recent prospec-
tive study with a birth cohort of 2,232 British children have suggested that extending 
the age-of-onset criterion to age 12 resulted in a negligible increase in ADHD preva-
lence by age 12 years of 0.1% ( 53 ). Following the evidence questionning the external 
validity and to some extent the discriminant validity and reliability of ADHD subty-
pes ( 54 – 56 ), including data from longitudinal, comorbidity, treatment response, and 
clinical outcome studies suggesting that the nominal DSM-IV subtype categories are 
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unstable due to both systematic and random changes over time ( 55 – 57 ), the DSM-IV 
subtype model has been revised. Therefore, the three main subtypes in DSM-IV have 
been changed to three current presentations, with the addition of a a fourth one for a 
restrictive predominantly inattentive presentation ( 52 ). 
 While maintaining the overall structure, therefore keeping the two primary 
domains of inattention and hyperactivity/ impulsivity, and the exact wording of all 
ADHD criteria, another minor modification included in the next DSM-5 is the inclu-
sion of changes in the examples in the different items, to accommodate a life span 
relevance of each symptom and to improve clarity ( 52 ). Finally, in addition to remo-
ving pervasive developmental disorder from the exclusion criteria, another modifica-
tion to be included in DSM-5 is the recommendation, in an introductory paragraph, 
to obtain information from two different informants whenever possible, in contrast 
to DSM-IV does not specify how this data should be collected and verified ( 46 ,  58 ). 
 13.4  Interrelationship 
 Across the life span, ADHD is associated with significant impairment in many areas 
of functioning, and with important familial, societal, and personal costs, including 
detrimental adverse effects to the psychological and physical well-being of the indivi-
dual. At a functional level, children and  adolescents with ADHD have antecedents of 
educational problems and significantly higher rates of discipline problems, academic 
failure and completion rates than unaffected individuals, independently of their level 
of intelligence ( 59 – 62 ). Partly as a consequence of the executive function deficits seen 
in patients with ADHD of all ages, adults have more work-related problems, with dif-
ficulties in gaining and maintaining stable employment, and in productivity due to 
poor time management and distractibility, higher divorce rates, and reduced quality 
of life than matched controls ( 59 ,  62 – 64 ). Similarly, patients with ADHD are more 
likely to have domestic and traffic accidents, more medical emergency use, more 
legal problems, as well as higher psychiatric comorbidity rates across the different 
age ranges, including higher rates of  substance use disorders ( 9 ,  16 – 19 ,  21 ,  22 ,  24 ,  26 , 
 27 ,  37 ,  41 ,  63 ,  65 ). 
 13.4.1  Epidemiological evidence of the comorbidity of ADHD with SUD 
 SUD are amongst the most common comorbid psychiatric disorders in adolescent or 
adult patients with ADHD, and vice versa. Patients with ADHD have approximately 
a two-fold prevalence of  substance abuse or dependence, compared with general 
population ( 4 ,  18 ,  24 ,  37 ,  66 ). Similarly, patients with a SUD have higher rates than 
expected of a comorbid ADHD. The majority of studies coincide that 15 – 25% of adults 
with an addictive disorder have a comorbid ADHD ( 23 ,  26 ,  67 ,  68 ), rates much higher 
 13.4  Interrelationship   157
than individuals of same age from the general population. The importance of this 
 comorbidity derives both from the strong interrelationship between the two disorders, 
as evidenced in many different studies and in clinical practice, as well as from the 
adverse social, personal and clinical consequences of this dual pathology ( Table 13.1 ). 
There do not appear to exist differences between individuals with and without ADHD 
in the preference of the drug of choice ( 24 ,  68 ). Furthermore, contrary to what is often 
assumed, in a recent meta-analytic review conducted to obtain a best estimate of the 
prevalence of ADHD in SUD populations, whilst overall ADHD was present in almost 
one out of every four patients with SUD, a series of meta-regression analyses showed 
that the prevalence of ADHD was significantly lower in subjects with cocaine as their 
primary substance of abuse ( 26 ). 
 There is evidence of a lineal relationship between the severity of the symptoms of 
ADHD and the risk and severity of the SUD ( 69 ,  70 ). Studies in adult patients diagnosed 
with ADHD have reported rates of  alcohol abuse or dependence of 17 – 45% ( 71 – 73 ). 
Conversely, several studies have estimated that 19 – 42% of patients with an alcohol 
use disorder have a comorbid ADHD ( 74 – 76 ). In adult patients with alcohol abuse or 
dependence a diagnosis of ADHD is associated with significatively earlier onset of 
harmful alcohol use, significatively higher daily alcohol consumption, more alcohol 
related problems, and an increased severity of the SUD ( 74 ,  76 ,  77 ) (see  Table 13.1 ). 
Likewise, individuals with ADHD start smoking  tobacco products at a younger age, 
smoke more cigarettes daily, and are two times more likely to initiate smoking and 
almost three times more likely to become tobacco-dependent than non-ADHD indi-
viduals ( 66 ,  69 ,  78 – 82 ) and have more difficulties quitting smoking than their non-
ADHD counterparts ( 78 ,  83 ) (see  Table 13.1 ). In addition, although early initiation of 
alcohol,  cannabis or tobacco use is predictive of the subsequent risk of developing 
other  substance use disorders in individuals with ADHD, tobacco is the substance 
with the highest predictive value ( 84 ,  85 ). 
 Patients with ADHD and a comorbid SUD have lower retention rates in addiction treat-
ment programs, as well as lower remission rates and more chronicity of the SUD ( 86 ) 
 Table 13.1:  Clinical characteristics and outcome of patients with ADHD and a comorbid SUD compa-
red to patients with exclusively ADHD or a SUD 
 Earlier onset of substance use and abuse ( 23 ,  74 ,  76 ,  78 ,  79 ,  87 ) 
 More likely to initiate smoking and at a younger age, as well as become dependent on nicotine, 
and have more difficulty quitting smoking ( 78 ,  79 ,  83 ) 
 More severity and chronicity of the addictive disorder ( 23 ,  67 ,  74 ,  78 ,  86 ,  87 ,  89 ,  94 ) 
 A more severe course of illness of ADHD ( 12 ,  15 ,  86 ) 
 Less likely to achieve abstinence ( 15 ,  94 ) 
 Higher rates of poly-substance abuse ( 23 ,  78 ,  87 ) 
 Increased psychiatric comorbidity ( 17 ,  23 ,  67 ,  88 ,  94 ,  95 ) 
 Lower treatment retention rates ( 37 ,  86 ) 
 ADHD: attention-defi cit hyperactivity disorder, SUD: substance use disorders. 
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(see  Table 13.1 ). In clinical samples 10 – 35% of cocaine dependent individuals have a 
comorbid ADHD ( 87 – 89 ). In patients with a cocaine use disorder the coexistence of a 
diagnosis of ADHD is associated with an earlier onset of cocaine, as well as of  tobacco, 
 alcohol and  cannabis use ( 87 ,  89 ), with more frequent and more severe cocaine use 
( 87 ), and with more severe psychiatric comorbidity ( 88 ). The prevalence of ADHD in 
patients with opioid dependence is high as well, so that 19 – 55% of patients in metha-
done maintenance treatment have been reported to have a childhood history of ADHD 
( 67 ,  90 – 93 ). In opioid dependent individuals, the coexistence of ADHD is associated 
with more and more severe adverse consequences, including significatively higher 
rates of comorbid SUD and of other psychiatric disorders (particularly affective disor-
ders,  anxiety disorders, or antisocial personality disorder), more severity of the SUD, 
more difficulties in achieving abstinence and a more severe course of the dual disor-
ders ( 23 ,  67 ,  91 ,  92 ,  94 ) (see  Table 13.1 ). However, cannabis is the illicit substance most 
commonly abused by patients with a diagnosis of ADHD ( 72 ). 
 Although a history of conduct disorder increases the risk ( 61 ,  95 ), multiple studies 
( 24 ,  66 ,  69 ,  82 ,  96 ), including several systematic reviews with meta-analyses ( 80 ,  81 ) 
have evidenced that ADHD is an independent risk factor for developing a SUD during 
childhood and  adolescence, so that children with ADHD have a two-fold risk of 
developing nicotine, alcohol or other  substance abuse or dependence. Nonetheless, 
a childhood conduct disorder is the strongest predictor of differences in patterns of 
drug use severity ( 95 ). 
 13.4.2   The relationship between ADHD and comorbid SUD. Nature 
of the association 
 The association between ADHD and SUD is bidirectional. The nature and causes for 
this comorbidity are complex and most likely result from the interaction of various 
factors, including co-occurrence of other psychiatric disorders, such as conduct dis-
orders, antisocial personality disorders or bipolar disorders ( 19 ,  69 ,  95 ,  96 ), or the 
predominance of other associated symptoms and traits likes  impulsivity, novelty 
seeking or low self-esteem ( 20 ,  42 ). Similarly, at least a proportion of patients with 
ADHD may use tobacco, alcohol or other drugs of abuse in an attempt to self-medicate 
the sleeping problems, the restlessness or the low  mood ( 97 ,  98 ). The interrelationship 
between ADHD and SUD has been explained also through the executive dysfunction 
that is characteristic of ADHD and has been observed as well in adult patients with 
ADHD ( 62 ,  64 ,  99 ). In addition, there are solid neurobiological substrates underlying 
the association of ADHD and SUD ( 27 ,  100 – 103 ). 
 ADHD, like other developmental disorders, is the result of the complex interac-
tion of genetic, environmental and social factors. There is evidence of a strong genetic 
component to the vulnerability of the disorder, with heritability ranging from 60 – 90% 
( 104 ,  105 ). Thus, ADHD is often viewed as a genetically determined dysfunction of 
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the dopamine and noradrenergic catecholamine system ( 12 ,  100 ,  106 ). However, 
 estimates of heritability in adults with ADHD have been reported to be consistently 
lower and the extent of genetic influences on ADHD in adults remains to be clarified 
( 12 ,  105 ). Environmental factors are also likely to play a role in the etiology of ADHD, 
most likely by interaction with genetic components. As such, an association have 
been reported between maternal and paternal smoking, as well as  alcohol and other 
drug use during pregnancy and ADHD, with a 2 – 4-fold increased risk of ADHD ( 101 , 
 107 ,  108 ), therefore underpinning the link between ADHD and SUD. 
 Neurocognitive, neurophysiological and  neuroimaging studies have provided 
evidence of functional and structural brain anomalies underlying the pathophy-
siology of ADHD in children and adults, including dysfunctions in the frontostri-
atal network, involving the lateral  prefrontal cortex, the dorsal anterior cingulate 
cortex, the caudate nucleus and the putamen, that have key roles in executive 
function and attention ( 102 ,  103 ,  109 ,  110 ). Likewise, studies have shown deficits 
in the reward-motivation system in ADHD patients that might be responsible for 
many of ADHD related behaviors and reduced nucleus accumbens activation with 
hypo- responsiveness ( 102 ,  103 ), and a reduction in dopamine synaptic markers 
associated with symptoms of inattention has been shown in the dopamine reward 
pathway ( 102 ,  103 ). Indeed, the mesoaccumbens dopamine pathway, key to under-
stand reward and motivation ( 111 ) appears to be involved as well in the motivatio-
nal and reward deficits described in ADHD, and consequently with the decreased 
response to reward and the greater vulnerability to  substance abuse in patents with 
ADHD ( 103 ). 
 13.5  Assessment 
 Assessment of ADHD can be challenging, particularly in older  adolescents and adults 
not previously diagnosed, who may come to clinic for other comorbid psychiatric dis-
orders that can cloud or complicate the diagnostic picture and symptoms of ADHD 
overlooked ( 14 ,  112 ). Like all other psychiatric disorders, the diagnosis of ADHD in 
children, adolescents or adults, with or without other comorbid psychiatric disorders 
is made by careful and in-depth clinical and psychosocial assessment conducted by 
a qualified health care professional with training and expertise in the diagnosis of 
ADHD to look for the characteristic psychopathology ( 12 ,  13 ,  113 ,  114 ). To be most valid 
and effective this comprehensive assessment has to include a full developmental and 
psychiatric history, as well as the individual ’ s person ’ s mental state and a detailed 
and personal, medical, behavioral, educational, employment and social history to 
address the possible existence of symptoms, behavioral problems, and significant 
impairment across the different domains and settings ( 13 ,  114 ). Considering the ele-
vated heritability and the influence of other familial factors, it is also important to 
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inquire about the family history, particularly of ADHD and SUD, but also of other of 
psychiatric and neurological problems ( 12 ). 
 Whilst clinicians should be familiar with the various presentations of ADHD in 
adults, assessment of ADHD in adults and older  adolescents with comorbid SUD is 
not solely a matter of recognizing symptoms or identifying certain traits or charac-
teristics such as being excessively overactive or overenergetic, restless, fidgety, or 
easily distractible ( 14 ,  115 ). It involves a more comprehensive and thorough process 
that includes the careful examination of symptom severity and frequency, childhood 
onset, chronicity and pervasiveness of the disorder, and degree of impairment in major 
life activities ( 13 ,  112 ,  113 ). Specifically in patients with concurrent  substance abuse 
or dependence, it will be key to determine if ADHD, the comorbid SUD, or both best 
explain the presenting symptoms. It is therefore important that health care professi-
onals working with patients that commonly have an elevated prevalence of ADHD, 
such as those with a primary SUD are trained and well prepared to assess adequa-
tely and detect the dual disorders, and to make an adequate differential diagnosis. 
Although the patient appears to be the best informant, whenever possible, collateral 
evidence of current symptoms, and observer reports of the level of multiple domains of 
impairment, and the course of illness should be obtained from close relatives ( 13 ,  116 ). 
 Some authors recommend a period of a month prior to assessing the presence of 
current symptoms of ADHD, to obtain more reliable information and diagnosis ( 15 ). 
However, this is often not possible, and therefore the assessment will need to rely on 
a detailed history of symptoms during periods of abstinence or at a time prior to the 
onset of the substance use, in order to establish if these symptoms are primary or drug 
induced ( 117 ). 
 13.5.1  Screening and assessment instruments for ADHD 
 There are many valid and reliable screening instruments and diagnostic interviews 
specifically devised for ADHD, but no single psychological or biological test provide 
sufficient data to reliably make the diagnosis of ADHD ( 13 ,  14 ), and cannot be used for 
diagnosis without careful clinical confirmation and elicitation of the psychopatho-
logy for diagnosis ( 112 ). However, if administered properly, ADHD rating scales can 
be extremely helpful, both in adolescents and adults, as they help in obtaining and 
organizing information on the problems experienced, as well as in documenting the 
frequency and severity of ADHD symptoms, as well as assessing the response to treat-
ments ( 14 ). Similarly, there are no neuropsychological tests for ADHD with sufficient 
sensitivity and specificity to serve as an individual diagnostic test ( 12 ), but neuro-
psychological tests may serve to identify particular cognitive or executive problems 
in patients with ADHD or specific learning disabilities co-ocurring with ADHD ( 112 ). 
 There are many instruments from which to choose to aid the assessment of adults 
with probable ADHD. The most commonly used screening instruments, rating scales 
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 Table 13.2:  Most commonly ADHD screening instruments, rating scales and clinical interviews used 
for adults 
 Instrument  Informant  Criteria  Population target  Scope 
 Adult  ADHD 
Self-Report Scale 
(ASRS) ( 118 ) 
 Self-report  DSM-IV  Adults  Rating scale with 18 
items. The first six items 
are used as a screening 
test 
 ADHD Rating Scale 
IV (ADHD-RS-IV) 
( 119 ) 
 Generally self for 
adults (parent 
or teacher for 
children) 
 DSM-IV-TR  Children,  adole-
scents and adults 
Eighteen  items for 
evaluating adult ADHD 
symptoms 
 Barkley Adult 
ADHD Rating 
Scale – IV (BAARS-
IV) ( 120 ) 
 Self-report and 
observer-report 
rating scales 
 DSM-IV-TR  Children, 
adolescents 
and adults 
 Assessment of current 
ADHD symptoms and 
domains of impairment 
as well as recollections 
of childhood symptoms 
 Conners ’ Adult 
ADHD Rating Scale 
(CAARS) ( 121 ) 
 Self and/or 
observer rated 
 DSM-IV  Adults  Several versions, 
the 30-item version 
(scale 0 – 3) is used for 















 Focus on symptoms 
of inattention and 
 behaviors related to 
executive functioning 
 Wender Utah 
Rating Scale 
(WURS) ( 123 ) 





 Adults  Retrospective 
assessment for the 
occurrence of childhood 
symptoms associated 
ADHD 




( 125 ) 
 Semistructured 
clinical interview 
 DSM-IV  Adolescents and 
adults 
 Two sections: (1) A 
detailed childhood and 
adult developmental 
history, and (2) 
Assessment of each 
the 18 DSM-IV criteria, 
in both children and 
adults (with the specific 
examples) 
 Adult ADHD Clinical 
Diagnostic Scale 
(ACDS) ( 126 ) 
 Semistructured 
clinical interview 
 DSM-IV  Adults  Retrospective 
assessment of all DSM-IV 
criteria of childhood 
ADHD and an expanded 
assessment of recent 
(6 months) symptoms 
 ADHD: attention-defi cit hyperactivity disorder, DSM: diagnostical and statistical manual. 
162   13  ADHD: educational needs for an underdiagnosed condition
and clinical interviews for evaluating possible ADHD in adults are summarized in 
 Table 13.2 . The majority of these instruments are frequency scales that rely primarily 
on DSM-IV criteria. Such is the case of the World Health Organization (WHO) Adult 
 ADHD Self-Report Scale (ASRS) Symptom Checklist ( 118 ), a self-report instrument 
that includes questions for each of the 18 DSM-IV items reworded to better suit adults. 
The first six items of the test have been selected to be used as a screening test. Spe-
cificity of this and other screening tools seem to be lower in clinical samples with 
high rates of psychiatric comorbid ( 12 ). The 18-item ADHD Rating Scale IV (ADHD-RS-
IV) ( 119 ), based on DSM-IV-TR criteria, is another useful screening and rating instru-
ment that has been modified to evaluate ADHD symptoms in  adolescents and adults. 
Likewise, the Barkley Adult ADHD Rating Scale – IV (BAARS-IV) ( 120 ), an empirically 
developed scale, is another valid and reliable tool for assessing current ADHD sym-
ptoms and domains of impairment as well as recollections of childhood symptoms. 
The BAARS-IV, based on DSM-IV-TR criteria, uses both self-report and observer-report 
rating scales. 
 The Conners ’ Adult ADHD Rating Scale (CAARS) ( 121 ), based on DSM-IV criteria, 
is available and has been validated for both the observer-administered and self-rated 
versions. The 30-item frequency scale is used for screening and to evaluate treat-
ment outcome. The 40-item Brown Attention-Deficit Disorder Scale (BADDS) ( 122 ) 
is another instrument available in clinician-rated and self-report forms to guide the 
diagnostic assessment process that focuses on behaviors relating to executive func-
tioning and inattention. The BADDS was developed prior to DSM-IV-TR and addres-
ses over-inclusive ADHD-related symptoms. The Wender Utah Rating Scale (WURS) 
( 123 ) is a self-report instrument, developed to assess retrospectively the occurrence 
of childhood symptoms associated ADHD. Whilst the full version consists of 61 items, 
a shorter version with the 25 items which most strongly discriminate between adults 
with and without ADHD is also available. The items derive from the monograph 
Minimal Brain Dysfunction in Children ( 124 ), which are more detailed than the 18 
items in the DSM-IV criteria. 
 The Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) ( 125 ) is a 
semi-structured diagnostic interview divided in two blocks that can be useful tool 
in the diagnostic assessment. The first part consists of a detailed childhood and 
developmental history, that includes developmental, environmental, and medical 
history risk factors, as well as childhood and adult educational, occupational, and 
social/interpersonal histories, and health and psychiatric histories. Finally, the 
second part, separately evaluates the presence of each the 18 DSM-IV criteria, in 
both children and adults, with the aid of specific prompts and examples. The Adult 
ADHD Clinical Diagnostic Scale (ACDS) ( 126 ) is a semistructured clinical interview 
that incorporates a retrospective assessment of all DSM-IV criteria of childhood 
ADHD, and an expanded assessment of recent (past 6 months) symptoms that 
includes all 18 DSM-IV symptoms, as well as 14 non-DSM symptoms believed to be 
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relevant to adult ADHD, such as difficulties with planning and organization, inat-
tention, and mood lability. 
 13.5.2   Assessment of comorbid  substance abuse or dependence in patients 
with ADHD 
 All individuals undergoing a psychiatric evaluation should be screened for a SUD, 
regardless of their age, presentation, or referral source ( 127 ). This is also valid for 
patients with a primary ADHD, who should be closely monitored for substance abuse 
as well, considering the elevated prevalence of ADHD and SUD comorbidity. Diag-
nosis of a SUD in a patient with ADHD is based on a comprehensive psychiatric eva-
luation, that should include a detailed history of past and present of all substances 
used by the patient, including alcohol and  tobacco, as well as caffeine and xanthine 
derivatives. It is important to obtain information on age of initiation of each specific 
substance, routes of administration and frequency of use, the social context in which 
drug use takes place, the effects of drug use on the patient ’ s cognitive, psychologi-
cal, behavioral, and physiological functioning, the social, medical, educational and 
employment complications attributable to substance use, and any previous treat-
ment episodes ( 127 ,  128 ). In  adolescents, an age-appropriate clinical and psychosocial 
interview should be conducted and inquire for factors that are predictive of substance 
abuse ( 129 ). 
 Several validated screening instruments that do not require extensive training or 
time may be helpful in the assessment of a SUD and identifying patients with ADHD 
who may require a more in-depth evaluation for possible substance abuse prob-
lems. Among the screening questionnaires available, some of the most commonly 
used include the four-item CAGE questionnaire for  alcohol abuse (Have you ever 
felt the need to Cut down on drinking, been Annoyed by others ’ criticism of your 
drinking, felt Guilty about drinking, needed an Eye-opener drink first thing in the 
morning?), translated and validated in many different languages and countries ( 130 ), 
the 10-item Alcohol Use Disorders Identification Test, developed by an initiative of 
the WHO and widely used throughout the world in primary and other health care 
settings as part of screening and brief intervention programs ( 131 ), or the Drug Abuse 
Screening Test, a 20-item self-report questionnaire for commonly abused substances 
other than alcohol ( 132 ). Another useful tool is the Alcohol, Smoking & Substance 
Involvement Screening Tool (ASSIST)( 133 ), developed by WHO as well. It is a valid 
screening instru ment that can be used in different settings for identifying psychoac-
tive substance use in individuals who use a number of substances and have varying 
degrees of substance use. 
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 13.6  Conclusions 
 Considering the solid neurobiological, epidemiological and clinical link between 
SUD and ADHD, as well as the clinical implications and the limited efficacy of current 
treatment approaches for dually diagnosed patients, clinicians need to be aware that 
ADHD comorbidity is frequently present in substance-abusing populations, irrespec-
tive of age, gender, ethnicity and setting, and vice versa ( 26 ,  27 ). It is therefore very 
important to carefully and systematically assess for any substance use in patients 
with a suspected ADHD coming to initial assessment, and in those with an estab-
lished diagnosis of ADHD coming for follow-up visits, particularly if they have not 
been previously diagnosed or there are other comorbid disorders. Likewise, it is also 
very important to evaluate the presence of ADHD in any patient coming for treatment 
with an addictive disorder. Indeed, independently of the treatment setting or of the 
resources available, the most important and effective tool in the assessment and diag-
nosis of dually diagnosed patients with ADHD and a SUD is a full and comprehensive 
clinical and psychosocial assessment ( 12 ,  13 ). Whilst there are various valid and reli-
able rating and screening scales, for both SUD and ADHD in adult patients with dual 
pathology, diagnosis cannot rely exclusively on scores in any of the assessment ins-
truments available. It is essential to actively address and systematically incorporate 
training opportunities on the assessment, diagnosis and management of adult ADHD 
and dually diagnosed ADHD patients during postgraduate education for health care 
professionals, as well as during residency or specialist training for psychiatrists and 
other specilialists who may involve in the care of dually diagnosed patients. 
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 14   Cannabis and  youth seeking treatment 
for primary  mood or  anxiety concerns 
 Elizabeth  Osuch ,  Evelyn  Vingilis ,  Erin  Ross ,  Christeen  Forster 
and  Carolyn  Summerhurst 
 Cannabis use is common in youth and there is evidence that the co-occurrence of 
cannabis use (and other substance use) with mental illnesses predicts poorer out-
comes, including  suicide. The main purposes of this study were to: 1) identify rates 
of cannabis use and  substance use disorder risk, and 2) predictors for cannabis use 
among youth seeking help for mood and/or anxiety concerns in a sample population 
pre-screened to exclude primary substance use disorders; and 3) to determine if there 
was an association between cannabis use and  functional impairment in this sample. 
We investigated  substance use risk as well as hypothesized predictors of cannabis 
use and functional impairment including demographic characteristics, socioecono-
mic status,  trait coping style, age of onset of several  risk behaviors, current use of 
common addictive substances, measures of functional impairment, and current psy-
chiatric symptom severity. Results showed that approximately half of the participants 
were at moderate to high risk for a substance use disorder, and just over 4% appeared 
to have a primary substance use disorder. They also suggested an association between 
cannabis use and gender (male), age of first cannabis use, recent cigarette use, and 
functional impairment. Independently, functional impairment was predicted by inat-
tentive coping style,  depression severity and total cannabis use score. These results 
confirm a high risk for addictive disorders and an association between cannabis use 
and functional impairment in this sample. These results support the need for sub-
stance use treatment programs to optimize care wherever youth with primary mood 
and/or anxiety concerns are seen. 
 14.1  Introduction 
 Youth with substance use disorders (SUDs) often have problems with mental illnesses 
and youth with mental illnesses, including mood and anxiety disorders, often have 
problems with SUDs. In one study, 50% of youth with SUDs also had non-psychotic 
mental health problems, and youth with SUDs plus either  major depressive disorder 
(MDD) or  posttraumatic stress disorder ( PTSD) had more total disorders, more sub-
stance use related problems and lower quality of life ( 1 ). Research has shown that the 
rates of  alcohol dependence are significantly higher in people with combined anxiety 
and depression ( 2 ), and people (especially young males) with mood and anxiety dis-
orders are at high risk of comorbid SUDs ( 3 ). The co-occurrence of SUDs and mental 
illnesses are important to detect in youth because the combination of these condi-
tions worsens prognosis and complicates treatment ( 4 ). In addition, SUDs predispose 
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to completed  suicide in  youth and young adults ( 5 ), although in the case of  cannabis 
use this might be mediated through other risk factors ( 6 ). 
 A number of studies have demonstrated that cannabis use may precipitate the 
onset of  bipolar disorder,  depression and  anxiety (as well as psychosis) in geneti-
cally vulnerable youth ( 7 ). In fact, a growing body of research suggests an association 
between prior cannabis use and the onset of  mood and anxiety disorders in youth ( 8 – 11 ). 
This is especially problematic since cannabis is the most commonly used recreational 
drug and rates of cannabis use remain high, at over 25%, for North American youth 
( 12 ,  13 ). 
 For these reasons, we were interested in discovering the rates of SUD risk and 
cannabis use in a population of youth seeking specialized psychiatric evaluation and 
treatment for  mood and/or anxiety disorders. We were also interested in whether or 
not cannabis use was associated with functional impairment in this population. This 
involved the clinical program known as the  First Episode Mood and Anxiety Program 
(FEMAP) in London, Ontario, Canada. This is an outpatient psychiatric clinic affi-
liated with the London Health Sciences Centre that serves youth (aged 16 – 26 years) 
with the recent onset of primary mood and/or anxiety concerns. This program screens 
out and refers youth presenting with primary substance-related concerns to a specia-
lized SUD program in the community. However, it was noted by clinicians at FEMAP 
that cannabis use was common in spite of this pre-screening. 
 The current study sought to clarify the prevalence of youth at risk for SUDs within 
this psychiatric service aimed at youth clinically pre-screened not to have primary 
SUDs. It also sought to understand some of the associated features of youth cannabis 
use, and whether or not cannabis use was predictive of degree of  functional impair-
ment. Based on our clinical experiences, we believed that higher cannabis use would 
be associated with certain demographic features as well as some traits, life experi-
ences and  psychiatric symptoms. These included gender, age, socioeconomic status, 
inattentive and maladaptive coping style, age of first exposure to risky behaviors, 
rates of current substance use, and severity of psychiatric symptoms. Understanding 
the associations with cannabis use in this population could help to clarify the need for 
addiction specialists within primary care as well as within specialized mood/anxiety 
clinics for youth. 
 14.2  Our project 
 All clients coming to FEMAP between October, 2009 and July, 2012 were invited to par-
ticipate in the research since the inclusion and exclusion criteria for a clinical assess-
ment at FEMAP were identical to those for the research study. Participants were pro-
vided with information about the study, had all their questions answered, and then 
signed written, informed consent if willing to participate. The study was approved by 
the Human Research Ethics Board affiliated with the London Health Sciences Centre. 
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 Participants underwent a clinical evaluation by one of the clinical investigators 
(ER, CF, or CS) for assessment of their concerns, symptoms, function, substance use, 
living circumstances, and severity of illness. They completed self-report question-
naires as described in Section 14.2.3. Based on the clinical evaluation combined with 
the assessment instruments, a primary (single) final hypothesized diagnosis was 
made prior to the participant being scheduled with a psychiatrist for definitive dia-
gnostic assessment. Trauma related diagnoses [acute stress disorder and  posttrau-
matic stress disorder ( PTSD)] were identified and reported separately from the other 
 anxiety disorders due to the differences in clinical needs for these conditions. 
 14.2.1  Participants 
 Youth, aged 16 – 26 years, were screened and excluded if they had a major medical 
problem, history of serious head injury, developmental delay, or the presence of an 
attention problem severe enough to have warranted psycho-stimulant medication 
since childhood. They were also excluded if they had previously been treated with 
medications for a total of 18  months in their lifetime, since this was exclusionary 
for entry into FEMAP. In addition, if the individual reported that his/her  mood and/
or anxiety symptoms only occurred after the onset of frequent use of a substance of 
abuse, then he/she was excluded and referred to an addiction service for youth in the 
community. 
 14.2.2  Demographics 
 Participants were administered a demographic questionnaire that included age, 
gender, and information about their living situation and parents. Youth were asked 
about their family income as well as parental marital status and mother and father ’ s 
educational level. Unfortunately, many youth were not aware of their family ’ s income. 
As a proxy for socioeconomic status, parental marital status and mother ’ s educatio-
nal level were used. Mother ’ s educational status was considered a better proxy than 
father ’ s since family income (and child academic achievement) better coincides with 
mother ’ s education after divorce ( 14 ). 
 14.2.3  Questionnaires 
 The following well-validated questionnaires were administered to participants. The 
 Beck  Depression Inventory (BDI) ( 15 ) measures extent of depressive symptomato-
logy; the  SpielbergerState/Trait Anxiety Inventory-State (STAI) ( 16 ) measures extent 
of state anxiety symptomatology; the  Emotion Regulation Questionnaire (ERQ) ( 17 ) 
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rates coping strategies related to the regulation of emotional states and is divided 
into two subscores  – reappraisal and suppression; the Adult  ADHD Self-Report Scale-
version 1.1 (ASRS) ( 18 ) is a self-report measure of difficulties with attention; the  NIDA 
Modified ASSIST ( 19 ) measures substance use habits and predicts risk of SUDs; the 
 Sheehan Disability Scale (SDS) ( 20 ) includes three subscales that measure school/
work, family life and social  functional impairment; and the  Youth Risk Behavior 
Survey (YRBS) ( 21 ) asks about a wide range of historical and recent  risk behaviors 
common in youth populations. 
 Questionnaires representing  trait coping styles were the ERQ and the ASRS. 
A total ERQ score was calculated as the sum of the Reappraisal subscale (considered 
to be an adaptive approach to emotion regulation) minus the sum of the Suppres-
sion subscale (thought to be a maladaptive approach to emotion regulation) ( 22 ). 
Since the ASRS was being used here as a general proxy for cognitive dysfunction 
in the spectrum of inattention, rather than as a predictor of the diagnosis of ADHD, 
a total score was derived by adding the total scores for part A and part B of the 
 instrument. 
 Several items from the YRBS were analyzed as measures of early habits that we 
thought would be associated with subsequent  substance use risk. These included the 
YRBS questions on age of first smoking of a cigarette, age of first alcoholic drink, 
age of first use of marijuana, and age of first sexual intercourse. The original items 
rank the answers from  “ never, ” then  “ less than age 12 ” sequentially up to  “ 17 or more 
years old. ” For the linear regression analyses, these items were re-coded such that 
the answer  “ never ” was higher than the highest age of first use, thereby creating a 
logically consistent ordinal scale. The YRBS questions about use of  alcohol,  tobacco 
and  cannabis in the last 30 days were also hypothesized to be predictive of current 
cannabis use. The total scores for each substance from the ASSIST were used as risk 
scores for each of the substances of abuse, including cannabis, and the total ASSIST 
score provided a rating of overall risk for a SUD. 
 14.2.4  Analyses 
 Descriptive, frequency, regression and all other statistics were calculated using SPSS, 
version 20 ( 23 ). Data were explored for incorrect entries and these were corrected. 
Missing entries of data were treated by eliminating those cases from the analyses. 
 Backward selection multiple regression was chosen because this would provide 
the most parsimonious model to predict the dependent variable, given the identified 
independent variables which were all considered hypothetical predictors. A regres-
sion analysis was performed using the following variables to predict NIDA ASSIST 
total cannabis score: demographic variables of participants (age and gender); 
demographic variables of participants ’ families (parental marital status, mother ’ s 
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educational level); trait variables related to coping and cognition (ERQ and ASRS); 
participants ’ early  risk behaviors (age of first use of  tobacco,  alcohol and  cannabis 
and first sexual intercourse); recent substance use (alcohol, cannabis and tobacco), 
and lastly, measures of psychiatric symptoms and  functional impairment (BDI,  STAI, 
total SDS score). 
 In addition, in order to better understand the contributions to functional impair-
ment in this population and the extent of the association of cannabis use (and other 
variables) to functional impairment, a multiple regression using level of functional 
impairment (SDS score) as the dependent variable was conducted with the other vari-
ables listed above as predictor variables. 
 Skewness was evaluated for all variables used in the regression analyses and 
was found to be less than 1.5 for all. Although BDI and STAI were strongly correlated 
(r  =  0.64, p   <  0.0005), collinearity statistics for the group of variables did not indicate 
that the combination was problematic in the regression analyses (collinearity toleran-
ces for all variables  =  0.500). 
 14.3  Findings 
 Participants were 429  youth whose mean age was 19 (SD 2.7). These included 271 (63%) 
female and 158 (37%) male youth. The sample had well-educated mothers. The mean 
educational level was described as  “ some college or specialized education, ” and the 
mode was  “ graduate from a college or university. ” Fully 74% of respondents ’ mothers 
had at least some college or university education. A slim majority (54%) of partici-
pants came from families with married parents (including common-law married); 
while 46% came from families of separated, divorced or widowed parents. 
 14.3.1  Diagnostic characteristics 
 Of the participants, 325 (68%) received the primary hypothesized diagnosis of  depres-
sion,  anxiety or the combination of both, while 22 (4.5%) were thought to have a 
primary SUD, notwithstanding the pre-screen to exclude and refer such participants. 
Other diagnostic categories representing over 5% of the sample included:  bipolar dis-
order (7.8%), trauma disorders (5.9%), and DSM-Axis IV disorders (9.4%). This latter 
category included participants who were evaluated to have problems related to life 
stressors (conflicts within the family, lack of stable housing or food, etc.), but did not 
have  PTSD. For this category the clinical evaluator had to believe that these partici-
pants would not have sought help were it not for these stressors, and that the indivi-
dual would be symptom free if these were corrected. Another 4.4% had a mixture of 
other Axis I diagnoses. 
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 14.3.2  Coping styles 
 The mean difference score for the ERQ (Reappraisal minus Suppression) was 5.3 
(SD 8.7, range −19  –  36). The ASRS mean total score was 8.5 (SD 4.4, range 0 – 18). 
 14.3.3  Participant  risk behaviors 
 Among age of onset variables, the most frequently reported age of first smoking a ciga-
rette in this sample was  “ never ” (43% of sample). Only 38% of participants endorsed 
smoking a cigarette before the age of 17 (the remainder endorsed smoking for the first 
time at the age of 17 or older). In contrast, only 8% of subjects endorsed never having 
had a drink of  alcohol and 78% reported drinking for the first time before the age of 17. 
Thirty percent (30%) endorsed never having tried cannabis and just over half, or 53%, 
reported using  cannabis for the first time before the age of 17. Lastly, 33% of these 
 youth reported never having had sexual intercourse, while 43% had sex for the first 
time before the age of 17. 
 The YRBS includes 30-day frequency of use of multiple substances, including 
cigarettes, alcohol and cannabis. Sixty-four percent (64%) of our sample endorsed 
using no cigarettes in the past 30 days. In contrast, just under one third (31.5%) of 
participants reported no alcoholic drinks in the last 30 days, while 37.5% endorsed 
alcohol use on more than 3 days in the past 30 (the remainder used alcohol between 
1 and 3 days in the last 30). Lastly, 62% of our sample reported no cannabis use in the 
last 30 days, and 21% reported using cannabis 10 or more times in the last 30 days 
(the remainder used cannabis one to nine times). As expected, there was a high cor-
relation between 30-day cannabis use frequency and ASSIST total cannabis score 
(r  =  0.86, p   <  0.0005). Therefore, 30-day cannabis use frequency was not used in the 
regression analysis but 30-day  tobacco and alcohol use frequencies were. 
 14.3.4  Psychiatric and SUD symptoms 
 The symptoms score means, standard deviations (SD) and ranges were as follows for 
the various symptom questionnaires. BDI mean  =  31 (SD  =  11.6, range 0 – 59), which 
was in the severe range of depressive symptomatology;  STAI mean  =  56 (SD  =  12.0, 
range 20 – 80), which was at the high end of the moderate range of  anxiety; SDS 
mean  =  20 (SD  =  6.3, range 1 – 30); ASSIST total cannabis mean  =  8 (SD  =  10.9, range 
0 – 39). In addition, the ASSIST defines score ranges to identify low, moderate and 
high  substance use risk based on questionnaire total score. In this sample, 50.3% 
were at low, 32.6% were at moderate and 17.0% were at high risk for SUDs. 
 Use of other substances was also evaluated by the ASSIST, including cocaine, 
stimulants, methamphetamine, inhalants, sedatives, hallucinogens, street opioids, 
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prescription opioids, and  “ other ” drugs. In this sample, rates of use of these drugs 
were low. The most commonly used illicit drugs after  cannabis were sedatives, (16.3% 
of sample had non-zero total scores), and hallucinogens (16.1% had non-zero total 
scores). For all other substances less than 10% of participants admitted to having 
used each of them. 
 14.3.5  Multiple regression 
 Using the backward selection method, a significant model emerged as associated 
with ASSIST total cannabis score [F(7, 421)  =  37.943, p   <  0.0005. Adjusted R 2  =  0.377]. 
Significant variables are shown in  Table 14.1 . 
 Additionally, a significant model emerged as associated with total level of  func-
tional impairment per the SDS score [F(5, 423)  =  42.442, p   <  0.0005; Adjusted R 2  =  
0.326]. Significant predictor variables are shown in  Table 14.2 . 
 Table 14.1:  Multiple regression (backward selection) predicting  NIDA modified ASSIST total cannabis 
score* 
 Predictor variable  Adjusted beta  Significance (p)  95% Confidence interval for B 
    Lower bound  Upper bound 
 Gender (male  =  1, female  =  2)  − 0.195   <  0.0005  − 6.184  − 2.664 
 Age first use marijuana  − 0.263   <  0.0005  − 2.961  − 1.404 
 30-day cigarette use per day  0.278   <  0.0005  1.241  2.399 
 Sheehan Disability Scale score  0.137   <  0.001  0.104  0.370 
 * Independent variables that were not predictive in this model included: age; mother ’ s educational 
level; parental marital status;  ADHD Self-Report Scale; Emotion Regulation Questionnaire; age of 
fi rst  tobacco or  alcohol use or fi rst sexual intercourse; 30-day alcohol use; State Trait/State  Anxiety 
Inventory (state) score; and Beck  Depression Inventory score. 
 Table 14.2:  Multiple regression (backward selection) predicting total Sheehan Disability Scale score* 
 Predictor variable  Adjusted beta  Significance (p)  95% Confidence interval for B 
    Lower bound  Upper bound 
 ADHD Self-Rating Scale score  0.097  0.029  0.014  0.264 
 Beck Depression Inventory 
 score 
 0.494   <  0.0005  0.223  0.316 
 NIDA modified ASSIST total 
cannabis score 
 0.167   <  0.0005  0.045  0.148 
 * Independent variables that were not predictive in this model included: age; gender; mother ’ s 
educational level; parental marital status; Emotion Regulation Questionnaire score; age of fi rst 
cigarette, alcohol or marijuana use; age of fi rst sexual intercourse; 30-day alcohol use; 30-day 
cigarette use; and State Trait/State Anxiety Inventory (state) score. 
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 14.4  Discussion 
 In this chapter we investigated the risk levels of SUDs,  cannabis use, and  functio-
nal impairment in a sample population of 429  youth aged 16 – 26 who presented for 
evaluation and treatment of  mood and/or  anxiety problems, and who were screened 
to exclude youth with primary SUDs. In spite of this screening, a small percentage 
(4.5%) was thought to have had a primary SUD after clinical assessment. A much 
larger percentage of the youth, approximately half, were found to be at either mod-
erate or high risk for a SUD. 
 Our results showed that predictors of heavy cannabis use included being male, 
early first use of marijuana, high 30-day use of cigarettes, and high levels of functional 
impairment. Contrary to what might be expected, lower socioeconomic status, using 
the proxies of maternal educational level and parental marital status, was not predic-
tive in this model. However, it should be noted that the socioeconomic status of this 
population appeared to be higher than average compared with the general population. 
 The coping styles identified by ASRS and ERQ scores were also not predictive. 
This sample excluded subjects with ADHD diagnosed and treated in childhood, so 
participants were not representative of the full range of ASRS scores in a general cli-
nical population. This may account for an absence of predictive significance for this 
variable, although ASRS score was predictive of functional impairment in the regres-
sion analysis with the same participants. 
 Anxiety or  depression scores were not predictive of total cannabis score, which 
was also counter to our predictions, although total depression score (but not anxiety 
score) did predict overall functional impairment. 
 Interestingly, age of first cigarette and  alcohol use were not predictors of cannabis 
total score, but age of first cannabis use was, as would be expected. Even though an 
early onset of smoking  tobacco did not predict total cannabis score, 30-day tobacco 
use did. While the rate of tobacco use found here was quite low compared with that of 
cannabis, our cohort nevertheless reported almost twice the overall rate of cigarette 
use of high school students in North America ( 12 ,  13 ). Previous reports have found 
higher rates of tobacco use in individuals with mental health symptoms, including 
non-psychotic symptoms ( 24 – 26 ). Our findings indicated that only recent tobacco use 
was associated with higher scores of total cannabis use. 
 Our results lead to the conclusion that total cannabis use was best predicted by 
being male, younger age of onset of cannabis use (but not the other  risk behaviors 
measured), high frequency of recent cigarette (but not alcohol) use, and total degree 
of functional impairment. 
 This last predictor, functional impairment, was perhaps our most clinically rele-
vant variable. Investigated as the dependent variable as well, total level of functional 
impairment in our sample was predicted by ASRS (measuring cognitive coping style), 
BDI score (measuring current depressive symptom severity), and the total cannabis 
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score, but was not predicted by demographic variables, age of onset of  risk behaviors, 
emotion regulation style, state  anxiety, or recent substance use. These results confir-
med our clinical impression that greater  cannabis use was associated with a higher 
degree of dysfunction in our  youth seeking help for  mood and/or anxiety symptoms. 
We believe this to be the first report that investigated cannabis use and  functional 
impairment in youth with  mood and/or anxiety disorders. Since cannabis is the most 
commonly used illicit substance by youth in North America ( 12 ,  13 ), this association 
is clinically important. 
 There has been a dramatic decrease in the use of  tobacco products by youth since 
1997, while rates of cannabis use have fluctuated around a largely unchanged rate of 
use ( 12 ,  13 ). The cigarette smoking decreases may be related to public health cam-
paigns educating about the negative health effects of tobacco use ( 27 ). No similar 
public health campaign exists yet aimed at reducing cannabis use in youth. 
 The limitation of this study is the unknown representativeness of this clinical 
sample to youth with mood and/or anxiety disorders in general. Nonetheless, this 
research has suggested that roughly half of youth seeking help for  mood and/or 
anxiety disorders screened to exclude those with a primary SUD are, in fact, at risk 
for a SUD. It also showed that there was an association between cannabis use and 
functional impairment. Those at risk for cannabis use were more likely to be male, to 
have engaged in marijuana use at an earlier age, to have higher recent cigarette use, 
and to endorse greater functional impairment. This indicates a strong need for subs-
tance use specialists for the clinical youth population with mood and/or anxiety com-
plaints even when they do not appear to have a primary SUD. Including such services 
in primary care and specialized clinics treating youth with mental health concerns 
appears to be important for ensuring the best care to reduce symptom severity and 
negative outcomes associated with co-occurring  mental illness and SUDs, as well as 
to improve treatment responses. 
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 15   Military sexual trauma as a determinant 
in the  development of mental and physical 
illness in male and female  veterans 
 Betsy S.  O ’ Brien and  Leo  Sher 
 Military sexual trauma (MST) is defined as sexual harassment and or sexual assault 
experienced by a military service member. It is much more widespread and common 
than reported. It is associated with pre-combat traumatic experiences and  pathologic 
sequelae including mental and medical illness. Methods: An electronic search of the 
major behavioral science databases was conducted to retrieve studies detailing the 
social, epidemiological, and clinical characteristics of MST and its relationship to 
 psychiatric and medical illness. Results: Studies indicate that military sexual trauma 
is related to an increase in psychiatric pathology including  PTSD,  substance abuse and 
dependence,  depression,  anxiety, eating disorders, and  suicidal  behavior. MST is also 
related to an increase in medical illness, primarily pain related  symptoms  involving 
multiple organ systems including gastrointestinal, neurological,  genitourinary, 
and musculoskeletal. Conclusion: MST is associated with an increased prevalence 
of mental and physical illness. Although there are some gender differences in the 
 reported rates of MST and there may be some variables, such as prior traumatic expe-
riences, that may make and individual more vulnerable to the psychiatric and medical 
sequela of MST, it is clear that MST is a major health care issue that affects both sexes 
and warrants further attention and an increase in clinical resources devoted to it. 
Some preventive measures for decreasing the prevalence of MST may include incre-
asing education and legal prosecution of perpetrators in the military, and increasing 
access to mental health services for individuals who have suffered from MST. 
 15.1  Introduction 
 The Department of Veterans Affairs has defined Military Sexual Trauma (MST) as 
sexual harassment and or sexual assault experienced by a military service member 
without regard of the location of service, gender of the victim, or relationship of 
the victim to the perpetrator ( 1 ). In 1992, there was a congressional mandate for the 
Department of Veterans Affairs to treat veterans for symptoms related to MST ( 2 ). The 
data on the prevalence of MST contains some variability, depending if the studies 
only include actual or threatened sexual assault or more broadly include offensive 
sexual behavior or unwanted sexual attention. For example, Allard et  al ( 2 ) cited 
a prevalence estimate of between 22 – 45% as based on prevalence studies which 
 primarily include actual or threatened sexual assault. In 2006, the Department of 
Defense (DOD) conducted a study, which also estimated prevalence of MST and sited 
prevalence numbers for different types of MST. Specifically the DOD estimated that 
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52% of women and 29% of men reported offensive sexual behavior, 31% of women 
and 7% of men reported receiving unwanted sexual attention, 9% of women and 3% 
of men reported sexually coercive behavior, and 6.8% of women and 1.8% of men 
reported being sexually assaulted ( 1 ). Data from OEF/OIF (Operation Iraqi Freedom, 
OIF and Operation Enduring Freedom OEF, Afghanistan)  veterans suggests that 15.1% 
of women and 0.7% of men reported MST when screened ( 3 ). 
 Individuals that are most vulnerable for MST are most likely to be women between 
age of 30 and 49 years, White, highly educated, served in the reserves more than 5 years, 
and more likely to have a service-related disability ( 4 ).  Alcohol abuse is another risk 
factor that increases instances of MST and an estimated 50% of sexual assaults in the 
 military have alcohol involvement ( 5 ). As women become an increasing part of the total 
veteran population, prevalence of female veterans estimated at 15%, when including 
the wars in Iraq (Operation Iraqi Freedom, OIF) and Afghanistan (Operation Enduring 
Freedom OEF) ( 3 ), MST becomes a larger health issue affecting the military as well as 
the veteran population. 
 15.1.1  Recognition of MST 
 The diagnosis of  PTSD, included in the DSMIII and in the manual PTSD, was seen as 
the result of certain gender specific stressors mainly combat for men and rape and 
sexual trauma for women ( 6 ). Sources have suggested that seeing certain stressors 
as gender specific, such as rape for women and combat for men, has perhaps led to 
a decrease in reporting MST and thus artificially lowered the MST prevalence rates in 
male veterans ( 6 ). Initially in the first decade of DoD research on MST in servicemen, 
the reported rates were less than 1% ( 6 ). Then during the 1990s there was an increase 
in reported rates of men ’ s MST to 2 – 9% ( 6 ). Now reported rates of men ’ s MST vary 
widely across studies in the DoD from 0.02% to 12% ( 6 ). Sources have also looked at 
non-response rates, which ranged from 3 – 92%, and have extrapolated that 66% of 
men ’ s sexual assault incidents are not formally reported and that only 10% of sexual 
assaults on men at the service academies are thought to be reported ( 6 ). 
 The question arises as to what causes this under-recognition of MST especially 
in the male veteran population. Some studies have suggested that those who do not 
report want to avoid thinking or talking about an assault and do not want to disclose 
the event, whereas other sources have suggested that the military and government 
have created certain administrative barriers to reporting MST including length of 
questionnaires, substantial number of surveys to fill out, and fostering a perception 
that the surveys will not change policy ( 6 ). The military philosophy as well with its 
emphasis upon the need for cohesion, discipline, loyalty, and collectivism may create 
an environment that discourages reporting of sexual assault and the feeling that the 
victims will be attacked verbally and even physically for reporting ( 5 ,  6 ). Studies quote 
common reasons for not reporting MST to be that victim feels embarrassed, fearful of 
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reprisal through evaluations, belief that the incident was not important enough to 
warrant reporting, and fear nothing will be done ( 6 ). An element of guilt may also 
play a role in not reporting the crime as male victims of MST may interpret reporting 
to be a threat to their manhood ( 6 ). Studies have also shown that MST affects  mili-
tary careers as a substantial portion transfer or leave the services as a result of their 
 experiences ( 7 ), which may decrease the likelihood of reporting the incident. 
 15.1.2  Civilian traumatic experiences and MST 
 Military personnel in general report higher rates of trauma before, during, and after their 
military involvement than civilian population ( 2 ). Allard and colleagues ( 2 )  suggested 
that the prevalence of rape among female  veterans (49%) was significantly higher 
than among civilians (22%). Kelly and colleagues ( 8 ) reported that of the 135 female 
 participants that stated MST in their study, 95.4% also reported at least one trauma in 
addition to the MST, the most common being sexual abuse as adult civilians (77%) and 
then sexual abuse as children (53%) ( 8 ). 
 Being in the military does not make women less vulnerable to intimate partner 
violence. Studies have shown that in a sample of females enlisted in the army married 
to civilian spouses, the sample of women were almost four times more likely to be 
victims of unilateral violence from their non-military spouses than perpetrators of 
unilateral violence ( 4 ). The women were also three times more likely to be victims of 
severe violence from their partners, which is similar to non-military studies of intimate 
partner violence ( 4 ). 
 15.1.3  Literature search 
 An electronic search of the major behavioral science databases (PUBMED, PSYCINFO, 
MEDLINE) between the years 1990 – 2012 was conducted to retrieve studies detailing 
the social, epidemiological, and clinical characteristics of Military sexual trauma and 
its relationship to psychiatric and medical illness. Search items included  “ military 
sexual trauma, ”  “ childhood trauma, ”  “ veterans, ”  “ post-traumatic stress disorder, ” 
 “ depression, ”  “ female veterans, ”  “ male veterans, ” and  “ medical illness. ” Additional 
references were incorporated from the bibliographies of the retrieved articles. 
 15.2  Findings 
 Sources have shown that since returning from Iraq 15% of service members meet  criteria 
for major depression, generalized  anxiety disorder, or  PTSD and 11% from Afghanistan ( 3 ). 
The mental health consequences of MST include PTSD,  alcohol abuse,  depression, 
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somatization disorders,  suicidality, and impulsive behavior ( 3 ,  4 ,  7 ,  9 – 12 ). MST has 
also been correlated with difficulty with psychosocial readjustment to civilian live, 
 particularly in areas involving intimacy ( 13 ). 
 Studies have also associated MST with suicidality in both genders ( 4 ,  12 ). Inter-
personal trauma and sexual assault during  military service was associated with 
 suicide attempts in both military men and women ( 4 ). 
 15.2.1  MST and psychiatric illness in females 
 The most prevalent trauma-related mental health problem is  PTSD with the life-
time prevalence of PTSD among female veterans attending VA primary care clinics 
being 27% ( 7 ). Women  veterans who suffered from MST are nine times more likely 
to develop PTSD than women without a history of sexual assault ( 4 ). Studies have 
also identified that MST specifically, more than other trauma, is a stronger predic-
tor of PTSD ( 14 – 16 ). In one study, 60% of women veterans who suffered from MST 
were diagnosed with PTSD using the DSM-IV criteria versus 40% of women veterans 
who suffered from other traumas both pre-service, during service, and post-service 
including sexual and physical assault, witnessing violence, combat trauma, illness, 
accidents, traumatic deaths, and natural disasters ( 14 ). Suris and colleagues ( 16 ) 
also showed that MST specifically is a stronger predictor of PTSD than other sexual 
trauma. They found that female veterans were nine times more likely to have PTSD 
if they had a history of military sexual trauma versus seven times more likely if they 
had a history of child sexual abuse versus five times more likely if they had civilian 
sexual assault histories in comparison with female veterans who do not report a 
history of sexual assault ( 16 ). 
 MST is also correlated with other Axis I diagnoses, mental health symptoms, and 
use of prescription medication for mental health symptoms ( 17 ). For women who 
reported military-related sexual assault, screening prevalence for current  depression 
was three times higher and for current  alcohol abuse three times higher than for 
women veterans not reporting MST ( 11 ). Furthermore, some studies have sugges-
ted that the majority of female veterans with PTSD will have comorbid psychiatric 
illness, with some research supporting a link between PTSD and  substance abuse 
( 7 ). With respect to eating disorders and impulsive behavior, sources have suggested 
a prevalence of eating disorders of about 25% in female veterans who have suffered 
from MST ( 10 ). Studies have shown that MST itself has been linked to eating disor-
ders and  substance use ( 9 ). Other studies have identified four major coping strate-
gies for females with post-deployment stress including coping with the aftermath of 
MST. These coping strategies include disordered eating behavior, substance abuse, 
and impulsive  behavior including binging and purging, compulsive spending, over-
exercising, and prescription drug abuse ( 3 ). 
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 15.2.2  MST and psychiatric illness in males 
 Similar to female  veterans, male veterans who experienced sexual harassment and 
assault have greater incidence of  PTSD,  depression, and somatization disorders than 
male veterans who had not experienced sexual harassment ( 4 ). Studies have sugge-
sted that perhaps due to an increase stigma attached to MST in male veterans and 
a decrease in reporting of MST amongst male veterans, there may be greater levels 
of psychological sequel including PTSD and other  psychiatric symptoms as well as 
poorer physical health ( 2 ). Studies have shown that sexual harassment of men in the 
 military has shown a stronger association with psychological problems including 
more persistent sexual abuse trauma symptoms, more persistent sexual problems, 
more emotional problems, and a larger decrease in work productivity then women 
( 6 ,  18 ). Some studies have also shown that psychological problems also appear to be 
more persistent and treatment resistant after MST in men than in women ( 6 ) .
 15.2.3  MST and medical illness 
 Associations between stress reaction and physical illness are seen throughout 
medical systems including cardiovascular, respiratory, GI, cancer, and chronic pain 
problems in both females and males. Studies have shown that war zone stressor- 
related trauma was associated with increased disordered functioning in arterial, gast-
rointestinal, and musculoskeletal systems in female and male veterans ( 19 ). In female 
and male veterans, MST is associated with physical health problems, primarily pain 
related and affecting multiple organ systems including genitourinary, musculoskel-
etal,  neurological, and gastrointestinal ( 4 ). Individual physical symptoms include 
back pain, headaches, GI symptoms, and chronic fatigue ( 4 ). MST has also been 
 associated with an increase in health risk factors including obesity, smoking, and 
sedentary  lifestyles ( 4 ,  18 ). MST is also associated with chronic medical comorbities 
including liver disease and pulmonary disease ( 4 ). MST has also been associated with 
sexual dysfunction in both female and male veterans ( 2 ). 
 15.2.4  MST and medical illness in females 
 Many studies restricted the study population to female veterans as MST is more 
common in the female veteran population as highlighted above. These studies found 
that MST in female veterans was correlated with an increase in chronic medical 
 problems ( 17 ) as well as current symptoms across almost every organ system assessed 
including reproductive/gynecological, urological, neurological/rheumatological, gas-
trointestinal, pulmonary, cardiovascular, and other symptoms including chronic 
fatigue ( 20 ). Women veterans who reported sexual assault while in the military were 
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more likely to report a heart attack within the previous 12 months than women who 
had not reported sexual assault while in the  military ( 9 ). A reported history of MST 
was also associated with an increase in cardiac risk factors including obesity, smoking 
problem  alcohol use, and sedentary lifestyle ( 9 ). For female  veterans, metabolic 
comorbidities including hypothyroidismis also associated with MST ( 4 ). Women also 
reported more frequent symptoms of pelvic pain, vaginal bleeding/discharge, painful 
intercourse, rectal bleeding, bladder infections, and painful urination compared to 
those not sexually assaulted ( 4 ). Female veterans who were victims of MST also report 
sexual dysfunction including decreased sexual satisfaction as well as fear, disdain, or 
avoidance of sexual intimacy, and difficulty with arousal and desire ( 2 ). MST was also 
associated with poorer reproductive outcomes in women including infertility and lost 
pregnancies ( 20 ) as well as hysterectomy before the age 40 years ( 9 ). 
 15.3  Discussion 
 Sources have suggested that psychiatric sequela may mediate the relationship between 
MST and medical illness, especially  PTSD ( 14 ). Sources have shown that post- traumatic 
stress symptomatology (PSS) mediates the relationship between  violence and physical 
health symptoms ( 19 ). Some studies have suggested that there are gender differences in 
the relationship between MST and physical health  symptoms and that PSS mediates the 
relationship between MST and perceived physical health in men but not in women ( 19 ). 
 Smith and colleagues ( 19 ) separated sexual harassment from sexual assault 
and found that sexual harassment was not a significant predictor of post- traumatic 
stress symptomatology when warfare stressors were not included, thus indicating 
that warfare stressors may actually be the mediator between sexual harassment 
and  physical illness including gastrointestinal and neurological symptoms in male 
 veterans who suffered from sexual harassment ( 19 ). However, sexual assault was 
a  significant predictor of post-traumatic stress symptomatology (PSS) even when 
warfare stressors were controlled for ( 18 ). Furthermore, for veterans who suffered 
from sexual assault, PSS mediated the relationship between sexual assault and 
health  symptoms including gastrointestinal (primarily abdominal pain), genitouri-
nary  (primarily sexual  discomfort or difficulties), musculoskeletal (primarily muscle 
or joint pain), and  neurological (primarily headaches) ( 19 ). 
 15.3.1   Pre-military abuse as a predictor of PTSD and mediator between MST 
and mental and physical illness 
 Not all veterans who suffer from military trauma, whether it be MST or combat-related 
trauma, will go on to develop PTSD, but it does appear that veterans are more predis-
posed to PTSD symptomatology than the civilian population. As mentioned above, 
 15.3  Discussion   191
military personnel have a higher prevalence of trauma before, during and after their 
 military involvement ( 2 ). Studies have shown that female  veterans in Desert Storm 
who describe pre-service abuse reported greater  PTSD symptomatology than those 
denying pre-combat abuse ( 21 ). In a study with 2,392 male soldiers returning from 
Iraq, those that suffered from  childhood trauma were more likely to have positive 
screenings for both PTSD and  Depression ( 22 ). The same trend was seen with Vietnam 
veterans in which Vietnam Veterans with PTSD had higher rates of childhood phy-
sical abuse than Vietnam veterans without PTSD and veterans with PTSD overall 
had higher total traumatic events before joining the military than patients without 
PTSD ( 23 ). It is possible that this may apply to MST and that those who suffer from 
pre-MST abuse may be more vulnerable to PTSD symptomatology than those who 
deny pre-MST abuse. 
 If PTSD is a mediator between trauma and the  development of physical illness 
and the presence of multiple traumas is a predictor of PTSD, we propose that vete-
rans who suffer from multiple traumas, with MST being one of those traumas, are the 
veterans who are more vulnerable to developing physical illness in the aftermath of 
MST. Perhaps it is both the prevalence of multiple traumas and the development of 
PTSD that mediates the relationship between trauma and the development of both 
mental and physical illness. Previous studies have supported that multiple traumatic 
events increases vulnerability for medical illness. In the Adverse Child Experience 
Study (ACE Study 1998), children who have suffered from multiple adverse childhood 
(defined as experiencing 4 or more categories of childhood exposure) had a 4- to 
12-fold increased prevalence of multiple poor mental and physical health outcomes 
including alcoholism, drug abuse, depression,  suicide attempt, smoking, sexual pro-
miscuity and sexual transmitted diseases, obesity, and physical inactivity as well as 
increased risk for medical illness including ischemic heart disease, cancer, chronic 
lung disease, skeletal fractures, and liver disease ( 24 ). We suggest that there may be a 
similar outcome with the veteran population with those veterans who suffered from 
MST as well as multiple other adverse experiences pre-combat have an increased risk 
of mental and physical illnesses. 
 15.3.2  Prevention and treatment 
 Education of military personnel about MST as to increase awareness and reporting 
is necessary. Awareness and discussion of MST is often avoided especially if the 
 perpetrator is a coworker or a superior officer as it disrupts the focus of military 
 experience including closeness, dependence, cohesion, and leadership which in the 
military are often necessary for survival especially in combat ( 2 ). The reporting system 
in the  military also contributes to underreporting of MST as well as decreased law 
 enforcement against perpetrators of MST ( 5 ). The reporting system in the military is 
a two-tiered system ( 5 ). The first tier of reporting is where the victim anonymously 
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files a restricted report of the assault and can receive medical care and counseling, 
but does not prosecute the perpetrator ( 5 ). The second tier of reporting the victim also 
prosecutes the perpetrator, but no longer remains anonymous ( 5 ). Although this two-
tiered reporting system may increase the number of victims who seek treatment, it 
does not bring justice to the perpetrator and may do little to prevent the continuation 
or even escalation of MST in the  military ( 5 ). Thus in order to prevent the perpetua-
tion of MST it becomes important to not only educate military personnel but also to 
remove barriers to reporting and prosecuting perpetrators of MST. 
 In the aftermath of MST, treatment and access to treatment becomes essential. 
Increasing access to supports in the aftermath of trauma while  veterans are still in 
active duty may be necessary to facilitate recovery, but difficult in the military where 
deployment means one is cut off from primary support systems ( 2 ). That being 
said, barriers to treatment continue to exist after deployment. Access to treatment 
is important. Some studies where women veterans were interviewed described that 
female veterans did not feel comfortable seeking VA services as they felt that WWII, 
Korean, or Vietnam veterans should be entitled to VA services before them ( 3 ). For 
women who suffered from MST there is also a fear of utilizing services where they 
may encounter the same type of individuals who perpetrated the sexual trauma ( 3 ). 
Childcare also may be a barrier for women seeking services ( 3 ). There also needs to be 
an increased availability of mental health treatment specific for sexual assault related 
 psychopathology including Prolonged Exposure (PE) and Cognitive Processing 
Therapy (CPT) as well as some other less empirically supported modalities (Stress 
Inoculation  Training and Eye Movement Desensitization and Reprocessing) ( 1 ). 
 In conclusion, MST is a clinically significant issue that deserves recognition and 
discussion for both men and women. Although there are some gender differences in the 
reported rates of MST, physical and psychological sequela, it is clearly a major health 
care issue that affects both sexes and warrants further attention and an increase in 
 clinical resources devoted to it. 
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 16   Educating medical professionals about  suicide 
prevention among  military  veterans 
 Debora  Ganz and  Leo  Sher 
 The aim of this chapter was to discuss the results of a review into the literature related 
to  suicide in military veteran populations. Suicide in veteran populations has been 
increasing in recent years, and continues to be a medical and social problem across 
the globe. For medical health professionals, knowledge of the risk factors for suicide, 
careful assessment, and appropriate interventions are key to  suicide prevention. This 
review seeks to better understand the risk factors present in veteran suicide and how 
to best educate medical professionals in suicide prevention. Key suicide risk factors 
found in veteran populations include post-traumatic stress disorder,  major depressive 
disorder, physical injuries,  substance use disorders, traumatic brain injury, combat 
related guilt, access to firearms, and insufficient social support. Some psychosocial 
difficulties are unique to veteran populations, and medical professionals should be 
culturally sensitive to these factors. Psychosocial changes upon discharge from active 
duty, as well as stigma against mental health disorders and treatment, should also be 
considered and assessed. Since general practitioners may be the first line of defense 
for these veterans, they should be educated in risk factors for veteran suicide and 
proper assessment techniques. Any suicide risk in a veteran population should be 
taken very seriously, and responded to appropriately. 
 16.1  Introduction 
 In 2006, suicide was reported to be the 11th leading cause of death in the United States 
(US), with more than 32,000 individuals killing themselves each year ( 1 ). A cross-national 
study involving nine countries and over 40,000 persons found the rates/100 for suicide 
ideation ranged from 2.09 (Beirut) to 18.51 (Christchurch, New Zealand), with lifetime pre-
valence rates/100 for suicide attempts ranging from 0.72 (Beirut) to 5.93 (Puerto Rico) ( 2 ). 
 Suicidality exists along a continuum ranging from suicidal ideation to completed 
suicide. For the purposes of this article, we will focus on the research concerning 
suicidal ideation, suicide attempts and completed suicides in international military 
personnel. 
 Suicidal behavior is both a medical and social problem throughout the world. 
In the US in 2000, the average cost per case for a fatal self-inflicted injury (suicide) 
was  $ 2,596 in medical costs and  $ 1.0 million in lost productivity ( 3 ). Suicidality is 
also commonly associated a variety of medical and psychosocial factors, including 
depression,  alcohol and drug abuse, traumatic brain injury (TBI), suicide contagion, 
combat-related guilt and decreased social support ( 4 ). A necessary step in reducing 
these costs is educating medical professionals to recognize suicide risk factors and 
enact appropriate preventative measures. 
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 16.2  Prevalence of  suicidal behavior 
 Suicide rates in US  military typically fluctuate between 9.0 and 15.0 per 100,000 
persons per year ( 5 ). However, different studies across countries and over time have 
found disparate results, with some indicating that suicide rates are higher in  military 
than civilian populations, while others have found no significant  differences in 
suicide rates ( 6 – 14 ). According to some findings, suicide attempts in Canada as well as 
 completed suicides in US tend to be lower in the military than in  comparable  civilian 
 populations ( 7 ,  8 ). Other statistics indicate that from 1980 – 2004, the crude rate of 
US active duty military completed suicides averaged at 12.4 per 100,000 persons per 
year, while the civilian suicide rate averaged at 12.5 per 100,000 persons per year 
( 5 ,  9 ). Increases in the rates of  suicidality in the Romanian, Ukrainian and Norwegian 
militaries have been observed in recent years ( 7 ). Possible reasons for these disparate 
results, with suicide rates among  veterans sometimes being lower than in the general 
population, may be a result of screening procedures for mental health problems prior 
to enlistment,  suicide  prevention programs for enlisted soldiers or other protective 
factors within the  military ( 6 ,  7 ). 
 According to a recent CBS news study, veterans committed suicide at the rate of 
18.7 – 20.8 per 100,000, compared to the normative American population, who did so 
at the rate of 8.9 per 100,000 ( 10 ). Over 20% of Operations Enduring Freedom and 
Iraqi Freedom (OEF-OIF) veterans reported recent suicidal ideation (in the past 3 
months), compared to less than 3% in the general population ( 11 ,  12 ). Some studies 
suggest that male Veterans are at twice the risk of suicide than comparable men in 
the general population, and female veterans are thought to be at a three times higher 
risk of suicide than comparable female populations ( 13 ). Veteran ’ s aged 20 through 
24 who served during the war on terror had the highest suicide rate of all veterans 
(22.9 – 31.9 per 100,000), estimated between two and four times higher than the suicide 
rate for  civilians in the same age group (8.3 per 100,000) ( 10 ). However, other studies 
maintain that suicide risk of veterans overall (specifically gulf war veterans) was not 
 significantly different from that of the general population ( 6 ). While risk factors for sui-
cidality differ across nationality based on specific missions, social situations and rec-
ruitment  policies; it seems to be true that increased suicide rates are present in veteran 
populations and increasingly prevalent in armies that recruit more  adolescents (i.e., 
Israel) due to  elevated rates of adjustment disorder in that age group ( 6 ,  7 ,  10 ,  14 ). 
 16.3  Risk factors for veteran suicide 
 There are many possible reasons for the significant suicide rates among war  veterans; 
many of which are distinct from civilian suicide risk factors. While post- traumatic 
stress disorder ( PTSD) may be the most widely researched, other factors that 
 contribute to suicide in military personnel include  major depressive disorder (MDD), 
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physical injuries,  substance use disorders, TBI, combat guilt, survivor guilt, access to 
and familiarity with firearms, and psychosocial difficulties ( 4 ,  15 ,  16 ). In 2008, a US 
congressional report concluded that the main  suicide risk factors for  veterans were: 
combat exposure,  PTSD, mental health problems, TBI, poor social support and access 
to lethal means ( 16 ). 
 Psychopathology is typically associated with an increased risk for suicide att-
empts, and this is true of combat veterans as well. Combat veterans with  psychiatric 
symptoms are more likely to make a suicide attempt than combat veterans without 
psychiatric symptoms ( 15 ). Two studies involving more than 450 veterans from the 
UK indicated that personnel with mental health problems during service were likely 
to present with  depression (48%) and stress (28%) after discharge ( 17 ,  18 ). Specific 
cognitions that may indicate increased suicidal ideation in  military personal are 
those related to combat guilt and survivor guilt ( 19 ). These specific cognitions were 
also found to be associated with combat related PTSD ( 19 ), and may be a moderating 
factor between PTSD and  suicidality in veteran populations. 
 Some culturally specific factors that may contribute to suicidality include the 
aggressive nature of the army, the demands of a military lifestyle, increased access to and 
knowledge of firearms and possibility for suicide contagion among fellow soldiers ( 7 ). 
Decreased social support has also repetitively been found as a risk factor for suicide 
in veteran and civilian populations ( 4 ,  6 ,  7 ,  16 ). Some specific suicide risk factors asso-
ciated with negative life events that have been documented in military populations 
include wanting a change (in military position), anger at an external entity (e.g., their 
general), conflict in a romantic relationship and past suicide attempts ( 7 ,  20 ). 
 Recent veterans are at an elevated suicide risk, possibly because protective struc-
tures and cognitions that existed during active duty may no longer be in place ( 21 ). 
While a military lifestyle may be a protective factor for many, the transition from mili-
tary life to civilian life may serve to compound suicide risk by resulting in social exclu-
sion, homelessness,  alcohol misuse, unemployment, and/or poor mental health ( 6 ). 
 Since military and veteran lifestyles have unique psychosocial and economic 
challenges, training opportunities that incorporate role-play may help to prepare 
health care personnel to best treat veteran populations. 
 The interpersonal-psychological theory of suicide ( 20 ) is also able to account 
for some of the increased risk of completed suicide among military veterans ( 22 ). 
According to the interpersonal-psychological theory of suicide; the suicidal process 
is related to feelings of thwarted belongingness, perceived burdensomeness, and an 
acquired capability to overcome the pain associated with suicide ( 20 ). Within the 
realm of acquired capability to enact self harm, one of the factors contributing to com-
pleted suicides is access to lethal means ( 20 ). In fact, firearms account for nearly 50% 
of all US suicides ( 23 ). Due to military veterans increased access to and experience 
using firearms, an increase in their suicide risk has been found ( 16 ). 
 Within this theory, another important risk factor for completed suicide is that of 
increased pain tolerance. Such increased tolerance is often seen in war veterans due to 
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the fact that  “ repeated experiences with violence, even when directed towards others, 
may result in habituation and the acquisition of the capacity for self harm ” ( 20 ,  22 ). A 
study done on nearly 45,000 wounded Vietnam  veterans bolstered this hypothesis by 
finding an association between wounding and subsequent  suicide risk ( 24 ). Similarly, 
research suggests that combat exposure,  PTSD and TBI are each thought to increase the 
chance of suicide attempts; all of which are related to exposure to physical pain ( 16 ). 
 Research has found that TBI survivors are at increased risk for suicidal ideation, 
suicide attempts and completed suicides ( 25 ). TBI is also one of the leading injuries 
faced by US soldiers who served in Iraq and Afghanistan in recent years, thereby 
furthering the need for current suicide interventions for veterans. Medical professio-
nals should specifically be familiar with the biological interactions between TBI and 
suicide, and the relevant medications. 
 16.4   Suicide prevention and assessment 
 A recent survey study in the United Kingdom (UK) found that about 50% of veterans 
with self-reported mental health problems sought help from their general health prac-
titioner (GP) ( 17 ). In the US, a systematic review published in the Journal of the Ame-
rican Medical Association found that training primary care physicians in the recogni-
tion and screening of  depression might be one of the most effective ways to prevent 
suicide ( 26 ). These findings highlight the need for medical health professionals to be 
educated about suicide risk factors in veteran populations. 
 Medical health professionals should take any suicidal ideation present in veteran 
patient populations very seriously. They should also be aware that they may be the 
first, (and possibly only,) means of suicide prevention for these individuals. They 
should be especially concerned with a veteran who also presents as depressed, trau-
matized, guilty or hopeless. It is important to ask about social support and access to 
lethal means (especially firearms or pills) and be prepared to follow-up with approp-
riate preventative measures. 
 Perhaps one reason for insufficient suicide prevention in veteran populations is 
a result of limited education of medical professionals on recognizing veterans in dis-
tress. There should be lessons on these factors in  medical education and testing, role 
play of suicide related histories and cognitions, and increased distribution of what 
we know about suicide in veteran populations; via pamphlets, lectures and continual 
education courses. 
 Distribution of pragmatic and effective screening material is also imperative. A 
recent 3 question PTSD screen has been found to have a sensitivity of 78% and speci-
ficity of 87% in primary care settings ( 27 ). Such screening instruments may be a good 
place for GPs to start. However, since many veterans with suicide risk factors may not 
in fact be suicidal, a more comprehensive assessment may be necessary, with recogni-
tion that the more risk factors that are present, the higher the suicide risk ( 28 ). 
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 Reduction in stigma may also be an important factor for medical professionals 
to consider when asking about  suicidality, as a recent review found that US airmen 
avoided seeking professional help due to the stigma associated with mental health 
disorders and treatment ( 29 ). 
 16.5   Veteran suicidal ideation follow-up care and treatment 
 What should health care professionals do if they identify a veteran with suicidal 
 ideation, suicidal intent, or a  suicide plan? Rehabilitation options include inpatient 
and outpatient programs, hospitalization, and treatment of the related psychiatric, 
neurological and/or medical conditions. 
 If a veteran is determined to be in immediate risk of self-harm,  hospitalization 
should be encouraged and likely mandated. This may be indicated if a veteran 
 presents with many risk factors and an intent to die, expresses a great deal of hope-
lessness and has access to lethal means. If a veteran is determined to be at high risk 
with many risk factors, but not immediate risk, inpatient and/or day programs may be 
more appropriate. If a veteran presents with mild to moderate suicide risk, outpatient 
programs including cognitive behavioral therapy, family therapy and/or medication 
may be more appropriate ( 20 ,  22 ). Such an individual may have a few risk factors and 
occasional or passive thoughts about suicide, but deny access to means or any active 
suicidal intent. 
 For any level of suicide risk, a  suicide prevention plan should be considered, with 
the individual agreeing to contact either health care or a responsible family member if 
they get the urge to commit suicide in the future ( 22 ). For lower levels of suicide risk, 
providing the patient with a suicide hotline or mental health contact is  encouraged. 
This may be specifically helpful for veterans presenting with indications of  depression 
and/or  PTSD. 
 Regardless of the precise prevalence of suicide risk in each country, all veterans 
(if not all patients) should be asked about feelings of depression and suicidality ( 26 ). 
For all levels of suicide risk, proper consideration and appropriate safety planning 
should be effected with the patient. For any of these preventative measures to be 
effected, sufficient education of medical personnel is a necessary first step. 
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 Section VII: Public health, cultural, and legal issues 

 17   Does the physician density affect  suicide rates 
among  adolescents and young adults? 
 Leo  Sher 
 Higher physician-per-population ratio may improve access to medical care, decrease 
waiting times, increase the opportunity for contact between the patient and physician 
and has been associated with earlier stage of diagnosis and better prognosis in pati-
ents with some medical conditions. It appears that an increase in the physician density 
generally improves the quality of health care and should prevent suicides. However, 
several research reports suggest that of those people who committed suicide, many 
saw a physician shortly before their suicide completion. Besides, studies show that 
many physicians do not have adequate training in suicide evaluation techniques and 
treatment approaches to suicidal patients, especially young people. Therefore, we 
hypothesized that the physician density does not affect suicide rates among adole-
scents and young adults. Methods: Correlations were computed to examine relation-
ships between suicide rates in 15 – 24-year-old and 25 – 34-year-old males and females 
and the physician density in European countries. Countries were also divided into two 
groups, according to the median split of the physician density. Suicide rates among 
15 – 24-year-old and 25 – 34-year-old males and females in these two groups were com-
pared using the t-test. Results: We found no relationships between suicide rates and 
the physician density. Conclusion: The results of our study suggest that either physici-
ans do not take an appropriate care of suicidal patients, or suicide is not preventable, 
or both. The results of this study should be treated with caution because many con-
founding variables are not taken into account. 
 17.1  Introduction 
 Physician density is the number of physicians, including generalist and specialist 
medical practitioners, per 1,000 of the population ( 1 ). It has been suggested that 
higher physician-per-population ratio may improve access, decrease waiting times 
and increase the opportunity for contact between the patient and physician ( 2 ). An 
increase in physician density tends to lead to physician-induced demand ( 3 ). The 
increase of health care consumption can be intuitively considered a  “ normal ” effect 
of increased care availability in regions with a previous  “ low ” physician density and 
unmet health needs. 
 The relationship between physician supply and the quality of care has recently 
sparked a debate about the required physician workforce in the US. The Association 
of American Medical Colleges called for an increase of medical school admissions 
by 30% annually to meet the increasing demand for health care of an aging 
population ( 4 ). 
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 A study in Canada suggested that an additional family physician per 10,000 
population has a statistically significant impact in the order of 2 – 4% on self- reported 
general health status, as well as, other quality of care outcomes ( 5 ). An analysis of 
the relationship between physician density and infant mortality, internationally and 
within the US has shown a strong relationship across countries but no relationship 
within the US, where physician density is on a relatively high level ( 6 ). One study 
found a negative correlation between metropolitan area level physician density and 
total mortality rates ( 7 ). The correlation becomes insignificant, however, when socio-
economic status is controlled for. A study in Germany found no systematic relation-
ship between physician density and the quality of life ( 8 ). 
 A research group used 2008 inpatient data from the Wisconsin Hospital Associ-
ation to identify all inflammatory bowel disease hospitalizations through ICD-9-CM 
discharge codes ( 9 ). County-level rates of primary care physicians and gastroentero-
logists were computed for each county using data from the American Medical Asso-
ciation and the US Census Bureau. It has been found that residence in counties with 
high physician density is associated with less complicated disease on hospitalization 
and lower hospitalization charges for inflammatory bowel disease. 
 Higher physician density has been associated with earlier stage of diagnosis of 
malignant melanoma, lower incidence of cervical cancer and earlier stage at diag-
nosis of breast cancer ( 10 – 13 ). It has been observed that higher gastroenterologist or 
primary care physicians density is associated with 14 – 17% lower incidence of late-
stage colorectal cancer in non-metropolitan counties or those with low population 
density ( 2 ). One study pursued to calculate the effect of physician-specialty density 
on melanoma prognosis ( 14 ). A higher density of dermatologists was associated with 
better prognosis (lower mortality to incidence ratio). Internist density was also a sig-
nificant predictor of better prognosis whereas increased family practitioner density 
was associated with worse prognosis. Another study investigated the effect of regio-
nal variations in the supply of health services on specific types of avoidable cancer 
deaths over 5 years using German districts as units of analysis ( 15 ). An increase in 
physician density tended to be associated with a small reduction in avoidable cancer 
death rates. 
 It appears that an increase in the physician density generally improves the quality 
of health care and should prevent suicides. However, several research reports suggest 
that of those people who committed  suicide, up to two thirds saw a primary care phy-
sician within a month or less of their suicide completion ( 16 – 19 ). One research group 
even estimated this percentage to be three fourths ( 20 ). Only 36% of the physicians in 
the study of primary care physicians reported that they would conduct a suicide risk 
assessment when treating a patient presenting with major  depression with moderate 
levels of severity ( 21 ). 
 The awareness of suicide as a major social and medical problem has increased 
significantly lately. However, many health care professionals who have frequent 
contact with high-risk patients do not have adequate training in suicide evaluation 
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techniques and treatment approaches to suicidal patients ( 22 – 24 ). Several studies 
in the US and UK have found that residency trainees, junior physicians and clinical 
psychology trainees report receiving limited training on the assessment and manage-
ment of  suicidal behavior ( 25 – 29 ). Regretfully, some physicians do not understand the 
clinical rationale for  suicide risk assessment and the role they play in preventing sui-
cidal behavior ( 30 ). The US Preventive Services Task Force believes that primary care 
providers should improve their knowledge and skills to be able to manage and assess 
suicide risk ( 31 ). Studies in Hungary, Sweden and Germany conducted over the past 
30 years have shown that current methods of training of general practitioners in the 
recognition and management of  suicidality are somewhat effective but not very effec-
tive ( 32 – 35 ). Medical students receive little training regarding  suicide prevention and 
continuing education offerings for practicing physicians are few ( 36 – 39 ). However, 
even well-trained medical professionals frequently have problems assessing patients 
for suicidality and disagree in their evaluation of suicide risk ( 40 ). 
 Suicide prevention efforts among  adolescents and young adults are restricted by 
the fact that there are many limitations related to the evaluation and management of 
suicidality in young people including the following ( 41 ): 
 (a) Many clinicians underestimate the magnitude of the issue of  suicidal behavior in 
adolescents and young adults and underestimate its prevalence; 
 (b) There is a misconception that direct questioning of patients, including adole-
scents and young adults about suicidality is sufficient to estimate suicide risk; 
 (c) Some medical professionals believe that adolescents and young adults with non-
psychiatric illnesses do not need to be evaluated for suicidality which is a mis-
conception; 
 (d) Many health care professionals do not know about or underappreciate the role of 
contagion in suicidal behavior among young people; and 
 (e) There is an erroneous belief that young men are at lower risk of suicide than 
young women. 
 In fact, male  youth die by suicide over four times more frequently than female youth 
( 42 ). It is important to note that young people usually visit physicians less frequently 
than individuals who are older. 
 We hypothesized that the physician density does not affect suicide rates among 
adolescents and young adults. To test this hypothesis, we examined the relation 
between physician density and suicide rates in adolescents and young adults in 
European countries. 
 17.2  Project 
 Information on suicide rates in 15 – 24-year-old and 25 – 34-year-old males and females 
was obtained from the World Health Organization (WHO) database ( 43 ). All European 
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countries for which the WHO data were available were included in the study. Thirty-
eight countries were included in the inquiry: Albania, Austria, Belarus, Belgium, 
Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Macedonia, Malta, Moldova, Netherlands, Norway, Poland, Portugal, 
Romania, Russia, Serbia, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, 
Ukraine, and United Kingdom. The most recent available data were used. Informa-
tion on the physician density in these countries was obtained from the US Central 
Intelligence Agency World Factbook ( 1 ). 
 Correlations were computed to examine relationships between  suicide rates in 
15 – 24-year-old and 25 – 34-year-old males and females and the physician ’ s density 
in European countries. Countries were also divided into two groups, according to 
the median split of the physician density. Suicide rates among 15 – 24-year-old and 
25 – 34-year-old males and females in these two groups were compared using the t-test. 
The SPSS program (version 19) was used to perform statistical analysis. 
 17.3  Findings 
 The raw data on the physician ’ s density and suicide rates in 15 – 24-year-old and 
25 – 34-year-old males and females in Europe are presented in  Table 17.1 . The general 
description of the sample is provided in  Table 17.2 . The highest physician density is 
in Greece (6.043 per 1,000 population) and the lowest physician density is in Albania 
(1.146 per 1,000 population). The highest suicide rate among 15 – 24-year-old males is 
in Russia (43.7 per 100,000 population per year). The highest suicide rate in females 
in the same age group is in Finland (8.7 per 100,000 population per year). Among 
25 – 34-year-old males, the highest suicide rate is in Russia (70.9 per 100,000 popula-
tion per year), and among 25 – 34-year-old females, the highest suicide rate was obser-
ved in Finland (12.1 per 100,000 population per year). 
 The correlation data are presented in  Table 17.3 . As expected, there were signifi-
cant correlations between suicide rates in all four demographic groups. There were no 
correlations between physician density and suicide rates in any of four demographic 
groups. When the countries were divided, according to the median split into countries 
with higher and lower physician density, no difference with regard to suicide rates 
was found (see  Table 17.4 ). 
 17.4  Discussion 
 The results of this study suggest that suicide rates are not related to physician density. 
This indicates that either physicians do not take an appropriate care of suicidal pati-
ents, or suicide is not preventable, or both. 
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 Do physicians fail to recognize significant clues to suicide? 
 The rates of visits to primary care physicians preceding suicide completion are much 
higher than the rates of visits to mental health specialists, giving primary care phy-
sicians/pediatricians a significant and important role in  suicide prevention ( 16 – 21 ). 
However, it has been observed that physicians tend to provide less than quality care, 
as measured by conducting a suicide risk assessment, for patients who present with 
depressive symptoms ( 20 ). 
 Possibly, physicians fail to forestall preventable deaths.  Adolescents are often 
at risk of suicide because of stresses of puberty and approaching adulthood. Pro-
longed loss of sleep, intake of  alcohol and drugs may result in loss of controls over 
self-destructive impulses. The management of suicidal adolescents and young adults 
includes diagnosis and treatment of existing psychiatric illnesses, assessment of 
suicide risk, and the reduction of access to highly lethal methods for committing 
suicide, such as guns ( 44 ). Collateral reports from parents, spouses, partners, family 
members, or friends can provide valuable information to clinicians. A physician may 
fail to take appropriate steps if his personal and cultural attitudes toward suicide and 
professional incompetence make him deny to himself that suicidal act is possible or 
imminent. A physician needs attention, sensitivity and intuition in listening for and 
responding to a distressed appeal for help, and a non-judgmental approach in dealing 
with suicidal patients, particularly with adolescents and young adults. 
 Table 17.4:  Comparison of  suicide rates in countries with higher and lower physicians ’ density 
 Higher physician ’ s 
density 
 Lower physician ’ s 
density 
 Analysis 
 Mean  SD  Mean  SD  t  df  p 
 Suicide rate among 
15 – 24-year-old males 
(per 100,000 population 
per year) 
 15.78  12.05  14.49  8.10  − 0.39  36  0.70 
 Suicide rate among 
15 – 24-year-old females 
(per 100,000 population 
per year) 
 3.48  2.48  3.16  2.13  − 0.043  36  0.67 
 Suicide rate among 
25 – 34-year-old males 
(per 100,000 population 
per year) 
 22.00  17.56  22.07  11.60  0.01  36  0.99 
 Suicide rate among 
25 – 34-year-old females 
(per 100,000 population 
per year) 
 4.99  2.69  4.05  2.70  − 1.08  36  0.29 
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 Is  suicide preventable? 
 Health care professionals deal with almost no other event as rare as suicide. Although 
suicidal ideation and attempts are associated with elevated suicide risk, most indivi-
duals with suicidal thoughts or attempts will never commit suicide. Suicide attempts 
and ideation occur in about 0.7% and 5.6%, respectively, of the general US population 
( 45 ). In comparison, in the US the annual incidence of suicide in the general popula-
tion is about 11 suicides for every 100,000 persons, or 0.011% of the total population 
per year ( 46 ). Even under the best conditions, the attempted prediction of a rare beha-
vior such as suicide inevitably generates a very large number of false-positive and 
false-negative cases ( 47 ). It has been shown that for realistic assumptions of sensiti-
vity and specificity, a screening test for suicide risk would have a positive predictive 
value of 0.3% and generate a vast number of false positives ( 47 ). Besides, the predic-
tion of suicidal behavior is based on inexact criteria that are in adequate at predicting 
the behavior of a given person, and suicidal individuals often hide or deny suicidal 
thoughts in order to evade unwanted intervention efforts, such as involuntary hospi-
talization. Clearly, it is very difficult to predict and prevent suicide in any age group. 
 Limitations 
 The results of this study should be treated with caution, because many confounding 
variables are not taken into account. For example, prevalence of psychiatric illnesses, 
especially  depression and  alcohol abuse, socioeconomic factors, divorce rates, and 
cultural aspects may affect suicide rates ( 48 – 50 ). 
 Conclusive remarks 
 It is unclear what educational measures or interventions may be the answer to having 
a positive impact on the long observed low quality of suicide risk assessment by 
primary care and specialty physicians. Regretfully, even psychiatrists sometimes do 
not perform an appropriate suicide risk assessment. 
 Physicians should to be aware of and use published  suicide prevention gui-
delines for patient care. The training of physicians including pediatricians with 
regard to suicide prevention and management of suicidal patients should be 
improved. Continuing education on suicide should be required. Physicians should 
use a screening instrument for  suicide assessment with all of their patients, espe-
cially those from at-risk or vulnerable populations such as older adults or patients 
with pain. 
 It is essential to note that our concern about prediction of suicide is related to our 
inability to prevent all suicides ( 51 ). Absence of suicide produces no data. If suicide 
is difficult to predict, its prevention is even more difficult to notice. Possibly, many 
suicidal individuals are recognized and successfully treated. 
214   17  Does the physician density affect suicide rates among adolescents and young adults?
 References 
   1.  US Central Intelligence Agency World Factbook  https://www.cia.gov/library/publications/
the-world-factbook. Accessed June 18, 2012. 
   2.  Ananthakrishnan AN, Hoffmann RG, Saeian K. Higher physician density is associated with lower 
incidence of late-stage colorectal cancer. J Gen Intern Med 2010;25(11):1164 – 71. 
   3.  L é onard C, Stordeur S, Roberfroid D. Association between physician density and health care 
consumption: a systematic review of the evidence. Health Policy 2009;91(2):121 – 34. 
   4.  Association of American Medical Colleges: AAMC Statement on the Physician Workforce.  https://
www.aamc.org/download/55458/data/workforceposition.pdf. Accessed June 16, 2012. 
   5.  Sarma S, Peddigrew C. The relationship between family physician density and health related 
outcomes: the Canadian evidence. Can Sociol Demogr Med 2008;48(1):61 – 105. 
   6.  Chen MK, Lowenstein F. The physician/population ratio as a proxy measure of the adequacy of 
health care. Int J Epidemiol 1985;14:300 – 3. 
   7.  Shi L, Starfield B. The effect of primary care physician supply and income inequality on mortality 
among blacks and whites in US metropolitan areas. Am J Public Health 2001;91:1246 – 50. 
   8.  J ü rges H, Pohl V. Medical guidelines, physician density, and quality of care: evidence from German 
SHARE data. Eur J Health Econ 2012;13(5):635 – 49. 
   9.  Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. Physician density and hospitalization for 
inflammatory bowel disease. Inflamm Bowel Dis 2011;17(2):633 – 8. 
 10.  Roetzheim RG, Pal N, van Durme DJ, Wathington D, Ferrante JM, Gonzalez EC, et al. Increasing 
supplies of dermatologists and family physicians are associated with earlier stage of melanoma 
detection. J Am Acad Dermatol 2000;43:211 – 8. 
 11.  Campbell RJ, Ramirez AM, Perez K, Roetzheim RG. Cervical cancer rates and the supply of primary 
care physicians in Florida. Fam Med 2003;35:60 – 4. 
 12.  Ferrante JM, Gonzalez EC, Pal N, Roetzheim RG. Effects of physician supply on early detection of 
breast cancer. J Am Board Fam Pract 2000;13:408 – 14. 
 13.  Fleisher JM, Lou JQ, Farrell M. Relationship between physician supply and breast cancer survival: 
a geographic approach. J Commun Health 2008;33:179 – 82. 
 14.  Eide MJ, Weinstock MA, Clark MA. The association of physician-specialty density and melanoma 
prognosis in the United States, 1988 to 1993. J Am Acad Dermatol 2009;60(1):51 – 8. 
 15.  Sundmacher L, Busse R. The impact of physician supply on avoidable cancer deaths in Germany. 
A spatial analysis. Health Policy 2011;103(1):53 – 62. 
 16.  Blumenthal SJ. Suicide: a guide to risk factors, assessment, and treatment of suicidal patients. 
Med Clin North Am 1988;72:937 – 71. 
 17.  Pirkis J, Burgess P. Suicide and recency of health care contacts. A systematic review. Br J Psychiatry 
1998;173:462 – 74. 
 18.  Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before 
suicide: a review of the evidence. Am J Psychiatry 2002;159:909 – 16. 
 19.  Robins E, Murphy GE, Wilkinson RH Jr, Gassner S, Kayes J. Some clinical considerations in the 
prevention of suicide based on a study of 134 successful suicides. Am J Pub Health 1959;49:
888 – 99. 
 20.  Feldman MD, Franks P, Duberstein PR, Vannoy S, Epstein R, Kravitz RL. Let ’ s not talk about it: 
suicide inquiry in primary care. Ann Fam Med 2007;5(5):412 – 8. 
 21.  Hooper LM, Epstein SA, Weinfurt KP, DeCoster J, Qu L, Hannah NJ. Predictors of primary care 
physicians ’ self-reported intention to conduct suicide risk assessments. J Behav Health Serv Res 
2012;39(2):103 – 15. 
 22.  US Department of Health and Human Services. National Strategy for Suicide Prevention: Goals 
and Objectives for Action. Rockville, MD: Public Health Service, 2001. 
 References   215
 23.  Taliaferro LA, Borowsky IW. Perspective: physician education: a promising strategy to prevent 
adolescent suicide. Acad Med 2011;86:342 – 7. 
 24.  Sher L. Teaching medical professionals about suicide prevention: what ’ s missing? Q J Med 2011;
104(11):1005 – 8. 
 25.  Sudak D, Roy A, Sudak H, Lipschitz A, Maltsberger J, Hendin H. Deficiencies in suicide training in 
primary care specialties: a survey of training directors. Acad Psychiatry 2007;31:345 – 9. 
 26.  Bongar B, Harmatz M. Clinical psychology graduate education in the study of suicide: availability, 
resources, and importance. Suicide Life Threat Behav 1991;21:231 – 44. 
 27.  Bongar B, Harmatz M. Graduate training in clinical psychology and the study of suicide. 
Professional Psychol Res Pract 1989;20:209 – 13. 
 28.  Weissberg M. The meagerness of physicians ’ training in emergency psychiatric intervention. 
Acad Med 1990;65:747 – 50. 
 29.  Boris NW, Fritz GK. Pediatric residents ’ experiences with suicidal patients: implications for 
training. Acad Psychiatry 1998;22:21 – 8. 
 30.  Boeke M, Griffin T, Reidenberg DJ. The physician ’ s role in suicide prevention: lessons learned 
from a public awareness campaign. Minn Med 2011;94:44 – 6. 
 31.  Gaynes BN, West SL, Ford CA, Frame P, Klein J, Lohr KN. U.S. Preventive Services Task Force. 
Screening for suicide risk in adults: a summary of the evidence for the U.S. Preventive Services 
Task Force. Ann Intern Med 2004;140:822 – 35. 
 32.  Rutz W, Walinder J, von Knorring L, Rihmer Z, Pihlgren H. Prevention of depression and suicide 
by education and medication: impact on male suicidality. An update from the Gotland study. Int J 
Psychiatry Clin Pract 1997;1:39 – 46. 
 33.  Henriksson S, Isacsson G. Increased antidepressant use and fewer suicides in Jamtland county, 
Sweden, after a primary care educational programme on the treatment of depression. Acta 
Psychiatr Scand 2006;114:159 – 67. 
 34.  Szanto K, Kalmar S, Hendin H, Rihmer Z, Mann JJ. A suicide prevention program in a region with a 
very high suicide rate. Arch Gen Psychiatry 2007;64:914 – 20. 
 35.  Hegerl U, Althaus D, Schmidtke A, Niklewski G. The alliance against depression: 2-year evaluation 
of a community-based intervention to reduce suicidality. Psychol Med 2006;36:1225 – 33. 
 36.  Bongar B, Lomax JW, Harmatz M. Training and supervisory issues in the assessment and 
management of the suicidal patient. In: Bongar B, ed. Suicide: Guidelines for Assessment, 
Management, and Treatment. New York: Oxford University Press, 1992:253 – 67. 
 37.  Ellis TE, Dickey TO. Procedures surrounding the suicide of a trainee ’ s patient: a national survey 
of psychology internships and psychiatry residency programs. Professional Psychol Res Pract 
1998;29:492 – 7. 
 38.  Ellis TE, Dickey TO, Jones EC. Patient suicide in psychiatry residency programs: a national survey 
of training and postvention practices. Acad Psychol 1998;22:181 – 9. 
 39.  Kleespies PM, ed. Emergencies in Mental Health Practice: Evaluation and Management. New 
York: Guilford, 1998. 
 40.  Way BB, Allen MH, Mumpower JL, Stewart TR, Banks SM. Interrater agreement among psychi-
atrists in psychiatric emergency assessments. Am J Psychiatry 1998;155:1423 – 8. 
 41.  Sher L. Teaching medical professionals and trainees about adolescent suicide prevention: five 
key problems. Int J Adolesc Med Health 2012;24(2):121 – 3. 
 42.  National Center for the Prevention of Youth Suicide. Youth Suicidal Behavior Fact Sheet.  http://
www.suicidology.org/c/document_library/get_file?folderId=248&name=DLFE-500.pdf. 
Accessed October 3, 2012. 
 43.  World Health Organization. Mental health. Country reports and charts available.  http://www.who.
int/mental_health/prevention/suicide/country_reports/en/. Accessed June 21, 2012. 
 44.  Sher L. Preventing suicide. Q J Med 2004;97(10):677 – 80. 
216   17  Does the physician density affect suicide rates among adolescents and young adults?
 45.  Crosby AE, Cheltenham MP, Sacks JJ. Incidence of suicidal ideation and behavior in the United 
States, 1994. Suicide Life Threat Behav 1999;29:131 – 40. 
 46.  Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat 
Rep 2002;50:1 – 119. 
 47.  Gaynes BN, West SL, Ford CA, Frame P, Klein J, Lohr KN. Screening for suicide risk in adults: a 
summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2004;140:
822 – 35. 
 48.  Maris RW. Suicide. Lancet 2002;360(9329):319 – 26. 
 49.  Sher L, Oquendo MA, Mann JJ. Risk of suicide in mood disorders. Clin Neurosci Res 2001;(1)5:
337 – 44. 
 50.  Sher L. Alcohol use and suicide rates. Med Hypotheses 2005;65(6):1010 – 2. 
 51.  Murphy GE. The prediction of suicide: why is it so difficult? Am J Psychother 1984;38:341 – 9. 
 18   Suicidal behavior in Indian  adolescents 
 Diana  Samuel and  Leo  Sher 
 Suicide is both a public and mental health problem as it is a leading cause of deaths, 
especially among adolescents. Two factors that contribute to adolescents who 
commit suicide are having a primary  mood disorder and/or substance use. In the 
Indian culture, the family unit has both a positive and negative impact on suicide. 
The family serves as a protective factor providing a strong support for the individual, 
but alternately creating an inseparable individual when seeking mental health care 
which often complicates the situation. Due to the stigma, Indians typically perceive 
having a  mental illness as shameful. Religion is integral to the Indian culture so much 
so that individuals often use herbal remedies, seek help from religious leaders and 
attend religious establishments prior to obtaining a mental health evaluation in those 
that were subsequently deemed as mentally ill. Despite suicides being underreported 
and misdiagnosed in India, the highest rates are among those less than 30 years old. 
The methods most commonly used to commit suicide in India include use of poison 
(often pesticides), hanging, burning and drowning. When immigrating, Indians tend 
to switch the methods they use to commit suicide from use of poison to hanging 
which may reflect a lack of availability of poison or the influence of the host culture. 
Considering the high suicide rates in adolescents, the importance of providing psy-
choeducation, restricting access to lethal means, and promoting social integration in 
immigrants are ways we may be able to help prevent suicides in Indian adolescents. 
 18.1  Introduction 
 Suicide is the act of intentionally causing one ’ s own death. Suicide attempts as 
defined by Kar are  “ any act of self-damage inflicted with self-destructive intentions ” 
( 1 ). The factors that contribute to any particular suicide are diverse and complex. Con-
sidering that suicide is the third leading cause of death among those between the ages 
of 15 – 24 years ( 2 ), it is one that must be explored further. In 2011, in the US alone, 
15.8% of high school students had seriously considered attempting suicide during the 
12 months before the survey ( 3 ). During the same time, 12.8% of students had made a 
plan of how they would commit suicide and 7.8% had attempted suicide at least once 
( 3 ). Approximately 50 – 75% of children and adolescents who commit suicide have had 
a mood disorder, most commonly major  depression ( 4 ). About one quarter to two-
thirds of adolescents who commit suicide received a diagnosis of  substance abuse 
or dependence ( 5 ,  6 ). The stigma associated with mental illness is often a significant 
barrier to obtaining psychiatric care. When considering the limited mental health 
resources in countries such as India, it is not surprising that suicide rates for instance 
may be underreported and/or misclassified in order to prevent further shame to the 
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family. Despite the continuous and growing impact of urbanization, secularization, 
and Westernization, the traditional joint household, both in ideal and in practice, 
remains the primary social force in the lives of most Indians. 
 18.2  Indian psyche 
 Indian psyche is distinct as it has been influenced by various invaders into the country, 
collectivism and interdependence ( 7 ). In India, people learn the essential themes of 
cultural life within the bosom of a family. In most of the country, the basic units of 
society are the patrilineal family unit and wider kinship groupings. The most widely 
desired residential unit is the joint family, ideally consisting of three or four patriline-
ally related generations, all living under one roof, working, eating, worshiping, and 
cooperating together in mutually beneficial social and economic activities. Patrilineal 
joint families include men related through the male lineage, along with their wives 
and children. Most young women expect to live with their husband ’ s relatives after 
marriage, while retaining important bonds with their biological families. Indians 
consider the relationships within a family very intimate, spread over several people 
including grandparents, parents, uncles, aunts and siblings, thus often making the 
parents not the sole guardians of the child ( 7 ). With age, a series of similar relation-
ships of varying intensities and duration develop and most often, consequently most 
Indians do not assume full individuality ( 7 ). Therefore, unlike the self-reliant, inde-
pendent nature that is most often nurtured and even idealized in individuals of the 
Western world, one of the core values of Indians is based on intimacy, family security 
and its stability ( 7 ). The emotional interdependence that family members feel with 
each other is often so intense that the family becomes almost an organic unit. Ego 
boundaries are permeable to others in the family, and any notion of a separate self 
is often dominated by a sense of what psychoanalyst Alan Roland has termed a more 
inclusive  “ familial self. ” Interpersonal empathy, closeness, loyalty, and interdepen-
dency are all crucial to life within the family. It is the intimate nature of the family unit 
that forms a practically inseparable indentify from the individual making it impossi-
ble to separate when attempting to treat a person with  mental illness ( 7 ). 
 Nonetheless, it is this same family that provides the support that is protective 
against  suicide. Family support has been shown to be a positive factor for those that 
are at risk for suicide and also integral in the treatment of these individuals. In one 
study of  adolescents that were at risk for suicide in US adolescents with higher levels 
of family support had significantly higher levels of self-esteem and self-esteem was 
found to be a protective factor against suicide ( 8 ). Self-esteem is formed when one 
recognizes themselves as competent and worthy which subsequently creates a sense 
of self-acceptance, self-respect, and satisfaction with one ’ s self and life ( 8 ). Feeling 
connected to the family may reduce feelings of social isolation and loneliness which 
are often antecedents to suicide behaviors. Family support creates a feeling that 
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one is cared for, wanted and loved by its members which diminishes the likelihood 
that an adolescent will consider  suicide as a  “ rational ” alternative for solving their 
 problems ( 9 ). 
 Religion is an integral aspect of life in India, so far as that religious prayers and 
healers often play a role in the treatment of all illnesses, including  mental illness 
( 10 ). In one study, it was found that ninety percent of the time that those who were 
studied had experienced any type of symptom of illness, they initially relied entirely 
on home remedies and other forms of self-treatment ( 11 ). This implies that religious 
beliefs impact the way one perceives illness in India, whether it be physical or mental 
ailments. In addition to one ’ s religion, educational level, caste and social class, reli-
gious affiliation as well as religious attendance affected the psychiatric care sought 
by those individuals ( 10 ). In a study conducted in North India, 84% of patients even-
tually seen in a psychiatric institution had been to a local temple prior to obtaining 
treatment ( 12 ) which may be due to having a poor understanding of mental illness or 
rather a denial of the actual illness. In terms of those people that saw religious healers 
for mental illness prior to seeking an official psychiatric consultation, the highest 
rates of psychiatric diagnoses were in the group diagnosed as having  schizophrenia 
and delusional disorders ( 10 ). This implies that many individuals with chronic mental 
illness may not initially recognize their psychiatric illness as being purely psychiatric 
or they may feel that their illness is better treated through religious means, at least 
initially. 
 18.3  Suicide in India 
 The Indian subcontinent encompasses eight distinct countries, India, Pakistan, 
Afghanistan, Sri Lanka, Bangladesh, Nepal, Bhutan, and the Maldives and collec-
tively, these countries comprise 1.3 billion people. Information gathered on suicide 
on the Indian subcontinent comes mainly from India, Sri Lanka and Pakistan as the 
remaining countries have poorly developed mental health services and consequently, 
mental health issues including suicide is given little importance when compared to 
other priorities such as infectious diseases and sanitation. Some of the problems in 
obtaining records for suicides in countries of the Indian subcontinent include legal, 
social and religious reasons ( 13 ). For example, suicide is considered a criminal act in 
Pakistan and punishable with a jail term and heavy financial penalty. This has led to 
both suicides and attempted suicides being underdiagnosed and underreported ( 14 ). 
Until 1994, attempting suicide was a punishable act in India ( 13 ). Under section 309 
of the Indian Penal Code from 1833 it states,  “ Whoever attempts to commit suicide 
and does any act towards the commission of such an offence shall be punished with 
simple imprisonment for a term which may extend to 1 year, or with a fine or with 
both ” ( 15 ). It was only in 1994 that the Supreme Court of India found this code was 
unconstitutional and Justice Rajinder Sachar of the Delhi High Court said in his 
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judgment:  “ Instead of society hanging its head in shame that there should be such 
social strains that a young man should be driven to commit  suicide, it compounds 
its inadequacy by treating the boy as a criminal. Instead of sending him to the psy-
chiatric clinic it gleefully sends him to mingle with criminals, as if trying its best to 
see that in future he does fall foul of the punitive section of the Penal Code ” ( 15 ). In 
1996, the Supreme Court held that the right to life in Article 21 of the Constitution did 
not include the right to die and court struck down Section 309 of the Penal as being a 
violation of Article 21 and thus unconstitutional ( 15 ). Therefore, suicide attempts and 
the abetting of suicide continue to be misdemeanors in India and a person convicted 
of an offense of attempted suicide may be indicted to imprisonment for a term not 
exceeding 1 year, or a fine, or both ( 15 ). 
 From 1978 to 1990, there was an increase of 41.3% in suicide from 6.4 to 8.9 (per 
100,000). This attributes to a growth rate of 4.1% per year from 1980 to 1990 in suicide. 
This rate of suicide increase in India during this time is comparable with the global 
increase in suicide during the same time ( 16 ). In 2008, 125,017 people were recorded to 
have committed suicide, which was a 1.9% increase from the previous year of 122,637 
suicides ( 17 ). Even within India there are wide variations in the suicide rates such that 
the southern states (Kerala, Karnataka, Andhra Pradesh and Tamil Nadu) having a 
rate greater than 15 per 100,000 while in the northern states (Punjab, Uttar, Pradesh, 
Bihar and Jammu and Kashmir) the suicide rate is less than 3 per 100,000 ( 18 ). This 
pattern has remained stable within the last 20 years. Some factors that may contri-
bute to this variation are that in the southern states, there is higher literacy, better 
reporting system, and higher socioeconomic status ( 18 ). 
 The highest percentage of people who commit suicide in India (37.8%) are below 
30 years of age ( 19 ). One out of every three of reported suicides every 15 minutes in 
India were committed by a  youth between the ages of 15 – 29 ( 19 ). Kerala, well-known 
for being India ’ s first fully literate state, has the highest number of suicides with 
32 people committing suicide in this state every day ( 19 ). Compared to the US where 
the overall rate of suicide is about 11 deaths per 100,000 persons, it remains slightly 
higher then the 10.5 suicides reported in India ( 20 ,  21 ). However, this difference may 
be better attributed to underreporting rather then a true difference according to many 
studies, but is unclear. 
 Due to the stigma associated with  mental illness, it is thought that the actual 
suicide rate in India may be higher than that reported due to concern about the harm to 
family reputation or police involvement ( 22 ). In 2010, it was reported that 33.1% of sui-
cides were accounted for by ingestion of poison, 31.4% by hanging, 8.8% by fire/ “ self-
immolation ” and 6.2% by drowning ( 23 ). Also, it is possible and questionable whether 
the suicides recorded as acts of  “ self-immolation ” may be underestimated and that 
those deaths reported as accidental deaths due to fire may be due to suicides ( 22 ). It 
has been suggested that the annual suicide rate could be six to nine times the official 
rate ( 18 ) which is likely due to non-reporting, underreporting and misclassification due 
to stigmas, religious sanctions, legal issues and insufficient registration systems ( 24 ). 
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Burning has also been a method used as a means of successful  suicide among young 
women ( 16 ) with about 30% of immigrant Indians committing suicide by burning 
( 25 ). A suicidology study, conducted from March to October of 1988 in a Madurai Hos-
pital in India of 100 cases of consecutive burn victims, found that the majority of 
these cases were caused by suicide and found to be grouped into three categories- 
those with marital problems (36/100), other stressful family and life circumstances 
(26/100), and dowry related problems (5/100) ( 16 ). This information was gathered by 
contacting the survivors of suicide attempts, family members of those who commit-
ted suicide, in addition to the Department of Plastic Surgery and Forensic medicine 
reviewing each case individually and deciding whether they were likely accidental, 
suicidal or homicidal ( 16 ). One of the differences found between the accidental versus 
suicidal burns were that 15 of the cases were mentally ill in the suicidal group while 
only three in the accidental group. Among the suicide group, eight cases had made 
prior suicide attempts but not by burn injury (two of which were psychiatrically ill, 
and other two who were physically ill) ( 16 ). This suggests that in India like many other 
countries, suicide is associated with psychiatric pathology. 
 18.3.1   Adolescent suicide in India 
 In India, each year greater than 100,000 people commit suicide with a gradual upward 
trend being noted ( 17 ). With the highest percentage of those being below the age of 30, 
accounting for about 37% of all suicides in India in 2009 ( 19 ,  21 ) it is important to 
identify factors that may differentiate this group. In a study of 149 suicide attempters, 
adolescents differentiated themselves from the other age groups in that 90% of them 
made their attempts impulsively with only 9% of the attempts being of high potential 
in terms of risk ( 26 ). Within this adolescent population, the most common predispo-
sing factor to suicide was reported  childhood trauma while  mental illness was the 
least when compared to other age groups ( 27 ). In addition, all of these adolescents 
reported experiencing negative life events ( 27 ), which typically included failing exa-
minations and minor violations of discipline with anticipation of negative consequen-
ces ( 27 ,  28 ). Among the listed reasons,  “ illness, ”  “ family problems, ” and  “ failure in 
examination ” were the main reasons for suicide among children ( 23 ). In comparison, 
adults that attempted suicides typically had an underlying psychiatric illness and the 
methods they used were considered more serious attempts, while suicide attempts by 
adolescents in India were more impulsive and due to  “ anomalous life conditions ” ( 1 ). 
 18.3.2  Immigration and suicide 
 Although there are no studies found that specifically examined  adolescent suicide 
among Indian adolescents in the US, one study published in the British Journal 
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of  Psychiatry looked at the  suicide patterns among immigrants in Britain that 
immigrated from the Indian subcontinent. From 1970 to 1978, it was found that 
145 Indian men and 86 Indian women committed suicide in England and Wales which 
accounted for 1.8% of male death and 2.7% of female death among Indians in England 
and Wales ( 25 ). When compared to the same period and rates of suicide in England 
and Wales, only 0.8% and 0.6% respectively of male and female deaths were accoun-
ted for by suicide ( 25 ). Among both genders, suicide mortality was higher among 
young Indians, specifically Indian women between the ages of 15 – 24 who had over an 
80% higher suicide rate than women of corresponding ages ( 25 ). 
 When individuals from different cultures immigrate to a host country, the immi-
grants assume similar suicide rates and methods to members of the host culture ( 29 ). 
Generally, suicide rates among first generation immigrants are lower and most resem-
ble rates typical of their country of origin ( 30 ) with subsequent generations have incre-
ased rates comparable to North American trends ( 31 ). Some factors that contribute to 
assimilation and may impact these rates include acculturative stress, process of accul-
turation, risk factors (i.e., single, drug use and rejection by host culture) and protective 
factors (family support, belonging to an ethnic community, being married, living in 
a large city) ( 29 ). The stress associated with immigration, whether or not there is an 
underlying  mental illness, can lead to severe and possibly chronic behavioral issues 
including  alcohol and illicit drug abuse,  depression,  anxiety, and  posttraumatic stress 
disorder which subsequently place these individuals at higher risk for suicide ( 32 ). 
First generation immigrant populations within North America tend to choose methods 
of suicide that are influenced by their cultural heritage ( 29 ), however, it was noted that 
Indian immigrants tend to switch methods of suicide from poisoning with pesticides to 
hanging, which may reflect the lack of availability of pesticides in the host countries or 
may indicate that the host culture has an influence on the immigrant ( 33 ). 
 18.3.3  Preventing  suicidal behavior in Indian  adolescents 
 For many who engage in suicidal behavior, there is often an appropriate alternative 
resolution to the precipitating problems that lead to suicide ( 18 ). Non-governmental 
organizations (NGOs) are a large support system that should be used to help support 
suicidal individuals ( 18 ). NGOs can serve not only as an entry point for individuals 
requiring professional services, but also provide education, raise awareness in the 
public and establish intervention programs ( 18 ). Reducing access to lethal means 
including pesticide and  alcohol which are associated with high rates of suicide in 
India would be part of the national plan for  suicide prevention ( 18 ). Encouraging 
and promoting responsible reporting of suicide and issues relating to suicide, sup-
porting NGOs, improving the capacity of primary care workers and mental health 
specialists, and providing support for those who suffer from the loss of someone who 
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committed  suicide should all be part of the solution to preventing suicide in India 
( 18 ). In general, an overall improvement in psychoeducation and subsequent incre-
ased awareness of people in the community concerning  mental illness would likely 
decrease the stigma and hopefully improve suicide outcomes. 
 Features of  impulsivity which include poor impulse control, quick provocation, 
and disregard of external constraints are at higher levels at age 17 and with a slower 
decline with age in those who attempted suicide when compared to non-attempters 
( 34 ). Therefore, it is imperative that public health interventions such as restricting 
access to pesticides ( 35 ), increased surveillance, training and community action on 
the use of pesticides (i.e., safe storage and proper dilutions) ( 36 ), and stricter alcohol 
laws may prevent many deaths caused by suicide in India. Secondary prevention 
is also very important and includes recognizing and treating psychiatric disorders, 
particularly mood disorders and  alcohol abuse ( 37 ) which would also decrease 
suicide risk. 
 The well-known theory by Emile Durkheim stresses the importance of commu-
nity and social networking as being protective against suicide ( 38 ). He felt that dif-
ference in suicide rates seen between cultures was an inverse function of the level of 
social integration, such that individuals with strong social bonds had a lower risk for 
suicide then those with less developed networks. Supporting this theory, living in a 
large city is protective against suicide. Factors that need to be strengthened in Indian 
 adolescents that immigrate to another county are maintaining culture and establi-
shing an ethnic community ( 29 ). It is this ethnic community that appears to similarly 
serve as the family unit for immigrants. 
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 19   American juvenile justice system: history 
in the making 
 Aaron  Meng ,  Roland  Segal and  Eric  Boden 
 The original theory behind separating juvenile offenders from adult offenders was to 
provide care and direction for youngsters instead of isolation and punishment. This 
idea took hold in the 19th century and became mainstream by the early 20th century. 
In the 1950s and 1960s, public concern grew because of perceived lack of  effectiveness 
and lack of rights. The Supreme Court made a series of rulings solidifying juvenile 
rights including the right to receive notice of charges, right to have an attorney, and 
proof of beyond a reasonable doubt. In the 1980s, the public view was that the juvenile 
court system was too lenient and that juvenile crimes were on the rise. In the 1990s, 
many states passed punitive laws, including mandatory sentencing and blanket trans-
fers to adult courts for certain crimes. As a result, the pendulum is now swinging back 
toward the middle from rehabilitation toward punishment. 
 19.1  Introduction 
 The economic developments of the 19th century brought the legal status of children 
to the public ’ s eye. The first years of the 1800s were characterized by expansionary 
fiscal policy. The country was booming and the government was spending freely on 
infrastructure improvements and real estate speculation, increasing banking activity. 
By 1818, Americans began to lose confidence in the banks, forcing the government to 
begin to contract the economy. This economic slowdown intensified, and in 1819, the 
US plunged into its first true economic crisis, the Great Panic of 1819 ( 1 ). This crisis 
forced most children factory workers out of their jobs and into a state of unsupervised 
 inactivity. Concern about these children began the transformation of social safety net 
institutions to institutions designed to help these children. In 1824, in New York City, 
the Society for Prevention of Pauperism became the Society for Reformation of Juve-
nile Delinquents. This Society opened the first  “ House of Refuge ” in US in 1825, follo-
wed by similar agencies in Boston and Philadelphia in 1828. These institutions were 
designed to prevent civil unrest by maintaining class status ( 2 ). 
 The purpose of these juvenile facilities, a.k.a. training schools, was to isolate the 
juvenile delinquents from the corruption of hardened adult criminals, and to provide 
them discipline and guidance. A large part of the adjudicated minor ’ s daily schedule 
was devoted to supervised labor for the purpose of education and discipline, but also 
to support the operating expenses. In addition, students were taught literacy and reli-
gion. Today ’ s training schools continue to house a large number of juvenile offenders. 
However, over the years, the emphasis changed toward recovery with individualized 
diagnosis and treatment, improved education, and rehabilitation services ( 3 ). 
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 Later in the 19th century, the Industrial Age transformed the workplace to one 
in which workers required an increasingly complex skill set ( 4 ). Manufacturing 
began focusing on production of interchangeable parts with repeatable precision 
and mass production. With steam power, electrical power and internal combustion 
engines came the use of production machinery that required specific learned skill 
sets to operate ( 5 ). As these skills took time to acquire,  youths required a longer tran-
sition between childhood and working adulthood. Thus the concept of  adolescence 
began to develop, and so did the idea that the responsibilities of this newly defined 
demographic should be different from those of adults. In what is now known as the 
Progressive Era, laws were enacted requiring school attendance, limiting the hours 
of employment, and increasing the age at which one could marry ( 4 ). During this 
time period, more parents began working outside of the home and, therefore, could 
not home-school their children. The burden of educating children, both academically 
and socially, then fell upon the school system ( 6 ). 
 Prior to this Progressive Era, there was no separate juvenile justice system, and 
juvenile offenders were prosecuted under the same criminal law constructs as adults 
( 7 ). Some additional protections were afforded to youths, however, as immaturity 
could be used to reduce culpability. For example, depending on jurisdiction,  “ infancy ” 
was considered an absolute defense until the age of 7 or 10 years. After that, there was 
a presumption that a youth was incapable of forming criminal intent until the age of 
14 years. This presumption could be rebutted if the prosecution could present suffici-
ent evidence of maturity ( 8 ,  9 ). Children fourteen and older were presumed capable of 
understanding wrongfulness, but the defense could rebut this presumption by estab-
lishing immaturity ( 10 ). 
 19.2  Juvenile courts 
 In 1899, the nation ’ s first juvenile court was established in Cook County, Illinois ( 11 ). 
In the first juvenile courts, instead of the adversarial trials of adult courts which 
sought an answer of guilt versus innocence, judges investigated the character and 
social background of children. They attempted to interpret the reasons and moti-
vations behind the children ’ s actions to help determine their moral character ( 12 ). 
Instead of using the terminology of guilt, innocence, trial or sentence, these courts 
spoke of adjudication and disposition. Instead of focusing on the offense at hand, 
they focused on the best interests of the juvenile ( 13 ). These courts began to distance 
themselves from adult criminal courts by seeking rehabilitation for youths rather 
than punishment ( 12 ). 
 Since the objective was treatment, the proceedings of these courts differed sig-
nificantly from criminal courts. Due process and rules of evidence were viewed as 
unnecessary and possibly detrimental to the goal of assisting the wayward youths. 
With the key question being amenability to treatment, rather than culpability, social 
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workers, probation officers, and mental health professionals played key roles, as they 
were best equipped to answer the question at hand ( 8 ). 
 Additionally, children could be adjudicated for  “ status offenses, ” behaviors 
that were illegal for a person under the age of 18 years, but legal if committed by an 
adult. These offenses included sexual acts,  alcohol consumption, smoking cigarettes, 
running away, and truancy. Under the public policy of parens patriae (the power of the 
state to protect the individuals who need protection), the juvenile courts were given 
control over all juvenile matters, both delinquent (i.e., criminal) and status offence. 
Unfortunately, children were often adjudicated into reform schools for both delin-
quent matters and status offences for unreasonable durations without due process 
( 14 ). Children could also be adjudicated for  “ predeliquency ” even if no crime was yet 
committed, as long as they had caused trouble for an authority figure ( 15 ). 
 In 1974, the National Juvenile Justice and Delinquency Prevention Act was 
enacted. The purpose of this act was to give the states money in order to enact four 
core items: (a) the deinstitutionalization of juvenile status offenders from detention 
centers and jails, (b) the provision of  “ sight and sound ” separation between juve-
nile and adult offenders, (c) the prevention imprisonment of  youth in adult jails, and 
(d) an investigation of the issue of over-representation of minorities in the justice 
system ( 16 ). 
 19.3   The Supreme Court of the United States ’ role 
in defining the juvenile justice system 
 The US Supreme Court noticed the imbalance in juvenile rights and responded. In 
1966, Kent v. United States began a surge of reformations aimed at providing juveniles 
rights similar to defendants in criminal courts. The petitioner in Kent v. United States 
was a 16-year-old male who was arrested for charges of housebreaking, robbery, and 
rape. As a 16-year-old, he was subject to the jurisdiction of the juvenile court unless 
after a  “ full investigation, ” that court waived jurisdiction and remanded him to the 
District Court for trial. He was waived to the District Court after a  “ full investigation, ” 
but without due process. He moved to dismiss this indictment and was overruled. The 
US Court of Appeals upheld this decision, but the US Supreme Court reversed the deci-
sion, stating that due process and assistance of counsel are necessary in order for such 
a waiver to occur. Justice Fortas said,  “ … the child receives the worst of both worlds: he 
gets neither the protections accorded to adults nor the solicitous care and regenerative 
treatment postulated for children ” ( 17 ,  18 ). 
 A year later, the US Supreme Court expanded the rights of minors facing charges 
in their decision on the case of In re Gault. Gerald Gault was a 15-year-old male who 
was brought into custody for making obscene phone calls. His parents were not noti-
fied of his arrest, they were not officially notified of his charges, and he was not given 
an opportunity to confront his accuser. Despite the lack of due process, Gault was 
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committed to the State Industrial School for 6 years as a juvenile delinquent. The US 
Supreme Court opined that in most cases the Constitutional protections afforded to 
adults facing criminal charges should also apply to  youths. As such, juveniles had 
a right to be advised of their right to counsel, have timely notice of their hearings, 
cross-examine witnesses testifying against them, and invoke their right against self-
incrimination ( 17 ,  19 ). 
 In 1969, the Supreme Court heard a case in which Samuel Winship, a 12-year-old, 
was charged as a juvenile delinquent for stealing  $ 112 from a woman ’ s purse. In the 
New York Family Court, at that time, the standard for proving a juvenile ’ s guilt was 
based on  “ preponderance of evidence ” (i.e., more likely than not). Using this stan-
dard, Winship was found guilty, even though the Family Court acknowledged that 
the evidence against Winship would not meet the standard of  “ beyond a reasonable 
doubt, ” the much higher standard used in criminal courts. The Supreme Court ruled 
that the standard of  “ beyond a reasonable doubt ” must be used in all criminal cases, 
both for adults and for juveniles ( 17 ,  20 ). 
 Despite the changes that occurred from these cases, the US Supreme Court con-
tinued to support significant differences between juvenile adjudication courts and 
adult criminal courts. For example, the Supreme Court drew the line at the right to 
jury trials for youths in McKeiver v. Pennsylvania in 1971. Justice Harry Blackmun wrote 
that juveniles were entitled to some, but not all of the Constitutional rights of adults 
in the criminal justice process ( 17 ,  21 ). 
 In 1975, The Supreme Court upheld the ideal that the juvenile justice system was 
a more benevolent entity than the adult justice system, and that it offered significant 
social benefits. Through their decision in Breed v. Jones, the Court gave youths the 
protection against double jeopardy in transfers to adult courts and opined that having 
such waiver hearings prior to adjudication hearings would not unduly strain the juve-
nile justice system ( 17 ,  22 ). 
 The US Supreme Court, focused on the Eighth Amendment of the US Constitu-
tion. In the 2002 case of Atkins v. Virginia the US Supreme Court opined that it is cruel 
and unusual to execute mentally retarded individuals. The justices sited the  “ evolving 
standards of decency. ” Based on that standard, in the 2005 case of Roper v. Simmons, 
the Supreme Court of US held that it is unconstitutional to impose death sentence if 
the perpetrator was less than 18 years of age at the time of the crime ( 23 ). 
 19.4  More recent changes 
 In the late 1980s, there was a significant increase in lethal violence perpetra-
ted by youths. By 1994, homicides and aggravated assaults committed by teens 
aged 13 – 17  years more than doubled. School violence in the suburbs and small 
towns nationwide was also on the rise ( 24 ). Public opinion is a major driving 
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force in democratic societies. In 1991, the general opinion was that juveniles who 
committed seriously violent offences should be punished. However, the majority of 
people did not think that incarceration of juvenile offenders in adult facilities was 
appropriate. Public opinion changed, however in the early 21st century, when a 
public poll showed that the majority of respondents favored treating violent, juvenile 
offenders between the ages of 14 and 17  the same as adults ( 8 ). The legislatures in 
most states responded to the public opinion that juvenile crime had reached 
epidemic proportions by increasingly modeling their juvenile justice system after 
their adult criminal systems. This resulted in lowering the age and broadening 
the offense criteria for trying teenagers in adult criminal court as opposed to juvenile 
court ( 24 ). 
 19.5  Current controversies 
 Juvenile justice is a complex issue that spans many boundaries and touches many 
lives. As long as we are open to discuss the controversies that exist within the system 
we will be able to improve on what we currently have. 
 One of these controversies is the question of whether lack of punishment is a 
cause of the increase in juvenile violent crimes. During the period between 1970s and 
1990s, the juvenile justice system became more adjudicative than punitive. During 
the same period, rates of juvenile violent crimes had grown almost twice as fast as the 
adult crime rates ( 25 ). 
 Another controversy is about blanket provisions that transfer juvenile offenders 
from the juvenile to the adult justice system for certain charges ( 26 ). Currently 23 
states do not specify a minimum age for transfer to adult court for one or more offense 
classifications. In addition, 46 states allow the transfer of a case into the adult crimi-
nal system based on the type of the offense ( 27 ). 
 Yet another controversy is whether juvenile status offense laws are justified or if 
they should be abolished. Many behavioral health experts believe that status offense 
behaviors are precursors to more serious crimes ( 13 ). 
 19.6  Summary 
 From its beginnings within the same framework as the adult criminal code, to the 
reformations that attempted to transform the system into a therapeutic rather than 
punitive entity, and more recently the shift back to increased punishment, the juve-
nile justice system of US has been in a state of frequent flux. The current controversies 
and varying opinions as to whether a more punitive or more therapeutic approach 
should prevail will likely continue this trend of change. 
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of the master of science program in gerontology in our collaboration with the Center 
for Multidisciplinary Research in Aging. In 2010 collaborations with the Division of 
Pediatrics, Hadassah Medical Center, Hebrew University, Jerusalem, Israel. 
 22.3  Research activities 
 The affiliated staff have over the years published work from projects and research 
activities in this national and international collaboration. In the year 2000, the 
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 International Journal of  Adolescent Medicine and Health and in 2005 the International 
Journal on Disability and Human  Development of De Gruyter Publishing House (Berlin 
and New York), in the year 2003 the TSW-Child Health and Human Development and 
in 2006 the TSW-Holistic Health and Medicine of the Scientific World Journal (New York 
and Kirkkonummi, Finland), all peer-reviewed international journals were affilia-
ted with the National Institute of Child Health and Human Development. From 2008 
also the International Journal of Child Health and Human Development (Nova Science, 
New York), the International Journal of Child and Adolescent Health (Nova Science) 
and the Journal of Pain Management (Nova Science) affiliated and from 2009 the 
Intern ational Public Health Journal (Nova Science) and Journal of Alternative Medicine 
Research (Nova Science). 
 22.4  National collaborations 
 Nationally the NICHD works in collaboration with the Faculty of Health Sciences, Ben 
Gurion University of the Negev; Department of Physical Therapy, Sackler School of 
Medicine, Tel Aviv University; Autism Center, Assaf HaRofeh Medical Center; National 
Rett and PKU Centers at Chaim Sheba Medical Center, Tel HaShomer; Department of 
Physiotherapy, Haifa University; Department of Education, Bar Ilan University, Ramat 
Gan, Faculty of Social Sciences and Health Sciences; College of Judea and Samaria 
in Ariel and in 2011 affiliation with Center for Pediatric Chronic Diseases and Center 
for Down Syndrome, Department of Pediatrics, Hadassah-Hebrew University Medical 
Center, Mount Scopus Campus, Jerusalem. 
 22.5  International collaborations 
 Internationally with the Department of Disability and Human Development, College 
of Applied Health Sciences, University of Illinois at Chicago; Strong Center for Deve-
lopmental Disabilities, Golisano Children ’ s Hospital at Strong, University of Roches-
ter School of Medicine and Dentistry, New York; Centre on Intellectual Disabilities, 
University of Albany, New York; Centre for Chronic Disease Prevention and Control, 
Health Canada, Ottawa; Chandler Medical Center and Children ’ s Hospital, Kentucky 
Children ’ s Hospital, Section of Adolescent Medicine, University of Kentucky, Lexing-
ton; Chronic Disease Prevention and Control Research Center, Baylor College of 
Medicine, Houston; Division of Neuroscience, Department of  Psychiatry, Columbia 
University, New York; Institute for the Study of Disadvantage and Disability, Atlanta; 
Center for Autism and Related Disorders, Department Psychiatry, Children ’ s Hospital 
Boston, Boston; Department of Paediatrics, Child Health and Adolescent Medicine, 
Children ’ s Hospital at Westmead, Westmead, Australia; International Centre for the 
Study of Occupational and Mental Health, D ü sseldorf, Germany; Centre for  Advanced 
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Studies in Nursing, Department of General Practice and Primary Care, University of 
Aberdeen, Aberdeen, UK; Quality of Life Research Center, Copenhagen, Denmark; 
Nordic School of Public Health, Gottenburg, Sweden, Scandinavian Institute of 
Quality of Working Life, Oslo, Norway; Centre for Quality of Life of the Hong Kong 
Institute of Asia-Pacific Studies and School of Social Work, Chinese University, Hong 
Kong. 
 22.6  Targets 
 Our focus is on research, international collaborations, clinical work, teaching and 
policy in health, disability and human  development and to establish the NICHD as 
a permanent institute at one of the residential care centers for persons with intel-
lectual disability in Israel in order to conduct model research and together with the 
four university schools of public health/medicine in Israel establish a national master 
and doctoral program in disability and human development at the institute to secure 
the next generation of professionals working in this often non-prestigious/low-status 
field of work. 
 22.7  Contact 
 Joav Merrick, MD, DMSc 
 Professor of Pediatrics, Child Health and Human Development 
 Medical Director, Health Services, Division for Intellectual and Developmental Dis-
abilities, Ministry of Social Affairs and Social Services, POB 1260, IL-91012 Jerusalem, 
Israel 
 E-mail: jmerrick@zahav.net.il 
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